# EDGAR Filing Document

**Accession Number:** 0001035443
**File Stem:** 0001035443-25-000179
**Filing Date:** 2025-7
**Character Count:** 570214
**Document Hash:** 4a0c29124a46f85bb4464314038a48a5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001035443-25-000179.hdr.sgml**: 20250721

**ACCESSION NUMBER**: 0001035443-25-000179

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 113

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250721

**DATE AS OF CHANGE**: 20250721

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALEXANDRIA REAL ESTATE EQUITIES, INC.
- **CENTRAL INDEX KEY:** 0001035443
- **STANDARD INDUSTRIAL CLASSIFICATION:** REAL ESTATE INVESTMENT TRUSTS [6798]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 954502084
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12993
- **FILM NUMBER:** 251137363

**BUSINESS ADDRESS:**
- **STREET 1:** 26 NORTH EUCLID AVENUE
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91101
- **BUSINESS PHONE:** 6265780777

**MAIL ADDRESS:**
- **STREET 1:** 26 NORTH EUCLID AVENUE
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91101

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALEXANDRIA REAL ESTATE EQUITIES INC
- **DATE OF NAME CHANGE:** 19970311

?xml version='1.0' encoding='ASCII'? are-20250630

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

☒**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2025**

**OR**

☐**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** 

**EXCHANGE ACT OF 1934**

For the transition period from ____________ to ____________

Commission file number 1-12993

**ALEXANDRIA REAL ESTATE EQUITIES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Maryland** | **95-4502084** |
| (State or other jurisdiction of<br>incorporation or organization)<br>| (I.R.S. Employer Identification Number) |

---

**26 North Euclid Avenue, Pasadena, California91101**

(Address of principal executive offices) (Zip code)

**(626) 578-0777**

(Registrant's telephone number, including area code)

**N/A**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.01 par value per share | ARE | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and

posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period

that the registrant was required to submit and post such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting

company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting

company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Smaller reporting company  | ☐ |
| Accelerated filer  | ☐ | Emerging growth company  | ☐ |
| Non-accelerated filer | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐No☒

As of July 15, 2025, 172,958,948shares of common stock, par value $0.01 per share, were outstanding.

i

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | Page |
| [PART I – FINANCIAL INFORMATION](#i2766d4fb64774af4ad63e2d95e6a0c82_13) | [PART I – FINANCIAL INFORMATION](#i2766d4fb64774af4ad63e2d95e6a0c82_13) |  |
| [Item 1.](#i2766d4fb64774af4ad63e2d95e6a0c82_16) | [FINANCIAL STATEMENTS (UNAUDITED)](#i2766d4fb64774af4ad63e2d95e6a0c82_16) |  |
|  | [Consolidated Balance Sheets as of](#i2766d4fb64774af4ad63e2d95e6a0c82_19)June 30, 2025 and December 31, 2024............................................................. | [1](#i2766d4fb64774af4ad63e2d95e6a0c82_13) |
|  | Consolidated Financial Statements for the Three and Six Months Ended June 30, 2025 and 2024: |  |
|  | [Consolidated Statements of Operations](#i2766d4fb64774af4ad63e2d95e6a0c82_22)................................................................................................................... | [2](#i2766d4fb64774af4ad63e2d95e6a0c82_22) |
|  | [Consolidated Statements of Comprehensive Income](#i2766d4fb64774af4ad63e2d95e6a0c82_25)............................................................................................ | [3](#i2766d4fb64774af4ad63e2d95e6a0c82_25) |
|  | [Consolidated Statements of Changes in Stockholders' Equity and Noncontrolling Interests](#i2766d4fb64774af4ad63e2d95e6a0c82_28).......................... | [4](#i2766d4fb64774af4ad63e2d95e6a0c82_28) |
|  | [Consolidated Statements of Cash Flows](#i2766d4fb64774af4ad63e2d95e6a0c82_34) for the Six Months Ended June 30, 2025 and 2024................................ | [8](#i2766d4fb64774af4ad63e2d95e6a0c82_34) |
|  | [Notes to Consolidated Financial Statements](#i2766d4fb64774af4ad63e2d95e6a0c82_37).................................................................................................................... | [10](#i2766d4fb64774af4ad63e2d95e6a0c82_37) |
| [Item 2.](#i2766d4fb64774af4ad63e2d95e6a0c82_190) | [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF](#i2766d4fb64774af4ad63e2d95e6a0c82_190)<br>[OPERATIONS](#i2766d4fb64774af4ad63e2d95e6a0c82_190)........................................................................................................................................................................<br>| [46](#i2766d4fb64774af4ad63e2d95e6a0c82_190) |
| [Item 3.](#i2766d4fb64774af4ad63e2d95e6a0c82_385) | [QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#i2766d4fb64774af4ad63e2d95e6a0c82_385)......................................................... | [119](#i2766d4fb64774af4ad63e2d95e6a0c82_385) |
| [Item 4.](#i2766d4fb64774af4ad63e2d95e6a0c82_388) | [CONTROLS AND PROCEDURES](#i2766d4fb64774af4ad63e2d95e6a0c82_388)..................................................................................................................................... | [120](#i2766d4fb64774af4ad63e2d95e6a0c82_388) |
| [PART II – OTHER INFORMATION](#i2766d4fb64774af4ad63e2d95e6a0c82_391) | [PART II – OTHER INFORMATION](#i2766d4fb64774af4ad63e2d95e6a0c82_391) |  |
| [Item 1.](#i2766d4fb64774af4ad63e2d95e6a0c82_394) | [LEGAL PROCEEDINGS](#i2766d4fb64774af4ad63e2d95e6a0c82_394)...................................................................................................................................................... | [121](#i2766d4fb64774af4ad63e2d95e6a0c82_394) |
| [Item 1A.](#i2766d4fb64774af4ad63e2d95e6a0c82_397) | [RISK FACTORS](#i2766d4fb64774af4ad63e2d95e6a0c82_397).................................................................................................................................................................... | [122](#i2766d4fb64774af4ad63e2d95e6a0c82_397) |
| [Item 2.](#i2766d4fb64774af4ad63e2d95e6a0c82_3496) | [UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#i2766d4fb64774af4ad63e2d95e6a0c82_3496)................................................... | [125](#i2766d4fb64774af4ad63e2d95e6a0c82_3496) |
| [Item 5.](#i2766d4fb64774af4ad63e2d95e6a0c82_400) | [OTHER INFORMATION](#i2766d4fb64774af4ad63e2d95e6a0c82_400)....................................................................................................................................................... | [125](#i2766d4fb64774af4ad63e2d95e6a0c82_400) |
| [Item 6.](#i2766d4fb64774af4ad63e2d95e6a0c82_403) | [EXHIBITS](#i2766d4fb64774af4ad63e2d95e6a0c82_403)............................................................................................................................................................................... | [126](#i2766d4fb64774af4ad63e2d95e6a0c82_403) |
| [SIGNATURES](#i2766d4fb64774af4ad63e2d95e6a0c82_406)................................................................................................................................................................................................. | [SIGNATURES](#i2766d4fb64774af4ad63e2d95e6a0c82_406)................................................................................................................................................................................................. | [127](#i2766d4fb64774af4ad63e2d95e6a0c82_406) |

---

ii

**GLOSSARY**

The following abbreviations or acronyms that may be used in this document

shall have the adjacent meanings set forth below:

---

| | |
|:---|:---|
| ASU | Accounting Standards Update |
| ATM | At the Market  |
| CIP | Construction in Progress |
| EPS | Earnings per Share |
| FASB | Financial Accounting Standards Board |
| FFO | Funds From Operations |
| GAAP | U.S. Generally Accepted Accounting Principles |
| IRS | Internal Revenue Service |
| JV | Joint Venture |
| Nareit | National Association of Real Estate Investment Trusts |
| NAV | Net Asset Value |
| NYSE | New York Stock Exchange |
| REIT | Real Estate Investment Trust |
| RSF | Rentable Square Feet/Foot |
| SEC | Securities and Exchange Commission |
| SF | Square Feet/Foot |
| SoDo | South of Downtown submarket of Seattle |
| SOFR | Secured Overnight Financing Rate |
| SoMa | South of Market submarket of the San Francisco Bay Area |
| U.S. | United States |
| VIE | Variable Interest Entity |

---

![](are-20250630_g1.gif)

**PART I – FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)**

**Alexandria Real Estate Equities, Inc.**

**Consolidated Balance Sheets** 

*(In thousands)*

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
|  | *(Unaudited)* |  |
| Assets |  |  |
| Investments in real estate | $32160600 | $32110039 |
| Investments in unconsolidated real estate joint ventures | 40234 | 39873 |
| Cash and cash equivalents | 520545 | 552146 |
| Restricted cash | 7403 | 7701 |
| Tenant receivables | 6267 | 6409 |
| Deferred rent | 1232719 | 1187031 |
| Deferred leasing costs  | 491074 | 485959 |
| Investments | 1476696 | 1476985 |
| Other assets  | 1688091 | 1661306 |
| Total assets | $37623629 | $37527449 |
| Liabilities, Noncontrolling Interests, and Equity |  |  |
| Secured notes payable  | $153500 | $149909 |
| Unsecured senior notes payable  | 12042607 | 12094465 |
| Unsecured senior line of credit and commercial paper | 1097993 |  |
| Accounts payable, accrued expenses, and other liabilities | 2360840 | 2654351 |
| Dividends payable | 229686 | 230263 |
| Total liabilities | 15884626 | 15128988 |
| Commitments and contingencies |  |  |
| Redeemable noncontrolling interests | 9612 | 19972 |
| Alexandria Real Estate Equities, Inc.'s stockholders' equity: |  |  |
| Common stock | 1701 | 1722 |
| Additional paid-in capital | 17200949 | 17933572 |
| Accumulated other comprehensive loss | (27415) | (46252) |
| Alexandria Real Estate Equities, Inc.'s stockholders' equity | 17175235 | 17889042 |
| Noncontrolling interests | 4554156 | 4489447 |
| Total equity | 21729391 | 22378489 |
| Total liabilities, noncontrolling interests, and equity | $37623629 | $37527449 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g1.gif)

**Alexandria Real Estate Equities, Inc.**

**Consolidated Statements of Operations**

*(In thousands, except per share amounts)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Revenues: |  |  |  |  |
| Income from rentals | $737279 | $755162 | $1480454 | $1510713 |
| Other income | 24761 | 11572 | 39744 | 25129 |
| Total revenues | 762040 | 766734 | 1520198 | 1535842 |
| Expenses: |  |  |  |  |
| Rental operations | 224433 | 217254 | 450828 | 435568 |
| General and administrative | 29128 | 44629 | 59803 | 91684 |
| Interest | 55296 | 45789 | 106172 | 86629 |
| Depreciation and amortization | 346123 | 290720 | 688185 | 578274 |
| Impairment of real estate | 129606 | 30763 | 161760 | 30763 |
| Total expenses | 784586 | 629155 | 1466748 | 1222918 |
| Equity in (losses) earnings of unconsolidated real estate joint <br>ventures<br>| (9021) | 130 | (9528) | 285 |
| Investment loss | (30622) | (43660) | (80614) | (376) |
| Gain on sales of real estate |  |  | 13165 | 392 |
| Net (loss) income | (62189) | 94049 | (23527) | 313225 |
| Net income attributable to noncontrolling interests | (44813) | (47347) | (92414) | (95978) |
| Net (loss) income attributable to Alexandria Real Estate Equities, <br>Inc.'s stockholders<br>| (107002) | 46702 | (115941) | 217247 |
| Net income attributable to unvested restricted stock awards | (2609) | (3785) | (5269) | (7444) |
| Net (loss) income attributable to Alexandria Real Estate Equities, <br>Inc.'s common stockholders<br>| $(109611) | $42917 | $(121210) | $209803 |
| Net (loss) income per share attributable to Alexandria Real Estate <br>Equities, Inc.'s common stockholders:<br>|  |  |  |  |
| Basic | $(0.64) | $0.25 | $(0.71) | $1.22 |
| Diluted | $(0.64) | $0.25 | $(0.71) | $1.22 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g1.gif)

**Alexandria Real Estate Equities, Inc.**

**Consolidated Statements of Comprehensive Income**

*(In thousands)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income | $(62189) | $94049 | $(23527) | $313225 |
| Other comprehensive income (loss) |  |  |  |  |
| Unrealized gains (losses) on foreign currency <br>translation:<br>|  |  |  |  |
| Unrealized foreign currency translation gains <br>(losses) arising during the period<br>| 18787 | (3895) | 18837 | (11814) |
| Unrealized gains (losses) on foreign currency <br>translation, net<br>| 18787 | (3895) | 18837 | (11814) |
| Total other comprehensive income (loss) | 18787 | (3895) | 18837 | (11814) |
| Comprehensive (loss) income | (43402) | 90154 | (4690) | 301411 |
| Less: comprehensive income attributable to <br>noncontrolling interests<br>| (44813) | (47347) | (92414) | (95978) |
| Comprehensive (loss) income attributable to Alexandria <br>Real Estate Equities, Inc.'s stockholders<br>| $(88215) | $42807 | $(97104) | $205433 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g2.gif)

**Alexandria Real Estate Equities, Inc.**

**Consolidated Statement of Changes in Stockholders' Equity and Noncontrolling Interests**

*(Dollars in thousands)*

*(Unaudited)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | | | |
|  | Number of<br>Common<br>Shares<br>| Common<br>Stock<br>| Additional<br>Paid-In <br>Capital<br>| Retained<br>Earnings<br>| Accumulated <br>Other <br>Comprehensive <br>Loss<br>| <br>Noncontrolling<br>Interests<br>| <br>Total<br>Equity<br>| <br>Redeemable<br>Noncontrolling<br>Interests<br>|
| Balance as of March 31, 2025 | 170129883 | $1701 | $17509148 | $— | $(46202) | $4525299 | $21989946 | $9612 |
| Net (loss) income |  |  |  | (107002) |  | 44612 | (62390) | 201 |
| Total other comprehensive income |  |  |  |  | 18787 |  | 18787 |  |
| Contributions from and sales of noncontrolling interests |  |  | 19 |  |  | 41628 | 41647 |  |
| Distributions to and redemption of noncontrolling interests |  |  |  |  |  | (57383) | (57383) | (201) |
| Issuance pursuant to stock plan | 25786 |  | 27776 |  |  |  | 27776 |  |
| Taxes related to net settlement of equity awards | (9600) |  | (693) |  |  |  | (693) |  |
| Repurchase of common stock |  |  |  |  |  |  |  |  |
| Dividends declared on common stock ($1.32 per share) |  |  |  | (228299) |  |  | (228299) |  |
| Reclassification of distributions and net loss |  |  | (335301) | 335301 |  |  |  |  |
| Balance as of June 30, 2025 | 170146069 | $1701 | $17200949 | $— | $(27415) | $4554156 | $21729391 | $9612 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g2.gif)

**Alexandria Real Estate Equities, Inc.**

**Consolidated Statement of Changes in Stockholders' Equity and Noncontrolling Interests**

*(Dollars in thousands)*

*(Unaudited)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | | | |
|  | Number of<br>Common<br>Shares<br>| Common<br>Stock<br>| Additional<br>Paid-In <br>Capital<br>| Retained<br>Earnings<br>| Accumulated <br>Other <br>Comprehensive <br>Loss<br>| <br>Noncontrolling<br>Interests<br>| <br>Total<br>Equity<br>| <br>Redeemable<br>Noncontrolling<br>Interests<br>|
| Balance as of March 31, 2024 | 172007967 | $1720 | $18434690 | $— | $(23815) | $4326703 | $22739298 | $16620 |
| Net income |  |  |  | 46702 |  | 47076 | 93778 | 271 |
| Total other comprehensive loss |  |  |  |  | (3895) |  | (3895) |  |
| Contributions from and sales of noncontrolling interests |  |  | 499 |  |  | 77907 | 78406 |  |
| Distributions to and redemption of noncontrolling interests  |  |  | (14) |  |  | (59880) | (59894) | (451) |
| Issuance pursuant to stock plan | 14394 |  | 30691 |  |  |  | 30691 |  |
| Taxes related to net settlement of equity awards | (4687) |  | (549) |  |  |  | (549) |  |
| Dividends declared on common stock ($1.30 per share) |  |  |  | (227408) |  |  | (227408) |  |
| Reclassification of distributions in excess of earnings |  |  | (180706) | 180706 |  |  |  |  |
| Balance as of June 30, 2024 | 172017674 | $1720 | $18284611 | $— | $(27710) | $4391806 | $22650427 | $16440 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g2.gif)

**Alexandria Real Estate Equities, Inc.**

**Consolidated Statement of Changes in Stockholders' Equity and Noncontrolling Interests**

*(Dollars in thousands)*

*(Unaudited)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | | | |
|  | Number of<br>Common<br>Shares<br>| Common<br>Stock<br>| Additional<br>Paid-In <br>Capital<br>| Retained<br>Earnings<br>| Accumulated <br>Other <br>Comprehensive <br>Loss<br>| <br>Noncontrolling<br>Interests<br>| <br>Total<br>Equity<br>| <br>Redeemable<br>Noncontrolling<br>Interests<br>|
| Balance as of December 31, 2024 | 172203443 | $1722 | $17933572 | $— | $(46252) | $4489447 | $22378489 | $19972 |
| Net (loss) income |  |  |  | (115941) |  | 91943 | (23998) | 471 |
| Total other comprehensive income |  |  |  |  | 18837 |  | 18837 |  |
| Contributions from and sales of noncontrolling interests |  |  | 73 |  |  | 95982 | 96055 |  |
| Distributions to and redemption of noncontrolling interests |  |  | (7048) |  |  | (123216) | (130264) | (10831) |
| Issuance pursuant to stock plan | 151066 | 1 | 60531 |  |  |  | 60532 |  |
| Taxes related to net settlement of equity awards | (56147) |  | (5428) |  |  |  | (5428) |  |
| Repurchase of common stock | (2152293) | (22) | (208165) |  |  |  | (208187) |  |
| Dividends declared on common stock ($2.64 per share) |  |  |  | (456645) |  |  | (456645) |  |
| Reclassification of distributions and net loss |  |  | (572586) | 572586 |  |  |  |  |
| Balance as of June 30, 2025 | 170146069 | $1701 | $17200949 | $— | $(27415) | $4554156 | $21729391 | $9612 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g2.gif)

**Alexandria Real Estate Equities, Inc.**

**Consolidated Statement of Changes in Stockholders' Equity and Noncontrolling Interests**

*(Dollars in thousands)*

*(Unaudited)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | Alexandria Real Estate Equities, Inc.'s Stockholders' Equity | | | |
|  | Number of<br>Common<br>Shares<br>| Common<br>Stock<br>| Additional<br>Paid-In <br>Capital<br>| Retained<br>Earnings<br>| Accumulated <br>Other <br>Comprehensive <br>Loss<br>| <br>Noncontrolling<br>Interests<br>| <br>Total<br>Equity<br>| <br>Redeemable<br>Noncontrolling<br>Interests<br>|
| Balance as of December 31, 2023 | 171910599 | $1719 | $18485352 | $— | $(15896) | $4135338 | $22606513 | $16480 |
| Net income |  |  |  | 217247 |  | 95435 | 312682 | 543 |
| Total other comprehensive loss |  |  |  |  | (11814) |  | (11814) |  |
| Contributions from and sales of noncontrolling interests |  |  | 7700 |  |  | 258885 | 266585 |  |
| Distributions to and redemption of noncontrolling interests  |  |  | (8084) |  |  | (127787) | (135871) | (833) |
| Transfer of noncontrolling interests |  |  |  |  |  | (250) | (250) | 250 |
| Reallocation of capital to joint venture partner |  |  | (30185) |  |  | 30185 |  |  |
| Issuance pursuant to stock plan | 179178 | 2 | 70067 |  |  |  | 70069 |  |
| Taxes related to net settlement of equity awards | (72103) | (1) | (7944) |  |  |  | (7945) |  |
| Dividends declared on common stock ($2.57 per share) |  |  |  | (449542) |  |  | (449542) |  |
| Reclassification of distributions in excess of earnings |  |  | (232295) | 232295 |  |  |  |  |
| Balance as of June 30, 2024 | 172017674 | $1720 | $18284611 | $— | $(27710) | $4391806 | $22650427 | $16440 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g1.gif)

---

| | | |
|:---|:---|:---|
| **Alexandria Real Estate Equities, Inc.**<br>**Consolidated Statements of Cash Flows**<br>*(In thousands)*<br>*(Unaudited)* | **Alexandria Real Estate Equities, Inc.**<br>**Consolidated Statements of Cash Flows**<br>*(In thousands)*<br>*(Unaudited)* | **Alexandria Real Estate Equities, Inc.**<br>**Consolidated Statements of Cash Flows**<br>*(In thousands)*<br>*(Unaudited)* |
|  | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 |
| Operating Activities: |  |  |
| Net (loss) income | $(23527) | $313225 |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 688185 | 578274 |
| Impairment of real estate | 161760 | 30763 |
| Gain on sales of real estate | (13165) | (392) |
| Equity in losses (earnings) of unconsolidated real estate joint ventures | 9528 | (285) |
| Distributions of earnings from unconsolidated real estate joint ventures | 1289 | 1652 |
| Amortization of loan fees | 9306 | 8288 |
| Amortization of debt discounts | 684 | 646 |
| Amortization of acquired above- and below-market leases | (25418) | (52855) |
| Deferred rent | (40559) | (96589) |
| Stock compensation expense | 22594 | 31632 |
| Investment loss | 80614 | 376 |
| Changes in operating assets and liabilities: |  |  |
| Tenant receivables | 168 | 1373 |
| Deferred leasing costs | (43727) | (54560) |
| Other assets | (10750) | (3046) |
| Accounts payable, accrued expenses, and other liabilities | (148792) | (5548) |
| Net cash provided by operating activities | 668190 | 752954 |
| Investing Activities: |  |  |
| Proceeds from sales of real estate | 149027 | 16670 |
| Additions to real estate | (1081006) | (1241214) |
| Purchases of real estate  |  | (201049) |
| Change in escrow deposits | (8108) | (2473) |
| Investments in unconsolidated real estate joint ventures | (11055) | (3713) |
| Additions to non-real estate investments | (120645) | (122708) |
| Sales of and distributions from non-real estate investments | 42134 | 86008 |
| Net cash used in investing activities | $(1029653) | $(1468479) |

---

![](are-20250630_g1.gif)

---

| | | |
|:---|:---|:---|
| **Alexandria Real Estate Equities, Inc.**<br>**Consolidated Statements of Cash Flows**<br>*(In thousands)*<br>*(Unaudited)* | **Alexandria Real Estate Equities, Inc.**<br>**Consolidated Statements of Cash Flows**<br>*(In thousands)*<br>*(Unaudited)* | **Alexandria Real Estate Equities, Inc.**<br>**Consolidated Statements of Cash Flows**<br>*(In thousands)*<br>*(Unaudited)* |
|  | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 |
| Financing Activities: |  |  |
| Borrowings under secured note payable | $4029 | $14974 |
| Proceeds from issuance of unsecured senior notes payable | 548532 | 998806 |
| Repayment of unsecured senior notes payable | (600000) |  |
| Proceeds from issuances under commercial paper program | 8468015 | 5006950 |
| Repayments of borrowings under commercial paper program | (7368015) | (4906950) |
| Payments of loan fees | (5406) | (10118) |
| Taxes paid related to net settlement of equity awards | (6271) | (27017) |
| Repurchase of common stock | (208187) |  |
| Dividends on common stock | (457217) | (443958) |
| Contributions from and sales of noncontrolling interests  | 96055 | 159644 |
| Distributions to and purchases of noncontrolling interests | (141436) | (171871) |
| Net cash provided by financing activities | 330099 | 620460 |
| Effect of foreign exchange rate changes on cash and cash equivalents | (535) | 147 |
| Net decrease in cash, cash equivalents, and restricted cash | (31899) | (94918) |
| Cash, cash equivalents, and restricted cash as of the beginning of period | 559847 | 660771 |
| Cash, cash equivalents, and restricted cash as of the end of period | $527948 | $565853 |
| Supplemental Disclosure and Non-Cash Investing and Financing Activities: |  |  |
| Cash paid during the period for interest, net of interest capitalized | $87986 | $56878 |
| Accrued construction for current-period additions to real estate | $206036 | $402923 |
| Transfer of real estate assets and/or equipment from tenants | $171153 | $45719 |
| Notes receivable issued in connection with sales of real estate | $91000 | $— |
| Derecognition of net investment in real estate from sales-type lease | $4677 | $— |
| Contribution of assets from and issuance of noncontrolling interest to real estate joint <br>venture partner<br>| $— | $103547 |
| Reallocation of additional paid-in capital to consolidated joint venture partner's non-<br>controlling interest<br>| $— | $30185 |

---

The accompanying notes are an integral part of these consolidated financial statements.

![](are-20250630_g1.gif)

**Alexandria Real Estate Equities, Inc.**

**Notes to Consolidated Financial Statements**

*(Unaudited)*

**1. ORGANIZATION AND BASIS OF PRESENTATION**

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500<sup>®</sup> life science REIT, is the pioneer of the life science real estate

niche since its founding in 1994. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative

Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area,

San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2025, Alexandria has a total market capitalization

of$25.7 billionand an asset base in North America that includes39.7 million RSF of operating properties and 4.4 million RSF of Class

A/A+ properties undergoing construction and one100% pre-leasedcommitted near-term project expected to commence construction in

the next year. As used in this quarterly report on Form 10-Q, references to the "Company," "Alexandria," "ARE," "we," "us," and "our"

refer to Alexandria Real Estate Equities, Inc. and its consolidated subsidiaries. The accompanying unaudited consolidated financial

statements include the accounts of Alexandria Real Estate Equities, Inc. and its consolidated subsidiaries. All significant intercompany

balances and transactions have been eliminated.

We have prepared the accompanying interim consolidated financial statements in accordance with GAAP and in conformity

with the rules and regulations of the SEC. In our opinion, these interim consolidated financial statements presented herein reflect all

adjustments, of a normal recurring nature, that are necessary to fairly present the interim consolidated financial statements. The results

of operations for the interim period are not necessarily indicative of the results that may be expected for the year ending December 31,

2025. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial

statements and the notes thereto included in our annual report on Form 10-K for the year ended December 31, 2024. Any references to

our total market capitalization, number or quality of buildings or tenants, quality of location, square footage, number of leases, or

occupancy percentage, and any amounts derived from these values in these notes to consolidated financial statements are outside the

scope of our independent registered public accounting firm's procedures.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**<u>Consolidation</u>**

On an ongoing basis, as circumstances indicate the need for reconsideration, we evaluate each legal entity that is not wholly

owned by us in accordance with the consolidation accounting guidance. Our evaluation considers all of our variable interests, including

equity ownership, as well as fees paid to us for our involvement in the management of each partially owned entity. To fall within the

scope of the consolidation guidance, an entity must meet both of the following criteria:

• The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity

can be in the form of a partnership, limited liability company, or corporation, among others; and

• We have a variable interest in the legal entity — i.e., variable interests that are contractual, such as equity ownership, or

other financial interests that change with changes in the fair value of the entity's net assets.

If an entity does not meet both criteria above, we apply other accounting literature, such as the equity method of accounting. If

an entity does meet both criteria above, we evaluate such entity for consolidation under either the variable interest model if the legal

entity meets any of the characteristics below to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.

A legal entity is determined to be a VIE if it has any of the following three characteristics:

1)The entity does not have sufficient equity to finance its activities without additional subordinated financial support;

2)The entity is established with non-substantive voting rights (i.e., the entity deprives the majority economic interest

holder(s) of voting rights); or

3)The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion

if they lack any of the following:

• The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence

the entity's economic performance, as evidenced by:

• Substantive participating rights in day-to-day management of the entity's activities; or

• Substantive kick-out rights over the party responsible for significant decisions;

• The obligation to absorb the entity's expected losses; or

• The right to receive the entity's expected residual returns.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

For an entity, including our real estate joint ventures, structured as a limited partnership or a limited liability company, our

evaluation of whether the equity holders (equity partners other than the general partner or the managing member of a joint venture) lack

the characteristics of a controlling financial interest includes the evaluation of whether the limited partners or non-managing members

(the noncontrolling equity holders) lack both substantive participating rights and substantive kick-out rights, defined as follows:

• Participating rights provide the noncontrolling equity holders the ability to direct significant financial and operating

decisions made in the ordinary course of business that most significantly influence the entity's economic performance.

• Kick-out rights allow the noncontrolling equity holders to remove the general partner or managing member without cause.

If we conclude that any of the three characteristics of a VIE are met, including that the equity holders lack the characteristics of

a controlling financial interest because they lack both substantive participating rights and substantive kick-out rights, we conclude that

the entity is a VIE and evaluate it for consolidation under the variable interest model.

**Variable interest model**

If an entity is determined to be a VIE, we evaluate whether we are the primary beneficiary. The primary beneficiary analysis is

a qualitative analysis based on power and benefits. We consolidate a VIE if we have both power and benefits — that is, (i) we have the

power to direct the activities of a VIE that most significantly influence the VIE's economic performance (power) and (ii) we have the

obligation to absorb losses of or the right to receive benefits from the VIE that could potentially be significant to the VIE (benefits). We

consolidate VIEs whenever we determine that we are the primary beneficiary. Refer to Note 4 – "Consolidated and unconsolidated real

estate joint ventures" and Note 7 – "Investments" to our unaudited consolidated financial statements for information on specific entities

that qualify as VIEs. If we have a variable interest in a VIE but are not the primary beneficiary, we account for our investment using the

equity method.

**Voting model**

If a legal entity fails to meet any of the three characteristics of a VIE (i.e., insufficiency of equity, existence of non-substantive

voting rights, or lack of a controlling financial interest), we then evaluate such entity under the voting model. Under the voting model, we

consolidate the entity if we determine that we, directly or indirectly, have greater than 50% of the voting shares (or own a majority of the

limited partnership's kick-out rights through voting interests), and that other equity holders do not have substantive participating rights.

Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements for

information on specific joint ventures that qualify for evaluation under the voting model.

**<u>Use of estimates</u>**

The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions

that affect the reported amounts of assets, liabilities, and equity; the disclosure of contingent assets and liabilities as of the date of the

consolidated financial statements; and the amounts of revenues and expenses during the reporting period. Actual results could

materially differ from those estimates.

**<u>Investments in real estate</u>**

**Evaluation of business combination or asset acquisition**

We evaluate each acquisition of real estate or in-substance real estate (including equity interests in entities that predominantly

hold real estate assets) to determine whether the integrated set of assets and activities acquired meets the definition of a business and

needs to be accounted for as a business combination. An acquisition of an integrated set of assets and activities that does not meet the

definition of a business is accounted for as an asset acquisition. If either of the following criteria is met, the integrated set of assets and

activities acquired would not qualify as a business:

• Substantially all of the fair value of the gross assets acquired is concentrated in either a single identifiable asset or a group

of similar identifiable assets; or

• The integrated set of assets and activities is lacking, at a minimum, an input and a substantive process that together

significantly contribute to the ability to create outputs (i.e., revenue generated before and after the transaction).

An acquired process is considered substantive if:

• The process includes an organized workforce (or includes an acquired contract that provides access to an organized

workforce) that is skilled, knowledgeable, and experienced in performing the process;

• The process cannot be replaced without significant cost, effort, or delay; or

• The process is considered unique or scarce.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

Generally, our acquisitions of real estate or in-substance real estate do not meet the definition of a business because

substantially all of the fair value is concentrated in a single identifiable asset or group of similar identifiable assets (i.e., land, buildings,

and related intangible assets) or because the acquisition does not include a substantive process in the form of an acquired workforce or

an acquired contract that cannot be replaced without significant cost, effort, or delay. When evaluating acquired service or management

contracts, we consider the nature of the services performed, the terms of the contract relative to similar arm's-length contracts, and the

availability of comparable vendors in evaluating whether the acquired contract constitutes a substantive process.

**Recognition of real estate acquired**

We evaluate each acquisition of real estate or in-substance real estate (including equity interests in entities that predominantly

hold real estate assets) to determine whether the integrated set of assets and activities acquired meets the definition of a business and

needs to be accounted for as a business combination. An acquisition of an integrated set of assets and activities that does not meet the

definition of a business is accounted for as an asset acquisition.

For acquisitions of real estate or in-substance real estate that are accounted for as business combinations, we allocate the

acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, noncontrolling interests, and

previously existing ownership interests at fair value as of the acquisition date. Assets include intangible assets such as tenant

relationships, acquired in-place leases, and favorable intangibles associated with in-place leases in which we are the lessor. Liabilities

include unfavorable intangibles associated with in-place leases in which we are the lessor. In addition, for acquired in-place finance or

operating leases in which we are the lessee, acquisition consideration is allocated to lease liabilities and related right-of-use assets,

adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. Any excess (deficit) of the

consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill (bargain purchase gain).

Acquisition costs related to business combinations are expensed as incurred.

Generally, we expect that acquisitions of real estate or in-substance real estate will not meet the definition of a business

because substantially all of the fair value is concentrated in a single identifiable asset or group of similar identifiable assets (i.e., land,

buildings, and related intangible assets). The accounting model for asset acquisitions is similar to the accounting model for business

combinations, except that the acquisition consideration (including acquisition costs) is allocated to the individual assets acquired and

liabilities assumed on a relative fair value basis. Any excess (deficit) of the consideration transferred relative to the sum of the fair value

of the assets acquired and liabilities assumed is allocated to the individual assets and liabilities based on their relative fair values. As a

result, asset acquisitions do not result in the recognition of goodwill or a bargain purchase gain. Incremental and external direct

acquisition costs related to acquisitions of real estate or in-substance real estate (such as legal and other third-party services) are

capitalized.

We exercise judgment to determine the key assumptions used to allocate the purchase price of real estate acquired among its

components. The allocation of the consideration to the various components of properties acquired during the year can have an effect on

our net income due to the useful depreciable and amortizable lives applicable to each component and the recognition of the related

depreciation and amortization expense in our consolidated statements of operations. We apply judgment in utilizing available

comparable market information to assess relative fair value. We assess the relative fair values of tangible and intangible assets and

liabilities based on available comparable market information, including estimated replacement costs, rental rates, and recent market

transactions. In addition, we may use estimated cash flow projections that utilize appropriate discount and capitalization rates.

Estimates of future cash flows are based on a number of factors, including the historical operating results, known and anticipated

trends, and market/economic conditions that may affect the property.

The value of tangible assets acquired is based upon our estimation of fair value on an "as if vacant" basis. The value of

acquired in-place leases includes the estimated costs during the hypothetical lease-up period and other costs that would have been

incurred in the execution of similar leases under the market conditions at the acquisition date of the acquired in-place lease. If there is a

bargain fixed-rate renewal option for the period beyond the noncancelable lease term of an in-place lease, we evaluate intangible

factors, such as the business conditions in the industry in which the lessee operates, the economic conditions in the area in which the

property is located, and the ability of the lessee to sublease the property during the renewal term, in order to determine the likelihood

that the lessee will renew. When we determine that there is reasonable assurance that such bargain purchase option will be exercised,

we consider the option in determining the intangible value of such lease and its related amortization period. We also recognize the

relative fair values of assets acquired, the liabilities assumed, and any noncontrolling interest in acquisitions of less than a 100%

interest when the acquisition constitutes a change in control of the acquired entity.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**Depreciation and amortization**

The values allocated to buildings and building improvements, land improvements, tenant improvements, and equipment are

depreciated on a straight-line basis. For buildings and building improvements, we depreciate using the shorter of the respective ground

lease terms or their estimated useful lives, not to exceed40 years. Land improvements are depreciated over their estimated useful

lives, not to exceed 20 years. Tenant improvements are depreciated over their respective lease terms or estimated useful lives, and

equipment is depreciated over the shorter of the lease term or its estimated useful life. The values of the right-of-use assets are

amortized on a straight-line basis over the remaining terms of each related lease. The values of acquired in-place leases and

associated favorable intangibles (i.e., acquired above-market leases) are classified in other assets in our consolidated balance sheets

and are amortized over the remaining terms of the related leases as a reduction of income from rentals in our consolidated statements

of operations. The values of unfavorable intangibles (i.e., acquired below-market leases) associated with acquired in-place leases are

classified in accounts payable, accrued expenses, and other liabilities in our consolidated balance sheets and are amortized over the

remaining terms of the related leases as an increase in income from rentals in our consolidated statements of operations.

**Capitalized project costs**

We capitalize project costs, including pre-construction costs, interest, property taxes, insurance, and other costs directly

related and essential to the development, redevelopment, pre-construction, or construction of a project. Capitalization of development,

redevelopment, pre-construction, and construction costs is required while activities are ongoing to prepare an asset for its intended use.

Fluctuations in our development, redevelopment, pre-construction, and construction activities could result in significant changes to total

expenses and net income. Costs incurred after a project is substantially complete and ready for its intended use are expensed as

incurred. Should development, redevelopment, pre-construction, or construction activity cease, interest, property taxes, insurance, and

certain other costs would no longer be eligible for capitalization and would be expensed as incurred. Expenditures for repairs and

maintenance are expensed as incurred.

**Real estate sales**

A property is classified as held for sale when all of the following criteria for a plan of sale have been met: (i) management,

having the authority to approve the action, commits to a plan to sell the property; (ii) the property is available for immediate sale in its

present condition, subject only to terms that are usual and customary; (iii) an active program to locate a buyer and other actions

required to complete the plan to sell have been initiated; (iv) the sale of the property is probable and is expected to be completed within

one year; (v) the property is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and

(vi) actions necessary to complete the plan of sale indicate that it is unlikely that significant changes to the plan will be made or that the

plan will be withdrawn. Depreciation of assets ceases upon designation of a property as held for sale.

If the disposal of a property represents a strategic shift that has (or will have) a major effect on our operations or financial

results, such as (i) a major line of business, (ii) a major geographic area, (iii) a major equity method investment, or (iv) other major parts

of an entity, then the operations of the property, including any interest expense directly attributable to it, are classified as discontinued

operations in our consolidated statements of operations, and amounts for all prior periods presented are reclassified from continuing

operations to discontinued operations. The disposal of an individual property generally will not represent a strategic shift and therefore

will typically not meet the criteria for classification as a discontinued operation.

We recognize gains or losses on real estate sales in accordance with the accounting standard on the derecognition of

nonfinancial assets arising from contracts with noncustomers. Our ordinary output activities consist of the leasing of space to our

tenants in our operating properties, not the sales of real estate. Therefore, sales of real estate (in which we are the seller) qualify as

contracts with noncustomers. In our transactions with noncustomers, we apply certain recognition and measurement principles

consistent with our method of recognizing revenue arising from contracts with customers. Derecognition of the asset is based on the

transfer of control. If a real estate sales contract includes our ongoing involvement with the property, then we evaluate each promised

good or service under the contract to determine whether it represents a separate performance obligation, constitutes a guarantee, or

prevents the transfer of control. If a good or service is considered a separate performance obligation, an allocated portion of the

transaction price is recognized as revenue as we transfer the related good or service to the buyer.

The recognition of gain or loss on the sale of a partial interest also depends on whether we retain a controlling or

noncontrolling interest in the property. If we retain a controlling interest in the property upon completion of the sale, we continue to

reflect the asset at its book value, record a noncontrolling interest for the book value of the partial interest sold, and recognize additional

paid-in capital for the difference between the consideration received and the partial interest at book value. Conversely, if we retain a

noncontrolling interest upon completion of the sale of a partial interest of real estate, we recognize a gain or loss as if 100% of the asset

were sold.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**<u>Impairment of long-lived assets</u>**

Prior to and subsequent to the end of each quarter, we review current activities and changes in the business conditions of all of

our long-lived assets to determine the existence of any triggering events or impairment indicators requiring an impairment analysis. If

triggering events or impairment indicators are identified, we review an estimate of the future undiscounted cash flows, including, if

necessary, a probability-weighted approach if multiple outcomes are under consideration.

Long-lived assets to be held and used, including our rental properties, CIP, land held for development, right-of-use assets

related to operating leases in which we are the lessee, and intangibles, are individually evaluated for impairment when conditions exist

that may indicate that the carrying amount of a long-lived asset may not be recoverable. The carrying amount of a long-lived asset to be

held and used is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual

disposition of the asset. Triggering events or impairment indicators for long-lived assets to be held and used are assessed by project

and include significant fluctuations in estimated net operating income, occupancy changes, significant near-term lease expirations,

current and historical operating and/or cash flow losses, construction costs, estimated completion dates, rental rates, and other market

factors. We assess the expected undiscounted cash flows based upon numerous factors, including, but not limited to, projected rental

rates, estimated exit capitalization rates, and anticipated construction costs for projects under construction, which are based on

available market information, current and historical operating results, known trends, current market/economic conditions that may affect

the asset, and our assumptions about the use of the asset, including, if necessary, a probability-weighted approach if multiple outcomes

are under consideration.

Upon determination that an impairment has occurred, a write-down is recognized to reduce the carrying amount of the asset to

its estimated fair value. If an impairment charge is not required to be recognized, the recognition of depreciation or amortization is

adjusted prospectively, as necessary, to reduce the carrying amount of the asset to its estimated disposition value over the remaining

period that the asset is expected to be held and used. We may adjust depreciation of properties that are expected to be disposed of or

redeveloped prior to the end of their useful lives.

We use the held for sale impairment model for our properties classified as held for sale, which is different from the held and

used impairment model. Under the held for sale impairment model, an impairment charge is recognized if the carrying amount of the

long-lived asset classified as held for sale exceeds its fair value less cost to sell. Because of these two different models, it is possible for

a long-lived asset previously classified as held and used to require the recognition of an impairment charge upon classification as held

for sale.

**<u>International operations</u>**

In addition to operating properties in the U.S., we have11 properties in Canada. The functional currency for our subsidiaries

operating in the U.S. is the U.S. dollar. The local currency of a foreign subsidiary serves as its functional currency. The assets and

liabilities of our foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect as of the financial statement date.

Revenue and expense accounts of our foreign subsidiaries are translated using the weighted-average exchange rate for the periods

presented. Gains or losses resulting from the translation are classified in accumulated other comprehensive income (loss) as a

separate component of total equity and are excluded from net income (loss).

Whenever a foreign investment meets the criteria for classification as held for sale, we evaluate the recoverability of the

investment under the held for sale impairment model. We may recognize an impairment charge if the carrying amount of the investment

exceeds its fair value less cost to sell. In determining an investment's carrying amount, we consider its net book value and any

cumulative unrealized foreign currency translation adjustment related to the investment.

The appropriate amounts of foreign exchange rate gains or losses classified in accumulated other comprehensive income

(loss) are reclassified to net income (loss) when realized upon the sale of our investment or upon the complete or substantially

complete liquidation of our investment.

**<u>Investments</u>**

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. As a

REIT, we generally limit our ownership of each individual entity's voting stock to less than 10%. We evaluate each investment to

determine whether we have the ability to exercise significant influence, but not control, over an investee. We evaluate investments in

which our ownership is equal to or greater than 20%, but less than or equal to 50%, of an investee's voting stock with a presumption

that we have this ability. For our investments in limited partnerships that maintain specific ownership accounts, we presume that such

ability exists when our ownership interest exceeds 3% to 5%. In addition to our ownership interest, we consider whether we have a

board seat or whether we participate in the investee's policymaking process, among other criteria, to determine if we have the ability to

exert significant influence, but not control, over an investee. If we determine that we have such ability, we account for the investment

under the equity method, as described below. From time to time, we may hold equity investments in publicly traded companies that are

subject to temporary contractual sale restrictions. We do not recognize a discount related to a contractual sale restriction.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**Investments accounted for under the equity method** 

Under the equity method of accounting, we initially recognize our investment at cost and subsequently adjust the carrying

amount of the investment for our share of earnings or losses reported by the investee, distributions received, and other-than-temporary

impairments. For additional information about our investments accounted for under the equity method, refer to Note 7 – "Investments" to

our unaudited consolidated financial statements.

**Investments that do not qualify for the equity method of accounting**

For investees over which we determine that we do not have the ability to exercise significant influence or control, we account

for each investment depending on whether it is an investment in a (i) publicly traded company, (ii) privately held entity that reports NAV

per share, or (iii) privately held entity that does not report NAV per share, as described below.

*Investments in publicly traded companies*

Our investments in publicly traded companies are classified as investments with readily determinable fair values and are

presented at fair value in our consolidated balance sheets, with changes in fair value classified in investment income (loss) in our

consolidated statements of operations. The fair values for our investments in publicly traded companies are determined based on sales

prices or quotes available on securities exchanges.

*Investments in privately held companies*

Our investments in privately held entities without readily determinable fair values consist of (i) investments in privately held

entities that report NAV per share and (ii) investments in privately held entities that do not report NAV per share. These investments are

accounted for as follows:

<u>Investments in privately held entities that report NAV per share</u>

Investments in privately held entities that report NAV per share, such as our privately held investments in limited partnerships,

are presented at fair value using NAV as a practical expedient, with changes in fair value classified in investment income (loss) in our

consolidated statements of operations. We use NAV per share reported by limited partnerships generally without adjustment, unless we

are aware of information indicating that the NAV reported by a limited partnership does not accurately reflect the fair value of the

investment at our reporting date.

<u>Investments in privately held entities that do not report NAV per share</u>

Investments in privately held entities that do not report NAV per share are accounted for using a measurement alternative

under which these investments are measured at cost, adjusted for observable price changes and impairments, with changes classified

in investment income (loss) in our consolidated statements of operations.

An observable price arises from an orderly transaction for an identical or similar investment of the same issuer, which is

observed by an investor without expending undue cost and effort. Observable price changes result from, among other things, equity

transactions of the same issuer executed during the reporting period, including subsequent equity offerings or other reported equity

transactions related to the same issuer. To determine whether these transactions are indicative of an observable price change, we

evaluate, among other factors, whether these transactions have similar rights and obligations, including voting rights, distribution

preferences, and conversion rights to the investments we hold.

**Impairment evaluation of equity method investments and investments in privately held entities that do not report NAV per share**

We monitor equity method investments and investments in privately held entities that do not report NAV per share for new

developments, including operating results, prospects and results of clinical trials, new product initiatives, new collaborative agreements,

capital-raising events, and merger and acquisition activities. These investments are evaluated on the basis of a qualitative assessment

for indicators of impairment by monitoring the presence of the following triggering events or impairment indicators:

(i)a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee;

(ii)a significant adverse change in the regulatory, economic, or technological environment of the investee;

(iii)a significant adverse change in the general market condition, including the research and development of technology and

products that the investee is bringing or attempting to bring to the market;

(iv)significant concerns about the investee's ability to continue as a going concern; and/or

(v)a decision by investors to cease providing support or reduce their financial commitment to the investee.

If such indicators are present, we are required to estimate the investment's fair value and immediately recognize an

impairment charge in an amount equal to the investment's carrying value in excess of its estimated fair value.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**Investment income/loss recognition and classification** 

We recognize both realized and unrealized gains and losses in our consolidated statements of operations, classified in

investment income (loss) in our consolidated statements of operations. Unrealized gains and losses represent:

(i)changes in fair value for investments in publicly traded companies;

(ii)changes in NAV for investments in privately held entities that report NAV per share;

(iii)observable price changes for investments in privately held entities that do not report NAV per share; and

(iv)our share of unrealized gains or losses reported by our equity method investees.

Realized gains and losses on our investments represent the difference between proceeds received upon disposition of

investments and their historical or adjusted cost basis. For our equity method investments, realized gains and losses represent our

share of realized gains or losses reported by the investee. Impairments are realized losses, which result in an adjusted cost basis, and

represent charges to reduce the carrying values of investments in privately held entities that do not report NAV per share and equity

method investments, if impairments are deemed other than temporary, to their estimated fair value.

**<u>Revenues</u>**

The table below provides details of our consolidated total revenues for the three and six months ended June 30, 2025 and

2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Income from rentals: |  |  |  |  |
| Revenues subject to the lease accounting standard: |  |  |  |  |
| Operating leases | $722935 | $745626 | $1454356 | $1491687 |
| Direct financing and sales-type leases | 1089 | 662 | 1899 | 1321 |
| Revenues subject to the lease accounting standard | 724024 | 746288 | 1456255 | 1493008 |
| Revenues subject to the revenue recognition <br>accounting standard<br>| 13255 | 8874 | 24199 | 17705 |
| Income from rentals | 737279 | 755162 | 1480454 | 1510713 |
| Other income | 24761 | 11572 | 39744 | 25129 |
| Total revenues | $762040 | $766734 | $1520198 | $1535842 |

---

During the three and six months ended June 30, 2025, revenues that were subject to the lease accounting standard

aggregated $724.0 million and $1.5 billion, respectively, and represented95.0% and 95.8% of our total revenues. During the three and

six months ended June 30, 2024, revenues that were subject to the lease accounting standard aggregated $746.3 million and

$1.5 billion, respectively, and represented97.3% and 97.2% of our total revenues. Our other income consisted primarily of management

fees and interest income earned during each period presented. For a detailed discussion related to our revenue streams, refer to

"Lease accounting" and "Recognition of revenue arising from contracts with customers" in Note 2 – "Summary of significant accounting

policies" to our unaudited consolidated financial statements.

**<u>Lease accounting</u>**

**Definition and classification of a lease**

When we enter into a contract or amend an existing contract, we evaluate whether the contract meets the definition of a lease.

To meet the definition of a lease, the contract must meet all three criteria:

(i)One party (lessor) must hold an identified asset;

(ii)The counterparty (lessee) must have the right to obtain substantially all of the economic benefits from the use of the asset

throughout the period of the contract; and

(iii)The counterparty (lessee) must have the right to direct the use of the identified asset throughout the period of the contract.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

We classify our leases as either finance leases or operating leases if we are the lessee, or sales-type, direct financing, or

operating leases if we are the lessor. We use the following criteria to determine if a lease is a finance lease (as a lessee) or sales-type

or direct financing lease (as a lessor):

(i)Ownership is transferred from lessor to lessee by the end of the lease term;

(ii)An option to purchase is reasonably certain to be exercised;

(iii)The lease term is for the major part of the underlying asset's remaining economic life;

(iv)The present value of lease payments equals or exceeds substantially all of the fair value of the underlying asset; or

(v)The underlying asset is specialized and is expected to have no alternative use at the end of the lease term.

If we meet any of the above criteria, we account for the lease as a finance, a sales-type, or a direct financing lease. If we do

not meet any of the criteria, we account for the lease as an operating lease.

A lease is accounted for as a sales-type lease if it is considered to transfer control of the underlying asset to the lessee. A

lease is accounted for as a direct financing lease if risks and rewards are conveyed without the transfer of control, which is normally

indicated by the existence of a residual value guarantee from an unrelated third party other than the lessee.

This classification will determine the method of recognition of the lease:

• For an operating lease, we recognize income from rentals if we are the lessor, or rental operations expense if we are the

lessee, over the term of the lease on a straight-line basis.

• For a sales-type lease or a direct financing lease, we recognize the income from rentals, or for a finance lease, we

recognize rental operations expense, over the term of the lease using the effective interest method.

• At inception of a sales-type lease or a direct financing lease, if we determine the fair value of the leased property is lower

than its carrying amount, we recognize a selling loss immediately at lease commencement. If fair value exceeds the

carrying amount of a lease, a gain is recognized at lease commencement on a sales-type lease. For a direct financing

lease, a gain is deferred at lease commencement and amortized over the lease term.

**Lessor accounting**

*Costs to execute leases*

We capitalize initial direct costs, which represent only incremental costs to execute a lease that would not have been incurred

if the lease had not been obtained. Costs that we incur to negotiate or arrange a lease, regardless of its outcome, such as for fixed

employee compensation, tax or legal advice to negotiate lease terms, and other costs, are expensed as incurred.

*Operating leases*

We account for the revenue from our lease contracts by utilizing the single component accounting policy. This policy requires

us to account for, by class of underlying asset, the lease component and nonlease component(s) associated with each lease as a single

component if two criteria are met:

(i)The timing and pattern of transfer of the lease component and the nonlease component(s) are the same; and

(ii)The lease component would be classified as an operating lease if it were accounted for separately.

Lease components consist primarily of fixed rental payments, which represent scheduled rental amounts due under our

leases, and contingent rental payments. Nonlease components consist primarily of tenant recoveries representing reimbursements of

rental operating expenses under our triple net lease structure, including recoveries for property taxes, insurance, utilities, repairs and

maintenance, and common area expenses.

If the lease component is the predominant component, we account for all revenues under such lease as a single component in

accordance with the lease accounting standard. Conversely, if the nonlease component is the predominant component, all revenues

under such lease are accounted for in accordance with the revenue recognition accounting standard. Our operating leases qualify for

the single component accounting, and the lease component in each of our leases is predominant. Therefore, we account for all

revenues from our operating leases under the lease accounting standard and classify these revenues as income from rentals in our

consolidated statements of operations.

We commence recognition of income from rentals related to the operating leases at the date the property is ready for its

intended use by the tenant and the tenant takes possession or controls the physical use of the leased asset. When a lease includes

construction of improvements, we determine whether the improvements are landlord or tenant assets. In determining if the

improvements are landlord or tenant improvements, we consider various factors, including, but not limited to, the following:

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

• Which party retains legal title to the improvements upon lease expiration;

• Whether the improvements are expected to have significant residual value at the end of the lease term;

• Whether the improvements are unique to the tenant;

• What happens to the improvements upon lease expiration (i.e., whether they are removed or preserved for the landlord);

• Which party bears all costs of the improvements (including the risk of cost overruns); and

• Which party supervises the construction of the improvements.

If the improvements are landlord assets, we capitalize such improvements. If the improvements are tenant assets, we do not

capitalize these assets. Improvements that qualify as tenant assets, if funded by us, are accounted for as lease incentives and

amortized as a reduction of revenue over the term of the lease. If the tenant funds improvements without reimbursement from us, and

we determine these improvements to be landlord assets, we consider the amount associated with the improvements to be non-cash

lease payments, which are recognized as incremental revenue over the term of the lease.

Income from rentals related to fixed rental payments under operating leases is recognized on a straight-line basis over the

respective operating lease terms. We classify amounts expected to be received in later periods as deferred rent in our consolidated

balance sheets. Amounts received currently but recognized as revenue in future periods are classified in accounts payable, accrued

expenses, and other liabilities in our consolidated balance sheets.

Income from rentals related to variable payments includes tenant recoveries and contingent rental payments. Tenant

recoveries, including reimbursements of utilities, repairs and maintenance, common area expenses, real estate taxes and insurance,

and other operating expenses, are recognized as revenue in the period during which the applicable expenses are incurred and the

tenant's obligation to reimburse us arises. Income from rentals related to other variable payments is recognized when associated

contingencies are removed.

We assess collectibility from our tenants of future lease payments for each of our operating leases. If we determine that

collectibility is probable, we recognize income from rentals based on the methodology described above. If we determine that

collectibility is not probable, we recognize an adjustment to lower our income from rentals. Furthermore, we may recognize a general

allowance at a portfolio level (not the individual level) if we do not expect to collect future lease payments in full.

For each lease for which we determine that collectibility of future lease payments is not probable, we cease the recognition of

income from rentals on a straight-line basis and limit the recognition of income to the lesser of payments collected from the lessee or

lease income that would have been recognized on a straight-line basis. We do not resume straight-line recognition of income from

rentals for these leases until we determine that the collectibility of future payments related to these leases is probable. We also record a

general allowance related to the deferred rent balances that at the portfolio level (not the individual level) are not expected to be

collected in full through the lease term. As of June 30, 2025 and December 31, 2024, our general allowance balance aggregated

$14.3 million and $21.3 million, respectively.

*Direct financing and sales-type leases*

Income from rentals related to direct financing and sales-type leases is recognized over the lease term using the effective

interest rate method. At lease commencement, we derecognize the underlying asset classified within investments in real estate and

record net investment in a lease within other assets in our consolidated balance sheets. This initial net investment is determined by

aggregating the present values of the total future lease payments and the estimated residual value of the property, less any unearned

income related to a direct financing lease. Over the lease term, the investment in the lease accretes in value, producing a constant

periodic rate of return on the net investment in the lease. Income from these leases is classified in income from rentals in our

consolidated statements of operations. Our net investment is reduced over time as lease payments are received.

We evaluate our net investment in direct financing and sales-type leases for impairment under the current expected credit

losses accounting standard. For additional information, refer to "Provision for expected credit losses" in Note 2 – "Summary of

significant accounting policies" to our unaudited consolidated financial statements.

As a lessor, we classify a lease with variable lease payments that do not depend on an index or a rate as an operating lease

on the commencement date of the lease if both of the following criteria are met:

(i)The lease would have been classified as a sales-type lease or direct financing lease under the current lease accounting

standard; and

(ii)The sales-type lease or direct financing lease classification would have resulted in a selling loss at lease commencement.

We do not derecognize the underlying asset and do not recognize a loss upon lease commencement but continue to

depreciate the underlying asset over its useful life.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**Lessee accounting**

We have operating lease agreements in which we are the lessee consisting of ground and office leases. At the lease

commencement date (or at the acquisition date if the lease is acquired as part of a real estate acquisition), we are required to recognize

a liability to account for our future obligations under these operating leases, and a corresponding right-of-use asset.

The lease liability is measured based on the present value of the future lease payments, including payments during the term

under our extension options that we are reasonably certain to exercise. The present value of the future lease payments is calculated for

each operating lease using each respective remaining lease term and a corresponding estimated incremental borrowing rate, which is

the interest rate that we estimate we would have to pay to borrow on a collateralized basis over a similar term for an amount equal to

the lease payments. Subsequently, the lease liability is accreted by applying a discount rate established at the lease commencement

date to the lease liability balance as of the beginning of the period and is reduced by the payments made during the period. We classify

the operating lease liability in accounts payable, accrued expenses, and other liabilities in our consolidated balance sheets.

The right-of-use asset is measured based on the corresponding lease liability, adjusted for initial direct leasing costs and any

other consideration exchanged with the landlord prior to the commencement of the lease, as well as adjustments to reflect favorable or

unfavorable terms of an acquired lease when compared with market terms at the time of acquisition. Subsequently, the right-of-use

asset is amortized on a straight-line basis during the lease term. We classify the right-of-use asset in other assets in our consolidated

balance sheets.

**<u>Recognition of revenue arising from contracts with customers</u>**

We recognize revenues associated with transactions arising from contracts with customers, excluding revenues subject to the

lease accounting standard discussed in "Lease accounting" above, in accordance with the revenue recognition accounting standard. A

customer is distinguished from a noncustomer by the nature of the goods or services that are transferred. Customers are provided with

goods or services that are generated by a company's ordinary output activities, whereas noncustomers are provided with nonfinancial

assets that are outside of a company's ordinary output activities.

We generally recognize revenue representing the transfer of goods and services to customers in an amount that reflects the

consideration to which we expect to be entitled in the exchange. In order to determine the recognition of revenue from customer

contracts, we use a five-step model to (i) identify the contract with the customer, (ii) identify the performance obligations in the contract,

(iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will

not occur, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we

satisfy the performance obligation.

We identify contractual performance obligations and determine whether revenue should be recognized at a point in time or

over time, based on when control of goods and services transfers to a customer. We consider whether we control the goods or services

prior to the transfer to the customer in order to determine whether we should account for the arrangement as a principal or agent. If we

determine that we control the goods or services provided to the customer, then we are the principal to the transaction, and we recognize

the gross amount of consideration expected in the exchange. If we simply arrange but do not control the goods or services being

transferred to the customer, then we are considered to be an agent to the transaction, and we recognize the net amount of

consideration we are entitled to retain in the exchange.

Total revenues subject to the revenue recognition accounting standard and classified within income from rentals in our

consolidated statements of operations for the three and six months ended June 30, 2025 included$13.3 million and $24.2 million,

respectively, primarily related to short-term parking revenues associated with long-term lease agreements. Short-term parking revenues

do not qualify for the single component accounting policy, as discussed in "Lessor accounting" in Note 2 – "Summary of significant

accounting policies," due to the difference in the timing and pattern of transfer of our parking service obligations and associated lease

components within the same lease agreement. We recognize short-term parking revenues in accordance with the revenue recognition

accounting standard when the service is provided and the performance obligation is satisfied, which normally occurs at a point in time.

**<u>Monitoring of tenant credit quality</u>**

During the term of each lease, we monitor the credit quality and any related material changes of our tenants by (i) monitoring

the credit rating of tenants that are rated by a nationally recognized credit rating agency, (ii) reviewing financial statements of the

tenants that are publicly available or that are required to be delivered to us pursuant to the applicable lease, (iii) monitoring news

reports regarding our tenants and their respective businesses, and (iv) monitoring the timeliness of lease payments.

![](are-20250630_g3.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**<u>Notes receivable</u>**

We carry notes receivable at amortized cost, adjusted for an estimated provision for expected credit losses. Interest income on

notes receivable is recognized using the effective interest rate method and is classified within other income in our consolidated

statements of operations. Direct costs incurred in originating notes, along with any premium or discount, are deferred and amortized as

an adjustment to interest income over the note's term using the effective interest rate method. Notes receivable are classified within

other assets in our consolidated balance sheets. Refer to Note 8 – "Other assets" to our unuaudited consolidated financial statements

for additional details.

**<u>Provision for expected credit losses</u>**

We are required to estimate and recognize lifetime expected losses, rather than incurred losses, for most of our financial

assets measured at amortized cost and certain other instruments, including trade, notes, and other receivables (excluding receivables

arising from operating leases), loans, held-to-maturity debt securities, net investments in leases arising from sales-type and direct

financing leases, and off-balance-sheet credit exposures (e.g., loan commitments). The recognition of such expected losses, even if the

expected risk of credit loss is remote, typically results in earlier recognition of credit losses. At each reporting date, we reassess our

provision for expected credit losses, and, if necessary, we recognize an adjustment for our current estimate of expected credit losses.

Refer to Note 5 – "Leases" and Note 8 – "Other assets" to our unaudited consolidated financial statements for additional details.

An assessment of the collectibility of operating lease payments and the recognition of an adjustment to lease income based on

this assessment is governed by the lease accounting standard discussed in "Lease accounting" earlier in Note 2 — "Summary of

significant accounting policies" to our unaudited consolidated financial statements.

**<u>Income taxes</u>**

We are organized and operate as a REIT pursuant to the Internal Revenue Code (the "Code"). Under the Code, a REIT that

distributes at least90% of its REIT taxable income to its stockholders annually (excluding net capital gains) and meets certain other

conditions is not subject to federal income tax on its distributed taxable income, but could be subject to certain federal, foreign, state,

and local taxes. We distribute 100% of our taxable income annually; therefore, a provision for federal income taxes is not required. In

addition to our REIT returns, we file federal, foreign, state, and local tax returns for our subsidiaries. We file with jurisdictions located in

the U.S., Canada, and other international locations. Our tax returns are subject to routine examination in various jurisdictions for the

2019 through 2024 calendar years.

**<u>Employee and non-employee share-based payments</u>**

We have implemented an entity-wide accounting policy to account for forfeitures related to unmet service conditions of share-

based awards granted to employees and non-employees when they occur. Under this policy, when forfeitures occur, any previously

recognized expense related to those forfeited awards is reversed in the period of forfeiture.

Our employee and non-employee share-based awards are measured at fair value on the grant date and recognized over the

recipient's required service period. For share-based awards with performance conditions, we continue to assess the probability of

achieving the performance conditions and recognize expense only when it becomes probable that the performance targets will be met.

Conversely, for share-based awards with market conditions, expense is recognized regardless of whether the market condition is met.

Dividends paid on share-based awards with nonforfeitable dividends are initially classified in retained earnings and reclassified

to compensation cost only if the underlying awards are forfeited. Conversely, for share-based awards with forfeitable dividends,

declared dividends are initially classified in retained earnings and in dividends payable within our consolidated balance sheets. If the

underlying awards are forfeited, the corresponding accrued dividend is reversed in the period of forfeiture. Upon vesting of the

underlying share-based awards with forfeitable dividends, the accumulated dividend payment is made and the dividend payable liability

is settled.

**<u>Forward equity sales agreements</u>**

From time to time, we enter into forward equity sales agreements and account for them in accordance with the accounting

guidance governing financial instruments and derivatives. Under the accounting guidance, our forward equity sales agreements are not

deemed to be liabilities as they do not embody obligations to repurchase our shares, nor do they embody obligations to issue a variable

number of shares for which the monetary value is predominantly fixed, varied with something other than the fair value of our shares, or

varied inversely in relation to our shares. We also evaluate whether the agreements meet the derivatives and hedging guidance scope

exception to be accounted for as equity instruments. Our forward equity sales agreements are classified as equity contracts based on

the following assessment: (i) none of the agreements' exercise contingencies are based on observable markets or indices besides

those related to the market for our own stock price and operations; and (ii) none of the settlement provisions preclude the agreements

from being indexed to our own stock.

![](are-20250630_g1.gif)

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**<u>Issuer and guarantor subsidiaries of guaranteed securities</u>**

Generally, a parent entity of an issuer that holds guaranteed securities must provide separate subsidiary issuer or guarantor

financial statements, unless it qualifies for disclosure exceptions. A parent entity may be eligible for disclosure exceptions if it meets the

following criteria:

(i)The subsidiary issuer or guarantor is a consolidated subsidiary of the parent company, and

(ii)The subsidiary issues a registered security that is:

• issued jointly and severally with the parent company, or

• fully and unconditionally guaranteed by the parent company.

A parent entity that meets the above criteria may instead present summarized financial information ("alternative disclosures")

either within the consolidated financial statements or in "Management's discussion and analysis of financial condition and results of

operations" in Item 2. We evaluated the criteria and determined that we are eligible for the disclosure exceptions, which allow us to

provide alternative disclosures; as such, we present alternative disclosures in "Management's discussion and analysis of financial

condition and results of operations" in Item 2.

**<u>Loan fees</u>**

Fees incurred in obtaining long-term financing are capitalized and classified with the corresponding debt instrument appearing

on our consolidated balance sheets. Loan fees related to our unsecured senior line of credit are capitalized and classified within other

assets. Capitalized amounts are amortized over the term of the related loan, and the amortization is classified in interest expense in our

consolidated statements of operations.

**<u>Distributions from equity method investments</u>**

We use the "nature of the distribution" approach to determine the classification within our consolidated statements of cash

flows of cash distributions received from equity method investments, including our unconsolidated real estate joint ventures and equity

method non-real estate investments. Under this approach, distributions are classified based on the nature of the underlying activity that

generated the cash distributions. If we lack the information necessary to apply this approach in the future, we will be required to apply

the "cumulative earnings" approach as an accounting change on a retrospective basis. Under the cumulative earnings approach,

distributions up to the amount of cumulative equity in earnings recognized are classified as cash inflows from operating activities, and

those in excess of that amount are classified as cash inflows from investing activities.

**<u>Restricted cash</u>**

We present cash and cash equivalents separately from restricted cash within our consolidated balance sheets. However, we

include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown

in the consolidated statements of cash flows. We provide a reconciliation between the consolidated balance sheets and the

consolidated statements of cash flows, which is required when the balance includes greater than one line item for cash, cash

equivalents, and restricted cash. We also provide a disclosure of the nature of the restrictions related to material restricted cash

balances.

**<u>Recent accounting pronouncements</u>**

On November 4, 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses*, that will require

entities to provide enhanced disclosures related to certain expense categories included in income statement captions. The ASU aims to

increase transparency and provide investors with additional detailed information about the nature of expenses reported on the face of

the income statement. The new standard does not change the requirements for the presentation of expenses on the face of the income

statement.

Under this ASU, entities are required to disaggregate, in a tabular format, expense captions presented on the face of the

income statement — excluding earnings or losses from equity method investments — if they include any of the following expense

categories: purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depreciation or depletion.

For any remaining items within each relevant expense caption, entities must provide a qualitative description of the nature of those

expenses. The new ASU is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods

beginning after December 15, 2027. Early adoption is permitted. We expect to adopt this ASU on January 1, 2027. Although the

adoption is not expected to have an impact on our financial statements, it is expected to result in incremental disclosures within the

footnotes to our consolidated financial statements.

![](are-20250630_g1.gif)

**3. INVESTMENTS IN REAL ESTATE**

Our consolidated investments in real estate consisted of the following as of June 30, 2025 and December 31, 2024 (in

thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Rental properties: |  |  |
| Land (related to rental properties) | $3536029 | $3863027 |
| Buildings and building improvements | 21218380 | 20377935 |
| Other improvements | 4585085 | 4354785 |
| Rental properties | 29339494 | 28595747 |
| Current and future development and redevelopment projects | 8543083 | 8618727 |
| **Gross investments in real estate**  | **37882577** | **37214474** |
| Less: accumulated depreciation | (6034352) | (5477082) |
| Investments in real estate assets held for sale<sup>(1)</sup> | 312375 | 372647 |
| Investments in real estate | $32160600 | $32110039 |

---

(1)Refer to "Assets held for sale" below.

**Assets held for sale**

As of June 30, 2025, we had eight operating properties aggregating 679,383 RSF and land parcels aggregating 878,205SF

that were classified as held for sale.

The disposal of properties classified as held for sale does not represent a strategic shift that has (or will have) a major effect

on our operations or financial results and therefore does not meet the criteria for classification as a discontinued operation. We cease

depreciation of our properties upon their classification as held for sale.

The following is a summary of net assets as of June 30, 2025 and December 31, 2024 for our real estate investments that

were classified as held for sale as of each respective date (in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Investments in real estate | $312375 | $372647 |
| Other assets | 20274 | 9488 |
| Total assets | 332649 | 382135 |
| Total liabilities | (11040) | (13462) |
| Total accumulated other comprehensive income | 2057 | 2584 |
| Net assets classified as held for sale | $323666 | $371257 |

---

For additional information, refer to "Real estate sales" in Note 2 – "Summary of significant accounting policies" to our unaudited

consolidated financial statements.

![](are-20250630_g1.gif)

**3. INVESTMENTS IN REAL ESTATE (continued)**

**Sales of real estate assets and impairment of real estate**

Our completed dispositions of real estate assets during the six months ended June 30, 2025 consisted of the following (dollars

in thousands):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Square Footage | Square Footage |  | Gain on <br>Sales of <br>Real Estate |
| Property | Submarket/Market | Date of <br>Sale<br>| Interest <br>Sold<br>| Operating | Land and <br>Future<br>| Sales Price | Gain on <br>Sales of <br>Real Estate |
| Costa Verde by Alexandria | University Town Center/<br>San Diego<br>| 1/31/25 | 100% | 8730 | 537000 | $124000<br><sup>(1)</sup> | $— |
| 2425 Garcia Avenue and 2400/2450 <br>Bayshore Parkway<br>| Greater Stanford/San <br>Francisco Bay Area<br>| 6/30/25 | 100% | 95901 |  | 11000 |  |
| Land parcel | Texas | 5/7/25 | 100% |  | 1350000 | 73287 |  |
| Other |  |  |  |  |  | 52352 | 13165 |
|  |  |  |  |  |  | $260639<br><sup>(2)</sup> | $13165 |

---

(1)As part of the transaction, we provided$91.0 million of seller financing during the three months ended March 31, 2025. This note receivable is classified within "Other

assets" in our consolidated balance sheet. Refer to Note 8 – "Other assets" to our consolidated financial statements for additional information.

(2)Represents the aggregate contractual sales price of our dispositions, which differs from proceeds from sales of real estate and contributions from and sales of

noncontrolling interests in our consolidated statement of cash flows under "Investing activities" and "Financing activities," respectively, primarily due to the timing of

payment, closing costs, and other sales adjustments such as prorations of rents and expenses.

<u>Impairment of real estate</u>

During the six months ended June 30, 2025, we recognized impairment of real estate aggregating $161.8 million, which

primarily included the following:

• During the three months ended March 31, 2025, we recognized an impairment charge of$32.2 million related to a ground

lease entered into in 2021 for a future development site in our San Francisco Bay Area market. Refer to "Lessee operating

costs" in Note 5 – "Leases" to our unaudited consolidated financial statements for additional information.

• In April 2025, an office property aggregating 182,276 RSF, located in Carlsbad, San Diego, met the criteria for classification as

held for sale based on our decision to dispose of this property. We expect to complete the sale within 12 months. Upon our

decision to commit to sell this property, we recognized an impairment charge of $35.4 million to reduce the carrying amount of

this asset to its estimated fair value less costs to sell of approximately$68.8 million.

• In June 2025, two operating properties aggregating 210,481 RSF located in our Sorrento Mesa submarket met the criteria for

classification as held for sale based on current negotiations with prospective buyers and our decision to dispose of these

properties. We expect to complete these sales within 12 months. Upon our decision to commit to sell these properties, we

recognized impairment charges aggregating $18.1 million to reduce the carrying amounts of these assets to their estimated

fair values less costs to sell of approximately$112.7 million.

• In June 2025, land parcels aggregating374,349 SF in our non-cluster/other submarket met the criteria for classification as held

for sale based on current negotiations with a prospective buyer and our decision to dispose of this asset. We expect to

complete this sale within 12 months. Upon our decision to sell this land parcel, we recognized an impairment charge of

$47.5 millionto reduce the carrying amount of the asset to its estimated fair value less costs to sell of approximately

$28.5 million.

![](are-20250630_g1.gif)

**3. INVESTMENTS IN REAL ESTATE (continued)**

<u>Other</u>

In 2006, ARE-East River Science Park, LLC, a subsidiary of Alexandria Real Estate Equities, Inc., was granted an option to

incorporate a land parcel adjacent to and north of the Alexandria Center<sup>®</sup> for Life Science – New York City ("ACLS-NYC") campus

("Option Parcel") into the existing ground lease of that campus. The Option Parcel will allow ARE-East River Science Park, LLC to

develop a future world-class life science building within the ACLS-NYC campus. ARE-East River Science Park, LLC's investment in pre-

construction costs related to the development of the Option Parcel, including costs related to design, engineering, environmental,

survey/title, and permitting and legal costs, aggregated $173.8 millionas of June 30, 2025.

On August 6, 2024, ARE-East River Science Park, LLC filed a lawsuit in the United States District Court for the Southern

District of New York against its landlord, New York City Health + Hospitals Corporation ("H+H"), and the New York City Economic

Development Corporation ("EDC"). On January 24, 2025, ARE-East River Science Park, LLC filed a first amended complaint. The

lawsuit alleges two principal claims against H+H and EDC: fraud in the inducement, and, in the alternative, breach of contract in

violation of the implied covenant of good faith and fair dealing. As alleged in the complaint, ARE-East River Science Park, LLC's claims

arise from H+H's and EDC's misrepresentations and concealment of material facts in connection with a floodwall, which H+H and EDC

are seeking to require ARE-East River Science Park, LLC to integrate into the development of the Option Parcel. ARE-East River

Science Park, LLC alleges that H+H's and EDC's misconduct have prevented it from commencing the development of the Option

Parcel. In light of the pending litigation, the closing date for our option and thus the commencement date for construction of the third

tower at the campus are presently indeterminate. Among other things, ARE-East River Science Park, LLC is seeking significant

damages and equitable relief from the court to confirm our understanding that the option is in full force and effect.

This matter exposes us to potential losses ranging from zero to the full amount of our investment in the project aggregating

$173.8 millionas of June 30, 2025, depending on any collection of damages and/or the ability to develop the project. We performed a

probability-weighted recoverability analysis based on estimates of various possible outcomes and determined no impairment was

present as of June 30, 2025.

![](are-20250630_g1.gif)

**4. CONSOLIDATED AND UNCONSOLIDATED REAL ESTATE JOINT VENTURES**

From time to time, we enter into joint venture agreements through which we own a partial interest in real estate entities that

own, develop, and operate real estate properties. As of June 30, 2025, our real estate joint ventures held the following properties:

---

| | | | |
|:---|:---|:---|:---|
| Property<sup>(1)</sup> | Market | Submarket | Our Ownership <br>Interest |
| *Consolidated real estate joint ventures:* |  |  |  |
| 50 and 60 Binney Street | Greater Boston | Cambridge/Inner Suburbs | 34.0% |
| 75/125 Binney Street | Greater Boston | Cambridge/Inner Suburbs | 40.0% |
| 100 and 225 Binney Street and 300 Third Street | Greater Boston | Cambridge/Inner Suburbs | 30.0% |
| 99 Coolidge Avenue | Greater Boston | Cambridge/Inner Suburbs | 76.9% |
| 15 Necco Street | Greater Boston | Seaport Innovation District | 56.7% |
| 285, 299, 307, and 345 Dorchester Avenue | Greater Boston | Seaport Innovation District | 60.0% |
| Alexandria Center<sup>®</sup> for Science and Technology – <br>Mission Bay<sup>(2)</sup><br>| San Francisco Bay Area | Mission Bay | 25.0% |
| 601, 611, 651, 681, 685, and 701 Gateway <br>Boulevard<br>| San Francisco Bay Area | South San Francisco | 50.0% |
| 751 Gateway Boulevard | San Francisco Bay Area | South San Francisco | 51.0% |
| 211 and 213 East Grand Avenue | San Francisco Bay Area | South San Francisco | 30.0% |
| 500 Forbes Boulevard | San Francisco Bay Area | South San Francisco | 10.0% |
| Alexandria Center<sup>®</sup> for Life Science – Millbrae | San Francisco Bay Area | South San Francisco | 48.5% |
| 3215 Merryfield Row | San Diego | Torrey Pines | 30.0% |
| Campus Point by Alexandria<sup>(3)</sup> | San Diego | University Town Center | 55.0% |
| 5200 Illumina Way | San Diego | University Town Center | 51.0% |
| 9625 Towne Centre Drive | San Diego | University Town Center | 30.0% |
| SD Tech by Alexandria<sup>(4)</sup> | San Diego | Sorrento Mesa | 50.0% |
| Pacific Technology Park | San Diego | Sorrento Mesa | 50.0% |
| Summers Ridge Science Park<sup>(5)</sup> | San Diego | Sorrento Mesa | 30.0% |
| 1201 and 1208 Eastlake Avenue East | Seattle | Lake Union | 30.0% |
| 199 East Blaine Street | Seattle | Lake Union | 30.0% |
| 400 Dexter Avenue North | Seattle | Lake Union | 30.0% |
| 800 Mercer Street | Seattle | Lake Union | 60.0% |
| *Unconsolidated real estate joint ventures*<sup>(6)</sup>*:* |  |  |  |
| 1655 and 1725 Third Street | San Francisco Bay Area | Mission Bay | 10.0% |
| 1450 Research Boulevard | Maryland | Rockville | 73.2%<br><sup>(7)</sup> |
| 101 West Dickman Street | Maryland | Beltsville | 58.4%<br><sup>(7)</sup> |

---

(1)Refer to the table on the next page that shows the categorization of our joint ventures under the consolidation framework.

(2)Includes 409 and 499 Illinois Street, 1450, 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South.

(3)Includes 10210, 10260, 10290, and 10300 Campus Point Drive and 4110, 4135, 4155, 4161, 4165, 4224, and 4242 Campus Point Court.

(4)Includes 9605, 9645, 9675, 9725, 9735, 9805, 9808, 9855, and 9868 Scranton Road and 10055, 10065, and 10075 Barnes Canyon Road.

(5)Includes 9965, 9975, 9985, and 9995 Summers Ridge Road.

(6)In addition to the real estate joint ventures listed, we hold an interest in one insignificant unconsolidated real estate joint venture.

(7)Represents a joint venture with a local real estate operator in which our joint venture partner manages the day-to-day activities that significantly affect the economic

performance of the joint venture.

Our consolidation policy is described under "Consolidation" in Note 2 – "Summary of significant accounting policies" to our

unaudited consolidated financial statements. Consolidation accounting is highly technical, but its framework is primarily based on the

controlling financial interests and benefits of the joint ventures. We generally consolidate a joint venture that is a legal entity that we

control (i.e., we have the power to direct the activities of the joint venture that most significantly affect its economic performance)

through contractual rights, regardless of our ownership interest, and where we determine that we have benefits through the allocation of

earnings or losses and fees paid to us that could be significant to the joint venture (the "VIE model").

![](are-20250630_g1.gif)

**4. CONSOLIDATED AND UNCONSOLIDATED REAL ESTATE JOINT VENTURES (continued)**

We also generally consolidate joint ventures when we have a controlling financial interest through voting rights and where our

voting interest is greater than 50% (the "voting model"). Voting interest differs from ownership interest for some joint ventures. We

account for joint ventures that do not meet the consolidation criteria under the equity method of accounting by recognizing our share of

income and losses.

The table below shows the categorization of our real estate joint ventures under the consolidation framework:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Property<sup>(1)</sup> | Consolidation <br>Model <br>| Voting Interest | Consolidation Analysis | Conclusion |
| 50 and 60 Binney Street | VIE model | Not applicable <br>under VIE <br>model |  | Consolidated |
| 75/125 Binney Street | VIE model | Not applicable <br>under VIE <br>model | We have: | Consolidated |
| 100 and 225 Binney Street and 300 <br>Third Street<br>| VIE model | Not applicable <br>under VIE <br>model |  | Consolidated |
| 99 Coolidge Avenue | VIE model | Not applicable <br>under VIE <br>model<br> (i) | The power to direct the <br>activities of the joint venture <br>that most significantly affect its <br>economic performance; and  | Consolidated |
| 15 Necco Street | VIE model | Not applicable <br>under VIE <br>model | The power to direct the <br>activities of the joint venture <br>that most significantly affect its <br>economic performance; and  | Consolidated |
| 285, 299, 307, and 345 Dorchester <br>Avenue<br>| VIE model | Not applicable <br>under VIE <br>model | The power to direct the <br>activities of the joint venture <br>that most significantly affect its <br>economic performance; and  | Consolidated |
| Alexandria Center<sup>®</sup> for Science and <br>Technology – Mission Bay<br>| VIE model | Not applicable <br>under VIE <br>model | The power to direct the <br>activities of the joint venture <br>that most significantly affect its <br>economic performance; and  | Consolidated |
| 601, 611, 651, 681, 685, and 701 <br>Gateway Boulevard<br>| VIE model | Not applicable <br>under VIE <br>model | The power to direct the <br>activities of the joint venture <br>that most significantly affect its <br>economic performance; and  | Consolidated |
| 751 Gateway Boulevard | VIE model | Not applicable <br>under VIE <br>model |  | Consolidated |
| 211 and 213 East Grand Avenue | VIE model | Not applicable <br>under VIE <br>model | Benefits that can be significant <br>to the joint venture. | Consolidated |
| 500 Forbes Boulevard | VIE model | Not applicable <br>under VIE <br>model | Benefits that can be significant <br>to the joint venture. | Consolidated |
| Alexandria Center<sup>®</sup> for Life Science – <br>Millbrae<br>| VIE model | Not applicable <br>under VIE <br>model | Benefits that can be significant <br>to the joint venture. | Consolidated |
| 3215 Merryfield Row | VIE model | Not applicable <br>under VIE <br>model | Benefits that can be significant <br>to the joint venture. | Consolidated |
| Campus Point by Alexandria | VIE model | Not applicable <br>under VIE <br>model | Benefits that can be significant <br>to the joint venture. | Consolidated |
| 5200 Illumina Way | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| 9625 Towne Centre Drive | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| SD Tech by Alexandria | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| Pacific Technology Park | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| Summers Ridge Science Park | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| 1201 and 1208 Eastlake Avenue East | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| 199 East Blaine Street | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| 400 Dexter Avenue North | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| 800 Mercer Street | VIE model | Not applicable <br>under VIE <br>model | Therefore, we are the primary <br>beneficiary of each VIE | Consolidated |
| 1450 Research Boulevard | VIE model | Not applicable <br>under VIE <br>model | We do not control the joint venture <br>and are therefore not the primary <br>beneficiary. | Equity method <br>of accounting |
| 101 West Dickman Street | VIE model | Not applicable <br>under VIE <br>model | We do not control the joint venture <br>and are therefore not the primary <br>beneficiary. | Equity method <br>of accounting |
| 1655 and 1725 Third Street | Voting model | Does not <br>exceed 50% | Our voting interest is 50% or less. | Equity method <br>of accounting |
| 1655 and 1725 Third Street | Voting model | Does not <br>exceed 50% | Our voting interest is 50% or less. | Equity method <br>of accounting |

---

(1)In addition to the real estate joint ventures listed, we hold an interest in one insignificant unconsolidated real estate joint venture.

![](are-20250630_g1.gif)

**4. CONSOLIDATED AND UNCONSOLIDATED REAL ESTATE JOINT VENTURES (continued)**

**Consolidated VIEs' balance sheet information**

We, together with joint venture partners, hold interests in real estate joint ventures that we consolidate in our financial

statements. These existing joint ventures provide significant equity capital to fund a portion of our future construction spending, and our

joint venture partners may also contribute equity into these entities for financing-related activities.

The table below aggregates the balance sheet information of our consolidated VIEs (in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Investments in real estate | $7773223 | $8917718 |
| Cash and cash equivalents | 258718 | 335223 |
| Other assets | 811124 | 777033 |
| Total assets | $8843065 | $10029974 |
| Secured note payable | $153500 | $149321 |
| Other liabilities | 475757 | 626460 |
| Total liabilities | 629257 | 775781 |
| Redeemable noncontrolling interests |  | 10360 |
| Alexandria Real Estate Equities, Inc.'s share of equity | 3659652 | 4754386 |
| Noncontrolling interests' share of equity | 4554156 | 4489447 |
| Total liabilities and equity | $8843065 | $10029974 |

---

In determining whether to aggregate the balance sheet information of consolidated VIEs, we considered the similarity of each

VIE, including the primary purpose of these entities to own, manage, operate, and lease real estate properties owned by the VIEs, and

the similar nature of our involvement in each VIE as a managing member. Due to the similarity of the characteristics, we present the

balance sheet information of these entities on an aggregated basis. None of our consolidated VIEs' assets have restrictions that limit

their use to settle specific obligations of the VIE. There are no creditors or other partners of our consolidated VIEs that have recourse to

our general credit, and our maximum exposure to our consolidated VIEs is limited to our variable interests in each VIE, except for our

99 Coolidge Avenue real estate joint venture in which the VIE's secured construction loan is guaranteed by us. Refer to Note 10 –

"Secured and unsecured senior debt" to our unaudited consolidated financial statements for additional information.

**Unconsolidated real estate joint ventures**

Our maximum exposure to our unconsolidated VIEs is limited to our investment in each VIE, except for our 1450 Research

Boulevard and 101 West Dickman Street unconsolidated real estate joint ventures in which we guarantee up to $6.7 million of the

outstanding balance related to each VIE's secured loan. Our investments in unconsolidated real estate joint ventures, accounted for

under the equity method and classified in investments in unconsolidated real estate joint ventures in our consolidated balance sheets,

consisted of the following as of June 30, 2025 and December 31, 2024 (in thousands):

---

| | | |
|:---|:---|:---|
| Property | June 30, 2025 | December 31, 2024 |
| 1655 and 1725 Third Street | $20368 | $10574 |
| 1450 Research Boulevard | 8657 | 9193 |
| 101 West Dickman Street | 9666 | 9749 |
| Other | 1543 | 10357 |
|  | $40234 | $39873 |

---

Below are key terms of unconsolidated real estate joint ventures' secured loans as of June 30, 2025 (dollars in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | Interest <br>Rate<sup>(1)</sup> | At 100% | At 100% | Our <br>Share |
| Unconsolidated Joint Venture | Maturity Date | Stated Rate | Interest <br>Rate<sup>(1)</sup> | Aggregate <br>Commitment <br>| Debt <br>Balance<sup>(2)</sup><br>| Our <br>Share |
| 101 West Dickman Street | 11/10/26 | SOFR+1.95%<br><sup>(3)</sup> | 6.34% | $26750 | $19081 | 58.4% |
| 1450 Research Boulevard | 12/10/26 | SOFR+1.95%<br><sup>(3)</sup> | 6.40% | 13000 | 8965 | 73.2% |
| 1655 and 1725 Third Street<sup>(4)</sup> | 2/10/35 | 6.37% | 6.44% | 500000 | 496709 | 10.0% |
|  |  |  |  | $539750 | $524755 |  |

---

(1)Includes interest expense and amortization of loan fees.

(2)Represents outstanding principal, net of unamortized deferred financing costs, as of June 30, 2025.

(3)This loan is subject to a fixed SOFR floor of 0.75%.

(4)During the three months ended March 31, 2025, the unconsolidated real estate joint venture refinanced $500 million of its $600 million existing fixed-rate debt with a new

secured note payable maturing in 2035.The remaining debt balance of approximately $100 million was repaid through contributions from the unconsolidated joint

venture partners, including our share of $10.8 million.

![](are-20250630_g1.gif)

**5. LEASES**

Refer to "Lease accounting" in Note 2 – "Summary of significant accounting policies" to our unaudited consolidated financial

statements for information about lease accounting standards that set principles for the recognition, measurement, presentation, and

disclosure of leases for both parties to a lease agreement (i.e., lessees and lessors).

**Leases in which we are the lessor**

As of June 30, 2025, we had 384 properties aggregating39.7 million operating RSF in key cluster locations, including Greater

Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. We primarily focus on

developing Class A/A+ properties in AAA life science innovation cluster locations that offer the scale and strategic design integral to our

Megacampus strategy. Strategically located near top academic and medical research institutions and equipped with curated amenities

and services, and convenient access to transit, our Megacampus ecosystems are designed to support our tenants in attracting and

retaining top talent, which we believe is a key driver of tenant demand for our properties.

As of June 30, 2025, all leases in which we are the lessor were classified as operating leases, with the exception of one direct

financingand one sales-type lease. Our leases are described below.

*Operating leases*

As of June 30, 2025, our384properties were subject to operating lease agreements. Sevenof these properties are subject to

operating lease agreements that each contain a purchase option as described below:

(i)Two of these properties, representing two land parcels in our San Francisco Bay Area market, are subject to lease

agreements that each contain an option for the lessee to purchase the underlying asset from us at fair market value during

each of the 30-day periods commencing on the dates that are15 years, 30 years, and 74.5 years after the rent

commencement date of October 1, 2017. The remaining lease term related to each of the two land parcels is 67.4 years.

(ii)Two operating properties in our Seattle market, held by a consolidated real estate joint venture, are subject to purchase

options held by our partner in this joint venture, which is also a tenant at these properties. One purchase option allows our

partner to purchase our 30% interest in one property for $40.0 million in 2031. Contingent upon the exercise of this option,

the second purchase option allows our partner to purchase our 30% interest in one property for $69.1 million in 2034. Our

partner's remaining lease terms for these operating leases are5.7 years and 19.3 years, respectively.

(iii)Threeproperties subject to operating lease agreements contain purchase options with a weighted-average (based on

property RSF) exercise date in October 2027.

Certain operating leases contain options for the tenant to extend their lease at prevailing market rates at the time of expiration.

In addition, certain operating leases contain an early termination option that requires advance notification and payment of an early

termination fee by the tenant.

At the commencement of each lease, we establish the lease term comprising the noncancelable period for each lease together

with periods covered by options to extend or terminate the lease that we determine the lessee is reasonably certain to exercise. Our

assessment of whether a lessee is reasonably certain to exercise or not exercise an option considers all economic factors relevant to

the assessment, including property-based, market-based, and tenant-based factors. We do not reassess the lease term or a lessee

option to purchase the underlying asset unless there is a lease modification that is not accounted for as a separate contract.

Future lease payments to be received under the terms of our operating lease agreements, excluding expense

reimbursements, in effect as of June 30, 2025 are outlined in the table below (in thousands):

---

| | |
|:---|:---|
| Year | Amount |
| 2025 | $917038 |
| 2026 | 1768314 |
| 2027 | 1691484 |
| 2028 | 1584647 |
| 2029 | 1482012 |
| Thereafter | 9809227 |
| Total | $17252722 |

---

Refer to Note 3 – "Investments in real estate" to our unaudited consolidated financial statements for additional information

about our owned real estate assets, which are the underlying assets under our operating leases.

![](are-20250630_g1.gif)

**5. LEASES (continued)**

*Direct financing and sales-type leases*

As of June 30, 2025, we have one direct financing lease agreement, with a net investment balance of$41.9 million, for a

parking structure with a remaining lease term of 67.4 years. The lessee has an option to purchase the underlying asset at fair market

value during each of the 30-day periods commencing on the dates that are 15 years, 30 years, and 74.5 yearsafter the rent

commencement date of October 1, 2017.

As of June 30, 2025, we also haveone sales-type lease for a property located in the Seattle market with the lease term

through August 2025, after which the ownership of the property transfers to the tenant. As of June 30, 2025, the net investment in this

lease is $18.4 million. Upon recognition of the sales-type lease during the three months ended March 31, 2025, we recognized a gain

on sale of real estate aggregating $12.7 millionclassified in gain on sales of real estate within our unaudited consolidated statement of

operations for the six months ended June 30, 2025.

The components of our aggregate net investment in our direct financing lease and our sales-type lease as of June 30, 2025

and December 31, 2024 are summarized in the table below (in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Gross investment in direct financing and sales-type leases | $268879 | $251405 |
| Less: unearned income on direct financing lease | (206391) | (207734) |
| Less: provision for expected credit losses | (2217) | (2168) |
| Net investment in leases | $60271 | $41503 |

---

As of June 30, 2025, our estimated provision for expected credit loss related to our direct financing lease aggregated

$2.2 million, unchanged from December 31, 2024. We estimate the provision for expected credit loss related to our direct financing

lease using a probability of default methodology, which incorporates the borrower's investment-grade credit rating from S&P Global

Ratings, to evaluate the probability of default. Additionally, we incorporate the projected value of the real estate securing the

investments to estimate potential recoveries in the event of default, among other inputs.

During the three months ended March 31, 2025, we recognized an estimated provision for expected credit loss aggregating

$49 thousand related to the sales-type lease discussed above. This estimate was determined using historical industry losses and

transaction-specific information, including the estimated fair value of the underlying real estate asset securing this transaction, the short-

term nature of this lease, and other available information. As of June 30, 2025, this estimate remained unchanged.

We classify adjustments to estimated provision for expected credit loss related to our direct financing and sales-type leases

within other income in our consolidated statement of operations. For further details, refer to "Provision for expected credit losses" in

Note 2 – "Summary of significant accounting policies" to our unaudited consolidated financial statements.

Future lease payments to be received under the terms of our direct financing lease and our sales-type lease as of June 30,

2025 are outlined in the table below (in thousands):

---

| | |
|:---|:---|
| Year | Total |
| 2025 | $19450 |
| 2026 | 2036 |
| 2027 | 2097 |
| 2028 | 2160 |
| 2029 | 2224 |
| Thereafter | 240912 |
| Total | $268879 |

---

![](are-20250630_g1.gif)

**5. LEASES (continued)**

*Income from rentals*

Our income from rentals includes revenue related to agreements for the rental of our real estate, which primarily includes

revenues subject to the lease accounting standard and the revenue recognition accounting standard as shown below (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Income from rentals: |  |  |  |  |
| Revenues subject to the lease accounting standard: |  |  |  |  |
| Operating leases | $722935 | $745626 | $1454356 | $1491687 |
| Direct financing and sales-type leases | 1089 | 662 | 1899 | 1321 |
| Revenues subject to the lease accounting standard | 724024 | 746288 | 1456255 | 1493008 |
| Revenues subject to the revenue recognition <br>accounting standard<br>| 13255 | 8874 | 24199 | 17705 |
| Income from rentals | $737279 | $755162 | $1480454 | $1510713 |

---

Our revenues that are subject to the revenue recognition accounting standard and are classified in income from rentals consist

primarily of short-term parking revenues that are not considered lease revenues under the lease accounting standard. Refer to

"Revenues" and "Recognition of revenue arising from contracts with customers" in Note 2 – "Summary of significant accounting policies"

to our unaudited consolidated financial statements for additional information.

*Residual value risk management strategy*

Our leases do not have guarantees of residual value on the underlying assets. We manage risk associated with the residual

value of our leased assets by (i) evaluating each potential acquisition of real estate to determine whether it meets our business

objective to invest primarily in high-demand markets, (ii) directly managing our leased properties, conducting frequent property

inspections, proactively addressing potential maintenance issues, and/or timely resolving any occurring issues, and (iii) carefully

selecting our tenants and monitoring their credit quality throughout their respective lease terms.

**Leases in which we are the lessee**

*Operating lease agreements*

We have operating lease agreements in which we are the lessee consisting of ground and office leases. Certain of these

leases have options to extend or terminate the contract terms upon meeting certain criteria. There are no notable restrictions or

covenants imposed by the leases, nor guarantees of residual value.

We recognize a right-of-use asset, which is classified within other assets in our consolidated balance sheets, and a related

liability, which is classified within accounts payable, accrued expenses, and other liabilities in our consolidated balance sheets, to

account for our future obligations under ground and office lease arrangements in which we are the lessee. Refer to "Lessee accounting"

in Note 2 – "Summary of significant accounting policies" to our unaudited consolidated financial statements.

As of June 30, 2025, the present value of the remaining contractual payments aggregating $784.2 million under our operating

lease agreements, including our extension options that we are reasonably certain to exercise, was $363.4 million. Our corresponding

operating lease right-of-use assets, adjusted for initial direct leasing costs and other consideration exchanged with the landlord prior to

the commencement of the lease, aggregated$717.1 million. As of June 30, 2025, the weighted-average remaining lease term of

operating leases in which we are the lessee was approximately54 years, including extension options that we are reasonably certain to

exercise, and the weighted-average discount rate was4.7%. The weighted-average discount rate is based on the incremental

borrowing rate estimated for each lease, which is the interest rate that we estimate we would have to pay to borrow on a collateralized

basis over a similar term for an amount equal to the lease payments.

Ground lease obligations as of June 30, 2025 included leases for 31 of our properties, which accounted for approximately 8%

of our total number of properties. Excluding one ground lease that expires in 2036 related to one operating property with a net book

value of $5.3 million as of June 30, 2025, our ground lease obligations have remaining lease terms ranging from approximately29 to 81

years, including extension options that we are reasonably certain to exercise.

![](are-20250630_g1.gif)

**5. LEASES (continued)**

The reconciliation of future lease payments under noncancelable operating leases in which we are the lessee to the operating

lease liability reflected in our unaudited consolidated balance sheet as of June 30, 2025 is in the table below (in thousands):

---

| | |
|:---|:---|
| Year | Total |
| 2025 | $10777 |
| 2026 | 22768 |
| 2027 | 21849 |
| 2028 | 21517 |
| 2029 | 21025 |
| Thereafter | 686242 |
| Total future payments under our operating leases in which we are the lessee | 784178 |
| Effect of discounting | (420759) |
| Operating lease liability | $363419 |

---

*Lessee operating costs*

Operating lease costs relate to our ground and office leases in which we are the lessee. Ground leases generally require fixed

annual rent payments and may also include escalation clauses and renewal options. For the six months ended June 30, 2025 and

2024, amounts paid and classified as operating activities in our unaudited consolidated statements of cash flows for leases in which we

are the lessee aggregated$156.1 million and $16.4 million, respectively. The increase is primarily due to the second installment of a

ground lease prepayment aggregating $135.0 million made in January 2025 for a 24-year lease term extension to our existing ground

lease agreement at the Alexandria Technology Square<sup>®</sup> Megacampus in our Cambridge submarket.

Our operating lease obligations related to our office leases have remaining terms of up to 11 years, exclusive of extension

options. For the three and six months ended June 30, 2025 and 2024, our costs of operating leases in which we are the lessee were as

follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Gross operating lease costs | $12859 | $9930 | $25218 | $19141 |
| Capitalized lease costs | (720) | (518) | (1413) | (1046) |
| Expenses for operating leases in which we are the lessee | $12139 | $9412 | $23805 | $18095 |

---

During the three months ended March 31, 2025, we recognized an impairment charge related to a ground lease entered into in

2021 for a future development site in the San Francisco Bay Area market. Based on our current financial outlook for this project, we

made the determination to no longer proceed with this project and recognized an impairment charge of $32.2 million to write off our

remaining right-of-use asset balance. As of June 30, 2025 and December 31, 2024, we had no operating lease liability associated with

this ground lease, as the related lease obligation had been fully prepaid.

**6. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH**

Cash, cash equivalents, and restricted cash consisted of the following as of June 30, 2025 and December 31, 2024 (in

thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Cash and cash equivalents | $520545 | $552146 |
| Restricted cash: |  |  |
| Funds held in escrow for real estate acquisitions | 2955 | 2954 |
| Other  | 4448 | 4747 |
|  | 7403 | 7701 |
| Total | $527948 | $559847 |

---

![](are-20250630_g1.gif)

**7. INVESTMENTS**

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. As a

REIT, we generally limit our ownership of each individual entity's voting stock to less than 10%. We evaluate each investment to

determine whether we have the ability to exercise significant influence, but not control, over an investee. We evaluate investments in

which our ownership is equal to or greater than 20%, but less than or equal to 50%, of an investee's voting stock with a presumption

that we have this ability. For our investments in limited partnerships that maintain specific ownership accounts, we presume that such

ability exists when our ownership interest exceeds 3% to 5%. In addition to our ownership interest, we consider whether we have a

board seat or whether we participate in the investee's policy-making process, among other criteria, to determine if we have the ability to

exert significant influence, but not control, over an investee. If we determine that we have such ability, we account for the investment

under the equity method, as described below.

From time to time, we may hold equity investments in publicly traded companies that are subject to temporary contractual sale

restrictions. We do not recognize a discount related to such contractual sale restrictions.

**Investments accounted for under the equity method** 

Under the equity method of accounting, we initially recognize our investment at cost and subsequently adjust the carrying

amount of the investment for our share of earnings or losses reported by the investee, distributions received, and other-than-temporary

impairments.

As of June 30, 2025, we had ten investments in limited partnerships maintaining specific ownership accounts for each investor,

which were accounted for under the equity method. These investments aggregated $276.8 million. Our ownership interest in each of

these ten investments was greater than 5%.

**Investments that do not qualify for the equity method of accounting**

For investees over which we determine that we do not have the ability to exercise significant influence or control, we account

for each investment depending on whether it is an investment in a (i) publicly traded company, (ii) privately held entity that reports NAV

per share, or (iii) privately held entity that does not report NAV per share, as described below.

*Investments in publicly traded companies*

Our investments in publicly traded companies are classified as investments with readily determinable fair values and are

presented at fair value in our consolidated balance sheets, with changes in fair value classified in investment income (loss) in our

consolidated statements of operations. The fair values for our investments in publicly traded companies are determined based on sales

prices or quotes available on securities exchanges.

*Investments in privately held companies*

Our investments in privately held entities without readily determinable fair values consist of (i) investments in privately held

entities that report NAV per share and (ii) investments in privately held entities that do not report NAV per share. These investments are

accounted for as follows:

<u>Investments in privately held entities that report NAV per share</u> 

Investments in privately held entities that report NAV per share, such as our privately held investments in limited partnerships,

are presented at fair value using NAV as a practical expedient, with changes in fair value classified in investment income (loss) in our

consolidated statements of operations. We use NAV per share reported by limited partnerships generally without adjustment, unless we

are aware of information indicating that the NAV reported by a limited partnership does not accurately reflect the fair value of the

investment at our reporting date.

<u>Investments in privately held entities that do not report NAV per share</u>

Investments in privately held entities that do not report NAV per share are accounted for using a measurement alternative

under which these investments are measured at cost, adjusted for observable price changes and impairments, with changes classified

in investment income (loss) in our consolidated statements of operations.

An observable price arises from an orderly transaction for an identical or similar investment of the same issuer, which is

observed by an investor without expending undue cost and effort. Observable price changes result from, among other things, equity

transactions of the same issuer executed during the reporting period, including subsequent equity offerings or other reported equity

transactions related to the same issuer. To determine whether these transactions are indicative of an observable price change, we

evaluate, among other factors, whether these transactions have similar rights and obligations, including voting rights, distribution

preferences, and conversion rights to the investments we hold.

![](are-20250630_g1.gif)

**7. INVESTMENTS (continued)**

**Impairment evaluation of equity method investments and investments in privately held entities that do not report NAV per share**

We monitor equity method investments and investments in privately held entities that do not report NAV per share for new

developments, including operating results, prospects and results of clinical trials, new product initiatives, new collaborative agreements,

capital-raising events, and merger and acquisition activities. These investments are evaluated on the basis of a qualitative assessment

for indicators of impairment by monitoring the presence of the following triggering events or impairment indicators:

(i)a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee;

(ii)a significant adverse change in the regulatory, economic, or technological environment of the investee;

(iii)a significant adverse change in the general market condition, including the research and development of technology and

products that the investee is bringing or attempting to bring to the market;

(iv)significant concerns about the investee's ability to continue as a going concern; and/or

(v)a decision by investors to cease providing support or reduce their financial commitment to the investee.

If such indicators are present, we are required to estimate the investment's fair value and immediately recognize an

impairment charge in an amount equal to the investment's carrying value in excess of its estimated fair value.

**Investment income/loss recognition and classification** 

We recognize both realized and unrealized gains and losses in our consolidated statements of operations, classified in

investment income (loss) in our consolidated statements of operations. Unrealized gains and losses represent:

(i)changes in fair value for investments in publicly traded companies;

(ii)changes in NAV for investments in privately held entities that report NAV per share;

(iii)observable price changes for investments in privately held entities that do not report NAV per share; and

(iv)our share of unrealized gains or losses reported by our equity method investees.

Realized gains and losses on our investments represent the difference between proceeds received upon disposition of

investments and their historical or adjusted cost basis. For our equity method investments, realized gains and losses represent our

share of realized gains or losses reported by the investee. Impairments are realized losses, which result in an adjusted cost basis, and

represent charges to reduce the carrying values of investments in privately held entities that do not report NAV per share and equity

method investments, if impairments are deemed other than temporary, to their estimated fair value.

**Funding commitments to investments in privately held entities that report NAV**

We are committed to funding approximately $351.0 million for our investments in privately held entities that report NAV. Our

funding commitments expire at various dates over the next 12 years, with a weighted-average expiration of 8.0 yearsas of June 30,

2025. These investments are not redeemable by us, but we may receive distributions from these investments throughout their terms.

Our investments in privately held entities that report NAV generally have expected initial terms in excess of 10 years. The weighted-

average remaining term during which these investments are expected to be liquidated was 5.2 yearsas of June 30, 2025.

![](are-20250630_g1.gif)

**7. INVESTMENTS (continued)**

The following tables summarize our investments as of June 30, 2025 and December 31, 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 |
|  | Cost | Unrealized <br>Gains<br>| Unrealized <br>Losses<br>| Carrying <br>Amount<br>|
| Publicly traded companies | $183859 | $18365 | $(120299) | $81925 |
| Entities that report NAV | 497975 | 97201 | (43013) | 552163 |
| Entities that do not report NAV: |  |  |  |  |
| Entities with observable price changes  | 78105 | 64585 | (9156) | 133534 |
| Entities without observable price changes | 432299 |  |  | 432299 |
| Investments accounted for under the equity method | N/A | N/A | N/A | 276775 |
| Total investments | $1192238 | $180151 | $(172468) | $1476696 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
|  | Cost | Unrealized <br>Gains<br>| Unrealized <br>Losses<br>| Carrying <br>Amount<br>|
| Publicly traded companies | $188653 | $24262 | $(107248) | $105667 |
| Entities that report NAV | 518074 | 126077 | (34285) | 609866 |
| Entities that do not report NAV: |  |  |  |  |
| Entities with observable price changes | 99932 | 77761 | (2956) | 174737 |
| Entities without observable price changes | 400487 |  |  | 400487 |
| Investments accounted for under the equity method | N/A | N/A | N/A | 186228 |
| Total investments | $1207146 | $228100 | $(144489) | $1476985 |

---

Cumulative gains and losses (realized and unrealized) on investments in privately held entities that do not report NAV still held

as of June 30, 2025 aggregated to a loss of $123.3 million, which consisted of upward adjustments aggregating $64.6 million,

downward adjustments aggregating $9.2 million, and impairments aggregating $178.7 million.

Our investment income (loss) for the three and six months ended June 30, 2025 and 2024 consisted of the following (in

thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Realized (losses) gains | $(8684)<br><sup>(1)</sup> | $20578 | $9469<br><sup>(1)</sup> | $34704 |
| Unrealized losses | (21938) | (64238) | (90083) | (35080) |
| Investment loss | $(30622) | $(43660) | $(80614) | $(376) |

---

(1)Consists of realized gains of $30.5 million and $59.9 million, partially offset by impairment charges of $39.2 million and $50.4 millionduring the three and six months

ended June 30, 2025, respectively.

During the six months ended June 30, 2025, gains and losses on investments in privately held entities that do not report NAV

still held as of June 30, 2025 aggregated to a loss of$57.6 million, which consisted of upward adjustments aggregating $8.8 million and

downward adjustments and impairments aggregating $66.4 million.

During the six months ended June 30, 2024, gains and losses on investments in privately held entities that do not report NAV

still held as of June 30, 2024 aggregated to a loss of $13.7 million, which consisted of upward adjustments aggregating $15.7 million

and downward adjustments and impairments aggregating $29.4 million.

Unrealized gains or losses related to investments still held (excluding investments accounted for under the equity method) as

of June 30, 2025 and 2024 aggregated to a loss of$30.7 million and a loss of $1.8 millionduring the six months ended June 30, 2025

and 2024, respectively.

Our investment loss of $80.6 millionfor the six months ended June 30, 2025 also included$102 thousand of equity in losses of

our equity method investments.

Refer to "Investments" in Note 2 – "Summary of significant accounting policies" to our unaudited consolidated financial

statements for additional information.

![](are-20250630_g1.gif)

**8. OTHER ASSETS**

The following table summarizes the components of other assets as of June 30, 2025 and December 31, 2024 (in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Acquired in-place leases | $255170 | $305144 |
| Deferred compensation plan | 49943 | 47727 |
| Deferred financing costs – unsecured senior line of credit | 44231 | 49056 |
| Deposits | 29772 | 21768 |
| Furniture, fixtures, equipment, and software | 54352 | 39558 |
| Net investment in leases | 60271 | 41503 |
| Notes receivable | 216762 | 120546 |
| Operating lease right-of-use assets | 717125<br><sup>(1)</sup> | 764472 |
| Other assets | 101423 | 96690 |
| Prepaid expenses | 27109 | 33567 |
| Property, plant, and equipment | 131933 | 141275 |
| Total | $1688091 | $1661306 |

---

(1)Refer to "Leases in which we are the lessee" section within Note 5 – "Leases" for information about the decrease in this balance since December 31, 2024.

**Notes receivable**

Our notes receivable as of June 30, 2025 and December 31, 2024 consisted of the following (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | As of June 30, 2025 | As of June 30, 2025 | As of June 30, 2025 |  |
|  | Weighted Average | Weighted Average |  |  |
| Notes Receivable | Effective <br>Interest Rate<br>| Maturity <br>Date<br>| Balance | December 31, 2024 |
| Secured by real estate assets in San Diego | 10.1% | 11/4/28 | $199505 | $103427 |
| Secured by real estate assets in Greater Boston | 4.6% | 12/16/29 | 17730 | 17356 |
| Less: provision for expected credit losses |  |  | (473) | (237) |
| Notes receivable |  |  | $216762 | $120546 |

---

Our notes receivable represent held-to-maturity debt securities carried at amortized costs and are generally secured by real

estate. Under the current expected credit losses accounting standard, we are required to estimate and, if necessary, recognize a

provision for expected credit losses related to these notes. We do not have a history of losses on such securities; therefore, we utilize

available information on historical losses for the commercial real estate industry. We determine expected credit losses for our notes

receivable using historical industry losses and considering loan-specific information, including credit ratings of the borrowers, estimated

fair values of underlying real estate assets, loan-to-value ratios, the presence of guarantors, and/or other available information. During

the three months ended June 30, 2025, no adjustment to the provision for expected credit losses related to our notes receivable was

required. The provision is reevaluated on an ongoing basis, with any necessary adjustments recognized in the corresponding period.

![](are-20250630_g1.gif)

**9. FAIR VALUE MEASUREMENTS**

We provide fair value information about all financial instruments for which it is practicable to estimate fair value. We measure

and disclose the estimated fair value of financial assets and liabilities by utilizing a fair value hierarchy that distinguishes between data

obtained from sources independent of the reporting entity and the reporting entity's own assumptions about market participant

assumptions. This hierarchy consists of three broad levels, as follows: (i) quoted prices in active markets for identical assets or liabilities

(Level 1), (ii) significant other observable inputs (Level 2), and (iii) significant unobservable inputs (Level 3). Significant other observable

inputs can include quoted prices for similar assets or liabilities in active markets, as well as inputs that are observable for the asset or

liability, such as interest rates, foreign exchange rates, and yield curves. Significant unobservable inputs are typically based on an

entity's own assumptions, since there is little, if any, related market activity. In instances in which the determination of the fair value

measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the

entire fair value measurement falls is based on the lowest level of input that is significant to the fair value measurement in its entirety.

Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers

factors specific to the asset or liability.

**Assets and liabilities measured at fair value on a recurring basis**

The following table sets forth the assets that we measure at fair value on a recurring basis by level in the fair value hierarchy

(in thousands). There were no liabilities measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024. There

were no transfers of assets measured at fair value on a recurring basis to or from Level 3 in the fair value hierarchy during the six

months ended June 30, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | Fair Value Measurement Using | Fair Value Measurement Using | Fair Value Measurement Using |
| Description  | Total | Quoted Prices in<br>Active Markets<br>for Identical Assets<br>(Level 1)<br>| Significant<br>Other<br>Observable Inputs<br>(Level 2)<br>| Significant<br>Unobservable<br>Inputs<br>(Level 3)<br>|
| Investments in publicly traded companies:  |  |  |  |  |
| As of June 30, 2025 | $81925 | $81925 | $— | $— |
| As of December 31, 2024 | $105667 | $105667 | $— | $— |

---

Our investments in publicly traded companies represent investments with readily determinable fair values, and are carried at

fair value, with changes in fair value classified in investment income (loss) in our consolidated financial statements. We also hold

investments in privately held entities, which consist of (i) investments that report NAV and (ii) investments that do not report NAV, as

further described below.

Our investments in privately held entities that report NAV, such as our privately held investments in limited partnerships, are

carried at fair value using NAV as a practical expedient, with changes in fair value classified in net income. As of June 30, 2025 and

December 31, 2024, the carrying values of investments in privately held entities that report NAV aggregated $552.2 million and

$609.9 million, respectively. These investments are excluded from the fair value hierarchy above as required by the fair value

accounting standard. We estimate the fair value of each of our investments in limited partnerships based on the most recent NAV

reported by each limited partnership. As a result, the determination of fair values of our investments in privately held entities that report

NAV generally does not involve significant estimates, assumptions, or judgments.

![](are-20250630_g1.gif)

**9. FAIR VALUE MEASUREMENTS (continued)**

**Assets and liabilities measured at fair value on a nonrecurring basis**

The following table sets forth the assets measured at fair value on a nonrecurring basis by level within the fair value hierarchy

as of June 30, 2025 and December 31, 2024 (in thousands).

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | Fair Value Measurement Using | Fair Value Measurement Using | Fair Value Measurement Using | Fair Value Measurement Using | Fair Value Measurement Using |
| Description  | Carrying <br>Amount<br>|  | Quoted Prices in<br>Active Markets<br>for Identical Assets<br>(Level 1)<br>| Significant<br>Other<br>Observable Inputs<br>(Level 2) | Significant<br>Other<br>Observable Inputs<br>(Level 2) | Significant<br>Unobservable<br>Inputs<br>(Level 3) | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
| Real estate assets held for sale with carrying values <br>adjusted to fair value less costs to sell:<br>|  |  |  |  |  |  |  |
| As of June 30, 2025 | $289673 | (1) | $— | $— |  | $289673 | (2) |
| As of December 31, 2024 | $322662 | (1) | $— | $— |  | $322662 | (2) |
| Investments in privately held entities that do not <br>report NAV:<br>|  |  |  |  |  |  |  |
| As of June 30, 2025 | $150943 |  | $— | $133534 | (3) | $17409 | (4) |
| As of December 31, 2024 | $184236 |  | $— | $174737 | (3) | $9499 | (4) |

---

(1)These amounts are included in the total balances of our net assets classified as held for sale aggregating$323.7 million and $371.3 million as of June 30, 2025 and

December 31, 2024, respectively, disclosed in Note 3 – "Investments in real estate," and represent assets held for sale as of June 30, 2025 and December 31, 2024, for

which impairments were recognized.

(2)These amounts represent the aggregate carrying amounts of assets held for sale after adjustments to their respective fair values less costs to sell based on executed

purchase and sale agreements, letters of intent, or valuations provided by third-party real estate brokers.

(3)These amounts represent the total carrying amounts of our equity investments in privately held entities with observable price changes, which are included in the

investments balances of$1.5 billionand $1.5 billion in our unaudited consolidated balance sheets as of June 30, 2025 and December 31, 2024, respectively, disclosed

in Note 7 – "Investments" to our unaudited consolidated financial statements.

(4)These amounts are included in the investments in privately held entities without observable price changes balances aggregating $432.3 million and $400.5 million as of

June 30, 2025 and December 31, 2024, respectively, disclosed in Note 7 – "Investments" to our unaudited consolidated financial statements. The aforementioned

balances represent the carrying amounts of investments in privately held entities that do not report NAV for which impairments have been recognized in accordance with

the measurement alternative guidance described in "Investments" in Note 2 – "Summary of significant accounting policies" to our unaudited consolidated financial

statements.

*<u>Real estate assets classified as held for sale measured at fair value less costs to sell</u>*

Our real estate assets classified as held for sale and measured at fair value less costs to sell are presented in the table above.

These properties are subsets of our total real estate assets classified as held for sale as of June 30, 2025 and December 31, 2024. The

fair values for these real estate assets were estimated based on executed purchase and sale agreements, letters of intent, or valuations

provided by third-party real estate brokers. Refer to "Investments in real estate" in Note 2 – "Summary of significant accounting policies"

and "Assets held for sale" in Note 3 – "Investments in real estate" to our unaudited consolidated financial statements for additional

information.

*<u>Investments in privately held entities that do not report NAV</u>*

Our investments in privately held entities that do not report NAV are measured at cost, adjusted for observable price changes

and impairments, with changes recognized in net income (loss). These investments are adjusted based on the observable price

changes in orderly transactions for the identical or similar investment of the same issuer. Further adjustments are not made until

another observable transaction occurs. Therefore, the determination of fair values of our investments in privately held entities that do

not report NAV does not involve significant estimates and assumptions or subjective and complex judgments.

We also subject our investments in privately held entities that do not report NAV to a qualitative assessment for indicators of

impairment. If indicators of impairment are present, we are required to estimate the investment's fair value and immediately recognize

an impairment charge in an amount equal to the investment's carrying value in excess of its estimated fair value.

The estimates of fair value typically incorporate valuation techniques that include an income approach reflecting a discounted

cash flow analysis, and a market approach that includes a comparative analysis of acquisition multiples and pricing multiples generated

by market participants. In certain instances, we may use multiple valuation techniques for a particular investment and estimate its fair

value based on an average of multiple valuation results.

Refer to Note 7 – "Investments" to our unaudited consolidated financial statements for additional information.

![](are-20250630_g1.gif)

**9. FAIR VALUE MEASUREMENTS (continued)**

**Assets and liabilities not measured at fair value in the statement of financial position but for which the fair value is disclosed**

The fair value of our secured note payable and unsecured senior notes payable, and the amounts outstanding on our

unsecured senior line of credit and commercial paper program, were estimated using widely accepted valuation techniques, including

discounted cash flow analyses using significant other observable inputs such as available market information on discount and

borrowing rates with similar terms, maturities, and credit ratings. Because the valuations of our financial instruments are based on these

types of estimates, the actual fair value of our financial instruments may differ materially if our estimates do not prove to be accurate.

Additionally, the use of different market assumptions or estimation methods may have a material effect on the estimated fair value

amounts.

As of June 30, 2025 and December 31, 2024, the book and estimated fair values of our secured note payable and unsecured

senior notes payable and the amounts outstanding under our unsecured senior line of credit and commercial paper program, including

the level within the fair value hierarchy for which the estimates were derived, were as follows (in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 |
|  | Book Value | Fair Value Hierarchy | Fair Value Hierarchy | Fair Value Hierarchy | Estimated <br>Fair Value |
|  | Book Value | Quoted Prices in<br>Active Markets<br>for Identical Assets<br>(Level 1)<br>| Significant<br>Other<br>Observable Inputs<br>(Level 2)<br>| Significant<br>Unobservable<br>Inputs<br>(Level 3)<br>| Estimated <br>Fair Value |
| Liabilities: |  |  |  |  |  |
| Secured note payable | $153500 | $— | $153521 | $— | $153521 |
| Unsecured senior notes payable | $12042607 | $— | $10548383 | $— | $10548383 |
| Unsecured senior line of credit | $— | $— | $— | $— | $— |
| Commercial paper program | $1097993 | $— | $1098989 | $— | $1098989 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
|  | Book Value | Fair Value Hierarchy | Fair Value Hierarchy | Fair Value Hierarchy | Estimated <br>Fair Value |
|  | Book Value | Quoted Prices in<br>Active Markets<br>for Identical Assets<br>(Level 1)<br>| Significant<br>Other<br>Observable Inputs<br>(Level 2)<br>| Significant<br>Unobservable<br>Inputs<br>(Level 3)<br>| Estimated <br>Fair Value |
| Liabilities: |  |  |  |  |  |
| Secured notes payable | $149909 | $— | $149413 | $— | $149413 |
| Unsecured senior notes payable | $12094465 | $— | $10472993 | $— | $10472993 |
| Unsecured senior line of credit | $— | $— | $— | $— | $— |
| Commercial paper program | $— | $— | $— | $— | $— |

---

The carrying values of cash and cash equivalents, restricted cash, tenant receivables, deposits, notes receivable, accounts

payable, accrued expenses, and other short-term liabilities approximate their fair value.

![](are-20250630_g2.gif)

**10. SECURED AND UNSECURED SENIOR DEBT**

The following table summarizes our outstanding indebtedness and respective principal payments remaining as of June 30, 2025 (dollars in thousands):

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Stated <br>Rate | Interest <br>Rate<sup>(1)</sup> | Maturity <br>Date<sup>(2)</sup> | Principal Payments Remaining for the Periods Ending December 31, | Principal Payments Remaining for the Periods Ending December 31, | Principal Payments Remaining for the Periods Ending December 31, | Principal Payments Remaining for the Periods Ending December 31, | Principal Payments Remaining for the Periods Ending December 31, | Principal Payments Remaining for the Periods Ending December 31, |  | Unamortized <br>(Deferred <br>Financing <br>Cost), <br>(Discount)/ <br>Premium |  |
| Debt | Stated <br>Rate | Interest <br>Rate<sup>(1)</sup> | Maturity <br>Date<sup>(2)</sup> | 2025 | 2026 | 2027 | 2028 | 2029 | Thereafter | Principal | Unamortized <br>(Deferred <br>Financing <br>Cost), <br>(Discount)/ <br>Premium | Total |
| Secured note payable |  |  |  |  |  |  |  |  |  |  |  |  |
| Greater Boston<sup>(3)</sup> | SOFR+2.70% | 7.16% | 11/19/26<br><sup>(3)</sup> | $— | $153624 | $— | $— | $— | $— | $153624 | $(124) | $153500 |
| Unsecured senior line of credit and <br>commercial paper program<sup>(4)</sup><br>| <sup>(4)</sup> | 4.71<br><sup>(4)</sup> | 1/22/30<br><sup>(4)</sup> |  |  |  |  |  | 1100000 | 1100000 | (2007) | 1097993 |
| Unsecured senior notes payable | 4.30% | 4.50 | 1/15/26 |  | 300000 |  |  |  |  | 300000 | (284) | 299716 |
| Unsecured senior notes payable | 3.80% | 3.96 | 4/15/26 |  | 350000 |  |  |  |  | 350000 | (408) | 349592 |
| Unsecured senior notes payable | 3.95% | 4.13 | 1/15/27 |  |  | 350000 |  |  |  | 350000 | (812) | 349188 |
| Unsecured senior notes payable | 3.95% | 4.07 | 1/15/28 |  |  |  | 425000 |  |  | 425000 | (1100) | 423900 |
| Unsecured senior notes payable | 4.50% | 4.60 | 7/30/29 |  |  |  |  | 300000 |  | 300000 | (916) | 299084 |
| Unsecured senior notes payable | 2.75% | 2.87 | 12/15/29 |  |  |  |  | 400000 |  | 400000 | (1860) | 398140 |
| Unsecured senior notes payable | 4.70% | 4.81 | 7/1/30 |  |  |  |  |  | 450000 | 450000 | (1872) | 448128 |
| Unsecured senior notes payable | 4.90% | 5.05 | 12/15/30 |  |  |  |  |  | 700000 | 700000 | (4339) | 695661 |
| Unsecured senior notes payable | 3.375% | 3.48 | 8/15/31 |  |  |  |  |  | 750000 | 750000 | (4027) | 745973 |
| Unsecured senior notes payable | 2.00% | 2.12 | 5/18/32 |  |  |  |  |  | 900000 | 900000 | (6506) | 893494 |
| Unsecured senior notes payable | 1.875% | 1.97 | 2/1/33 |  |  |  |  |  | 1000000 | 1000000 | (6675) | 993325 |
| Unsecured senior notes payable | 2.95% | 3.07 | 3/15/34 |  |  |  |  |  | 800000 | 800000 | (6857) | 793143 |
| Unsecured senior notes payable | 4.75% | 4.88 | 4/15/35 |  |  |  |  |  | 500000 | 500000 | (4730) | 495270 |
| Unsecured senior notes payable | 5.50% | 5.66 | 10/1/35 |  |  |  |  |  | 550000 | 550000 | (6624) | 543376 |
| Unsecured senior notes payable | 5.25% | 5.38 | 5/15/36 |  |  |  |  |  | 400000 | 400000 | (3939) | 396061 |
| Unsecured senior notes payable | 4.85% | 4.93 | 4/15/49 |  |  |  |  |  | 300000 | 300000 | (2814) | 297186 |
| Unsecured senior notes payable | 4.00% | 3.91 | 2/1/50 |  |  |  |  |  | 700000 | 700000 | 9916 | 709916 |
| Unsecured senior notes payable | 3.00% | 3.08 | 5/18/51 |  |  |  |  |  | 850000 | 850000 | (11034) | 838966 |
| Unsecured senior notes payable | 3.55% | 3.63 | 3/15/52 |  |  |  |  |  | 1000000 | 1000000 | (13450) | 986550 |
| Unsecured senior notes payable | 5.15% | 5.26 | 4/15/53 |  |  |  |  |  | 500000 | 500000 | (7482) | 492518 |
| Unsecured senior notes payable | 5.625% | 5.71 | 5/15/54 |  |  |  |  |  | 600000 | 600000 | (6580) | 593420 |
| Unsecured debt weighted-average interest <br>rate/subtotal<br>|  | 3.97 |  |  | 650000 | 350000 | 425000 | 700000 | 11100000 | 13225000 | (84400) | 13140600 |
| Weighted-average interest rate/total  |  | 4.01% |  | $— | $803624 | $350000 | $425000 | $700000 | $11100000 | $13378624 | $(84524) | $13294100 |

---

(1)Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.

(2)Reflects any extension options that we control.

(3)Represents a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, where we have a 76.9%interest. As of June 30, 2025, this joint venture has $41.7 millionavailable under existing lender

commitments. We expect to repay the entire $153.5 millionbalance inAugust 2025.

(4)Refer to "$5.0 billion unsecured senior line of credit" and "$2.5 billion commercial paper program" on the following page.

![](are-20250630_g1.gif)

**10. SECURED AND UNSECURED SENIOR DEBT (continued)**

The following table summarizes our secured and unsecured senior debt and amounts outstanding under our unsecured senior

line of credit and commercial paper program as of June 30, 2025 (dollars in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Fixed-Rate <br>Debt | Variable-Rate <br>Debt | | | Weighted-Average | Weighted-Average |
|  | Fixed-Rate <br>Debt | Variable-Rate <br>Debt | | | | Remaining <br>Term<br>(in years) |
|  | Fixed-Rate <br>Debt | Variable-Rate <br>Debt | <br>Total | <br>Percentage  | Interest<br>Rate<sup>(1)</sup> | Remaining <br>Term<br>(in years) |
| Secured note payable | $— | $153500 | $153500 | 1.2% | 7.16% | 1.4 |
| Unsecured senior notes payable | 12042607 |  | 12042607 | 90.5 | 3.90 | 12.8 |
| Unsecured senior line of credit <br>and commercial paper program<br>|  | 1097993 | 1097993<br><sup>(2)</sup> | 8.3 | 4.71<br><sup>(2)</sup> | 4.6<br><sup>(3)</sup> |
| Total/weighted average | $12042607 | $1251493 | $13294100 | 100.0% | 4.01% | 12.0<br><sup>(3)</sup> |
| Percentage of total debt | 90.6% | 9.4% | 100% |  |  |  |

---

(1)Represents the weighted-average interest rate as of the end of the applicable period, including expense/income related to the amortization of loan fees, amortization of

debt premiums (discounts), and other bank fees.

(2)As of June 30, 2025, we had no outstanding balance on our unsecured senior line of credit and $1.1 billion of commercial paper notes outstanding.

(3)We calculate the weighted-average remaining term of our commercial paper notes by using the maturity date of our unsecured senior line of credit. Using the maturity

date of our outstanding commercial paper notes, the consolidated weighted-average maturity of our debt is11.6 years. The commercial paper notes sold during the six

months ended June 30, 2025 were issued at a weighted-average yield to maturity of4.67% and had a weighted-average maturity term of 16 days.

**Issuance and repayment of unsecured senior notes payable**

In February 2025, we issued $550.0 million of unsecured senior notes payable, due 2035, with an interest rate of 5.50%.

In April 2025, we repaid our 3.45% unsecured senior notes payable aggregating $600.0 million upon their maturity, using

proceeds from our February 2025 unsecured senior notes payable offering, with no gain or loss incurred in connection with this

repayment.

**$5.0 billion unsecured senior line of credit**

As of June 30, 2025, our unsecured senior line of credit, which matures in 2030, including extension options under our control,

had aggregate commitments of $5.0 billion and bore an interest rate of SOFR plus 0.855%. In addition to the cost of borrowing, the

unsecured senior line of credit is subject to an annual facility fee of 0.145% based on the aggregate commitments outstanding. Based

upon our ability to achieve certain annual sustainability metrics, the interest rate and facility fee rate are also subject to upward or

downward adjustments of up to four basis points with respect to the interest rate and up to one basis point with respect to the facility fee

rate.

Based on certain sustainability metrics achieved in accordance with the terms of our unsecured senior line of credit

agreement, the borrowing rate was reduced for a one-year period by two basis points to SOFR plus 0.855%, from SOFR plus 0.875%,

and the facility fee was reduced by 0.5 basis point to 0.145% from 0.15%. As of June 30, 2025, we had no outstanding balance on our

unsecured line of credit.

**$2.5 billion commercial paper program**

Our commercial paper program provides us with the ability to issue up to$2.5 billion of commercial paper notes that bear

interest at short-term fixed rates with a maturity of generally 30 days or less and a maximum maturity of 397 days from the date of

issuance.Our commercial paper program is backed by our unsecured senior line of credit, and at all times we expect to retain a

minimum undrawn amount of borrowing capacity under our unsecured senior line of credit equal to any outstanding notes issued under

our commercial paper program. We use the net proceeds from the issuances of the notes for general working capital and other general

corporate purposes. General corporate purposes may include, but are not limited to, the repayment of other debt and selective

development, redevelopment, or acquisition of properties. During the six months ended June 30, 2025, the commercial paper notes

were issued at a weighted-average yield to maturity of4.67% and had a weighted-average maturity term of 16 days. As of June 30,

2025, we had a$1.1 billionoutstanding balance on our commercial paper program.

![](are-20250630_g1.gif)

**10. SECURED AND UNSECURED SENIOR DEBT (continued)**

**Interest expense**

The following table summarizes interest expense for the three and six months ended June 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Interest incurred | $137719 | $126828 | $268660 | $249508 |
| Capitalized interest | (82423) | (81039) | (162488) | (162879) |
| Interest expense | $55296 | $45789 | $106172 | $86629 |

---

**11. ACCOUNTS PAYABLE, ACCRUED EXPENSES, AND OTHER LIABILITIES**

The following table summarizes the components of accounts payable, accrued expenses, and other liabilities as of June 30,

2025 and December 31, 2024 (in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Accounts payable and accrued expenses | $406957 | $534803 |
| Accrued construction | 328298 | 500890 |
| Acquired below-market leases | 153289 | 180407 |
| Conditional asset retirement obligations | 45559 | 53968 |
| Deferred rent liabilities | 12123 | 11461 |
| Operating lease liability | 363419 | 507127 |
| Unearned rent and tenant security deposits | 890689 | 691873 |
| Other liabilities | 160506 | 173822 |
| Total | $2360840 | $2654351 |

---

As of June 30, 2025 and December 31, 2024, our conditional asset retirement obligations liability primarily consisted of the soil

and groundwater remediation liabilities associated with certain of our properties. Some of our properties may contain asbestos or may

be subjected to other hazardous or toxic substances, which, under certain conditions, requires remediation. We engage independent

environmental consultants to conduct Phase I or similar environmental assessments at our properties. This type of assessment

generally includes a site inspection, interviews, and a public records review; asbestos, lead-based paint, and mold surveys; subsurface

sampling; and other testing. We recognize a liability for the fair value of a conditional asset retirement obligation (including asbestos)

when the fair value of the liability can be reasonably estimated. In addition, environmental laws and regulations subject our tenants, and

potentially us, to liability that may result from our tenants' routine handling of hazardous substances and wastes as part of their

operations at our properties. These assessments and investigations of our properties have not to date revealed any additional

environmental liability we believe would have a material adverse effect on our business and financial statements or that would require

additional disclosures or recognition in our consolidated financial statements.

![](are-20250630_g1.gif)

**12. EARNINGS PER SHARE**

With respect to dividend rights, we have granted two types of restricted stock awards: (i) restricted stock awards with

nonforfeitable dividends and (ii) restricted stock awards with forfeitable dividends.

We account for unvested restricted stock awards ("RSAs") with nonforfeitable dividends as participating securities and include

these securities in the computation of EPS using the two-class method. Under the two-class method, we allocate net income (after

amounts attributable to noncontrolling interests) to common stockholders and unvested RSAs with nonforfeitable dividends by using the

weighted-average shares of each class outstanding for quarter-to-date and year-to-date periods independently, based on their

respective participation rights to dividends declared (or accumulated) and undistributed earnings.

Unvested RSAs with forfeitable dividends do not qualify as participating securities under the two-class method because the

dividends are forfeited if the awards do not vest. As a result, undistributed earnings are not allocated to these awards prior to vesting,

and these awards have no effect on the computation of basic EPS while unvested. Once these awards vest, they are included in the

denominator of basic EPS, weighted for the portion of the reporting period they were vested. Prior to vesting, these awards are included

in the denominator of diluted EPS if they are dilutive, which is determined using the treasury stock method. Under this method,

incremental shares are calculated as the difference between the total unvested shares and the number of shares that could

hypothetically be repurchased using the assumed proceeds (including unrecognized compensation cost related to these awards).

These incremental shares are weighted for the portion of the reporting period they were unvested, and are included in the diluted EPS

denominator only if their inclusion reduces EPS (i.e., if they are not antidilutive).

In addition, from time to time, we enter into forward equity sales agreements. We consider the potential dilution resulting from

the forward equity sales agreements on the EPS calculations. At inception, the agreements do not have an effect on the computation of

basic EPS as no shares are delivered until settlement. The common shares issued upon the settlement of the forward equity sales

agreements, weighted for the period these common shares were outstanding, are included in the denominator of basic EPS. To

determine the dilution resulting from the forward equity sales agreements during the period of time prior to settlement, we calculate the

number of weighted-average shares outstanding – diluted using the treasury stock method. As of June 30, 2025, no forward equity

sales agreements were outstanding.

The table below reconciles the numerators and denominators of the basic and diluted EPS computations for the three and six

months ended June 30, 2025 and 2024 (in thousands, except per share amounts):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income | $(62189) | $94049 | $(23527) | $313225 |
| Net income attributable to noncontrolling interests | (44813) | (47347) | (92414) | (95978) |
| Net income attributable to unvested RSAs with nonforfeitable <br>dividends<br>| (2609) | (3785) | (5269) | (7444) |
| Numerator for basic and diluted EPS – net (loss) income <br>attributable to Alexandria Real Estate Equities, Inc.'s <br>common stockholders<br>| $(109611) | $42917 | $(121210) | $209803 |
| Denominator for basic EPS – weighted-average shares of <br>common stock outstanding<br>| 170135 | 172013 | 170328 | 171981 |
| Dilutive effect of unvested RSAs with forfeitable dividends |  |  |  |  |
| Denominator for diluted EPS – weighted-average shares of <br>common stock outstanding <br>| 170135 | 172013 | 170328 | 171981 |
| Net (loss) income per share attributable to Alexandria Real <br>Estate Equities, Inc.'s common stockholders:<br>|  |  |  |  |
| Basic | $(0.64) | $0.25 | $(0.71) | $1.22 |
| Diluted | $(0.64) | $0.25 | $(0.71) | $1.22 |

---

![](are-20250630_g1.gif)

**13. STOCKHOLDERS' EQUITY**

**Common equity transactions**

*Common stock repurchase program* 

Under our common stock repurchase program authorized in December 2024, we may repurchase up to $500.0 million of our

common stock in the open market, in privately negotiated transactions, or otherwise through December 31, 2025.

During the three months ended March 31, 2025, we repurchased 2.2 million shares of common stock under this repurchase

program at an average price per share of $96.71.

During the three months ended June 30, 2025, we did not repurchase any shares. As of June 30, 2025, the approximate value

of shares that may yet be purchased under this program was $241.8 million.

*ATM common stock offering program*

In February 2024, we entered into an ATM common stock offering program that allows us to sell up to an aggregate of

$1.5 billion of our common stock.

During the six months ended June 30, 2025, we had no activity under our ATM program. As of June 30, 2025, the remaining

aggregate amount available under our ATM program for future sales of common stock was$1.47 billion.

**Dividends**

During the three months ended March 31, 2025, we declared cash dividends on our common stock aggregating $228.3 million,

or $1.32 per share.

During the three months ended June 30, 2025, we declared cash dividends on our common stock aggregating $228.3 million,

or $1.32 per share.

**Accumulated other comprehensive loss**

The change in accumulated other comprehensive loss attributable to Alexandria Real Estate Equities, Inc.'s stockholders

during the six months ended June 30, 2025 was entirely due to net unrealized gains of$18.8 millionon foreign currency translation

related to our operations primarily in Canada.

**Common stock, preferred stock, and excess stock authorizations**

Our charter authorizes the issuance of 400.0 million shares of common stock, of which 170.1 million shares were issued and

outstanding as of June 30, 2025. Our charter also authorizes the issuance of up to100.0 million shares of preferred stock, none of

which were issued and outstanding as of June 30, 2025. In addition,200.0 million shares of "excess stock" (as defined in our charter)

are authorized, none of which were issued and outstanding as of June 30, 2025.

![](are-20250630_g1.gif)

**14. NONCONTROLLING INTERESTS**

Noncontrolling interests represent the third-party interests in certain entities in which we have a controlling interest. As of

June 30, 2025, these entities owned63 properties, which are included in our consolidated financial statements. Noncontrolling interests

are adjusted for additional contributions and distributions, the proportionate share of the net earnings or losses, and other

comprehensive income or loss. Distributions, profits, and losses related to these entities are allocated in accordance with the respective

operating agreements. During the six months ended June 30, 2025 and 2024, we distributed $123.6 millionand $119.9 million,

respectively, to our consolidated real estate joint venture partners.

Certain of our noncontrolling interests have the right to require us to redeem their ownership interests in the respective entities.

We classify these ownership interests in the entities as redeemable noncontrolling interests outside of total equity in our consolidated

balance sheets. Redeemable noncontrolling interests are adjusted for additional contributions and distributions, the proportionate share

of the net earnings or losses, and other comprehensive income or loss. If the amount of a redeemable noncontrolling interest is less

than the maximum redemption value at the balance sheet date, such amount is adjusted to the maximum redemption value.

Subsequent declines in the redemption value are recognized only to the extent that previous increases have been recognized.

In March 2025, we redeemed our partner's entire noncontrolling interests in three real estate joint ventures in our Greater

Boston market, with a book value aggregating $10.4 million, and recognized$7.0 millionof consideration in excess of the book value in

additional paid-in capital.

Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial

statements for additional information.

**15. SEGMENT INFORMATION** 

We are a life science REIT focused on developing, redeveloping, and operating properties that provide space for lease to

tenants primarily in the life science industry. Our properties are leased predominantly through triple-net lease agreements and share

key characteristics, including generic and reusable improvements, consistent lease structures, and business strategy. All properties are

located within North America, predominantly in the U.S., and operate within a comparable regulatory environment.

*Operating segments*

Our Chief Operating Decision Maker ("CODM"), represented by our Executive Chairman and our Chief Executive Officer,

evaluates operating results at the geographic market level to assess performance and allocate resources. Our operating segments align

with our markets, including Greater Boston, San Francisco Bay Area, San Diego, and Seattle, among others. Regular market

performance updates are provided directly to the CODM. These updates include each market's net operating income ("NOI"), which

serves as the profit or loss measure used by the CODM for performance assessment and resource allocation. NOI provides useful

information regarding performance of each market as it reflects income and expenses incurred in connection with real estate operations

in each market. This metric enables the CODM to evaluate the profitability and performance of each market on a consistent and

comparable basis, supporting decisions on capital resource allocation, including in connection with development, redevelopment,

acquisition, and disposition activities in each market.

*Evaluation of economic similarity and aggregation of operating segments*

In accordance with the segment reporting accounting standard, we evaluate the economic similarity of our operating

segments. Seven of our nine operating segments exhibit consistent long-term economic characteristics, including similar historical long-

term NOI margins, which are also expected to remain similar in the future. Additionally, these markets share similar operational

characteristics, including nature of services provided (i.e., leasing, operating, developing, and redeveloping life science properties),

tenant base (i.e., a variety of tenants involved in the life science industry), methods of operation (i.e., consistent lease structures,

property management practices, and business strategies), nature of the regulatory environment (consistent across North America,

where all our operating segments are located). Based on shared economic characteristics, we have aggregated our seven operating

segments into one reportable segment for segment reporting purposes.Two of our operating segments, specifically our New York City

and Canada markets, do not meet the aggregation criteria and individually do not meet the quantitative thresholds to qualify as

reportable segments. Therefore, these operating segments are included in the "all other" category in the tables below*.*

![](are-20250630_g1.gif)

**15. SEGMENT INFORMATION (continued)**

The following table presents the reportable segment profit or loss measure, net operating income, for the three and six months

ended June 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Reportable segment revenues: |  |  |  |  |
| Revenues from external customers | $703457 | $713949 | $1402656 | $1434514 |
| Other income | 10488 | 5677 | 17015 | 11352 |
| Reportable segment total revenues | 713945 | 719626 | 1419671 | 1445866 |
| Reportable segment total rental operating expenses | (212402) | (199930) | (424838) | (391021) |
| Reportable segment net operating income (reportable <br>segment profit or loss)<br>| $501543 | $519696 | $994833 | $1054845 |

---

Significant expenses included in the reportable segment profit or loss measure (i.e., net operating income) are represented by

the reportable segment total rental operating expenses and are disclosed in the table above. These expenses primarily include property

taxes, utilities, repairs and maintenance, engineering, janitorial, and other costs.

Presented below are reconciliations of the reportable segment total revenues to the consolidated revenues, the reportable

segment total rental operating expenses to consolidated rental operations, the reportable segment NOI to the consolidated net income,

and the reportable segment investments in real estate assets to the consolidated investments in real estate assets (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| *Reconciliation of reportable segment revenues to* <br>*consolidated total revenues:*<br>|  |  |  |  |
| Reportable segment total revenues | $713945 | $719626 | $1419671 | $1445866 |
| All other revenues | 48095 | 47108 | 100527 | 89976 |
| Consolidated revenues | $762040 | $766734 | $1520198 | $1535842 |
| *Reconciliation of reportable segment total rental operating* <br>*expenses to consolidated rental operations:*<br>|  |  |  |  |
| Reportable segment total rental operating expenses | $(212402) | $(199930) | $(424838) | $(391021) |
| All other rental operating expenses | (12031) | (17324) | (25990) | (44547) |
| Consolidated rental operations | $(224433) | $(217254) | $(450828) | $(435568) |
| *Reconciliation of reportable segment net operating income* <br>*to consolidated net income:*<br>|  |  |  |  |
| Reportable segment net operating income (reportable <br>segment profit or loss)<br>| $501543 | $519696 | $994833 | $1054845 |
| All other revenues | 48095 | 47108 | 100527 | 89976 |
| All other rental operating expenses | (12031) | (17324) | (25990) | (44547) |
| *Other items not allocated to segments:* |  |  |  |  |
| General and administrative | (29128) | (44629) | (59803) | (91684) |
| Interest expense | (55296) | (45789) | (106172) | (86629) |
| Depreciation and amortization | (346123) | (290720) | (688185) | (578274) |
| Impairment of real estate | (129606) | (30763) | (161760) | (30763) |
| Equity in (losses) earnings of unconsolidated real <br>estate joint ventures<br>| (9021) | 130 | (9528) | 285 |
| Investment loss | (30622) | (43660) | (80614) | (376) |
| Gain on sale of real estate |  |  | 13165 | 392 |
| Consolidated net (loss) income | $(62189) | $94049 | $(23527) | $313225 |

---

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| *Reconciliation of reportable segment assets to consolidated investments in real* <br>*estate assets:* <br>|  |  |
| Reportable segment investments in real estate | $30476127 | $30393144 |
| All other investments in real estate | 1684473 | 1716895 |
| Consolidated investments in real estate | $32160600 | $32110039 |

---

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Forward-looking statements**

Certain information and statements included in this quarterly report on Form 10-Q, including, without limitation, statements

containing the words "forecast," "guidance," "goals," "projects," "estimates," "anticipates," "believes," "expects," "intends," "may," "plans,"

"seeks," "should," "targets," or "will," or the negative of those words or similar words, constitute "forward-looking statements" within the

meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements involve inherent risks and uncertainties regarding events, conditions, and financial trends that

may affect our future plans of operations, business strategy, results of operations, and financial position. A number of important factors

could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including,

but not limited to, the following:

• Operating factors, such as a failure to operate our business successfully in comparison to market expectations or in

comparison to our competitors, our inability to obtain capital when desired or refinance debt maturities when desired, and/

or a failure to maintain our status as a REIT for federal tax purposes;

• Market and industry factors, such as adverse developments concerning the life science industry and/or our tenants;

• Government factors, such as any unfavorable effects resulting from federal, state, local, and/or foreign government

policies, laws, and/or funding levels;

• Global factors, such as negative economic, social, political, financial, credit market, banking conditions, and/or regional

armed hostilities; and

• Other factors, such as climate change, cyber intrusions, and/or changes in laws, regulations, and financial accounting

standards.

**Global Trade Policies**

We have been monitoring and will continue to monitor macroeconomic trends and uncertainties. In particular, we are

assessing how recent fluctuations in international trade relations and trade policies could adversely affect our business or the

businesses of our tenants.

In early March 2025, the U.S. government imposed or indicated that it would impose a series of tariffs on certain goods from

Canada and Mexico as well as raise tariffs on Chinese imports. President Trump has also indicated his intent to impose a "major"

pharmaceutical-specific tariff, which could adversely affect our business and/or the business of our tenants. As a result of these

developments, the global securities and trade markets have reacted with volatility, and trade tensions remain high.

The imposition of tariffs or the potential future imposition of additional or modified tariffs in the current geopolitical climate could

have material adverse effects on the net profitability, revenues, or operations of Alexandria and many other companies. While we are

evaluating the potential impacts of such tariffs, as well as our ability to mitigate such impacts, these recent trends may in the meantime

interrupt supply chains, fragment international business relationships, and create unknown risks that would thereby affect our or our

tenants' business operations.

This list of risks and uncertainties is not exhaustive. Additional information regarding risk factors that may affect us is included

under Part I; "Item 1A. Risk factors"; and "Item 7. Management's discussion and analysis of financial condition and results of

operations" in our annual report on Form 10-K for the year ended December 31, 2024 and under respective sections in this quarterly

report on Form 10-Q. Readers of this quarterly report on Form 10-Q should also read our other documents filed publicly with the SEC

for further discussion regarding such factors.

**Overview**

We are a Maryland corporation formed in October 1994 that has elected to be taxed as a REIT for federal income tax

purposes. Alexandria Real Estate Equities, Inc. (NYSE: ARE), anS&P 500<sup>®</sup> company, is a best-in-class, mission-driven life science

REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate

niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in

AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland,

Research Triangle, and New York City. As of June 30, 2025, Alexandria has a total market capitalization of$25.7 billion and an asset

base in North America that includes 39.7 million RSF of operating properties and4.4 million RSF of Class A/A+ properties undergoing

construction and one100% pre-leased committed near-term project expected to commence construction in the next year.

We develop dynamic Megacampus ecosystems that enable and inspire some of the world's most brilliant minds and innovative

companies to create life-changing scientific and technological innovations. We believe in the utmost professionalism, humility, and

teamwork. Our tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science

product, service, and medical device companies; digital health, advanced technology, and agtech companies; academic and medical

research institutions; U.S. government research agencies; non-profit organizations; and venture capital firms. Alexandria has a long-

standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus

environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency,

creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital

platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in

higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

As of June 30, 2025:

• Investment-grade or publicly traded large cap tenants represented 53% of our annual rental revenue;

• Approximately 97%of our leases (on an annual rental revenue basis) contained effective annual rent escalations

approximating3% that were either fixedor indexed based on a consumer price index or other index;

• Approximately 91%of our leases (on an annual rental revenue basis) were triple net leases, which require tenants to pay

substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other

operating expenses (including increases thereto) in addition to base rent;

• Approximately 92% of our leases (on an annual rental revenue basis) provided for the recapture of capital expenditures

(such as HVAC maintenance and/or replacement, roof replacement, and parking lot resurfacing) that we believe would

typically be borne by the landlord in traditional office leases; and

• 84% of our leasing activity during the last twelve months was generated from our existing tenant base.

A key element of our business strategy is our unique focus on Class A/A+ properties primarily located in collaborative

Megacampus ecosystems in AAA life science innovation clusters. Our Megacampus ecosystems are designed for optionality and

scalability, offering our tenants a clear path to address their growth requirements, including through our future developments and

redevelopments. Strategically located near top academic and medical research institutions and equipped with curated amenities and

services, and convenient access to transit, our Megacampus ecosystems are designed to support our tenants in attracting and retaining

top talent and in meeting our tenants' growth needs, which we believe is a key driver of tenant demand for our properties. Our strategy

also includes drawing upon our deep, broad, and long-standing real estate and life science industry relationships in order to retain

tenants, identify and attract new and leading tenants, and source additional real estate.

**Executive summary**

*<u>Operating results</u>*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income attributable to Alexandria's <br>common stockholders – diluted:<br>|  |  |  |  |
| *In millions* | $(109.6) | $42.9 | $(121.2) | $209.8 |
| *Per share* | $(0.64) | $0.25 | $(0.71) | $1.22 |
| Funds from operations attributable to Alexandria's <br>common stockholders – diluted, as adjusted:<br>|  |  |  |  |
| *In millions* | $396.4 | $405.5 | $788.4 | $809.4 |
| *Per share* | $2.33 | $2.36 | $4.63 | $4.71 |

---

For additional information, refer to "Funds from operations and funds from operations, as adjusted, attributable to Alexandria

Real Estate Equities, Inc.'s common stockholders" under "Definitions and reconciliations" and to the tabular presentation of these items

in "Results of operations" in Item 2.

*<u>A sector-leading REIT with a high-quality, diverse tenant base and strong margins</u>*

---

| | |
|:---|:---|
| *(As of June 30, 2025, unless stated otherwise)* |  |
| Occupancy of operating properties in North America | 90.8%<br> <sup>(1)</sup> |
| Percentage of total annual rental revenue in effect from Megacampus platform | 75% |
| Percentage of total annual rental revenue in effect from investment-grade or publicly traded large cap tenants | 53% |
| Adjusted EBITDA margin for the three months ended June 30, 2025 | 71% |
| Percentage of leases containing annual rent escalations | 97% |
| Weighted-average remaining lease term: |  |
| Top 20 tenants | 9.4<br> years |
| All tenants | 7.4<br> years |
| Sustained strength in tenant collections: |  |
| July 2025 tenant rents and receivables collected as of the date of this report | 99.4% |
| Tenant rents and receivables for the three months ended June 30, 2025 collected as of the date of this <br>report<br>| 99.9% |

---

(1)Reflectstemporary vacancies aggregating 668,795 RSF, or 1.7%, which are now leased and expected to be occupied upon completion of building and/or tenant

improvements. The weighted-average expected delivery date is January 2, 2026. Refer to "Summary of occupancy percentages in North America" in Item 2 for additional

details.

*<u>Strong and flexible balance sheet with significant liquidity;</u><u>top 10%</u><u>credit rating ranking among all publicly traded U.S. REITs</u>*

As of June 30, 2025, unless stated otherwise:

*•*Net debt and preferred stock to Adjusted EBITDA of 5.9x andfixed-charge coverage ratio of 4.1x for the three months ended

June 30, 2025 annualized, with targets for the three months ended December 31, 2025 annualized of less than or equal to

5.2x and 4.0x to 4.5x, respectively.

• Significant liquidity of$4.6 billion.

• Only 9% of our total debt matures through 2027.

• 12.0 years weighted-average remaining term of debt,longest among S&P 500 REITs.

• Since 2021, our quarter-end fixed-rate debt averaged 97.2%.

• Total debt and preferred stock to gross assets of 30%.

• $297.3 million of capital contribution commitments from existing consolidated real estate joint venture partners to fund

construction from July 1, 2025 through 2027 and beyond, including $116.7 million from July 1, 2025 to December 31, 2025.

*<u>Leasing volume and rental rate increases</u>*

• Leasing volume of 769,815 RSF during the three months ended June 30, 2025.

• In July 2025, we executed the largest life science lease in company history with a long-standing multinational pharmaceutical

tenant for a 16-year expansion build-to-suit lease, aggregating466,598 RSF, located on the Campus Point by Alexandria

Megacampus in our University Town Center submarket. If this were included in the leasing volume for the three months ended

June 30, 2025, the total leased RSF would have increased to1.2 million RSF for the three months ended June 30, 2025 from

769,815 RSF. Refer to "New Class A/A+ development and redevelopment properties: current projects" in Item 2 for additional

information.

• Rental rate increases on lease renewals and re-leasing of space of5.5% and 6.1% (cash basis) for the three months ended

June 30, 2025 and 13.2% and 6.9% (cash basis) for the six months ended June 30, 2025.

• 84%of our leasing activity during the last twelve months was generated from our existing tenant base.

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | June 30, 2025 |
|  | Three Months Ended | Six Months Ended |
| Total leasing activity – RSF | 769815 | 1800368 |
| Lease renewals and re-leasing of space: |  |  |
| RSF (included in total leasing activity above) | 483409 | 1367817 |
| Rental rate increase | 5.5% | 13.2% |
| Rental rate increase (cash basis) | 6.1% | 6.9% |
| Leasing of development and redevelopment space – RSF | 131768 | 138198 |

---

*<u>Key operating metrics</u>*

• Total revenues

• $762.0 million, down0.6%, for the three months ended June 30, 2025, compared to $766.7 million for the three months

ended June 30, 2024. Excluding dispositions completed after January 1, 2024, total revenues would have increased by

5.1% for the three months ended June 30, 2025.

• $1.52 billion, down 1.0%, for the six months ended June 30, 2025, compared to $1.54 billion for the six months ended

June 30, 2024. Excluding dispositions completed after January 1, 2024, total revenues would have increased by 4.6% for

the six months ended June 30, 2025.

• Net operating income (cash basis) of $2.0 billion for the three months ended June 30, 2025 annualized increased by

$111.4 million, or 5.8%, compared to the three months ended June 30, 2024 annualized. Refer to "Net operating income, net

operating income (cash basis), and operating margin" under "Definitions and reconciliations" in Item 2 for a reconciliation of our

net income to net operating income (cash basis).

• Same property net operating income changes

• (5.4)% and 2.0% (cash basis) for the three months ended June 30, 2025, compared to the three months ended June 30,

2024, which include lease expirations that became vacant during the three months ended March 31, 2025, aggregating

768,080 RSF across six properties and four submarkets, with a weighted-average lease expiration date of January 21,

2025. Excluding the impact of these lease expirations, same property net operating income changes for the three months

ended June 30, 2025 would have been (2.1)% and 6.5% (cash basis). As of June 30, 2025, 153,658 RSF was leased with

a weighted-average lease commencement date of April 30, 2026, and we expect to favorably resolve the remaining

614,422 RSF over the next several quarters. Refer to the "Summary of occupancy percentages in North America" in Item

2 for additional details.

• (4.3)% and 3.4% (cash basis) for the six months ended June 30, 2025, compared to the six months ended June 30, 2024.

• General and administrative expenses

• $59.8 million for the six months ended June 30, 2025, representing cost savings of$31.9 million, or 35%, compared to the

six months ended June 30, 2024, primarily the result of cost-control and efficiency initiatives on reducing personnel-

related costs and streamlining business processes.

• As a percentage of net operating income, our general and administrative expenses for the trailing twelve months ended

June 30, 2025 were 6.3%, representing the lowest level in the past ten years, compared to 9.2% for the trailing twelve

months ended June 30, 2024.

*<u>Dividend strategy to share net cash flows from operating activities with stockholders while retaining a significant portion for reinvestment</u>*

• Common stock dividend declared for the three months ended June 30, 2025of$1.32 per share aggregating$5.26per

common share for the twelve months ended June 30, 2025, up18 cents, or 3.5%, over the twelve months ended June 30,

2024. •By maintaining our recent dividend at$1.32per share, over$40 million of additional liquidity and equity capital can be

reinvested annually.

• Dividend yield of7.3% as of June 30, 2025.

• Dividend payout ratio of57% for the three months ended June 30, 2025.

• Significant net cash flows provided by operating activities after dividends retained for reinvestment aggregating $2.3 billionfor

the years ended December 31, 2021 through 2024 and the midpoint of our 2025 guidance range.

*<u>Ongoing</u> <u>execution of Alexandria's 2025 capital recycling strategy</u>*

We expect to fund a significant portion of our capital requirements for the year ending December 31, 2025 through dispositions

of non-core assets, land, partial interest sales, and sales to owner/users. We expect dispositions of land to represent 20%–30% of our

total dispositions and sales of partial interests in 2025 (in millions):

---

| | | |
|:---|:---|:---|
| Completed dispositions | $261 |  |
| Our share of pending transactions subject to non-refundable deposits, signed letters of intent, and/or <br>purchase and sale agreement negotiations<br>| 525 |  |
| Our share of completed and pending 2025 dispositions | 786 | 40% |
| Additional targeted dispositions | 1164 | 60 |
| 2025 guidance midpoint for dispositions and sales of partial interests | $1950 | 100% |

---

*<u>Significant leasing progress on temporary vacancy</u>*

---

| | |
|:---|:---|
| Occupancy as of June 30, 2025 | 90.8%<br><sup>(1)</sup> |
| Temporary vacancies now leased with future delivery | 1.7<br><sup>(2)</sup> |
| Occupancy as of June 30, 2025, including leased, but not yet delivered space | 92.5% |

---

(1)Refer to "Summary of properties and occupancy" in Item 2 for additional details.

(2)Represents temporary vacancies as of June 30, 2025 aggregating 668,795 RSF, primarily in the Greater Boston, San Francisco Bay Area, and San Diego markets,

which are now leased and expected to be occupied upon completion of building and/or tenant improvements. The weighted-average expected delivery date is January 2,

2026. *<u>Key capital metrics as of or for the</u> <u>three months ended June 30, 2025</u>*

• $25.7 billion in total market capitalization.

• $12.4 billion in total equity capitalization.

• Non-real estate investments aggregating $1.5 billion:

• Unrealized gains presented in our consolidated balance sheet were $7.7 million, comprising gross unrealized gains and

losses aggregating $180.2 million and $172.5 million, respectively.

• Investment loss of $30.6 million for the three months ended June 30, 2025 presented in our consolidated statement of

operations consisted of $30.5 million of realized gains, $21.9 million of unrealized losses, and $39.2 million of impairment

charges.

*<u>Key capital events</u>*

• Upon maturity on April 30, 2025, we repaid our 3.45% unsecured senior notes payable aggregating $600.0 million, using

proceeds from our February 2025 unsecured senior notes payable offering.

• Under our common stock repurchase program authorized in December 2024, we may repurchase up to $500.0 million of our

common stock through December 31, 2025.

• During the three months ended June 30, 2025, we did not repurchase any shares.

• As of the date of this report, the approximate value of shares authorized and remaining under this program was

$241.8 million.

• In August 2025, we expect to repay a secured construction loan held by our consolidated real estate joint venture at 99

Coolidge Avenue, a development project where we have a 76.9% interest. The project is currently 76% leased/negotiating and

is expected to deliver in 2026. We expect to repay the loan aggregating$153.5 million which matures in 2026 and bears an

interest rate of 7.16% as of June 30, 2025. As a result, we expect to recognize a loss on early extinguishment of debt of

$99 thousand for the write-off of unamortized deferred financing costs during the three months ending September 30, 2025.

<u>External growth and investments in real estate</u>

*<u>Alexandria's development and redevelopment pipeline delivered incremental annual net operating income of</u><u>$15 million</u><u>, commencing</u>*

*<u>during the</u> <u>three months ended June 30, 2025</u><u>, with an additional</u><u>$139 million</u> <u>of incremental annual net operating income anticipated to</u>*

*<u>deliver by the</u> <u>fourth quarter of 2026</u> <u>primarily from projects</u><u>84%</u> <u>leased/negotiating.</u>*

• During the three months ended June 30, 2025, we placed into service development and redevelopment projects aggregating

217,774 RSF that are 90% occupied across three submarketsand delivered incremental annual net operating income of

$15 million.

• A significant delivery during the three months ended June 30, 2025 was 119,202 RSF at 10935, 10945, and 10955

Alexandria Way located in this asset at the One Alexandria Square Megacampus in our Torrey Pines submarket.

• Improvements of100 bps and110 bps in initial stabilized yield and initial stabilized yield (cash basis), respectively,

were primarily driven by leasing space at higher rental rates than previously underwritten and a$23 million reduction

in total investment due to construction cost savings from overall project efficiencies.

• Annual net operating income (cash basis) from recently delivered projects is expected to increase by $57 million upon the

burn-off of initial free rent, which has a weighted-average burn-off period of approximately three months.

• During 2025-2026, we expect to deliver annual net operating income representing nearly 9% of the total net operating income

for 2024.

• 74%of RSF in our total development and redevelopment pipeline is within our Megacampus ecosystems.

---

| | | | |
|:---|:---|:---|:---|
| *(dollars in millions)* | Incremental<br>Annual Net <br>Operating Income<br>| RSF | Occupied/<br>Leased/<br>Negotiating <br>Percentage |
| Placed into service: |  |  |  |
| Three months ended March 31, 2025 | $37 | 309494 | 100% |
| Three months ended June 30, 2025 | 15<br><sup>(1)</sup> | 217774 | 90 |
| Total placed into service during six months ended June 30, 2025 | $52<br><sup>(1)</sup> | 527268 | 96% |
| Expected to be placed into service: |  |  |  |
| Third quarter of 2025 through fourth quarter of 2026 | $139<br><sup>(2)</sup> | 1155041<br><sup>(3)</sup> | 84%<br><sup>(4)</sup> |
| 2027 through 2028<sup>(5)</sup> | 261 | 3270238 | 28% |
|  | $400 |  |  |

---

(1)Excludes incremental annual net operating income from recently delivered spaces aggregating22,005 RSF that are vacant and/or unleased as of June 30, 2025.

(2)Includesexpected partial deliveries through the fourth quarter of 2026 from projects expected to stabilize in 2027 and beyond, including speculative future leasing

that is not yet fully committed. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current

projects" in Item 2 for additional information.

(3)Represents the RSF related to projects expected to stabilize by the fourth quarter of 2026. Does not include RSF for partial deliveries through the fourth quarter of

2026 from projects expected to stabilize in 2027 and beyond.

(4)Represents the leased/negotiating percentage of development and redevelopment projects that are expected to stabilize during the second half of 2025 and 2026.

(5)Includes one100% pre-leased committed near-term project expected to commence construction in the next year.

**Trends that may affect our future results**

Current identified key market trends and uncertainties that had or may have a negative effect on our business are discussed

below. Although we seek to minimize the risks posed by these trends and uncertainties as discussed in the mitigating factors section

below, there can be no assurance that these measures will be successful in preventing material impacts on our future results of

operations, financial position, and cash flows. Refer to "Item 1A. Risk factors" within "Part II – Other information" of this quarterly report

on Form 10-Q and "Item 1A. Risk factors" within Part I in our annual report on Form 10-K for the year ended December 31, 2024 for

discussion of additional risks we face.

• ***<u>New competitive supply may exert pressure on our rental rates and adversely affect our operating results.</u>***During and

after the COVID-19 pandemic, the shift toward hybrid and remote work arrangements has led certain office and other real

estate companies to repurpose their underutilized office spaces into laboratory facilities. Our success and the success of other

laboratory operators have prompted and may continue to prompt new and existing life science developers to commence

speculative redevelopment and/or development projects in anticipation of demand for laboratory facilities. These conversion

and speculative development projects have contributed to a significant influx of new laboratory properties in key markets such

as Boston, San Diego, and the San Francisco Bay Area, heightening competitive pressures and diluting landlords' pricing

power in certain submarkets.

The increase in the supply of laboratory properties may persist in the near future, potentially intensifying competition and

continuing to exert downward pressure on rental and occupancy rates. To remain competitive, retain existing tenants, or attract

new tenants, we may need to reduce our future rental rates and/or offer more tenant improvement allowances or additional

tenant concessions, including free rent. The table below reflects a trend of increasing tenant improvement and leasing

commissions per RSF, free rent, rental rate increases related to our renewed/re-leased space, and occupancy:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Tenant Improvements/<br>Leasing Commissions <br>per RSF <br>| Free Rent <br>Concessions per <br>Annum <br>(leases executed in <br>trailing 12 months)<br>| Rental Rate <br>Increases <br>| Occupancy <br>(as of each <br>period end) <br>|
| Fiscal year 2023 | $26.09 | 0.6 months | 29.4% | 94.6% |
| Fiscal year 2024 | $46.89 | 0.7 months | 16.9% | 94.6% |
| Six months ended June 30, 2025 | $80.68 | 0.9 months | 13.2% | 90.8% |
| Midpoint of 2025 guidance | N/A | N/A | 13.0% | 91.7% |

---

As of June 30, 2025, we anticipate that 4.4 million RSF of our projects undergoing construction and one100% pre-leased

committed near-term project expected to commence construction in the next year will be placed into service from 2025 through

2028 and will generate $400 million in future incremental annual net operating income. These projects are49%leased or

under lease negotiations as of June 30, 2025. Realization of the aforementioned risks could hinder our ability to secure tenants

for the remaining unleased RSF related to these projects at the expected rates, or at all, potentially leading to a shortfall in, or

delays in the commencement of, the projected incremental annual net operating income.

• ***<u>Unfavorable capital markets and overall macroeconomic environment negatively impacting the value of our real</u>***

***<u>estate and non-real estate portfolios may limit our ability to raise capital to further our business objectives.</u>***

The effective execution of our development and redevelopment activities is contingent upon our access to the required capital.

In 2025, we expect to incur $1.75 billion in construction spending at the midpoint of our 2025 guidance range.

*•<u>Lower property valuations and increased capitalization rates</u>*. A portion of our projected construction and acquisition and

other opportunistic uses of capital spending is expected to be funded through dispositions and sales of partial interests in

core and non-core real estate assets. Real estate investments are generally less liquid than many other investment types,

which can present challenges in selling our properties timely or at desirable prices, especially in an environment of

oversupply.

Real estate sales can be particularly challenging given the demand for real estate is impacted by an economic climate

marked by ongoing uncertainties around tenant demand for space and elevated interest rates, in addition to those related

to oversupply. Although the U.S. Federal Reserve lowered the federal funds target range during 2024 to 4.25%–4.50%

from 5.25%–5.50% at the end of 2023, interest rates remain elevated. This could continue to limit access to debt and/or

equity financing for prospective buyers of our real estate assets, potentially eliminating their participation in the market or

forcing them to seek more expensive alternative funding options. All other aspects being equal, such challenges for

buyers lead to an excess of properties available for sale, which exert downward pressure on property valuations and

elevate capitalization rates, adversely impacting the sales proceeds we expect from our real estate asset sales.

The new supply, discussed above, combined with high interest rates and reduced market liquidity, may result in a

prolonged period of lower property valuations and higher capitalization rates, potentially leading to significant additional

real estate impairments and making it more challenging to execute asset sales within expected timelines. For additional

information about our sales of real estate, refer to "Sales of real estate assets and impairment of real estate" in Note 3 –

"Investments in real estate" to our unaudited consolidated financial statements in Item 1 for additional information. In

2025, we expect to complete dispositions and sales of partial interests of approximately $1.95 billion at the midpoint of our

2025 guidance range. However, we may not be able to achieve this and/or other targets disclosed in our 2025 guidance

as a result of the uncertainties discussed in this section as well as in "Item 1A. Risk factors" within "Part II – Other

information" of this quarterly report on Form 10-Q and "Item 1A. Risk factors" within Part I in our annual report on Form

10-K for the year ended December 31, 2024.

The table below presents total dispositions and a trend of increasing capitalization rates associated with dispositions and

sales of partial interests in our real estate assets (dollars in thousands), which is partly attributable to the quality of core

and non-core assets we sold during each period. There is no assurance that this upward trend will stabilize or reverse in

the future.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Total Dispositions and <br>Sales of Partial Interests<br>| Impairment of<br>Real Estate<br>| Capitalization <br>Rates<sup>(1)</sup><br>| Capitalization <br>Rates <br>(Cash Basis)<sup>(1)</sup><br>|
| 2023 | $1314414 | $461114 | 6.7% | 5.9% |
| 2024 | $1382453 | $223068 | 7.7% | 6.5% |
| Six months ended June 30, 2025 | $260640 | $161760 | N/A | N/A |
| Midpoint of 2025 guidance | $1950000 | N/A | N/A | N/A |

---

(1)Capitalization rates are calculated only for stabilized operating assets sold. Refer to "Capitalization rates" under "Definitions and reconciliations" in item

2 for additional information.

*•<u>Increased cost and limited availability of capital.</u>*In February 2025, we issued $550.0 million of unsecured senior notes

payable, primarily to refinance our$600.0 millionunsecured senior notes payable that matured in April 2025. Currently, we

do not expect to issue any additional new debt in 2025. However, should we encounter difficulties in selling our real estate

assets at our targeted prices, we may need to increase our reliance on debt financing to fund our construction projects,

which are projected to aggregate approximately $1.75 billion in construction spending based on the midpoint of our 2025

guidance. If the current high interest rate environment persists or worsens, the debt funding option could become costlier,

less accessible, or even unavailable, potentially limiting our ability to complete our development and redevelopment

projects on schedule and thereby delaying our expected incremental annual net operating income generation and

negatively affecting our business.

The table below reflects interest rates related to our unsecured senior notes payable issued in 2023, 2024, and in

February 2025 (dollars in thousands). There is no assurance that high debt costs will not continue into the future.

---

| | | |
|:---|:---|:---|
|  | Unsecured Senior <br>Notes Payable Issued<br>| Interest Rate<sup>(1)</sup> |
| 2023 | $1000000 | 5.07% |
| 2024 | $1000000 | 5.57% |
| February 2025 issuance and midpoint of our 2025 guidance | $550000 | 5.66% |

---

(1)Includes amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.

Furthermore, our active development and redevelopment projects under construction, primarily related to our

Megacampus ecosystems, have an estimated $2.9 billionof remaining costs to complete, of which $1.8 billion is not under

contract as of June 30, 2025. We estimate that 30%–40% of these$1.8 billion costs represent costs of materials that may

be subject to inflationary pressure and/or potential tariffs. Therefore, we estimate that each 10% increase in these costs of

materials may result in a decline in initial stabilized yields of approximately 3.5–4.5 basis points for our existing active

development and redevelopment projects. This estimate does not account for the cost of potential delays that may occur

in receiving or replacing materials subject to tariffs.

*•<u>Capitalized Interest.</u>*In 2025, our capitalized interest and interest expenses are expected to be $335 million and

$200 million, respectively, each at the midpoints of our 2025 guidance ranges. Our strategic focus is on prioritizing the

completion of our highly leased projects under construction. Additionally, we invest in our future pipeline with the goals of

enhancing value and reducing the timeline to allow for vertical construction. This is in response to our expectation of

increased future demand for these projects and is reflected in our expectation for capitalized interest. Refer to "Capitalized

interest" under "Definitions and reconciliations" in Item 2 for additional information.

The challenging macroeconomic environment, including the elevated supply of laboratory space, high costs or

unavailability of debt, and challenges in obtaining sufficient proceeds from real estate dispositions, as discussed above,

have, however, necessitated and may continue to necessitate a reevaluation of our current plans and lead to a temporary

suspension of our construction projects or delay of future projects. This could result in a decline in our capitalized interest

for 2025 and beyond below our current projections and a further increase in interest expense recognized in our

consolidated statement of operations.

The table below presents gross interest expense, capitalized interest, and interest expense in 2023 and 2024 and

projections for 2025 based on the midpoint of our 2025 guidance (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Gross Interest Expense | Capitalized Interest | Interest Expense |
| 2023 | $438182 | $(363978) | $74204 |
| 2024 | $516799 | $(330961) | $185838 |
| Midpoint of our 2025 guidance  | $535000 | $(335000) | $200000 |

---

During the six months ended June 30, 2025, our average real estate basis capitalized aggregated$8.1 billion. This

includes

• $2.9 billionrelated to development and redevelopment projects under construction and one100% pre-leased

committed near-term project expected to commence construction in the next year;

• $1.0 billionrelated to smaller redevelopments and repositioning capital projects;

• $1.2 billion related to key future Megacampus expansion pre-construction work; and

• $3.0 billion related to future pipeline projects expected to reach key milestones in the second half of 2025 and 2026,

including various phases of entitlement, design, site work, and other activities necessary to begin aboveground

vertical construction, onApril 3, 2026, on a weighted-average real estate investment basis. At that time, we may

evaluate whether to proceed with future pre-construction and/or construction activities based on leasing demand and

market conditions.

• *<u>Volatility in non-real estate investments</u>*<u>.</u> We hold strategic investments in publicly traded companies and privately held

entities primarily involved in the life science industry. These investments are subject to market and sector-specific risks

that can substantially affect their valuation. Like many other industries, the life science industry is susceptible to

macroeconomic challenges, such as ongoing economic uncertainty and a tighter capital environment. These factors may

lead to increased volatility in the valuation of our non-real estate investments.

In such a challenging environment, distributions from our investments — which we may receive as dividends, as

liquidation distributions from our investments in limited partnerships, or as a result of mergers and acquisitions that lead to

our privately held investees being acquired by other entities — may be limited and could result in lower realized gains.

Moreover, should market conditions worsen, we may face challenges in selling these securities at optimal prices,

potentially disrupting our capital strategy.

Due to the volatility in non-real estate investments, there is no assurance that we will be able to realize all of these gains

or sustain our historical level of annual realized gains in the future. The table below presents realized gains, impairments,

and unrealized losses on our non-real estate investments (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Non-Real Estate Investments | Non-Real Estate Investments | Non-Real Estate Investments |
|  | Realized Gains<sup>(1)</sup> | Impairments  | Unrealized Losses |
| 2023 | $80628 | $74550 | $201475 |
| 2024 | $117214 | $58090 | $112246 |
| Six months ended June 30, 2025 | $59865 | $50396 | $90083 |
| Midpoint of our 2025 guidance | $115000 | N/A | N/A |

---

(1)Excludes impairment charges.

Gross unrealized gains related to non-real estate investments as of June 30, 2025, December 31, 2024, and

December 31, 2023 aggregated to $180.2 million, $228.1 million, and $320.4 million, respectively.

Unfavorable market conditions could also indicate potential impairment of our investments in privately held entities that do

not report NAV per share and lead to the recognition of additional significant non-real estate impairments.

• *<u>Government policy and regulatory disruption</u>*. Recent and ongoing policy actions by the U.S. government have introduced

significant volatility and uncertainty into the life science ecosystem, with direct implications for our tenants, non-real estate

investments, and our overall business. Material developments include National Institutes of Health ("NIH") and U.S. Food

and Drug Administration ("FDA") workforce reductions, The Centers for Medicare & Medicaid Services ("CMS")

reimbursement cuts, a cap on NIH grant cost recovery, and defunding of research at certain U.S. research institutions.

These changes have led to the suspension of many research projects, delays in regulatory reviews and approvals of

drugs and other medical products, and increased barriers to clinical and regulatory progress, including for early-stage life

science companies. Moreover, foreign markets, especially China, are rapidly gaining ground as global biotech leaders due

to centralized funding, and faster regulatory timelines. The U.S. life science industry risks losing its competitive advantage

as companies increasingly look abroad to conduct research. Combined with new immigration restrictions that affect

international research talent, these actions threaten the long-term viability of the U.S. biomedical industry. The cumulative

effect of these developments may significantly reduce tenant demand for U.S. life science real estate. At the same time,

trade tensions and widespread tariffs may increase the cost of capital and and key materials, which could delay or reduce

our development pipeline. Refer to "Item 1A. Risk factors" within "Part II – Other information" of this quarterly report on

Form 10-Q for more information.

The realization of any of the aforementioned risks could have a material adverse impact on our revenues, particularly our

income from rentals, net operating income, results of operations, funds from operations, operating margins, initial stabilized yields

(unlevered) on new or existing construction projects, occupancy, EPS, FFO per share, our overall business, and the market value of

our common stock.

**•Mitigating factors:**

• ***<u>Megacampus strategy: focus on premier Class A/A+ assets in AAA life science innovation cluster locations.</u>***

Alexandria has established a high-quality Labspace<sup>®</sup> asset base predominantly concentrated in markets with high barriers

to entry. Despite a recent increase in the availability of laboratory space, we expect to continue to benefit from our focus

on Class A/A+ assets strategically clustered in Megacampus ecosystems in AAA life science innovation cluster locations

in close proximity to top academic and medical research institutions. This proximity is a key driver of tenant demand.

These campuses are used in two distinct ways: (i) to house the research operations of our tenants and (ii) to recruit and

retain the best talent available from a limited pool, which underscores why their scale, strategic design, and location are

critical.

Chief executive officers of life science companies typically anticipate rapid and exponential growth upon their companies'

achievement of scientific milestones. Our Megacampus ecosystems, which offer both high visibility and a clear path for

growth, are designed for scalability to accommodate our tenants' growth. Our future developments and redevelopments

aggregate27.5 million RSF as of June 30, 2025, of which74% is concentrated within our Megacampus ecosystems. Their

strategic locations and path for growth serve as powerful incentives for tenants to lease space from us.

Moreover, our tenants recognize that their success is directly linked to their ability to attract and retain personnel to

advance their science. With our Megacampus ecosystems, we aim to provide a superior set of amenities, services, and

access to transit that offer valuable optionality. With inspiring design and people-centric amenities, we believe these

campuses enhance our tenants' confidence in using these spaces as effective recruiting tools. In contrast, a significant

amount of the competitive supply in the market today consists of isolated, one-off buildings. These facilities may provide

operational space, but we believe they may fall short in offering the scale and strategic design that our Megacampus

ecosystems deliver.

Consequently, we believe an external growth strategy that focuses on the development of new Megacampus ecosystems,

and the enhancement of existing ones, serves as our most effective defense against competitive supply. Over the past

three decades, we have established a significant market presence in AAA innovation cluster locations, where our

Megacampus properties have been providing our life science tenants with a comprehensive solution, one that is

challenging to replicate due to the significant time and capital required to build this model. We believe our focus on our

Megacampus strategy will continue to position us favorably over the supply of new competitive laboratory spaces. This

strategy is partially responsible for our 2025 performance metrics listed below, which have been achieved despite the

current challenging macroeconomic environment:

• Occupancy of 90.8% as of June 30, 2025.

• Rental rate increases of 13.2% and 6.9% (cash basis) for the six months ended June 30, 2025.

• Leasing volume aggregating 1.8 million RSF for the six months ended June 30, 2025.

• In July 2025, we executed the largest life science lease in company history with a long-standing multinational

pharmaceutical tenant for a 16-year expansion build-to-suit lease, aggregating466,598 RSF, located on the

Campus Point by Alexandria Megacampus in our University Town Center submarket.

• The weighted-average lease term for leases executed during six months ended June 30, 2025 was 10.2 years.

• Projects expected to stabilize in 2025 and 2026 are84% leased/negotiating.

• ***<u>Operational excellence of our team.</u>*** Alexandria focuses on operational excellence in direct asset management and

operations of our Labspace<sup>®</sup> asset base. Our team is composed of highly experienced, educated, and professionally

credentialed facilities specialists. This expertise is essential in ensuring a secure and efficient environment for

groundbreaking scientific research and has been cultivated and maintained over many years. The demanding nature of

laboratory-based scientific research requires strict adherence to safety standards set by local, state, and federal

regulatory bodies. Key compliance aspects include good manufacturing practice and Clinical Laboratory Improvement

Amendments (CLIA) certifications, adherence to national biosafety level guidelines, proper permitting and handling of

hazardous waste generation and chemical storage, maintenance of safety stations, effective management of ultra-low

temperature freezers, and careful licensing and management of radioactive materials.

• ***<u>Strength of our brand.</u>***As a recognized leader in the life science and real estate sectors, Alexandria has successfully

built a diverse and high-quality tenant base. Over the past three decades, we have fostered long-standing relationships

and strategic partnerships with our tenants, which have enabled us to maintain strong occupancy, leasing, and growth in

net operating income and cash flows and to effectively navigate through various economic cycles. Key indicators of our

brand strength include the following:

• As of June 30, 2025, 84% of our leasing activity during the last twelve months was generated from our existing tenant

base.

• As of June 30, 2025, 89% of our top 20 tenant annual rental revenue is derived from investment-grade or publicly

traded large cap companies.

• As of June 30, 2025, our occupancy is 90.8%.

• Our tenant collections have remained consistently high over the last four years, averaging 99.8% since the beginning

of 2021 through June 30, 2025.

• ***<u>Life science fundamentals.</u>*** We monitor market demand trends, particularly in the life science industry, to optimally align

our property offerings with tenant requirements. The life science industry has shown strong long-term growth, fueled by

multifaceted sources of funding, including private venture capital, biopharma R&D spend, government funding, and

philanthropic support for biomedical innovation. We believe our focus on high-quality Labspace<sup>®</sup> assets in prime locations

positions us to effectively capitalize on these ongoing trends:

• The R&D expenditures by U.S. publicly traded life science companies nearly doubled in 2023 compared to 2014. As

of December 31, 2024, 17 of the top 20 pharma R&D spenders (for the year 2023) are Alexandria tenants.

• The sector's growth is further supported by substantial funding of life science companies by private-venture capital,

which aggregated over $40 billion in 2024, or over 2.5x the capital deployed in 2014.

• ***<u>Prudent financial management.</u>*** Our strong and flexible balance sheet and prudent balance sheet management are key

factors in our ability to navigate economic uncertainties and capitalize on new opportunities. The strength of our financial

position is highlighted by several key indicators:

• Our significant liquidity of $4.6 billionas of June 30, 2025 provides us the flexibility to address our operational needs

and to pursue strategic opportunities.

• We expect to have the ability to self-fund a large portion of our capital requirements through the following sources in

2025:

• $475 million in net cash provided by operating activities after dividends, at the midpoint of our 2025 guidance

range.

• $297.3 million in capital contributions to fund construction expected from our existing consolidated real estate

joint venture partners from July 1, 2025 through December 31, 2027 and beyond, including $116.7 million from

July 1, 2025 to December 31, 2025.

• $1.95 billion from dispositions and sales of partial interests in real estate assets at the midpoint of our 2025

guidance range.

• As of June 30, 2025, our credit ratings from S&P Global Ratings and Moody's Ratings wereBBB+ and Baa1,

respectively, which continued to rank in the top 10%among all publicly traded U.S. REITs.

• Our net debt and preferred stock to Adjusted EBITDA ratio was 5.9x for the three months ended June 30, 2025

annualized, with a target of less than or equal to 5.2x for the fourth quarter of 2025 annualized.

• As of June 30, 2025, our fixed-rate debt represents 90.6% of our total debt, which provides predictability in debt

servicing costs. Since 2021, our quarter-end fixed-rate debt averaged97.2%.

• Our debt maturity schedule is well laddered, which provides us with financial flexibility and reduces short-term

refinancing risks. As of June 30, 2025, only 9% of our debt matures through 2027.

• As of June 30, 2025, the weighted-average remaining term of our debt is 12.0 years,longest among S&P 500 REITs,

demonstrating our strategic approach to debt management and our focus on maintaining manageable annual debt

maturities.

***•<u>Other mitigating factors</u>***

• *<u>Improvement in office market.</u>* The increase in demand for premium office space since 2024, primarily driven by the

technology sector, particularly companies focused on artificial intelligence, absorbed some of the market's supply

previously anticipated for life science use, which is now being repositioned back into offices. High ceilings, improved

ventilation systems, and abundant natural light have become highly desirable features, appealing to office and

advanced technology tenants. We expect this trend may lead to the exit from the life science sector of inexperienced

life science real estate developers and expedite the resolution of the oversupply impacting the sector.

• *<u>Projected decrease in general and administrative expenses.</u>* Over the past two years, we have implemented

comprehensive measures to reduce our expenditures across our organization, including our general and

administrative expenses, which provided savings during the year ended December 31, 2024, compared to the year

ended December 31, 2023, and are expected to provide significant savings in 2025 and beyond. With these

initiatives, we anticipate a reduction in general and administrative expenses of approximately $49 million, or 29%,

during the year ending December 31, 2025, based on the midpoint of our 2025 guidance range, compared to the year

ended December 31, 2024. These savings are expected to stem from a variety of implemented cost-control and

efficiency initiatives, including, but not limited to, the following:

(i)Personnel-related matters, including:

• Reduction in headcount over the last two years.

• Restructuring of various compensation plans.

(ii)Streamlining of business processes:

• Implementation of systems upgrades, process improvements, and smarter technology.

• Renegotiation of contracts related to legal, technology, and operational support services, and

elimination of redundancies through better alignment and consolidation of roles.

A significant portion, but not all, of the cost reductions expected to be achieved in 2025 is anticipated to continue

beyond 2025.

**Operating summary**

---

| | | | |
|:---|:---|:---|:---|
| **Same Property**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Net Operating Income Performance** | **Same Property**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Net Operating Income Performance** | **Rental Rate Growth:** <br>**Renewed/Re-Leased Space** | **Rental Rate Growth:** <br>**Renewed/Re-Leased Space** |
| **Margins**<sup>(2)</sup> | **Margins**<sup>(2)</sup> | **Favorable Lease Structure**<sup>(3)</sup> | **Favorable Lease Structure**<sup>(3)</sup> |
| **Operating** | **Adjusted EBITDA** | **Strategic Lease Structure by Owner and** <br>**Operator of Collaborative Megacampus Ecosystems** | **Strategic Lease Structure by Owner and** <br>**Operator of Collaborative Megacampus Ecosystems** |
| 71% | 71% | *Increasing cash flows* |  |
| 71% | 71% | **Percentage of leases containing annual** <br>**rent escalations** | **97%** |
|  |  | *Stable cash flows* |  |
| **Long-Duration Lease Terms**<sup>(4)</sup> | **Long-Duration Lease Terms**<sup>(4)</sup> | **Percentage of triple net leases** | **91%** |
| 9.4 Years | 7.4 Years | *Lower capex burden* |  |
| 9.4 Years | 7.4 Years | **Percentage of leases providing for the** <br>**recapture of capital expenditures**  | **92%** |
| Top 20 Tenants | All Tenants |  |  |
| **Net Debt and Preferred Stock** <br>**to Adjusted EBITDA**<sup>(5)</sup> | **Net Debt and Preferred Stock** <br>**to Adjusted EBITDA**<sup>(5)</sup> | **Fixed-Charge Coverage Ratio**<sup>(5)</sup> | **Fixed-Charge Coverage Ratio**<sup>(5)</sup> |

---

![1](are-20250630_g4.gif)

![13](are-20250630_g5.gif)

![25](are-20250630_g6.gif)

![37](are-20250630_g7.gif)

![49](are-20250630_g8.gif)

![61](are-20250630_g9.gif)

**4.0x to 4.5x**

<sup>(1)</sup>

**(4.3)%**

---

| | |
|:---|:---|
| **2024** | **YTD** <br>**6/30/25**<br>|

---

Refer to "Same properties" and "Definitions and reconciliations" in Item 2 for additional details. "Definitions and reconciliations" contains the definitions of "Fixed-charge

coverage ratio," "Net debt and preferred stock to Adjusted EBITDA," and "Net operating income" and their respective reconciliations from the most directly comparable

financial measures presented in accordance with GAAP.

(1)Refer to footnote 1 in "Same properties" in Item 2 for additional details.

(2)For the three months ended June 30, 2025.

(3)Percentages calculated based on our annual rental revenue in effectas of June 30, 2025.

(4)Represents the weighted-average remaining term based on annual rental revenue in effect as of June 30, 2025.

(5)Quarter annualized.

---

| | |
|:---|:---|
| **Stable Cash Flows From Our High-Quality and Diverse Mix of** <br>**Approximately 750 Tenants** | **Stable Cash Flows From Our High-Quality and Diverse Mix of** <br>**Approximately 750 Tenants** |
| | **Investment-Grade or Publicly Traded** <br>**Large Cap Tenants** |
| | **Investment-Grade or Publicly Traded** <br>**Large Cap Tenants** |
|  | **89%** |
|  | **89%** |
|  | **89%** |
|  | of ARE's Top 20 Tenant <br>Annual Rental Revenue |
|  | **53%** |
|  | **53%** |
|  | **53%** |
|  | of ARE's Total Annual <br>Rental Revenue |
| Percentage of ARE's <br>Annual Rental Revenue | of ARE's Total Annual <br>Rental Revenue |

---

![25](are-20250630_g10.gif)

Life Science

Product,

Service, and

Device

Multinational

Pharmaceutical

Public

Biotechnology –

Approved or

Marketed

Product

Public

Biotechnology –

Preclinical or

Clinical Stage

Private

Biotechnology

Other<sup>(3)</sup>

Biomedical

Institutions<sup>(1)</sup>

Government

Institutions

Advanced Technologies<sup>(2)</sup>

As of June 30, 2025. Annual rental revenue represents amounts in effect as of June 30, 2025. Refer to "Definitions and reconciliations" in Item 2 for additional information.

(1)79%of our annual rental revenue from biomedical institutions is from investment-grade or publicly traded large cap tenants.

(2)63% of our annual rental revenue from advanced technology tenants is from investment-grade or publicly traded large cap tenants.

(3)Represents the percentage of our annual rental revenue generated by professional services, finance, telecommunications, construction/real estate companies, and

retail-related tenants.

---

| | | |
|:---|:---|:---|
| **Strong, Broad, and Diverse Life Science Tenant Base Drives Solid** <br>**Leasing and Long-Term Remaining Lease Terms** | **Strong, Broad, and Diverse Life Science Tenant Base Drives Solid** <br>**Leasing and Long-Term Remaining Lease Terms** | **Strong, Broad, and Diverse Life Science Tenant Base Drives Solid** <br>**Leasing and Long-Term Remaining Lease Terms** |
| | **Long-Duration Life Science Lease Terms** | **Long-Duration Life Science Lease Terms** |
|  |  | Remaining Lease <br>Term (in years)<sup>(1)</sup><br>|
|  | Multinational Pharmaceutical | 7.1 |
|  | Life Science Product, Service, and <br>Device<br>| 6.6 |
|  | Government Institutions | 5.1 |
|  | Biomedical Institutions | 7.8 |
|  | Private Biotechnology | 7.2 |
|  | Public Biotechnology | 7.1 |
| Percentage of Life Science <br>Leasing Activity by RSF<sup>(2)</sup> |  |  |

---

![1649267441989](are-20250630_g11.gif)

Multinational

Pharmaceutical

Public

Biotechnology

Life Science

Product,

Service, and

Device

Biomedical

Institutions

Private

Biotechnology

Other

Advanced

Technologies

(1)Average remaining lease term based on annual rental revenue in effect as of June 30, 2025.

(2)Represents the percentage of RSF for leases executed during the three months ended June 30, 2025 for each respective business type.

---

| | |
|:---|:---|
| **Sustained Operational Excellence and**<br>**Strength in Tenant Collections** | **Sustained Operational Excellence and**<br>**Strength in Tenant Collections** |
| **Tenant Rents And Receivables Collected**<sup>(1)</sup> | **99.9%**<br>**2Q25** |
| **Tenant Rents And Receivables Collected**<sup>(1)</sup> | **99.4%**<br>**July 2025** |
| **Tenant Rents And Receivables Collected**<sup>(1)</sup> | **99.8%**<br>**Average Tenant**<br>**Collections**<br>**1Q21–2Q25** |
| **Tenant Rents And Receivables Collected**<sup>(1)</sup> |  |

---

![1649267441895](are-20250630_g12.gif)

(1)Represents tenant collections for each quarter-end as of each respective quarterly or annual report filing date.

<u>Leasing Activity</u>

The following table summarizes our leasing activity at our properties:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Three Months Ended | Three Months Ended | Three Months Ended | Six Months Ended | Six Months Ended | Six Months Ended | Year Ended | Year Ended |
|  | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 | December 31, 2024 | December 31, 2024 |
| *(Dollars per RSF)* | Including <br>Straight-Line Rent | Including <br>Straight-Line Rent | Cash Basis | Including <br>Straight-Line Rent | Including <br>Straight-Line Rent | Cash Basis | Including <br>Straight-Line Rent<br>| Cash Basis |
| *Leasing activity:* |  |  |  |  |  |  |  |  |
| Renewed/re-leased space<sup>(1)</sup> |  |  |  |  |  |  |  |  |
| **Rental rate changes** | **5.5%** |  | **6.1%** | **13.2%** |  | **6.9%** | **16.9%** | **7.2%** |
| New rates | $64.78 |  | $68.27 | $60.11 |  | $59.72 | $65.48 | $64.18 |
| Expiring rates | $61.38 |  | $64.36 | $53.10 |  | $55.84 | $56.01 | $59.85 |
| RSF | 483409 |  |  | 1367817 |  |  | 3888139 |  |
| Tenant improvements/<br>leasing commissions<br>| $49.59 |  |  | $80.68 | (2) |  | $46.89 |  |
| Weighted-average lease <br>term<br>| 9.4 years |  |  | 9.8 years |  |  | 8.5 years |  |
| Developed/redeveloped/<br>previously vacant space <br>leased<sup>(3)</sup><br>|  |  |  |  |  |  |  |  |
| New rates | $58.12 |  | $58.73 | $55.31 |  | $55.61 | $59.44 | $57.34 |
| RSF | 286406 |  |  | 432551 |  |  | 1165815 |  |
| Weighted-average lease <br>term<br>| 12.3 years |  |  | 11.5 years |  |  | 10.0 years |  |
| *Leasing activity summary* <br>*(totals):*<br>|  |  |  |  |  |  |  |  |
| New rates | $62.30 |  | $64.72 | $58.96 |  | $58.73 | $64.16 | $62.68 |
| RSF | 769815 | (4) |  | 1800368 |  |  | 5053954 |  |
| Weighted-average lease <br>term<br>| 10.5 years |  |  | 10.2 years |  |  | 8.9 years |  |
| *Lease expirations*<sup>(1)</sup> |  |  |  |  |  |  |  |  |
| Expiring rates | $63.31 |  | $63.62 | $53.95 |  | $55.17 | $53.82 | $57.24 |
| RSF | 825583 |  |  | 2748631 |  |  | 5005638 |  |

---

Leasing activity includes 100% of results for properties in North America in which we have an investment.

(1)Excludes month-to-month leases aggregating 163,493 RSF and 136,131 RSF as of June 30, 2025and December 31, 2024, respectively. During the trailing twelve

months ended June 30, 2025, we granted free rent concessions averaging 0.9 months per annum.

(2)Includes tenant improvements and leasing commissions for one 11.4-year lease, executed during the three months ended March 31, 2025, at the Alexandria Technology

Square<sup>®</sup> Megacampus in our Cambridge submarket aggregating119,280 RSF. Excluding this lease, tenant improvements and leasing commissions per RSF for the six

months ended June 30, 2025 was$47.01.

(3)Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" in Item 2 for additional information, including total project costs.

(4)In July 2025, we executed the largest life science lease in company history with a long-standing multinational pharmaceutical tenant for a 16-year expansion build-to-suit

lease, aggregating 466,598 RSF, located on the Campus Point by Alexandria Megacampus in our University Town Center submarket. If this were included in the leasing

volume for the three months ended June 30, 2025, the total leased RSF would have increased to 1.2 million RSF for the three months ended June 30, 2025 from769,815

RSF.

<u>S</u><u>ummary of contractual lease expirations</u>

The following table summarizes the contractual lease expirations at our properties as of June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Year | RSF | Percentage of<br>Occupied RSF | Annual Rental Revenue<br>(per RSF)<sup>(1)</sup> | Percentage of <br>Annual Rental Revenue |
| 2025<br><sup>(2)</sup> | 1320692 | 3.7% | $51.73 | 3.3% |
| 2026 | 3137647 | 8.9% | $57.29 | 8.8% |
| 2027 | 3393561 | 9.6% | $50.88 | 8.4% |
| 2028 | 4015759 | 11.4% | $50.83 | 10.0% |
| 2029 | 2286491 | 6.5% | $48.02 | 5.4% |
| 2030 | 3078313 | 8.7% | $43.50 | 6.5% |
| 2031 | 3585208 | 10.2% | $54.35 | 9.5% |
| 2032 | 993042 | 2.8% | $57.50 | 2.8% |
| 2033 | 2592303 | 7.3% | $47.59 | 6.0% |
| 2034 | 3063408 | 8.7% | $68.56 | 10.2% |
| Thereafter | 7838957 | 22.2% | $76.19 | 29.1% |

---

Contractual lease expirations for properties classified as held for sale as of June 30, 2025 are excluded from the information on this page.

(1)Represents amounts in effect as of June 30, 2025.

(2)Excludes month-to-month leases aggregating 163,493 RSF as of June 30, 2025.

The following tables present our lease expirations by market for the remainder of 2025 and for 2026 as of June 30, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | 2025 Contractual Lease Expirations (in RSF) | 2025 Contractual Lease Expirations (in RSF) | 2025 Contractual Lease Expirations (in RSF) | 2025 Contractual Lease Expirations (in RSF) | 2025 Contractual Lease Expirations (in RSF) |  |
| Market | Leased | Negotiating/<br>Anticipating | Targeted for <br>Future <br>Development/<br>Redevelopment<sup>(1)</sup> | Remaining<br>Expiring Leases<sup>(2)</sup> | Total<sup>(3)</sup> | Annual Rental <br>Revenue<br>(per RSF)<sup>(4)</sup> |
| Market | Leased | Negotiating/<br>Anticipating | Targeted for <br>Future <br>Development/<br>Redevelopment<sup>(1)</sup> | Remaining<br>Expiring Leases<sup>(2)</sup> | Total<sup>(3)</sup> | Annual Rental <br>Revenue<br>(per RSF)<sup>(4)</sup> |
| Greater Boston | 214399 |  |  | 145329 | 359728 | $35.89 |
| San Francisco Bay Area | 134423 | 10208 |  | 279182 | 423813 | 95.48 |
| San Diego | 23327 |  |  | 68081 | 91408 | 55.21 |
| Seattle | 1868 |  |  | 54781 | 56649 | 32.64 |
| Maryland | 41283 |  |  | 23469 | 64752 | 22.61 |
| Research Triangle | 10478 | 8368 |  | 34461 | 53307 | 43.56 |
| New York City |  |  |  | 30384 | 30384 | 96.62 |
| Texas |  |  | 198972 |  | 198972 | N/A |
| Canada |  |  |  | 40679 | 40679 | 10.65 |
| Non-cluster/other markets |  |  |  | 1000 | 1000 | N/A |
| Total | 425778 | 18576 | 198972 | 677366 | 1320692 | $51.73 |
| Percentage of expiring leases | 32% | 1% | 15% | 52% | 100% |  |
|  | 2026 Contractual Lease Expirations (in RSF) | 2026 Contractual Lease Expirations (in RSF) | 2026 Contractual Lease Expirations (in RSF) | 2026 Contractual Lease Expirations (in RSF) | 2026 Contractual Lease Expirations (in RSF) |  |
| Market | Leased | Negotiating/<br>Anticipating | Targeted for <br>Future<br>Development/<br>Redevelopment | Remaining<br>Expiring Leases<sup>(2)</sup> | Total | Annual Rental <br>Revenue<br>(per RSF)<sup>(4)</sup> |
| Market | Leased | Negotiating/<br>Anticipating | Targeted for <br>Future<br>Development/<br>Redevelopment | Remaining<br>Expiring Leases<sup>(2)</sup> | Total | Annual Rental <br>Revenue<br>(per RSF)<sup>(4)</sup> |
| Greater Boston | 60418 | 11897 |  | 514566 | 586881 | $89.16 |
| San Francisco Bay Area | 28454 |  |  | 686304 | 714758 | 72.57 |
| San Diego |  |  |  | 846084 | 846084 | 48.90 |
| Seattle | 29604 | 50552 |  | 111720 | 191876 | 30.42 |
| Maryland |  |  |  | 255147 | 255147 | 18.85 |
| Research Triangle | 19753 |  |  | 159362 | 179115 | 39.19 |
| New York City |  |  |  | 73363 | 73363 | 103.16 |
| Texas |  |  |  |  |  |  |
| Canada |  | 247743 |  | 1755 | 249498 | 21.57 |
| Non-cluster/other markets |  | 9266 |  | 31659 | 40925 | 85.36 |
| Total | 138229 | 319458 |  | 2679960 | 3137647 | $57.29 |
| Percentage of expiring leases | 4% | 10% | 0% | 86% | 100% |  |

---

Contractual lease expirations for properties classified as held for sale as of June 30, 2025 are excluded from the information on this page.

(1)Primarily represents assets that were recently acquired for future development or redevelopment opportunities, for which we expect, subject to market conditions and

leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development. As of June 30, 2025, the

weighted-average annual rental revenue and expiration date of these leases expiring in 2025 is$895 thousand andJuly 1, 2025, respectively. Refer to "Investments in

real estate" under "Definitions and reconciliations" in Item 2 for additional details, including development and redevelopment square feet currently included in rental

properties.

(2)Includes 12 properties primarily located in Greater Boston, the San Francisco Bay Area, and San Diego markets aggregating 868,289 RSF with a weighted-average

lease expiration date of February 9, 2026 and annual rental revenue aggregating $70 million and are expected to be re-leased to new tenants, including the following:

(i)Three recently acquired properties in our Greater Stanford submarket aggregating 213,705 RSF for which we are evaluating options to reposition the campus for

advanced technology use;

(ii)One property aggregating 118,225 RSF in our Torrey Pines submarket for which we are evaluating options to re-lease or reposition the space from single tenancy

to multi-tenancy; and

(iii)One lease expiration aggregating 34,714 RSF at our Alexandria Technology Square Megacampus in our Cambridge submarket for which we are in the process of

repositioning the building for multi-tenant use.

We continue to evaluate the business plans and re-leasing strategies for these projects.

(3)Excludes month-to-month leases aggregating 163,493 RSFas of June 30, 2025.

(4)Represents amounts in effect as of June 30, 2025.

<u>Top 20 tenants</u>

**89% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade** 

**or Publicly Traded Large Cap Tenants**<sup>(1)</sup>

Our properties are leased to a high-quality and diverse group of tenants, with no individual tenant accounting for greater than

5.5% of our annual rental revenue in effect as of June 30, 2025. The following table sets forth information regarding leases with our 20

largest tenants in North America based upon annual rental revenue in effect as of June 30, 2025 (dollars in thousands, except average

market cap amounts):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | Remaining <br>Lease <br>Term<sup>(1)</sup><br> (in Years) | Aggregate<br>RSF | Annual<br>Rental<br>Revenue<sup>(1)</sup> | Percentage <br>of Annual <br>Rental <br>Revenue<sup>(1)</sup> | Investment-Grade <br>Credit Ratings | Investment-Grade <br>Credit Ratings | Average <br>Market <br>Cap<br>*(in billions)* |
|  |  | Remaining <br>Lease <br>Term<sup>(1)</sup><br> (in Years) | Aggregate<br>RSF | Annual<br>Rental<br>Revenue<sup>(1)</sup> | Percentage <br>of Annual <br>Rental <br>Revenue<sup>(1)</sup> | Investment-Grade <br>Credit Ratings | Investment-Grade <br>Credit Ratings | Average <br>Market <br>Cap<br>*(in billions)* |
|  | Tenant | Remaining <br>Lease <br>Term<sup>(1)</sup><br> (in Years) | Aggregate<br>RSF | Annual<br>Rental<br>Revenue<sup>(1)</sup> | Percentage <br>of Annual <br>Rental <br>Revenue<sup>(1)</sup> | Moody's | S&P | Average <br>Market <br>Cap<br>*(in billions)* |
| 1 | Bristol-Myers Squibb Company<sup>(2)</sup> | 5.8 | 1312184 | $113542 | 5.5% | A2 | A | $106.0 |
| 2 | Eli Lilly and Company | 9.3 | 1086165 | 91233 | 4.4 | Aa3 | A+ | $791.0 |
| 3 | Moderna, Inc. | 10.9 | 496814 | 88729 | 4.3 |  |  | $19.5 |
| 4 | Takeda Pharmaceutical Company Limited | 9.9 | 549759 | 47899 | 2.3 | Baa1 | BBB+ | $45.0 |
| 5 | AstraZeneca PLC | 6.4 | 450848 | 39637 | 1.9 | A1 | A+ | $227.0 |
| 6 | Eikon Therapeutics, Inc.<sup>(3)</sup> | 13.5 | 311806 | 38913 | 1.9 |  |  | $— |
| 7 | Roche | 7.7 | 647069 | 36373 | 1.7 | Aa2 | AA | $255.0 |
| 8 | Illumina, Inc. | 5.4 | 857967 | 35924 | 1.7 | Baa3 | BBB | $18.1 |
| 9 | Alphabet Inc. | 2.3 | 625015 | 34899 | 1.7 | Aa2 | AA+ | $2120.0 |
| 10 | United States Government | 5.1 | 429359 | 29502<br><sup>(4)</sup> | 1.4 | Aaa | AA+ | $— |
| 11 | Uber Technologies, Inc. | 57.3<br><sup>(5)</sup> | 1009188 | 27809 | 1.3 | Baa1 | BBB | $155.0 |
| 12 | Novartis AG | 3.1 | 387563 | 27709 | 1.3 | Aa3 | AA- | $238.0 |
| 13 | Cloud Software Group, Inc. | 1.0<br><sup>(6)</sup> | 292013 | 26446 | 1.3 |  |  | $— |
| 14 | Boston Children's Hospital | 11.7 | 309231 | 26294 | 1.3 | Aa2 | AA | $— |
| 15 | The Regents of the University of California | 9.9 | 363974 | 25309 | 1.2 | Aa2 | AA | $— |
| 16 | Sanofi | 5.5 | 267278 | 21851 | 1.0 | Aa3 | AA | $132.0 |
| 17 | New York University | 7.1 | 218983 | 21110 | 1.0 | Aa2 | AA- | $— |
| 18 | Merck & Co., Inc. | 8.2 | 333124 | 21001 | 1.0 | Aa3 | A+ | $250.0 |
| 19 | Charles River Laboratories, Inc. | 10.0 | 250905 | 20535 | 1.0 |  |  | $8.9 |
| 20 | Massachusetts Institute of Technology | 4.5 | 242428 | 20529 | 1.0 | Aaa | AAA | $— |
|  | Total/weighted-average | 9.4<br><sup>(5)</sup> | 10441673 | $795244 | 38.2% |  |  |  |

---

Annual rental revenue and RSF include 100% of each property managed by us in North America. Refer to "Annual rental revenue" and "Investment-grade or publicly traded large

cap tenants" under "Definitions and reconciliations" in Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated real

estate joint ventures and average market capitalization, respectively.

(1)Based on total annual rental revenue in effect as of June 30, 2025.

(2)During the three months ended June 30, 2025, Bristol-Myers Squibb Company acquired 2seventy bio, Inc., which was a Top 20 tenant as of March 31, 2025.

(3)Eikon Therapeutics, Inc. is a private biotechnology company led by renowned biopharma executive Roger Perlmutter, formerly an executive vice president at Merck & Co.,

Inc. As of February 25, 2025, the company has raised over$1.2 billion in private venture capital funding.

(4)Includes leases, which are not subject to annual appropriations, with governmental entities such as the National Institutes of Health and the General Services

Administration. Approximately 3% of the annual rental revenue derived from our leases with the United States Government is cancellable prior to the lease expiration date.

(5)Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings

aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual

rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue from our unconsolidated real

estate joint ventures. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 7.6 years as of June 30, 2025.

(6)Represents one lease encompassing four properties acquired in 2022 that we expect to reposition upon lease expiration. This lease with Cloud Software Group, Inc.

(formerly known as TIBCO Software, Inc.) was in place when we acquired the properties. Refer to footnote 2 in "Summary of contractual lease expirations" in Item 2 for

additional details.

<u>Locations of properties</u>

Our properties are strategically located in AAA life science innovation cluster markets. The following table sets forth the total

RSF, number of properties, and annual rental revenue in effect as of June 30, 2025 in each of our markets in North America (dollars in

thousands, except per RSF amounts):

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | RSF | RSF | RSF | RSF | RSF | Number of <br>Properties | Annual Rental Revenue | Annual Rental Revenue | Annual Rental Revenue |
| Market | Operating | Development | Redevelopment | Total | % of Total | Number of <br>Properties | Total | % of Total | Per RSF |
| Greater Boston | 9270787 | 632850 | 1626322 | 11529959 | 26% | 65 | $731510 | 35% | $87.55 |
| San Francisco Bay Area | 7991106 | 212796 | 344934 | 8548836 | 20 | 64 | 459269 | 22 | 69.82 |
| San Diego | 6851449 | 784590 |  | 7636039 | 17 | 74 | 324236 | 16 | 49.91 |
| Seattle | 3178090 | 227577 |  | 3405667 | 8 | 45 | 130470 | 6 | 45.45 |
| Maryland | 3848923 |  |  | 3848923 | 9 | 50 | 155975 | 7 | 43.70 |
| Research Triangle | 3825870 |  |  | 3825870 | 9 | 38 | 107155 | 5 | 30.19 |
| New York City | 921800 |  |  | 921800 | 2 | 4 | 75006 | 4 | 91.48 |
| Texas | 1845159 |  | 73298 | 1918457 | 4 | 15 | 37761 | 2 | 24.93 |
| Canada | 979575 |  | 56314 | 1035889 | 2 | 11 | 20208 | 1 | 22.74 |
| Non-cluster/other markets | 349099 |  |  | 349099 | 1 | 10 | 14577 | 1 | 57.54 |
| Properties held for sale | 679383 |  |  | 679383 | 2 | 8 | 25063 | 1 | 43.66 |
| **North America** | **39741241** | **1857813** | **2100868** | **43699922** | **100%** | **384** | **$2081230** | **100%** | **$58.68** |
|  |  | **3958681** | **3958681** |  |  |  |  |  |  |

---

<u>Summary of occupancy percentages in North America</u>

**Solid Historical Occupancy of95% Over Past 10 Years**<sup>(1)</sup> **From Historically Strong Demand for Our** 

**Class A/A+ Properties in AAA Locations**

The following table sets forth the occupancy percentages for our operating properties and our operating and redevelopment

properties in each of our North America markets, excluding properties held for sale, as of the following dates:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Operating Properties | Operating Properties | Operating Properties | Operating and Redevelopment Properties | Operating and Redevelopment Properties | Operating and Redevelopment Properties |
| Market | 6/30/25 | 3/31/25 | 6/30/24 | 6/30/25 | 3/31/25 | 6/30/24 |
| Greater Boston | 90.1%<br><sup>(2)</sup> | 91.8% | 94.2% | 76.7% | 78.4% | 81.7% |
| San Francisco Bay Area | 88.9<br><sup>(2)</sup> | 90.3 | 94.0 | 85.2 | 86.3 | 90.7 |
| San Diego | 94.8 | 94.3 | 95.1 | 94.8 | 94.3 | 95.1 |
| Seattle | 90.3 | 91.5 | 94.7 | 90.3 | 91.5 | 93.7 |
| Maryland | 93.9 | 94.1 | 96.5 | 93.9 | 94.1 | 96.5 |
| Research Triangle | 92.8<br><sup>(2)</sup> | 93.4 | 97.4 | 92.8 | 93.4 | 97.4 |
| New York City | 88.9<br><sup>(3)</sup> | 87.6 | 85.1 | 88.9 | 87.6 | 85.1 |
| Texas | 82.1<br><sup>(2)</sup> | 82.1 | 95.5 | 78.9 | 78.9 | 91.8 |
| Subtotal | 91.0 | 91.8 | 94.7 | 86.3 | 87.1 | 90.2 |
| Canada | 90.7 | 94.6 | 94.9 | 85.8 | 82.4 | 82.5 |
| Non-cluster/other markets | 72.6 | 73.0 | 75.6 | 72.6 | 73.0 | 75.6 |
| **North America** | **90.8%**<br><sup>(2)(4)</sup> | **91.7%** | **94.6%** | **86.2%** | **86.9%** | **89.9%** |

---

(1)Represents the average occupancy percentage of operating properties as of each December 31 from 2016 through 2024 and as of June 30, 2025.

(2)Includes previously disclosed lease expirations that became vacant during the three months ended March 31, 2025 aggregating 768,080 RSF across six properties and

four submarkets comprising the following: (i) 182,054 RSF at the Alexandria Technology Square<sup>®</sup> Megacampus in our Cambridge submarket, (ii) 234,249 RSF at

409 Illinois Street in our Mission Bay submarket, (iii) one property aggregating 104,531 RSF in our Research Triangle market, and (iv) two properties aggregating

247,246 RSF in our Austin submarket. As of June 30, 2025, 153,658 RSF was leased with a weighted-average lease commencement date of April 30, 2026, and we

expect to favorably resolve the remaining 614,422 RSF over the next several quarters.

(3)The Alexandria Center<sup>®</sup> for Life Science – New York City Megacampus is 97.8% occupied as of June 30, 2025. Occupancy percentage in our New York City market

reflects vacancy at the Alexandria Center<sup>®</sup> for Life Science – Long Island City property, which was 52.2% occupied as of June 30, 2025.

(4)Includes temporary vacancies as of June 30, 2025 aggregating 668,795 RSF, or 1.7%, primarily in the Greater Boston, San Francisco Bay Area, and San Diego markets,

which are leased and expected to be occupied upon completion of building and/or tenant improvements. The weighted-average expected delivery date is January 2,

2026. 66

**Investments in real estate**

A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new

Class A/A+ properties, and property enhancements identified during the underwriting of certain acquired properties, primarily located in

collaborative Megacampus ecosystems in AAA life science innovation clusters. These projects are focused on providing high-quality,

generic, and reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each development or

redevelopment project is expected to generate increases in rental income, net operating income, and cash flows. Our development and

redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher

occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. Our pre-construction

activities are undertaken in order to prepare the property for its intended use and include entitlements, permitting, design, site work, and

other activities preceding commencement of construction of aboveground building improvements.

Our investments in real estate consisted of the following as of June 30, 2025 (dollars in thousands):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | Development and Redevelopment | Development and Redevelopment | Development and Redevelopment | Development and Redevelopment | Development and Redevelopment | |
|  | | Under Construction | Under Construction | 100%<br>Pre-leased <br>Committed <br>Near Term<sup>(1)</sup> | | | |
|  | <br>Operating | 2025 and <br>2026<br>| 2027 and <br>Beyond<br>| 100%<br>Pre-leased <br>Committed <br>Near Term<sup>(1)</sup> | <br>Future | <br>Subtotal | <br>Total |
| **Square footage** |  |  |  |  |  |  |  |
| Operating | 39061858 |  |  |  |  |  | 39061858 |
| Future Class A/A+ development and redevelopment <br>properties<br>|  | 1155041 | 2803640 | 466598 | 24754090 | 29179369 | 29179369 |
| Future development and redevelopment square feet <br>currently included in rental properties<sup>(2)</sup><br>|  |  |  | (52620) | (2525858) | (2578478) | (2578478) |
| Total square footage, excluding properties held for sale | 39061858 | 1155041 | 2803640 | 413978 | 22228232 | 26600891 | 65662749 |
| Properties held for sale | 679383 |  |  |  | 878205 | 878205 | 1557588 |
| Total square footage | 39741241 | 1155041 | 2803640 | 413978 | 23106437 | 27479096 | 67220337 |
| **Investments in real estate** |  |  |  |  |  |  |  |
| Gross book value as of June 30, 2025<sup>(3)</sup> | $29681626 | $1128865 | $2657516 | $19965 | $4819006 | $8625352 | $38306978 |

---

(1)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a55% interest. The project is fully

leased to a longtime multinational pharmaceutical tenant that currently occupies two buildings within the Megacampus, one building aggregating52,620 RSF and

another building aggregating52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and development of the new,

build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the52,853 RSF building

to allow for the construction of an amenity which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until

our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata with our joint venture partner.

(2)Refer to "Investments in real estate" under "Definitions and reconciliations" in Item 2 for additional details, including future development and redevelopment square feet

currently included in rental properties.

(3)Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is

classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheet.

<u>Dispositions and sales of partial interests</u>

Our completed dispositions and sales of partial interests of real estate assets during the six months ended June 30, 2025 and pending as of the date of this report consisted of the

following (dollars in thousands):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Square Footage | Square Footage |  | Gain on <br>Sales of <br>Real Estate |
| Property | Submarket/Market | Date of <br>Sale<br>| Interest <br>Sold | Operating | Future <br>Development <br>| Sales Price | Gain on <br>Sales of <br>Real Estate |
| Completed during the six months ended June 30, 2025: | Completed during the six months ended June 30, 2025: |  |  |  |  |  |  |
| *Properties with vacancies* |  |  |  |  |  |  |  |
| 2425 Garcia Avenue and 2400/2450 Bayshore Parkway | Greater Stanford/San Francisco Bay Area | 6/30/25 | 100% | 95901 |  | $11000 | $— |
| Other |  |  |  |  |  | 18352 | 12661 |
| *Land* |  |  |  |  |  |  |  |
| Costa Verde by Alexandria | University Town Center/San Diego | 1/31/25 | 100% |  | 537000 | 124000<br><sup>(1)</sup> |  |
| Land parcel | Texas | 5/7/25 | 100% |  | 1350000 | 73287 |  |
| Other land parcels |  |  |  |  |  | 34000 | 504 |
|  |  |  |  |  |  | 260639 | $13165 |
| Our share of pending dispositions and sales of partial interests subject to <br>non-refundable deposits, signed letters of intent, and/or purchase and <br>sale agreement negotiations<br>|  |  |  |  |  | 524745 |  |
| Our share of completed and pending 2025 dispositions and sales of partial <br>interests<br>|  |  |  |  |  | $785384 |  |
| 2025 guidance range for dispositions and sales of partial interests |  |  |  |  | $1450000 – $2450000 | $1450000 – $2450000 |  |
| 2025 guidance midpoint for dispositions and sales of partial interests |  |  |  |  |  | $1950000 |  |

---

(1)As part of a completed transaction, we provided seller financing of $91.0 million. This note receivable is classified within "Other assets" in our consolidated balance sheet. Refer to Note 8 – "Other assets" to our consolidated financial

statements for additional information.

<u>New</u> <u>Class A/A+ development and redevelopment properties</u>

![pipelinepagev2.jpg](are-20250630_g13.jpg)

**ALEXANDRIA'S DEVELOPMENT AND REDEVELOPMENT** 

**DELIVERIES ARE EXPECTED TO PROVIDE INCREMENTAL** 

**GROWTH IN ANNUAL NET OPERATING INCOME**

---

| | | |
|:---|:---|:---|
| **Placed Into**<br>**Service** | **Near-Term** <br>**Deliveries** | **Intermediate-Term** <br>**Deliveries** |
| **1H25** | **3Q25–4Q26** | **2027–2028** |
| **$52M** | **$139M** | **$261M** |
| **$52M** | **$139M** | **$261M** |
| **96%**<br>**Occupied** | **84%**<br>**Leased/Negotiating** | **28%**<br>**Leased/Negotiating** |
| **527,268 RSF** | **1.2 millionRSF** | **3.3 millionRSF** |

---

**(2)** **(5)** **(4)** **(1)** **(3)** For the definition of "Net operating income" and a reconciliation from the most directly comparable GAAP measure, refer to the "Definitions and reconciliations"in Item 2.

(1)Excludes incremental annual net operating income from recently delivered spaces aggregating22,005 RSF that are vacant and/or unleased as of June 30, 2025.

(2)Includes expected partial deliveries through the fourth quarter of 2026 from projects expected to stabilize in 2027 and beyond, including speculative future leasing that is not yet fully committed. Our share of incremental annual net

operating income from development and redevelopment projects expected to be placed into service primarily commencing from the third quarter of 2025 through the fourth quarter of 2026 is projected to be $103 million. Refer to

the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in Item 2 for additional details.

(3)Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 2027 through 2028 is projected to be $236 million.

(4)Represents the leased/negotiating percentage of development and redevelopment projects that are expected to stabilize during the second half of 2025 and 2026.

(5)Represents the RSF related to projects expected to stabilize by the fourth quarter of 2026. Does not include RSF for partial deliveries through the fourth quarter of 2026 from projects expected to stabilize in 2027 and beyond.

<u>New Class A/A+ development and redevelopment properties: recent deliveries</u>

Incremental Annual Net Operating Income Generated From 1H25 Deliveries

Aggregated $52 Million, Including $15 Million<sup>(1)</sup> in 2Q25

---

| | | |
|:---|:---|:---|
| **230 Harriet Tubman Way** | **10935, 10945, and 10955** <br>**Alexandria Way**<sup>(2)</sup><br>| **10075 Barnes Canyon Road** |
| San Francisco Bay Area/<br>South San Francisco<br>| San Diego/Torrey Pines | San Diego/Sorrento Mesa |
| 285,346 RSF | 212,694 RSF | 17,718 RSF |
| 100% Occupancy | 100% Occupancy | 100% Occupancy |
| ![harriettubman.jpg](are-20250630_g14.jpg) | ![alexandriawayOAS.jpg](are-20250630_g15.jpg) | ![barnescanyon10075 v2.jpg](are-20250630_g16.jpg) |

---

The following table presents development and redevelopment of new Class A/A+ projects placed into service during the six months ended June 30, 2025 (dollars in thousands):

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Property/Market/Submarket** | **2Q25**<br>**Delivery** <br>**Date**<sup>(3)</sup> | **Our** <br>**Ownership** <br>**Interest** | **RSF Placed in Service** | **RSF Placed in Service** | **RSF Placed in Service** | **RSF Placed in Service** | **Occupancy** <br>**Percentage**<sup>(4)</sup> | **Total Project** | **Total Project** | **Unlevered Yields** | **Unlevered Yields** |
| **Property/Market/Submarket** | **2Q25**<br>**Delivery** <br>**Date**<sup>(3)</sup> | **Our** <br>**Ownership** <br>**Interest** | **Prior to** <br>**1/1/25** | **1Q25** | **2Q25** | **Total** | **Occupancy** <br>**Percentage**<sup>(4)</sup> | **Total Project** | **Total Project** | **Initial** <br>**Stabilized** | **Initial** <br>**Stabilized** <br>**(Cash Basis)** |
| **Property/Market/Submarket** | **2Q25**<br>**Delivery** <br>**Date**<sup>(3)</sup> | **Our** <br>**Ownership** <br>**Interest** | **Prior to** <br>**1/1/25** | **1Q25** | **2Q25** | **Total** | **Occupancy** <br>**Percentage**<sup>(4)</sup> | **RSF** | **Investment** | **Initial** <br>**Stabilized** | **Initial** <br>**Stabilized** <br>**(Cash Basis)** |
| **Development projects** |  |  |  |  |  |  |  |  |  |  |  |
| 230 Harriet Tubman Way/San Francisco Bay Area/South <br>San Francisco<br>| N/A | 48.5% |  | 285346 |  | 285346 | 100% | 285346 | 476000 | 7.5% | 6.2% |
| 10935, 10945, and 10955 Alexandria Way/San Diego/<br>Torrey Pines<br>| 5/11/25 | 100% | 93492 |  | 119202 | 212694 | 100% | 334996 | 480000<br><sup>(5)</sup> | 7.2<br><sup>(5)</sup> | 6.9<br><sup>(5)</sup> |
| 10075 Barnes Canyon Road/San Diego/Sorrento Mesa | N/A | 50.0% |  | 17718 |  | 17718 | 100% | 253079 | 321000 | 5.5 | 5.7 |
| **Redevelopment projects** |  |  |  |  |  |  |  |  |  |  |  |
| 651 Gateway Boulevard/San Francisco Bay Area/South <br>San Francisco<br>| N/A<sup>(6)</sup> | 50.0% | 67017 |  | 22005<br><sup>(6)</sup> | 89022 | 75%<br><sup>(6)</sup> | 326706 | 487000 | 5.0 | 5.1 |
| Canada | 5/29/25 | 100% | 78487 | 6430 | 76567 | 161484 | 100% | 250790 | 115000 | 6.0 | 6.0 |
| Weighted average/total | 5/14/25 |  | 238996 | 309494 | 217774 | 766264 |  | 1450917 | $1879000 | 6.3% | 6.0% |

---

(1)Excludes incremental annual net operating income from recently delivered spaces aggregating 22,005 RSF that are vacant and/or unleased as of June 30, 2025. Refer to footnote 6 below.

(2)Image represents 10955 Alexandria Way on the One Alexandria Square Megacampus.

(3)Represents the average delivery date for deliveries that occurred during the three months ended June 30, 2025, weighted by annual rental revenue.

(4)Occupancy relates to total operating RSF placed in service as of the most recent delivery.

(5)Improvements of 100 bps and 110 bps in initial stabilized yield and initial stabilized yield (cash basis), respectively, were primarily driven by leasing space at higher rental rates than previously underwritten and a $23 million reduction in total

investment due to construction cost savings from overall project efficiencies.

(6)Represents a turnkey space delivered vacant and unleased that did not generate incremental annual net operating income as of June 30, 2025.

<u>New Class A/A+ development and redevelopment properties: 2025 and 2026 stabilization ("near-term deliveries")</u>

---

| | | |
|:---|:---|:---|
| **99 Coolidge Avenue** | **500 North Beacon Street and** <br>**4 Kingsbury Avenue**<sup>(1)</sup><br>| **10935, 10945, and 10955** <br>**Alexandria Way**<sup>(2)</sup><br>|
| Greater Boston/<br>Cambridge/Inner Suburbs<br>| Greater Boston/<br>Cambridge/Inner Suburbs<br>| San Diego/Torrey Pines |
| 204,395 RSF | 36,444 RSF | 122,302 RSF |
| 76% Leased/Negotiating | 92% Leased/Negotiating | 100% Leased |
| ![99Coolidge.jpg](are-20250630_g17.jpg) | ![arsenalphaseii v2.jpg](are-20250630_g18.jpg) | ![alexandriawayOAS.jpg](are-20250630_g15.jpg) |

---

---

| | | |
|:---|:---|:---|
| **4135 Campus Point Court** | **10075 Barnes Canyon Road** | **8800 Technology Forest Place** |
| San Diego/<br>University Town Center<br>| San Diego/Sorrento Mesa | Texas/Greater Houston |
| 426,927 RSF | 235,361 RSF | 73,298 RSF |
| 100% Leased | 68% Leased/Negotiating | 41% Leased/Negotiating |
| ![Campuspoint4135.jpg](are-20250630_g19.jpg) | ![barnescanyon10075 v2.jpg](are-20250630_g16.jpg) | ![Techforest8800.jpg](are-20250630_g20.jpg) |

---

(1)Image represents 500 North Beacon Street on The Arsenal on the Charles Megacampus.

(2)Image represents 10955 Alexandria Way on the One Alexandria Square Megacampus.

<u>New Class A/A+ development and redevelopment properties:</u> <u>2</u><u>027 and beyond stabilization ("intermediate-term deliveries")</u>

---

| | | | |
|:---|:---|:---|:---|
| **311 Arsenal Street** | **421 Park Drive** | **401 Park Drive** | **40, 50, and 60 Sylvan Road**<sup>(1)</sup> |
| Greater Boston/<br>Cambridge/Inner Suburbs<br>| Greater Boston/Fenway | Greater Boston/Fenway | Greater Boston/Route 128 |
| 333,758 RSF | 392,011 RSF | 137,675 RSF | 596,064 RSF |
| ![arsenal311.jpg](are-20250630_g21.jpg) | ![parkdrive421.jpg](are-20250630_g22.jpg) | ![parkdrive401v2.jpg](are-20250630_g23.jpg) | ![60 Sylvan.jpg](are-20250630_g24.jpg) |

---

---

| | | | |
|:---|:---|:---|:---|
| **1450 Owens Street** | **651 Gateway Boulevard** | **269 East Grand Avenue** | **701 Dexter Avenue North** |
| San Francisco Bay Area/<br>Mission Bay<br>| San Francisco Bay Area/<br>South San Francisco<br>| San Francisco Bay Area/<br>South San Francisco<br>| Seattle/Lake Union |
| 212,796 RSF<sup>(2)</sup> | 237,684 RSF | 107,250 RSF | 227,577 RSF |
| ![owens1450.jpg](are-20250630_g25.jpg) | ![gateway651.jpg](are-20250630_g26.jpg) | ![269EGrand.jpg](are-20250630_g27.jpg) | ![701Dexter.jpg](are-20250630_g28.jpg) |

---

(1)Image represents 60 Sylvan Road on the Alexandria Center<sup>®</sup> for Life Science – Waltham Megacampus. The project is expected to capture demand in our Route 128 submarket.

(2)Image represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we

executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the

institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF to our presentation of the development project.

<u>New Class A/A+ development and redevelopment properties: current projects</u>

The following tables set forth a summary of our new Class A/A+ development and redevelopment properties under construction as of June 30, 2025 (dollars in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Property/Market/Submarket** | | **Square Footage** | **Square Footage** | **Square Footage** | **Percentage** | **Percentage** | **Occupancy**<sup>(1)</sup> | **Occupancy**<sup>(1)</sup> |
| **Property/Market/Submarket** | <br>**Dev/Redev** | **In Service** | **CIP** | **Total** | **Leased** | **Leased/**<br>**Negotiating** | **Initial** | **Stabilized** |
| **Under construction** |  |  |  |  |  |  |  |  |
| **<u>2025 and 2026 stabilization</u>** |  |  |  |  |  |  |  |  |
| 99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs | Dev | 116414 | 204395 | 320809 | 52% | 76% | 4Q23 | 2026 |
| 500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/<br>Cambridge/Inner Suburbs<br>| Dev | 211574 | 36444 | 248018 | 92 | 92 | 1Q24 | 2025 |
| 10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines | Dev | 212694 | 122302 | 334996 | 100 | 100 | 4Q24 | 2025 |
| 4135 Campus Point Court/San Diego/University Town Center | Dev |  | 426927 | 426927 | 100 | 100 | 2026 | 2026 |
| 10075 Barnes Canyon Road/San Diego/Sorrento Mesa | Dev | 17718 | 235361 | 253079 | 68 | 68 | 1Q25 | 2026 |
| 8800 Technology Forest Place/Texas/Greater Houston | Redev | 50094 | 73298 | 123392 | 41 | 41 | 2Q23 | 2026 |
| Canada | Redev | 194476 | 56314 | 250790 | 78 | 80 | 3Q23 | 2025 |
|  |  | 802970 | 1155041 | 1958011 | 80 | 84 |  |  |
| **<u>2027 and beyond stabilization</u>** |  |  |  |  |  |  |  |  |
| One Hampshire Street/Greater Boston/Cambridge | Redev |  | 104956 | 104956 |  |  | 2027 | 2028 |
| 311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs | Redev | 56904 | 333758 | 390662 | 7 | 7 | 2027 | 2027 |
| 421 Park Drive/Greater Boston/Fenway | Dev |  | 392011 | 392011 | 13 | 13 | 2027 | 2028 |
| 401 Park Drive/Greater Boston/Fenway | Redev |  | 137675 | 137675 |  |  | 2026 | 2027 |
| 40, 50, and 60 Sylvan Road/Greater Boston/Route 128 | Redev |  | 596064 | 596064 | 33 | 33 | 2026 | 2027 |
| Other/Greater Boston | Redev |  | 453869 | 453869 |  |  | 2027 | 2027 |
| 1450 Owens Street/San Francisco Bay Area/Mission Bay<sup>(2)</sup> | Dev |  | 212796 | 212796 |  | 49<br><sup>(2)</sup> | 2026 | 2027 |
| 651 Gateway Boulevard/San Francisco Bay Area/South San Francisco<sup>(3)</sup> | Redev | 89022 | 237684 | 326706 | 21 | 21 | 1Q24 | 2027 |
| 269 East Grand Avenue/San Francisco Bay Area/South San Francisco | Redev |  | 107250 | 107250 |  |  | 2026 | 2027 |
| 701 Dexter Avenue North/Seattle/Lake Union | Dev |  | 227577 | 227577 | 23 | 23 | 2026 | 2027 |
|  |  | 145926 | 2803640 | 2949566 |  |  |  |  |
| **<u>100%</u> <u>Pre-leased committed near-term project expected to commence construction in the next year</u>** | **<u>100%</u> <u>Pre-leased committed near-term project expected to commence construction in the next year</u>** | **<u>100%</u> <u>Pre-leased committed near-term project expected to commence construction in the next year</u>** |  |  |  |  |  |  |
| Campus Point by Alexandria/San Diego/University Town Center<sup>(4)</sup> | Dev |  | 466598 | 466598 | 100 | 100 | 2028 | 2028 |
| Total 2027 and beyond stabilization and committed near-term project |  | 145926 | 3270238 | 3416164 | 25 | 28 |  |  |
|  |  | 948896 | 4425279 | 5374175 | 45% | 49% |  |  |
| (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. | (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.<br>(2)Represents a multi-tenant project expanding the Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of <br>intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a <br>long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project. <br>(3)We continue to build out this project on a floor-by-floor basis. As of June 30, 2025, the remaining cost to complete is $138 million, or 28% of the total cost at completion. <br>(4)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently <br>occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and <br>development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity <br>which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata <br>with our joint venture partner. |

---

<u>New Class A/A+ development and redevelopment properties: current projects (continued)</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Our** <br>**Ownership** <br>**Interest** | **At 100%** | **At 100%** | **At 100%** | **At 100%** | **Unlevered Yields** | **Unlevered Yields** |
| **Property/Market/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **In Service** | **CIP** | **Cost to** <br>**Complete** | **Total at**<br>**Completion** | **Initial** <br>**Stabilized** | **Initial Stabilized** <br>**(Cash Basis)** |
| **Property/Market/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **In Service** | **CIP** | **Cost to** <br>**Complete** | **Total at**<br>**Completion** | **Initial** <br>**Stabilized** | **Initial Stabilized** <br>**(Cash Basis)** |
| **Under construction** |  |  |  |  |  |  |  |
| **<u>2025 and 2026 stabilization with</u> <u>84%</u> <u>leased/negotiating</u>** |  |  |  |  |  |  |  |
| 99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs | 76.9% | $136692 | $217195 | $90113 | $444000 | 6.0% | 6.8% |
| 500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/<br>Cambridge/Inner Suburbs<br>| 100% | 376928 | 45565 | 4507 | 427000 | 6.2% | 5.5% |
| 10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines | 100% | 258106 | 218712 | 3182 | 480000 | 7.2% | 6.9% |
| 4135 Campus Point Court/San Diego/University Town Center | 55.0% |  | 380816 | 143184 | 524000 | 7.3% | 6.2% |
| 10075 Barnes Canyon Road/San Diego/Sorrento Mesa | 50.0% | 16646 | 205116 | 99238 | 321000 | 5.5% | 5.7% |
| 8800 Technology Forest Place/Texas/Greater Houston | 100% | 60360 | 46373 | 5267 | 112000 | 6.3% | 6.0% |
| Canada | 100% | 96895 | 15088 | 3017 | 115000 | 6.0% | 6.0% |
|  |  | 945627 | 1128865 |  |  |  |  |
| **<u>2027 and beyond stabilization</u>**<sup>(1)</sup> |  |  |  |  |  |  |  |
| One Hampshire Street/Greater Boston/Cambridge | 100% |  | 170821 | TBD | TBD | TBD | TBD |
| 311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs | 100% | 21613 | 291434 | TBD | TBD | TBD | TBD |
| 421 Park Drive/Greater Boston/Fenway | 100% |  | 533157 | TBD | TBD | TBD | TBD |
| 401 Park Drive/Greater Boston/Fenway | 100% |  | 170697 | TBD | TBD | TBD | TBD |
| 40, 50, and 60 Sylvan Road/Greater Boston/Route 128 | 100% |  | 480940 | TBD | TBD | TBD | TBD |
| Other/Greater Boston | 100% |  | 157989 | TBD | TBD | TBD | TBD |
| 1450 Owens Street/San Francisco Bay Area/Mission Bay | 25.0% |  | 242946 | TBD | TBD | TBD | TBD |
| 651 Gateway Boulevard/San Francisco Bay Area/South San Francisco | 50.0% | 116544 | 232366 | 138090 | 487000 | 5.0% | 5.1% |
| 269 East Grand Avenue/San Francisco Bay Area/South San Francisco | 100% |  | 93905 | TBD | TBD | TBD | TBD |
| 701 Dexter Avenue North/Seattle/Lake Union | 100% |  | 283261 | TBD | TBD | TBD | TBD |
|  |  | 138157 | 2657516 |  |  |  |  |
|  |  | 1083784 | 3786381 |  |  |  |  |
| **<u>100%</u> <u>Pre-leased committed near-term project expected to commence construction in the next year</u>** | **<u>100%</u> <u>Pre-leased committed near-term project expected to commence construction in the next year</u>** | **<u>100%</u> <u>Pre-leased committed near-term project expected to commence construction in the next year</u>** |  |  |  |  |  |
| Campus Point by Alexandria/San Diego/University Town Center | 55.0% |  | 19965 | 640035 | 660000 | 7.3% | 6.5% |
| Total |  | $1083784 | $3806346 | $2880000<br><sup>(2)</sup> | $7780000<br><sup>(2)</sup> |  |  |
| Our share of investment<sup>(2)(3)</sup> |  | $990000 | $3180000 | $2440000 | $6610000 |  |  |
| Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. | Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters. <br>(2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not <br>been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign <br>materials required, and/or the higher cost on domestic materials. <br>(3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. |

---

<u>New Class A/A+ development and redevelopment properties: summary of pipeline</u>

74% of Our Total Development and Redevelopment Pipeline RSF Is Within Our Megacampus<sup>™</sup> Ecosystems

The following table summarizes the key information for all our development and redevelopment projects in North America as of June 30, 2025 (dollars in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Square Footage** | **Square Footage** | **Square Footage** | **Square Footage** |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Development and Redevelopment** | **Development and Redevelopment** | **Development and Redevelopment** | **Total**<sup>(1)</sup> |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Under** <br>**Construction**<br>| **Committed Near** <br>**Term**<br>| **Future** | **Total**<sup>(1)</sup> |
| Greater Boston |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **at One Kendall Square/Cambridge** | 100% | $170821 | 104956 |  |  | 104956 |
| *One Hampshire Street* |  |  |  |  |  |  |
| **Megacampus: The Arsenal on the Charles/Cambridge/Inner Suburbs** | 100% | 348966 | 370202 |  | 34157 | 404359 |
| *311 Arsenal Street, 500 North Beacon Street, and 4 Kingsbury Avenue* |  |  |  |  |  |  |
| **Megacampus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street, and 99** <br>**Coolidge Avenue/Cambridge/Inner Suburbs**<br>| <sup>(2)</sup> | 308792 | 204395 |  | 902000 | 1106395 |
| *446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Life Science – Fenway/Fenway** | 100% | 703854 | 529686 |  |  | 529686 |
| *401 and 421 Park Drive* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Life Science – Waltham/Route 128** | 100% | 544558 | 596064 |  | 515000 | 1111064 |
| *40, 50, and 60 Sylvan Road, and 35 Gatehouse Drive* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **at Kendall Square/Cambridge** | 100% | 209528 |  |  | 174500 | 174500 |
| *100 Edwin H. Land Boulevard* |  |  |  |  |  |  |
| **Megacampus: Alexandria Technology Square**<sup>®</sup>**/Cambridge** | 100% | 8239 |  |  | 100000 | 100000 |
| **Megacampus: 285, 299, 307, and 345 Dorchester Avenue/Seaport Innovation District** | 60.0% | 293055 |  |  | 1040000 | 1040000 |
| 10 Necco Street/Seaport Innovation District | 100% | 105734 |  |  | 175000 | 175000 |
| 215 Presidential Way/Route 128 | 100% | 6816 |  |  | 112000 | 112000 |
| Other development and redevelopment projects | 100% | 373732 | 453869 |  | 1348541 | 1802410 |
|  |  | **$3074095** | **2259172** | **—** | **4401198** | **6660370** |
| Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. |

---

<u>New Class A/A+ development and redevelopment properties: summary of pipeline (continued)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Square Footage** | **Square Footage** | **Square Footage** | **Square Footage** |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Development and Redevelopment** | **Development and Redevelopment** | **Development and Redevelopment** | **Total**<sup>(1)</sup> |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Under** <br>**Construction**<br>| **Committed Near** <br>**Term**<br>| **Future** | **Total**<sup>(1)</sup> |
| San Francisco Bay Area |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Science and Technology – Mission Bay/Mission** <br>**Bay**<br>| 25.0% | $242946<br><sup>(2)</sup> | 212796<br><sup>(2)</sup> |  |  | 212796 |
| *1450 Owens Street* |  |  |  |  |  |  |
| **Megacampus: Alexandria Technology Center**<sup>®</sup> **– Gateway/South San Francisco** | 50.0% | 258932 | 237684 |  | 291000 | 528684 |
| *651 Gateway Boulevard* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Advanced Technologies – South San** <br>**Francisco/South San Francisco**<br>| 100% | 100560 | 107250 |  | 90000 | 197250 |
| *211*<sup>(3)</sup> *and 269 East Grand Avenue* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Advanced Technologies – Tanforan/South San** <br>**Francisco**<br>| 100% | 420858 |  |  | 1930000 | 1930000 |
| *1122, 1150, and 1178 El Camino Real* |  |  |  |  |  |  |
| Alexandria Center<sup>®</sup> for Life Science – Millbrae/South San Francisco | 48.5% | 157008 |  |  | 348401 | 348401 |
| *201 and 231 Adrian Road and 30 Rollins Road* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup>**for Life Science – San Carlos/Greater Stanford** | 100% | 471861 |  |  | 1497830 | 1497830 |
| *960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road* |  |  |  |  |  |  |
| 3825 and 3875 Fabian Way/Greater Stanford | 100% | 161492 |  |  | 478000 | 478000 |
| 2100, 2200, 2300, and 2400 Geng Road/Greater Stanford | 100% | 38761 |  |  | 240000 | 240000 |
| **Megacampus: 88 Bluxome Street/SoMa** | 100% | 408649 |  |  | 1070925 | 1070925 |
|  |  | **$2261067** | **557730** | **—** | **5946156** | **6503886** |
| Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real <br>estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During <br>the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the <br>development project. <br>(3)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for additional details. |

---

<u>New Class A/A+ development and redevelopment properties: summary of pipeline (continued)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Square Footage** | **Square Footage** | **Square Footage** | **Square Footage** |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Development and Redevelopment** | **Development and Redevelopment** | **Development and Redevelopment** | **Total**<sup>(1)</sup> |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Under** <br>**Construction**<br>| **Committed Near** <br>**Term**<br>| **Future** | **Total**<sup>(1)</sup> |
| San Diego |  |  |  |  |  |  |
| **Megacampus: One Alexandria Square/Torrey Pines** | 100% | $281632 | 122302 |  | 125280 | 247582 |
| *10945 Alexandria Way and 10975 and 10995 Torreyana Road* |  |  |  |  |  |  |
| **Megacampus: Campus Point by Alexandria/University Town Center** | 55.0%<br><sup>(3)</sup> | 540207 | 426927 | 466598 | 500859 | 1394384 |
| *10010*<sup>(2)</sup>*, 10140*<sup>(2)</sup>*, 10210, and 10260 Campus Point Drive and 4135, 4161, 4165,* <br>*and 4224 Campus Point Court*<br>|  |  |  |  |  |  |
| **Megacampus: SD Tech by Alexandria/Sorrento Mesa** | 50.0% | 391642 | 235361 |  | 493845 | 729206 |
| *9805 Scranton Road and 10075 Barnes Canyon Road* |  |  |  |  |  |  |
| 11255 and 11355 North Torrey Pines Road/Torrey Pines | 100% | 156121 |  |  | 215000 | 215000 |
| **Megacampus: 5200 Illumina Way/University Town Center** | 51.0% | 17458 |  |  | 451832 | 451832 |
| 9625 Towne Centre Drive/University Town Center | 30.0% | 837 |  |  | 100000 | 100000 |
| **Megacampus: Sequence District by Alexandria/Sorrento Mesa** | 100% | 47565 |  |  | 1661915 | 1661915 |
| *6290, 6310, 6340, 6350, and 6450 Sequence Drive* |  |  |  |  |  |  |
| Scripps Science Park by Alexandria/Sorrento Mesa | 100% | 42700 |  |  | 154308 | 154308 |
| *10256 and 10260 Meanley Drive* |  |  |  |  |  |  |
| 4075 Sorrento Valley Boulevard/Sorrento Valley | 100% | 28174 |  |  | 144000 | 144000 |
| Other development and redevelopment projects | <sup>(4)</sup> | 78002 |  |  | 475000 | 475000 |
|  |  | **$1584338** | **784590** | **466598** | **4322039** | **5573227** |
| Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in <br>real estate" under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in this property.<br>(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after <br>which future capital would be contributed pro-rata with our partner.<br>(4)Includes a property in which we own a partial interest through a real estate joint venture.  |

---

<u>New Class A/A+ development and redevelopment properties: summary of pipeline (continued)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Square Footage** | **Square Footage** | **Square Footage** | **Square Footage** |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Development and Redevelopment** | **Development and Redevelopment** | **Development and Redevelopment** | **Total**<sup>(1)</sup> |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Under** <br>**Construction**<br>| **Committed Near** <br>**Term**<br>| **Future** | **Total**<sup>(1)</sup> |
| Seattle |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Advanced Technologies – South Lake Union/**<br>**Lake Union**<br>| <sup>(2)</sup> | $571319 | 227577 |  | 1057400 | 1284977 |
| *601 and 701 Dexter Avenue North and 800 Mercer Street* |  |  |  |  |  |  |
| 1010 4th Avenue South/SoDo | 100% | 61490 |  |  | 544825 | 544825 |
| 410 West Harrison Street/Elliott Bay | 100% |  |  |  | 91000 | 91000 |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Advanced Technologies – Canyon Park/Bothell** | 100% | 19248 |  |  | 230000 | 230000 |
| *21660 20th Avenue Southeast* |  |  |  |  |  |  |
| Other development and redevelopment projects | 100% | 149289 |  |  | 706087 | 706087 |
|  |  | **801346** | **227577** | **—** | **2629312** | **2856889** |
| Maryland |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Life Science – Shady Grove/Rockville** | 100% | 24020 |  |  | 296000 | 296000 |
| *9830 Darnestown Road* |  |  |  |  |  |  |
|  |  | **24020** | **—** | **—** | **296000** | **296000** |
| Research Triangle |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Life Science – Durham/Research Triangle** | 100% | 162011 |  |  | 2060000 | 2060000 |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Advanced Technologies and AgTech –** <br>**Research Triangle/Research Triangle**<br>| 100% | 109661 |  |  | 1170000 | 1170000 |
| *4 and 12 Davis Drive* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for NextGen Medicines/Research Triangle** | 100% | 112142 |  |  | 1055000 | 1055000 |
| *3029 East Cornwallis Road* |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Sustainable Technologies/Research Triangle** | 100% | 55122 |  |  | 750000 | 750000 |
| *120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle Drive* |  |  |  |  |  |  |
| 100 Capitola Drive/Research Triangle | 100% |  |  |  | 65965 | 65965 |
| Other development and redevelopment projects | 100% | 4185 |  |  | 76262 | 76262 |
|  |  | **$443121** | **—** | **—** | **5177227** | **5177227** |
| Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. | Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.<br>(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have <br>inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and <br>reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.<br>(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF. |

---

<u>New Class A/A+ development and redevelopment properties: summary of pipeline (continued)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Square Footage** | **Square Footage** | **Square Footage** | **Square Footage** |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Development and Redevelopment** | **Development and Redevelopment** | **Development and Redevelopment** | **Total**<sup>(1)</sup> |
| **Market**<br>**Property/Submarket** | **Our** <br>**Ownership** <br>**Interest** | **Book Value** | **Under** <br>**Construction**<br>| **Committed Near** <br>**Term**<br>| **Future** | **Total**<sup>(1)</sup> |
| New York City |  |  |  |  |  |  |
| **Megacampus: Alexandria Center**<sup>®</sup> **for Life Science – New York City/New York City** | 100% | $173815 |  |  | 550000<br><sup>(2)</sup> | 550000 |
|  |  | **173815** | **—** | **—** | **550000** | **550000** |
| Texas |  |  |  |  |  |  |
| Alexandria Center<sup>®</sup> for Advanced Technologies at The Woodlands/Greater Houston | 100% | 49280 | 73298 |  | 116405 | 189703 |
| *8800 Technology Forest Place* |  |  |  |  |  |  |
| 1001 Trinity Street and 1020 Red River Street/Austin | 100% | 10858 |  |  | 250010 | 250010 |
| Other development and redevelopment projects | 100% | 58577 |  |  | 344000 | 344000 |
|  |  | **118715** | **73298** | **—** | **710415** | **783713** |
| Canada | 100% | 15088 | 56314 |  | 371743 | 428057 |
| Other development and redevelopment projects | 100% | 47478 |  |  | 350000 | 350000 |
| Total pipeline as of June 30, 2025, excluding properties held for sale |  | **8543083** | **3958681** | **466598** | **24754090** | **29179369** |
| Properties held for sale |  | 82269 |  |  | 878205 | 878205 |
| Total pipeline as of June 30, 2025 |  | **$8625352**<br><sup>(3)</sup> | **3958681** | **466598** | **25632295** | **30057574** |

---

Refer to "Megacampus" under "Definitions and reconciliations" in Item 2 for additional information.

(1)Total square footage includes 2,578,478 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction subject to market conditions and leasing. Refer to "Investments in real estate"

under "Definitions and reconciliations" in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.

(2)During the three months ended September 30, 2024, we filed a lawsuit against the New York City Health + Hospitals Corporation and the New York City Economic Development Corporation for fraud and breach of contract concerning our

option to ground lease a land parcel to develop a future world-class life science building within the Alexandria Center<sup>®</sup> for Life Science – New York City Megacampus. Refer to "Legal proceedings" in Item 1 under Part II – Other Information

for additional details.

(3)Includes$3.8 billion of projects that are currently under construction and one100% pre-leased committed near-term project expected to commence construction in the next year.

**Results of operations**

We present a tabular comparison of items, whether gain or loss, that may facilitate a high-level understanding of our results

and provide context for the disclosures included in our annual report on Form 10-K for the year ended December 31, 2024 and our

subsequent quarterly reports on Form 10-Q. We believe that such tabular presentation promotes a better understanding for investors of

the corporate-level decisions made and activities performed that significantly affect comparison of our operating results from period to

period. We also believe that this tabular presentation will supplement for investors an understanding of our disclosures and real estate

operating results. Gains or losses on sales of real estate and impairments of real estate are related to corporate-level decisions to

dispose of real estate. Gains or losses on early extinguishment of debt are related to corporate-level financing decisions focused on our

capital structure strategy. Significant realized and unrealized gains or losses on non-real estate investments, impairments of real estate

and non-real estate investments, and acceleration of stock compensation expense due to the resignations of executive officers are not

related to the operating performance of our real estate assets as they result from strategic, corporate-level non-real estate investment

decisions and external market conditions. Impairments of non-real estate investments and changes in provision for expected credit

losses on financial instruments are not related to the operating performance of our real estate as they represent the write-down of non-

real estate investments when their fair values decrease below their respective carrying values due to changes in general market or

other conditions outside of our control. Significant items, whether a gain or loss, included in the tabular disclosure for current periods

are described in further detail in Item 2. Key items included in net income attributable to Alexandria's common stockholders for the three

and six months ended June 30, 2025 and 2024 and the related per share amounts were as follows (in millions, except per share

amounts):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 |
|  | Amount | Amount | Per Share – Diluted | Per Share – Diluted | Amount | Amount | Per Share – Diluted | Per Share – Diluted |
| Unrealized losses on non-real estate <br>investments<br>| $(21.9) | $(64.2) | $(0.13) | $(0.37) | $(90.1) | $(35.1) | $(0.53) | $(0.20) |
| Gain on sales of real estate |  |  |  |  | 13.2 | 0.4 | 0.08 |  |
| Impairment of non-real estate investments | (39.2) | (12.8) | (0.23) | (0.08) | (50.4) | (27.5) | (0.30) | (0.16) |
| Impairment of real estate | (129.6) | (30.8) | (0.76) | (0.18) | (161.8) | (30.8) | (0.95) | (0.18) |
| Increase in provision for expected credit <br>losses on financial instruments<br>|  |  |  |  | (0.3) |  |  |  |
| Total | $(190.7) | $(107.8) | $(1.12) | $(0.63) | $(289.4) | $(93.0) | $(1.70) | $(0.54) |

---

Refer to Note 3 – "Investments in real estate," Note 5 – "Leases," Note 7 – "Investments," and Note 8 – "Other assets" to our

unaudited consolidated financial statements in Item 1 for additional information.

<u>Same properties</u>

We supplement an evaluation of our results of operations with an evaluation of operating performance of certain of our

properties, referred to as "Same Properties." For additional information on the determination of our Same Properties portfolio, refer to

"Same property comparisons" under "Definitions and reconciliations" in Item 2. The following table presents information regarding our

Same Properties for the three and six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | June 30, 2025 |
|  | Three Months Ended | Six Months Ended |
| Percentage change in net operating income over comparable period from prior year<sup>(1)</sup> | (5.4)% | (4.3)% |
| Percentage change in net operating income (cash basis) over comparable period <br>from prior year<sup>(1)(2)</sup><br>| 2.0% | 3.4% |
| Operating margin | 68% | 68% |
| Number of Same Properties | 330 | 329 |
| RSF | 33904941 | 33709506 |
| Occupancy – current-period average | 91.3% | 92.5% |
| Occupancy – same-period prior-year average | 94.5% | 94.4% |

---

(1)Includes leases expirations during the three months ended March 31, 2025 aggregating 768,080 RSF, that are vacant as of June 30, 2025, across six properties and

four submarkets. Excluding the impact of the properties with these leases, same property net operating income changes for the three and six months ended June 30,

2025 would have been (2.1)% and 6.5% (cash basis) and (1.1)% and 7.6% (cash basis), respectively. Refer to "Summary of occupancy percentages in North America" in

Item 2 for additional details.

(2)Includes the impact of expiring initial free rent concessions that burned off after January 1, 2024 in connection with the development and redevelopment projects that

were placed into service in 2023 and, accordingly are part of our same property pool for the three and six months ended June 30, 2025, including at 325 Binney Street in

our Cambridge submarket, 15 Necco Street in our Seaport Innovation District submarket, and 751 Gateway Boulevard in our South San Francisco submarket. Excluding

the impact of these expiring initial free rent concessions, same property net operating income changes (cash basis) for the three and six months ended June 30, 2025

would have been (1.8)% and (0.8)%, respectively.

The following table reconciles the number of Same Properties to total properties for the six months ended June 30, 2025:

---

| | |
|:---|:---|
| Development – under construction | Properties |
| 99 Coolidge Avenue | 1 |
| 500 North Beacon Street and 4 Kingsbury Avenue | 2 |
| 1450 Owens Street | 1 |
| 10935, 10945, and 10955 Alexandria Way | 3 |
| 10075 Barnes Canyon Road | 1 |
| 421 Park Drive | 1 |
| 4135 Campus Point Court | 1 |
| 701 Dexter Avenue North | 1 |
|  | 11 |
| Development – placed into service after <br>January 1, 2024<br>| Properties |
| 9810 Darnestown Road | 1 |
| 9820 Darnestown Road | 1 |
| 1150 Eastlake Avenue East | 1 |
| 4155 Campus Point Court | 1 |
| 201 Brookline Avenue | 1 |
| 9808 Medical Center Drive | 1 |
| 230 Harriet Tubman Way | 1 |
|  | 7 |
| Redevelopment – under construction | Properties |
| 40, 50, and 60 Sylvan Road | 3 |
| 269 East Grand Avenue | 1 |
| 651 Gateway Boulevard | 1 |
| 401 Park Drive | 1 |
| 8800 Technology Forest Place | 1 |
| 311 Arsenal Street | 1 |
| One Hampshire Street | 1 |
| Canada | 4 |
| Other | 2 |
|  | 15 |

---

---

| | |
|:---|:---|
| Redevelopment – placed into service after <br>January 1, 2024<br>| Properties |
| 840 Winter Street | 1 |
| Alexandria Center<sup>®</sup> for Advanced Technologies – <br>Monte Villa Parkway<br>| 6 |
|  | 7 |
| Acquisitions after January 1, 2024 | Properties |
| Other | 3 |
|  | 3 |
| Unconsolidated real estate JVs | 4 |
| Properties held for sale | 8 |
| Total properties excluded from Same Properties | 55 |
| Same Properties | 329 |
| Total properties in North America as of <br>June 30, 2025<br>| 384 |

---

<u>Comparison of results for the three months ended</u> <u>June 30, 2025</u> <u>to the three months ended</u> <u>June 30, 2024</u>

The following table presents a comparison of the components of net operating income for our Same Properties and Non-Same

Properties for the three months ended June 30, 2025, compared to the three months ended June 30, 2024 (dollars in thousands). Refer

to "Definitions and reconciliations" in Item 2 for definitions of "Tenant recoveries" and "Net operating income" and their reconciliations

from the most directly comparable financial measures presented in accordance with GAAP, income from rentals and net income,

respectively.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Three Months Ended June 30, | Three Months Ended June 30, |
|  | 2025 | 2024 | $ Change | % Change |
| Income from rentals: |  |  |  |  |
| Same Properties | $462622 | $480547 | $(17925) | (3.7)% |
| Non-Same Properties | 90755 | 96288 | (5533) | (5.7) |
| Rental revenues | 553377 | 576835 | (23458) | (4.1) |
| Same Properties | 166465 | 155157 | 11308 | 7.3 |
| Non-Same Properties | 17437 | 23170 | (5733) | (24.7) |
| Tenant recoveries | 183902 | 178327 | 5575 | 3.1 |
| Income from rentals | 737279 | 755162 | (17883) | (2.4) |
| Same Properties | 429 | 379 | 50 | 13.2 |
| Non-Same Properties | 24332 | 11193 | 13139 | 117.4 |
| Other income | 24761 | 11572 | 13189 | 114.0 |
| Same Properties | 629516 | 636083 | (6567) | (1.0) |
| Non-Same Properties | 132524 | 130651 | 1873 | 1.4 |
| Total revenues | 762040 | 766734 | (4694) | (0.6) |
| Same Properties | 201305 | 183582 | 17723 | 9.7 |
| Non-Same Properties | 23128 | 33672 | (10544) | (31.3) |
| Rental operations | 224433 | 217254 | 7179 | 3.3 |
| Same Properties | 428211 | 452501 | (24290) | (5.4) |
| Non-Same Properties | 109396 | 96979 | 12417 | 12.8 |
| Net operating income | $537607 | $549480 | $(11873) | (2.2)%<br><sup>(1)</sup> |
| Net operating income – Same Properties | **$428211** | **$452501** | **$(24290)** | **(5.4)%** |
| Straight-line rent revenue  | (8463) | (38585) | 30122 | (78.1) |
| Amortization of acquired below-market leases | (9199) | (11349) | 2150 | (18.9) |
| Net operating income – Same Properties (cash basis) | **$410549** | **$402567** | **$7982** | **2.0%** |

---

(1)Decrease in total net operating income includes the impact of operating properties disposed of after January 1, 2024. Excluding these dispositions, net operating income

for the three months ended June 30, 2025 would have increased by 4.0% over the corresponding period in 2024.

*<u>Income from rentals</u>*

Total income from rentals for the three months ended June 30, 2025decreased by $17.9 million, or 2.4%, to $737.3 million,

compared to $755.2 million for the three months ended June 30, 2024, due to a decrease in rental revenues, as discussed below.

*Rental revenues*

Total rental revenues for the three months ended June 30, 2025decreased by $23.5 million, or 4.1%, to $553.4 million,

compared to $576.8 million for the three months ended June 30, 2024. The decrease was partially related to our Non-Same Properties

resulting from the dispositions of real estate assets since April 1, 2024.

Same Properties' rental revenues for the three months ended June 30, 2025decreased by $17.9 million, or 3.7%, to

$462.6 million, compared to $480.5 million for the three months ended June 30, 2024, primarily due to a decrease in Same Properties'

average occupancy to91.3% for the three months ended June 30, 2025 from 94.5%for the three months ended June 30, 2024, mainly

resulting from the lease expirations during the three months ended March 31, 2025 aggregating 768,080 RSF, comprising the following:

(i) 182,054 RSF at the Alexandria Technology Square<sup>®</sup> Megacampus in our Cambridge submarket, (ii) 234,249 RSF at 409 Illinois

Street in our Mission Bay submarket, (iii) one property aggregating 104,531 RSF in our Research Triangle market, and (iv) two

properties aggregating 247,246 RSF in our Austin submarket.

*Tenant recoveries*

Tenant recoveries for the three months ended June 30, 2025increased by $5.6 million, or 3.1%, to $183.9 million, compared to

$178.3 million for the three months ended June 30, 2024, primarily in connection with Same Properties.

Same Properties' tenant recoveries for the three months ended June 30, 2025increased by $11.3 million, or 7.3%, to

$166.5 million, compared to $155.2 million for the three months ended June 30, 2024, primarily due to higher operating expenses

during the three months ended June 30, 2025, as discussed under "Rental operations" below. As of June 30, 2025, 91% of our leases

(on an annual rental revenue basis) were triple net leases, which require tenants to pay substantially all real estate taxes, insurance,

utilities, repairs and maintenance, common area expenses, and other operating expenses (including increases thereto) in addition to

base rent.

*<u>Other income</u>*

Other income for the three months ended June 30, 2025increased by $13.2 million, or 114.0%, to $24.8 million, compared to

$11.6 million for the three months ended June 30, 2024, primarily related to an increase in interest income earned on our notes

receivable and fee income.

*<u>Rental operations</u>*

Total rental operating expenses for the three months ended June 30, 2025increased by $7.2 million, or 3.3%, to

$224.4 million, compared to $217.3 million for the three months ended June 30, 2024. The increase was primarily due to higher rental

operating expenses related to our Same Properties, as discussed below, partially offset by the decrease in Non-Same Properties' rental

operating expenses of $10.5 million primarily as a result of real estate dispositions since April 1, 2024.

Same Properties' rental operating expenses increased by $17.7 million, or 9.7%, to $201.3 million during the three months

ended June 30, 2025, compared to $183.6 million for the three months ended June 30, 2024, primarily as the result of increases in

(i) contractual costs aggregating $4.4 million, primarily due to increased tenant operations at certain properties delivered in 2023,

(ii) repairs and maintenance expenses aggregating $4.2 million, primarily due to an increase in services related to building maintenance

in our Greater Boston, San Diego, and Research Triangle markets, and (iii) property taxes aggregating $3.6 million, primarily due to

new developments in our Greater Boston and San Francisco Bay Area markets delivered in 2023, with property taxes based on these

properties' higher assessed values becoming effective subsequent to July 1, 2024.

*<u>Depreciation and amortization</u>*

Depreciation and amortization expense for the three months ended June 30, 2025increased by $55.4 million, or 19.1%, to

$346.1 million, compared to $290.7 million for the three months ended June 30, 2024. The increase primarily reflects the change in

useful lives related to certain buildings expected to be demolished prior to the end of their previous useful lives. In addition, the increase

relates to 1.7 million RSF of development and redevelopment projects placed into service subsequent to April 1, 2024 and three

operating properties aggregating401,560 RSF acquired subsequent to April 1, 2024, partially offset by the decrease in depreciation and

amortization related to properties that were sold or classified as held for sale subsequent to April 1, 2024.

*<u>Impairment of real estate</u>*

During the three months ended June 30, 2025, we recognized impairment charges aggregating $129.6 million, which primarily

included the following:

• In April 2025, an office property aggregating 182,276 RSF, located in Carlsbad, San Diego, met the criteria for classification as

held for sale based on our decision to dispose of this property. We expect to complete the sale within 12 months. Upon our

decision to commit to sell this property, we recognized an impairment charge of $35.4 million to reduce the carrying amount of

this asset to its estimated fair value less costs to sell of approximately$68.8 million.

• In June 2025, two operating properties aggregating 210,481 RSF located in our Sorrento Mesa submarket met the criteria for

classification as held for sale based on current negotiations with prospective buyers and our decision to dispose of these

properties. We expect to complete these sales within 12 months. Upon our decision to commit to sell these properties, we

recognized impairment charges aggregating $18.1 million to reduce the carrying amounts of these assets to their estimated

fair values less costs to sell of approximately $112.7 million.

• In June 2025, land parcels aggregating 374,349 SF in our non-cluster/other submarket met the criteria for classification as held

for sale based on current negotiations with a prospective buyer and our decision to dispose of this asset. We expect to

complete this sale within 12 months. Upon our decision to sell this land parcel, we recognized an impairment charge of $47.5

million to reduce the carrying amount of the asset to its estimated fair value less costs to sell of approximately $28.5 million.

During the three months ended June 30, 2024, we recognized impairment charges aggregating$30.8 million, primarily

consisting of pre-acquisition costs related to two potential acquisitions in our Greater Boston market, which we decided to no longer

proceed with these acquisitions as a result of the current macroeconomic environment that negatively impacted the financial outlooks

for these projects.

*<u>General and administrative expenses</u>*

General and administrative expenses for thethree months ended June 30, 2025decreasedby $15.5 million, or 34.7%, to

$29.1 million, compared to $44.6 million for the three months ended June 30, 2024, primarily due to cost-control and efficiency

initiatives implemented since 2024, including reduction in headcount, restructuring of compensation plans, systems upgrades, and

process improvements. As a percentage of net operating income, our general and administrative expenses for the trailing twelve

months ended June 30, 2025 and 2024 were 6.3% and 9.2%, respectively.

*<u>Interest expense</u>*

Interest expense for the three months ended June 30, 2025 and 2024 consisted of the following (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, |  |
| Component | 2025 | 2024 | Change |
| Gross interest | $137719 | $126828 | $10891 |
| Capitalized interest | (82423) | (81039) | (1384) |
| Interest expense | $55296 | $45789 | $9507 |
| Average debt balance outstanding<sup>(1)</sup> | $13269046 | $12454474 | $814572 |
| Weighted-average annual interest rate<sup>(2)</sup> | 4.2% | 4.1% | 0.1% |

---

(1)Represents the average debt balance outstanding during the respective periods.

(2)Represents annualized total interest incurred divided by the average debt balance outstanding during the respective periods.

The net change in interest expense during the three months ended June 30, 2025, compared to the three months ended June

30, 2024, resulted from the following (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
| Component | Interest Rate<sup>(1)</sup> | Effective Date | Change |
| Increases in interest incurred due to: |  |  |  |
| Issuances of debt: |  |  |  |
| $550 million of unsecured senior notes payable due 2035 | 5.66% | February 2025 | $7590 |
| Higher average outstanding balances under commercial paper program and/or <br>unsecured senior line of credit<br>|  |  | 6316 |
| Other increase in interest |  |  | 517 |
| Total increases |  |  | 14423 |
| Decreases in interest incurred due to: |  |  |  |
| Repayments of debt: |  |  |  |
| $600 million of unsecured senior notes payable due 2025 | 3.62% | April 2025 | (3532) |
| Total decreases |  |  | (3532) |
| Change in gross interest |  |  | 10891 |
| Increase in capitalized interest |  |  | (1384) |
| **Total change in interest expense** |  |  | **$9507** |

---

(1)Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and

other bank fees.

*<u>Investment loss</u>*

During the three months ended June 30, 2025, we recognized investment loss aggregating$30.6 million, which consisted of

$30.5 million of realizedgains, $21.9 million of unrealized losses, and $39.2 million of impairment charges.

During the three months ended June 30, 2024, we recognized investment loss aggregating $43.7 million, which consisted of

$33.4 million of realized gains, $64.2 million of unrealized losses, and $12.8 million of impairment charges.

For additional information about our investments, refer to Note 7 – "Investments" to our unaudited consolidated financial

statements. For our impairments accounting policy, refer to "Investments" in Note 2 – "Summary of significant accounting policies" to

our unaudited consolidated financial statements in Item 1.

*<u>Other comprehensive income (loss)</u>*

Total other comprehensive income for the three months ended June 30, 2025 aggregated$18.8 million, compared to total

other comprehensive loss of$3.9 million for the three months ended June 30, 2024. The difference is primarily due to unrealized foreign

currency translation gains related to our operations in Canada.

<u>Comparison of results for the</u> <u>six months ended June 30, 2025</u> <u>to the</u> <u>six months ended June 30, 2024</u>

The following table presents a comparison of the components of net operating income for our Same Properties and Non-Same

Properties for the six months ended June 30, 2025, compared to the six months ended June 30, 2024 (dollars in thousands). Refer to

"Definitions and reconciliations" in Item 2 for definitions of "Tenant recoveries" and "Net operating income" and their reconciliations from

the most directly comparable financial measures presented in accordance with GAAP, income from rentals and net income,

respectively.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | $ Change | % Change |
| Income from rentals: |  |  |  |  |
| Same Properties | $925636 | $950433 | $(24797) | (2.6%) |
| Non-Same Properties | 179853 | 207802 | (27949) | (13.4) |
| Rental revenues | 1105489 | 1158235 | (52746) | (4.6) |
| Same Properties | 335349 | 308553 | 26796 | 8.7 |
| Non-Same Properties | 39616 | 43925 | (4309) | (9.8) |
| Tenant recoveries | 374965 | 352478 | 22487 | 6.4 |
| Income from rentals | 1480454 | 1510713 | (30259) | (2.0) |
| Same Properties | 774 | 719 | 55 | 7.6 |
| Non-Same Properties | 38970 | 24410 | 14560 | 59.6 |
| Other income | 39744 | 25129 | 14615 | 58.2 |
| Same Properties | 1261759 | 1259705 | 2054 | 0.2 |
| Non-Same Properties | 258439 | 276137 | (17698) | (6.4) |
| Total revenues | 1520198 | 1535842 | (15644) | (1.0) |
| Same Properties | 403337 | 362407 | 40930 | 11.3 |
| Non-Same Properties | 47491 | 73161 | (25670) | (35.1) |
| Rental operations | 450828 | 435568 | 15260 | 3.5 |
| Same Properties | 858422 | 897298 | (38876) | (4.3) |
| Non-Same Properties | 210948 | 202976 | 7972 | 3.9 |
| Net operating income | $1069370 | $1100274 | $(30904) | (2.8%)<br><sup>(1)</sup> |
| Net operating income – Same Properties | **$858422** | **$897298** | **$(38876)** | **(4.3%)** |
| Straight-line rent revenue  | (13930) | (76294) | 62364 | (81.7) |
| Amortization of acquired below-market leases | (19097) | (22772) | 3675 | (16.1) |
| Net operating income – Same Properties (cash basis) | **$825395** | **$798232** | **$27163** | **3.4%** |

---

(1)Decrease in total net operating income includes the impact of operating properties disposed of after January 1, 2024. Excluding these dispositions, net operating income

for the six months ended June 30, 2025 would have increased by 3.2% over the corresponding period in 2024.

*<u>Income from rentals</u>*

Total income from rentals for the six months ended June 30, 2025decreased by $30.3 million, or (2.0)%, to $1.48 billion,

compared to $1.51 billion for the six months ended June 30, 2024, due to a decrease in rental revenues, partially offset by an increase

in tenant recoveries, as discussed below.

*Rental revenues*

Total rental revenues for the six months ended June 30, 2025decreased by $52.7 million, or (4.6)%, to $1.1 billion, compared

to $1.2 billion for the six months ended June 30, 2024. The decrease was primarily related to our Non-Same Properties resulting from

the dispositions of real estate assets since January 1, 2024.

Same Properties' rental revenues for the six months ended June 30, 2025decreased by $24.8 million, or (2.6)%, to

$925.6 million, compared to $950.4 million for the six months ended June 30, 2024, primarily due to a decrease in Same Properties'

average occupancy to92.5% for the six months ended June 30, 2025 from 94.4% for the six months ended June 30, 2024, mainly

resulting from lease expirations during the three months ended March 31, 2025 aggregating 768,080 RSF, comprising the following:

(i) 182,054 RSF at the Alexandria Technology Square<sup>®</sup> Megacampus in our Cambridge submarket, (ii) 234,249 RSF at 409 Illinois

Street in our Mission Bay submarket, (iii) one property aggregating 104,531 RSF in our Research Triangle market, and (iv) two

properties aggregating 247,246 RSF in our Austin submarket.

*Tenant recoveries*

Tenant recoveries for the six months ended June 30, 2025increased by $22.5 million, or 6.4%, to $375.0 million, compared to

$352.5 million for the six months ended June 30, 2024, primarily in connection with Same Properties.

Same Properties' tenant recoveries for the six months ended June 30, 2025increased by $26.8 million, or 8.7%, to

$335.3 million, compared to $308.6 million for the six months ended June 30, 2024, primarily due to higher operating expenses during

the six months ended June 30, 2025, as discussed under "Rental operations" below. As of June 30, 2025, 91%of our leases (on an

annual rental revenue basis) were triple net leases, which require tenants to pay substantially all real estate taxes, insurance, utilities,

repairs and maintenance, common area expenses, and other operating expenses (including increases thereto) in addition to base rent.

*<u>Other Income</u>*

Other income for the six months ended June 30, 2025increased by $14.6 million, or 58.2%, to $39.7 million, compared to

$25.1 million for the six months ended June 30, 2024, primarily related to an increase in interest income earned on our notes receivable

and fee income.

*<u>Rental operations</u>*

Total rental operating expenses for the six months ended June 30, 2025increased by $15.3 million, or 3.5%, to $450.8 million,

compared to $435.6 million for the six months ended June 30, 2024.The increase was primarily due to incremental expenses related to

our Same Properties' rental operating expenses as discussed below, partially offset by the decrease in Non-Same Properties' rental

operating expenses of $25.7 million primarily as a result of dispositions of real estate assets since January 1, 2024.

Same Properties' rental operating expenses increased by $40.9 million, or 11.3%, to $403.3 million during the six months

ended June 30, 2025, compared to $362.4 million for the six months ended June 30, 2024, primarily as the result of the increase in

(i) utilities expenses and contractual costs aggregating $16.2 million, primarily due to higher consumption related to certain tenants'

increased operations; (ii) property taxes aggregating $8.0 million, primarily due to new developments in our Greater Boston and San

Francisco Bay Area markets delivered in 2023, with property taxes based on these properties' higher assessed values becoming

effective subsequent to July 1, 2024; and (iii) repair and maintenance expenses aggregating $7.9 million, primarily due to a more

severe winter in 2025 compared to that in 2024 in our Greater Boston market.

*<u>Depreciation and amortization</u>*

Depreciation and amortization expense for the six months ended June 30, 2025increased by $109.9 million, or 19.0%, to

$688.2 million, compared to $578.3 million for the six months ended June 30, 2024. The increase primarily reflects the change in useful

lives related to certain buildings expected to be demolished prior to the end of their previous useful lives. In addition, the increase

relates to 3.0 million RSF of development and redevelopment projects placed into service subsequent to January 1, 2024 and three

operating properties aggregating 401,560 RSF acquired subsequent to January 1, 2024, partially offset by the decrease in depreciation

and amortization related to properties that were sold or classified as held for sale subsequent to January 1, 2024.

*<u>Impairment of real estate</u>*

During the six months ended June 30, 2025, we recognized impairment of real estate aggregating $161.8 million, which

primarily included the following:

• During the three months ended March 31, 2025, we recognized an impairment charge of $32.2 million related to a ground

lease entered into in 2021 for a future development site in our San Francisco Bay Area market. Refer to "Lessee operating

costs" in Note 5 – "Leases" to our unaudited consolidated financial statements for additional information.

• In April 2025, an office property aggregating 182,276 RSF, located in Carlsbad, San Diego, met the criteria for classification as

held for sale based on our decision to dispose of this property. We expect to complete the sale within 12 months. Upon our

decision to commit to sell this property, we recognized an impairment charge of $35.4 million to reduce the carrying amount of

this asset to its estimated fair value less costs to sell of approximately$68.8 million.

• In June 2025, two operating properties aggregating 210,481 RSF located in our Sorrento Mesa submarket met the criteria for

classification as held for sale based on current negotiations with prospective buyers and our decision to dispose of these

properties. We expect to complete these sales within 12 months. Upon our decision to commit to sell these properties, we

recognized impairment charges aggregating $18.1 million to reduce the carrying amounts of these assets to their estimated

fair values less costs to sell of approximately $112.7 million.

• In June 2025, land parcels aggregating 374,349 SF in our non-cluster/other submarket met the criteria for classification as held

for sale based on current negotiations with a prospective buyer and our decision to dispose of this asset. We expect to

complete this sale within 12 months. Upon our decision to sell this land parcel, we recognized an impairment charge of $47.5

million to reduce the carrying amount of the asset to its estimated fair value less costs to sell of approximately $28.5 million.

During the six months ended June 30, 2024, we recognized real estate impairment charges aggregating $30.8 million, which

primarily consisted of pre-acquisition costs related to two potential acquisitions in our Greater Boston market that we decided to no

longer proceed with as a result of the macroeconomic environment that negatively impacted the financial outlooks of these acquisitions.

*<u>General and administrative expenses</u>*

General and administrative expenses for the six months ended June 30, 2025decreased by $31.9 million, or 34.8%, to

$59.8 million, compared to $91.7 million for the six months ended June 30, 2024, primarily due to cost-control and efficiency initiatives

implemented in since 2024, including reduction in headcount, restructuring of compensation plans, systems upgrades, and process

improvements. As a percentage of net operating income, our general and administrative expenses for the trailing twelve months ended

June 30, 2025 and 2024 were 6.3% and 9.2%, respectively.

*<u>Interest expense</u>*

Interest expense for the six months ended June 30, 2025 and 2024 consisted of the following (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Six Months Ended June 30, | Six Months Ended June 30, |  |
| Component | 2025 | 2024 | Change |
| Gross interest | $268660 | $249508 | $19152 |
| Capitalized interest | (162488) | (162879) | 391 |
| Interest expense | $106172 | $86629 | $19543 |
| Average debt balance outstanding<sup>(1)</sup> | $13035595 | $12260781 | $774814 |
| Weighted-average annual interest rate<sup>(2)</sup> | 4.1% | 4.1% | —% |

---

(1)Represents the average debt balance outstanding during the respective periods.

(2)Represents annualized total interest incurred divided by the average debt balance outstanding during the respective periods.

The net change in interest expense during the six months ended June 30, 2025, compared to the six months ended June 30,

2024, resulted from the following (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
| Component | Interest Rate<sup>(1)</sup> | Effective Date | Change |
| Increases in interest incurred due to: |  |  |  |
| Issuances of debt: |  |  |  |
| $550 million of unsecured senior notes payable due 2035 | 5.66% | February 2025 | $11637 |
| $600 million of unsecured senior notes payable due 2054 | 5.71% | February 2024 | 4127 |
| $400 million of unsecured senior notes payable due 2036 | 5.38% | February 2024 | 2575 |
| Increases in construction borrowings and interest rates under secured note <br>payable<br>| 7.16% |  | 126 |
| Higher average outstanding balances under commercial paper program and/<br>or unsecured senior line of credit<br>|  |  | 3097 |
| Other increase in interest |  |  | 1121 |
| Total increases |  |  | 22683 |
| Decreases in interest incurred due to: |  |  |  |
| Repayments of debt: |  |  |  |
| $600 million of unsecured senior notes payable due 2025 | 3.62% | April 2025 | (3531) |
| Total decreases |  |  | (3531) |
| Change in gross interest |  |  | 19152 |
| Decrease in capitalized interest |  |  | 391 |
| **Total change in interest expense** |  |  | **$19543** |

---

(1)Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and

other bank fees.

*<u>Investment</u> <u>loss</u>*

During the six months ended June 30, 2025, we recognized investment loss aggregating $80.6 million, which consisted of

$59.9 million of realized gains, $90.1 million of unrealized losses, and $50.4 million of impairment charges.

During the six months ended June 30, 2024, we recognized investment loss aggregating $376 thousand, which consisted of

$62.2 million of realized gains and $35.1 million of unrealized losses, and $27.5 million of impairment charges.

For additional information about our investments, refer to Note 7 – "Investments" to our unaudited consolidated financial

statements in Item 1. For our impairments accounting policy, refer to "Investments" in Note 2 – "Summary of significant accounting

policies" to our unaudited consolidated financial statements in Item 1.

*<u>Other comprehensive</u> <u>income</u>*

Total other comprehensive income for the six months ended June 30, 2025 aggregated $18.8 million, compared to total other

comprehensive loss of $11.8 million for the six months ended June 30, 2024. The difference is primarily due to unrealized foreign

currency translation gains related to our operations in Canada.

<u>Summary of capital expenditures</u>

Our construction spending for the six months ended June 30, 2025 and projected spending for the year ending December 31,

2025 consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | Six Months Ended <br>June 30, 2025 | Projected Guidance Midpoint <br>for Year Ending<br>December 31, 2025 |
| Construction of Class A/A+ properties: |  |  |
| Active construction projects |  |  |
| Under construction | $612341 | $1240000 |
| Future pipeline pre-construction |  |  |
| Primarily Megacampus expansion pre-construction work (entitlement, <br>design, and site work)<br>| 226587 | 500000 |
| Revenue- and non-revenue-enhancing capital expenditures | 127772 | 415000<br><sup>(1)</sup> |
| Construction spending (before contributions from noncontrolling interests or <br>tenants):<br>| 966700 | 2155000 |
| Contributions from noncontrolling interests (consolidated real estate joint <br>ventures)<br>| (113268) | (230000)<br><sup>(2)</sup> |
| Tenant-funded and - built landlord improvements | (171153) | (175000) |
| Total construction spending | $682279 | $1750000 |
| 2025 guidance range for construction spending |  | $1450000 – $2050000 |

---

(1)Represents revenue-enhancing and non-revenue-enhancing capital expenditures before contributions from noncontrolling interests and tenant-funded and tenant-built

landlord improvements for the year ending December 31, 2025. Our share of the 2025 revenue-enhancing and non-revenue-enhancing capital expenditures is projected

to be $340 million at the midpoint of our guidance for 2025 construction spending.

(2)Represents contractual capital commitments from existing consolidated real estate joint venture partners to fund construction.

 <u>Projected capital contributions from partners in consolidated real estate joint ventures to fund construction</u>

The following table summarizes projected capital contributions from partners in our existing consolidated joint ventures to fund

construction through 2027 and beyond (in thousands):

---

| | |
|:---|:---|
| Projected timing | Amount<sup>(1)</sup> |
| July 1, 2025 through December 31, 2026 | $203691 |
| 2027 and beyond | 93585 |
| Total | $297276 |

---

(1)Amounts represent reductions to our consolidated construction spending.

<u>Average real estate basis used for capitalization of interest</u>

Our construction spending includes capitalized interest. The table below provides key categories of interest capitalized during

the six months ended June 30, 2025 (in thousands):

---

| | | |
|:---|:---|:---|
|  | Average Real Estate Basis Capitalized | Average Real Estate Basis Capitalized |
|  | Amount | Percentage |
| Construction of Class A/A+ properties: |  |  |
| Development and redevelopment of projects under construction and one 100% pre-leased <br>committed near-term project expected to commence construction in the next year<br>|  |  |
| 2025 and 2026 stabilization | $767453 | 10% |
| 2027 and beyond stabilization | 2102723 | 26 |
| Smaller redevelopments and repositioning capital projects | 1007166<br><sup>(1)</sup> | 12 |
| Key future Megacampus expansion pre-construction work | 1209540<br><sup>(2)</sup> | 15 |
| Future pipeline projects with key pre-construction milestones during 2H25 and 2026 | 2979991<br><sup>(3)</sup> | 37 |
|  | $8066873 | 100% |

---

(1)Includes 668,795 RSF that is leased, but not yet delivered. The weighted-average expected delivery date is January 2, 2026.

(2)Represents four key active and future Megacampus development projects at Alexandria Center<sup>®</sup>for Advanced Technologies – Tanforan, Alexandria Center<sup>®</sup> for Life

Science – San Carlos, Campus Point by Alexandria, andAlexandria Center<sup>®</sup> for Advanced Technologies – South Lake Union.

(3)Includes future pipeline projects that are expected to reach anticipated pre-construction milestones, including various phases of entitlement, design, site work and other

activities necessary to begin aboveground vertical construction, onApril 3, 2026, on a weighted-average real estate investment basis. We will evaluate whether to

proceed with future pre-construction and/or construction activities based on leasing demand and market conditions.

**Projected results**

We present updated guidance for EPS attributable to Alexandria's common stockholders – diluted, funds from operations per

share attributable to Alexandria's common stockholders – diluted, funds from operations per share attributable to Alexandria's common

stockholders – diluted, as adjusted, key assumptions, and key credit metric targets based on our current view of existing market

conditions and other assumptions for the year ending December 31, 2025, as set forth in the tables below. The tables below also

provide a reconciliation of EPS attributable to Alexandria's common stockholders – diluted, the most directly comparable financial

measure presented in accordance with GAAP, to funds from operations per share and funds from operations per share, as adjusted,

non-GAAP measures, and other key assumptions included in our updated guidance for the year ending December 31, 2025. There can

be no assurance that actual amounts will not be materially higher or lower than these expectations. Refer to our discussion of "Forward-

looking statements" and "Trends that may affect our future results" included in the beginning of this Item 2.

---

| | | |
|:---|:---|:---|
| **Projected 2025 Earnings per Share and Funds From Operations per Share Attributable to** <br>**Alexandria's Common Stockholders – Diluted**<br>| **As of 7/21/25** | **As of 4/28/25** |
| Earnings per share<sup>(1)</sup> | $0.40 to $0.60 | $1.36 to $1.56 |
| Depreciation and amortization of real estate assets | 7.05 | 7.05 |
| Gain on sales of real estate | (0.08) | (0.08) |
| Impairment of real estate – rental properties and land<sup>(2)</sup> | 0.77 | 0.21 |
| Allocation of unvested restricted stock awards | (0.03) | (0.03) |
| Funds from operations per share<sup>(3)</sup> | $8.11 to $8.31 | $8.51 to $8.71 |
| Unrealized losses on non-real estate investments | 0.53 | 0.40 |
| Impairment of non-real estate investments | 0.30 | 0.07 |
| Impairment of real estate | 0.23 | 0.19 |
| Allocation to unvested restricted stock awards | (0.01) | (0.01) |
| Funds from operations per share, as adjusted<sup>(3)</sup> | $9.16 to $9.36 | $9.16 to $9.36 |
| Midpoint | $9.26 | $9.26 |

---

(1)Excludes unrealized gains or losses on non-real estate investments after June 30, 2025that are required to be recognized in earnings and are excluded from funds from

operations per share, as adjusted.

(2)Refer to Note 3 – "Investments in real estate" to our unaudited consolidated financial statements in Item 1 for additional information.

(3)Refer to "Funds from operations and funds from operations, as adjusted, attributable to Alexandria Real Estate Equities, Inc.'s common stockholders" under "Definitions

and reconciliations" in Item 2 for additional information.

---

| | | |
|:---|:---|:---|
| **Key Assumptions**<sup>(1)</sup><br>*(Dollars in millions)* | **As of 7/21/25** | **As of 7/21/25** |
| **Key Assumptions**<sup>(1)</sup><br>*(Dollars in millions)* | Low | High |
| Occupancy percentage in North America as of December 31, 2025 | 90.9% | 92.5% |
| Lease renewals and re-leasing of space: |  |  |
| Rental rate changes | 9.0% | 17.0% |
| Rental rate changes (cash basis) | 0.5% | 8.5% |
| Same property performance: |  |  |
| Net operating income  | (3.7)% | (1.7)% |
| Net operating income (cash basis) | (1.2)% | 0.8% |
| Straight-line rent revenue | $96 | $116 |
| General and administrative expenses | $112 | $127 |
| Capitalization of interest | $320 | $350 |
| Interest expense | $185 | $215 |
| Realized gains on non-real estate investments<sup>(2)</sup> | $100 | $130 |

---

(1)Our assumptions presented in the table above are subject to a number of variables and uncertainties, including those discussed as "Forward-looking statements" under

Part I; "Item 1A. Risk factors"; and "Item 7. Management's discussion and analysis of financial condition and results of operations" in our annual report on Form 10-K for

the year ended December 31, 2024, as well as in "Item 1A. Risk factors"; and "Item 2. Trends that may affect our future results" within "Part II – Other information" of this

quarterly report on Form 10-Q. To the extent our full-year earnings guidance is updated during the year, we will provide additional disclosure supporting reasons for any

significant changes to such guidance.

(2)Represents realized gains and losses included in funds from operations per share – diluted, as adjusted, and excludes significant impairments realized on non-real

estate investments, if any. Refer to Note 7 – "Investments" to our unaudited consolidated financial statements in Item 1 for additional details.

---

| | |
|:---|:---|
| **Key Credit Metric Targets**<sup>(1)</sup> | **As of 7/21/25** |
| Net debt and preferred stock to Adjusted EBITDA – fourth quarter of 2025 annualized | Less than or equal to 5.2x |
| Fixed-charge coverage ratio – fourth quarter of 2025 annualized | 4.0x to 4.5x |

---

(1)Refer to "Definitions and reconciliations" in Item 2 for additional information.

**Consolidated and unconsolidated real estate joint ventures**

We present components of balance sheet and operating results information for the noncontrolling interest share of our

consolidated real estate joint ventures and for our share of investments in unconsolidated real estate joint ventures to help investors

estimate balance sheet and operating results information related to our partially owned entities. These amounts are estimated by

computing, for each joint venture that we consolidate in our financial statements, the noncontrolling interest percentage of each financial

item to arrive at the cumulative noncontrolling interest share of each component presented. In addition, for our real estate joint ventures

that we do not control and do not consolidate, we apply our economic ownership percentage to the unconsolidated real estate joint

ventures to arrive at our proportionate share of each component presented. Refer to Note 4 – "Consolidated and unconsolidated real

estate joint ventures" to our unaudited consolidated financial statements in Item 1 for further discussion.

---

| | | |
|:---|:---|:---|
| **Consolidated Real Estate Joint Ventures** | **Consolidated Real Estate Joint Ventures** | |
| Property/Market/Submarket | Noncontrolling<br>Interest Share | Operating RSF<br>at 100% |
| 50 and 60 Binney Street/Greater Boston/Cambridge/Inner Suburbs | 66.0% | 532395 |
| 75/125 Binney Street/Greater Boston/Cambridge/Inner Suburbs | 60.0% | 388270 |
| 100 and 225 Binney Street and 300 Third Street/Greater Boston/Cambridge/Inner Suburbs | 70.0% | 870641 |
| 99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs<sup>(1)</sup> | 23.1% | 116414 |
| 15 Necco Street/Greater Boston/Seaport Innovation District | 43.3% | 345996 |
| 285, 299, 307, and 345 Dorchester Avenue/Greater Boston/Seaport Innovation District | 40.0% | —<br><sup>(1)</sup> |
| Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay/San Francisco Bay Area/<br>Mission Bay<sup>(2)</sup><br>| 75.0% | 1013997 |
| 601, 611, 651<sup>(1)</sup>, 681, 685, and 701 Gateway Boulevard/San Francisco Bay Area/<br>South San Francisco<br>| 50.0% | 874234 |
| 751 Gateway Boulevard/San Francisco Bay Area/South San Francisco | 49.0% | 230592 |
| 211 and 213 East Grand Avenue/San Francisco Bay Area/South San Francisco | 70.0% | 300930 |
| 500 Forbes Boulevard/San Francisco Bay Area/South San Francisco | 90.0% | 155685 |
| Alexandria Center<sup>®</sup> for Life Science – Millbrae/San Francisco Bay Area/South San Francisco | 51.5% | 285346 |
| 3215 Merryfield Row/San Diego/Torrey Pines | 70.0% | 170523 |
| Campus Point by Alexandria/San Diego/University Town Center<sup>(1)(3)</sup> | 45.0%<br><sup>(4)</sup> | 1212414 |
| 5200 Illumina Way/San Diego/University Town Center | 49.0% | 792687 |
| 9625 Towne Centre Drive/San Diego/University Town Center | 70.0% | 163648 |
| SD Tech by Alexandria/San Diego/Sorrento Mesa<sup>(1)(5)</sup> | 50.0% | 816048 |
| Pacific Technology Park/San Diego/Sorrento Mesa | 50.0% | 544352 |
| Summers Ridge Science Park/San Diego/Sorrento Mesa<sup>(6)</sup> | 70.0% | 316531 |
| 1201 and 1208 Eastlake Avenue East/Seattle/Lake Union | 70.0% | 206134 |
| 199 East Blaine Street/Seattle/Lake Union | 70.0% | 115084 |
| 400 Dexter Avenue North/Seattle/Lake Union | 70.0% | 290754 |
| 800 Mercer Street/Seattle/Lake Union | 40.0% | —<br><sup>(1)</sup> |
| **Unconsolidated Real Estate Joint Ventures** | **Unconsolidated Real Estate Joint Ventures** |  |
| Property/Market/Submarket | Our Ownership <br>Share<sup>(7)</sup> | Operating RSF<br>at 100% |
| 1655 and 1725 Third Street/San Francisco Bay Area/Mission Bay | 10.0% | 586208 |
| 1450 Research Boulevard/Maryland/Rockville | 73.2%<br><sup>(8)</sup> | 42012 |
| 101 West Dickman Street/Maryland/Beltsville | 58.4%<br><sup>(8)</sup> | 135949 |

---

Refer to "Joint venture financial information" under "Definitions and reconciliations" in Item 2 for additional details.

(1)Represents a property currently under construction or in our future development and redevelopment pipeline. Refer to "New Class A/A+ development and redevelopment

properties" in Item 2 for additional details.

(2)Includes 409 and 499 Illinois Street, 1450, 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South.

(3)Includes 10210, 10260, 10290, and 10300 Campus Point Drive and 4110, 4135, 4155, 4161, 4165, 4224, and 4242 Campus Point Court.

(4)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the

campus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata with our partner. Refer to "New Class A/A+

development and redevelopment properties: current projects" in Item 2 for additional details.

(5)Includes 9605, 9645, 9675, 9725, 9735, 9805, 9808, 9855, and 9868 Scranton Road and 10055, 10065, and 10075 Barnes Canyon Road.

(6)Includes 9965, 9975, 9985, and 9995 Summers Ridge Road.

(7)In addition to the real estate joint ventures listed,we hold an interest in one insignificant unconsolidated real estate joint venture.

(8)Represents a joint venture with a local real estate operator in which our joint venture partner manages the day-to-day activities that significantly affect the economic

performance of the joint venture.

The following table presents key terms related to our unconsolidated real estate joint ventures' secured loans as of June 30,

2025 (dollars in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Maturity Date | Stated Rate | Interest <br>Rate<sup>(1)</sup> | At 100% | At 100% | Our <br>Share |
| Unconsolidated Joint Venture | Maturity Date | Stated Rate | Interest <br>Rate<sup>(1)</sup> | Aggregate <br>Commitment<br>| Debt Balance<sup>(2)</sup> | Our <br>Share |
| 101 West Dickman Street | 11/10/26 | SOFR+1.95%<br><sup>(3)</sup> | 6.34% | $26750 | $19081 | 58.4% |
| 1450 Research Boulevard | 12/10/26 | SOFR+1.95%<br><sup>(3)</sup> | 6.40% | 13000 | 8965 | 73.2% |
| 1655 and 1725 Third Street<sup>(4)</sup> | 2/10/35 | 6.37% | 6.44% | 500000 | 496709 | 10.0% |
|  |  |  |  | $539750 | $524755 |  |

---

(1)Includes interest expense and amortization of loan fees.

(2)Represents outstanding principal, net of unamortized deferred financing costs, as of June 30, 2025.

(3)This loan is subject to a fixed SOFR floor of 0.75%.

(4)During the three months ended March 31, 2025, the unconsolidated real estate joint venture refinanced $500 million of its $600 million existing fixed-rate debt with a new

secured note payable maturing in 2035.The remaining debt balance of approximately $100 million was repaid through contributions from the unconsolidated joint

venture partners, including our share of $10.8 million.

The following tables present information related to the operating results and financial positions of our consolidated and

unconsolidated real estate joint ventures as of and for the three and six months ended June 30, 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Noncontrolling Interest Share of Consolidated <br>Real Estate Joint Ventures | Noncontrolling Interest Share of Consolidated <br>Real Estate Joint Ventures | Our Share of Unconsolidated <br>Real Estate Joint Ventures | Our Share of Unconsolidated <br>Real Estate Joint Ventures |
|  | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 |
|  | Three Months Ended | Six Months Ended | Three Months Ended | Six Months Ended |
| Total revenues | $117958 | $234595 | $2688 | $5263 |
| Rental operations | (36039) | (70808) | (935) | (1983) |
|  | 81919 | 163787 | 1753 | 3280 |
| General and administrative | (930) | (1563) | (62) | (81) |
| Interest | (330) | (754) | (1097) | (2058) |
| Depreciation and amortization of real <br>estate assets<br>| (36047) | (69458) | (942) | (1996) |
| Impairment of real estate |  |  | (8673) | (8673) |
| Fixed returns allocated to <br>redeemable noncontrolling <br>interests<sup>(1)</sup><br>| 201 | 402 |  |  |
|  | $44813 | $92414 | $(9021) | $(9528) |
| Straight-line rent and below-market <br>lease revenue<br>| $6542 | $10194 | $176 | $334 |
| Funds from operations<sup>(1)</sup> | $80860 | $161872 | $594 | $1141 |

---

Refer to "Joint venture financial information" under "Definitions and reconciliations" in Item 2 for additional details.

(1)Refer to "Funds from operations and funds from operations, as adjusted, attributable to Alexandria Real Estate Equities, Inc.'s common stockholders" under "Definitions

and reconciliations" in Item 2 for the definition and its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

---

| | | |
|:---|:---|:---|
|  | As of June 30, 2025 | As of June 30, 2025 |
|  | Noncontrolling Interest <br>Share of Consolidated <br>Real Estate Joint Ventures<br>| Our Share of <br>Unconsolidated <br>Real Estate Joint Ventures<br>|
| Investments in real estate | $4250023 | $99775 |
| Cash, cash equivalents, and restricted cash | 144770 | 2917 |
| Other assets | 457402 | 10156 |
| Secured notes payable  | (35448) | (67378) |
| Other liabilities | (252979) | (5236) |
| Redeemable noncontrolling interests | (9612) |  |
|  | $4554156 | $40234 |

---

During the six months ended June 30, 2025 and 2024, our consolidated real estate joint ventures distributed an aggregate of

$123.6 million and $119.9 million, respectively, to our joint venture partners. Refer to our consolidated statements of cash flows and

Note 4 – "Consolidated and unconsolidated real estate joint ventures" to our unaudited consolidated financial statements in Item 1 for

additional information.

**Investments**

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. The

tables below summarize components of our investment income (loss) and non-real estate investments (in thousands). Refer to Note 7 –

"Investments" to our unaudited consolidated financial statements in Item 1 for additional information.

---

| | | | |
|:---|:---|:---|:---|
|  | **June 30, 2025** | **June 30, 2025** | **Year Ended** <br>**December 31, 2024** |
|  | **Three Months Ended** | **Six Months Ended** | **Year Ended** <br>**December 31, 2024** |
| Realized (losses) gains | $(8684)<br><sup>(1)</sup> | $9469<br><sup>(1)</sup> | $59124<br><sup>(2)</sup> |
| Unrealized losses | (21938)<br><sup>(3)</sup> | (90083)<br><sup>(4)</sup> | (112246)<br><sup>(5)</sup> |
| Investment loss | $(30622) | $(80614) | $(53122) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **December 31, 2024** |
| <br>**Investments** | **Cost** | **Unrealized** <br>**Gains**<br>| **Unrealized** <br>**Losses**<br>| **Carrying** <br>**Amount**<br>| **Carrying** <br>**Amount**<br>|
| Publicly traded companies | $183859 | $18365 | $(120299) | $81925 | $105667 |
| Entities that report NAV | 497975 | 97201 | (43013) | 552163 | 609866 |
| Entities that do not report NAV: |  |  |  |  |  |
| Entities with observable price changes | 78105 | 64585 | (9156) | 133534 | 174737 |
| Entities without observable price changes | 432299 |  |  | 432299 | 400487 |
| Investments accounted for under the equity <br>method<br>| N/A | N/A | N/A | 276775 | 186228 |
| June 30, 2025 | $1192238<br><sup>(6)</sup> | $180151 | $(172468) | $1476696 | $1476985 |
| December 31, 2024 | $1207146 | $228100 | $(144489) | $1476985 |  |

---

---

| | |
|:---|:---|
| **Public/Private Mix (Cost)** | **Tenant/Non-Tenant Mix (Cost)** |

---

![1](are-20250630_g29.gif)

![13](are-20250630_g30.gif)

**88%**

**Private**

**12%**

**Public**

**22%**

**Tenant**

**78%**

**Non-Tenant**

(1)Consists of realized gains of $30.5 million and $59.9 million, partially offset by impairment charges of $39.2 million and $50.4 millionduring the three and six months

ended June 30, 2025, respectively.

(2)Consists of realized gains of $117.2 million, partially offset by impairment charges aggregating $58.1 million during the year ended December 31, 2024.

(3)Consists of unrealized gains of $12.5 million primarily resulting from the increase in fair values of our investments in publicly traded entities and investments in privately

held entities that report NAV and $34.4 million resulting from accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our

realization of investments during the three months ended June 30, 2025.

(4)Primarily relates to the accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investmentsduring the six

months ended June 30, 2025.

(5)Primarily relates to the accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the year

ended December 31, 2024.

(6)Represents 2.7% of gross assets as of June 30, 2025. Refer to "Gross assets" under "Definitions and reconciliations" in Item 2 for additional details.

**Liquidity**

---

| | | |
|:---|:---|:---|
| **Liquidity** | **Liquidity** | **Minimal Outstanding Borrowings and** <br>**Significant Availability on** <br>**Unsecured Senior Line of Credit** |
| $4.6B | $4.6B | *(in millions)* |
| $4.6B | $4.6B | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| $4.6B | $4.6B | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| $4.6B | $4.6B | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| $4.6B | $4.6B | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| $4.6B | $4.6B | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| *(In millions)* |  | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| Availability under our unsecured senior line of credit, net of <br>amounts outstanding under our commercial paper program<br>| $3900 | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| Cash, cash equivalents, and restricted cash | 528 | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| Availability under our secured construction loan | 42 | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| Investments in publicly traded companies | 82 | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |
| Liquidity as of June 30, 2025 | $4552 | ![q225lineofcredit v2.jpg](are-20250630_g31.jpg) |

---

We expect to meet certain long-term liquidity requirements, such as requirements for development, redevelopment, other

construction projects, capital improvements, tenant improvements, property acquisitions, equity repurchases, leasing costs, non-

revenue-enhancing capital expenditures, scheduled debt maturities, distributions to noncontrolling interests, and payment of dividends

through net cash provided by operating activities, periodic asset dispositions, strategic real estate joint ventures, long-term secured and

unsecured indebtedness, borrowings under our unsecured senior line of credit, issuances under our commercial paper program, and

issuances of additional debt and/or equity securities.

We also expect to continue meeting our short-term liquidity and capital requirements, as further detailed in this section,

generally through our working capital and net cash provided by operating activities. We believe that the net cash provided by operating

activities will continue to be sufficient to enable us to make the distributions necessary to continue qualifying as a REIT.

For additional information on our liquidity requirements related to our contractual obligations and commitments, refer to

Note 5 – "Leases" and Note 10 – "Secured and unsecured senior debt" to our unaudited consolidated financial statements in Item 1.

Over the next several years, our balance sheet, capital structure, and liquidity objectives are as follows:

• Retain net cash flows from operating activities after payment of dividends and distributions to noncontrolling interests for

investment in development and redevelopment projects and/or acquisitions;

• Maintain significant balance sheet liquidity;

• Maintain credit profile and relative long-term cost of capital;

• Maintain diverse sources of capital, including sources from net cash provided by operating activities, unsecured debt,

secured debt, selective real estate asset sales, strategic real estate joint ventures, non-real estate investment sales, and

common stock;

• Maintain commitment to long-term capital to fund growth;

• Maintain prudent laddering of debt maturities;

• Maintain solid credit metrics;

• Prudently manage variable-rate debt exposure;

• Maintain a large, unencumbered asset pool to provide financial flexibility;

• Fund common stock dividends and distributions to noncontrolling interests from net cash provided by operating activities;

• Manage a disciplined level of development and redevelopment projects as a percentage of our gross real estate assets;

and

• Maintain high levels of pre-leasing and percentage leased in development and redevelopment projects.

The following table presents the availability under our unsecured senior line of credit, net of amounts outstanding under our

commercial paper program; cash, cash equivalents, and restricted cash; availability under our secured construction loan; and

investments in publicly traded companies as of June 30, 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| Description | Stated Rate | Aggregate<br>Commitments<br>| Outstanding<br>Balance<sup>(1)</sup><br>| Remaining <br>Commitments/<br>Liquidity<br>|
| Availability under our unsecured senior line of credit, net of <br>amounts outstanding under our commercial paper program<br>| SOFR+0.855% | $5000000 | $1097993 | $3900000 |
| Cash, cash equivalents, and restricted cash |  |  |  | 527948 |
| Secured construction loan<sup>(2)</sup> | SOFR+2.70% | $195300 | $153500 | 41676 |
| Investments in publicly traded companies |  |  |  | 81925 |
| Liquidity as of June 30, 2025 |  |  |  | $4551549 |

---

(1)Represents outstanding principal, net of unamortized deferred financing costs, as of June 30, 2025.

(2)In August 2025, we expect to repay a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, a development project where

we have a 76.9% interest. We expect to repay the loan aggregating$153.5 million which matures in 2026 and bears an interest rate of 7.16% as of June 30, 2025. As a

result, we expect to recognize a loss on early extinguishment of debt of $99 thousand for the write-off of unamortized deferred financing costs during the three months

ending September 30, 2025.

<u>Cash, cash equivalents, and restricted cash</u>

As of June 30, 2025 and December 31, 2024, we had $527.9 millionand $559.8 million, respectively, of cash, cash

equivalents, and restricted cash. We expect existing cash, cash equivalents, and restricted cash, net cash provided by operating

activities, proceeds from real estate asset sales, sales of partial interests, strategic real estate joint ventures, non-real estate investment

sales, borrowings under our unsecured senior line of credit, issuances under our commercial paper program, issuances of unsecured

senior notes payable, borrowings under our secured construction loans, and issuances of common stock to continue to be sufficient to

fund our operating activities and cash commitments for investing and financing activities, such as regular quarterly dividends,

distributions to noncontrolling interests, scheduled debt repayments, acquisitions, and certain capital expenditures, including

expenditures related to construction activities and any common stock repurchases.

<u>Cash flows</u>

We report and analyze our cash flows based on operating activities, investing activities, and financing activities. The following

table summarizes changes in our cash flows for the six months ended June 30, 2025 and 2024 (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Six Months Ended June 30, | Six Months Ended June 30, | |
|  | 2025 | 2024 | <br>Change |
| Net cash provided by operating activities | $668190 | $752954 | $(84764) |
| Net cash used in investing activities | $(1029653) | $(1468479) | $438826 |
| Net cash provided by financing activities | $330099 | $620460 | $(290361) |

---

*<u>Operating activities</u>*

Cash flows provided by operating activities are primarily dependent upon the occupancy level of our asset base, the rental

rates of our leases, the collectibility of rent and recovery of operating expenses from our tenants, the timing of completion of

development and redevelopment projects, and the timing of acquisitions and dispositions of operating properties. Net cash provided by

operating activities for the six months ended June 30, 2025decreased by$84.8 million to $668.2 million, compared to $753.0 million for

the six months ended June 30, 2024. The decrease was primarily due to the ground lease prepayment of $135.0 million made in

January 2025 for a 24-year lease term extension to our existing ground lease agreement at the Alexandria Technology Square<sup>®</sup>

Megacampus in our Cambridge submarket.

*<u>Investing activities</u>*

Cash used in investing activities for the six months ended June 30, 2025 and 2024 consisted of the following (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Six Months Ended June 30, | Six Months Ended June 30, | Change |
|  | 2025 | 2024 | Change |
| Sources of cash from investing activities:  |  |  |  |
| Proceeds from sales of real estate | $149027 | $16670 | $132357 |
| Sales of and distributions from non-real estate investments | 42134 | 86008 | (43874) |
|  | 191161 | 102678 | 88483 |
| Uses of cash for investing activities: |  |  |  |
| Purchases of real estate |  | 201049 | (201049) |
| Additions to real estate | 1081006 | 1241214 | (160208) |
| Change in escrow deposits | 8108 | 2473 | 5635 |
| Investments in unconsolidated real estate joint ventures | 11055 | 3713 | 7342 |
| Additions to non-real estate investments | 120645 | 122708 | (2063) |
|  | 1220814 | 1571157 | (350343) |
| Net cash used in investing activities | $1029653 | $1468479 | $(438826) |

---

The decrease in net cash used in investing activities for the six months ended June 30, 2025, compared to the six months

ended June 30, 2024, was primarily due to a decreased use of cash for purchases of and additions to real estate. Refer to Note 3 –

"Investments in real estate" to our unaudited consolidated financial statements in Item 1 for additional information.

*<u>Financing activities</u>*

Cash flows provided by financing activities for the six months ended June 30, 2025 and 2024 consisted of the following

(in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | Six Months Ended June 30, | Six Months Ended June 30, | |
|  | 2025 | 2024 | <br>Change |
| Borrowings under secured note payable | $4029 | $14974 | $(10945) |
| Proceeds from issuance of unsecured senior notes payable  | 548532 | 998806 | (450274) |
| Repayment of unsecured senior note payable | (600000) |  | (600000) |
| Proceeds from issuances under commercial paper program | 8468015 | 5006950 | 3461065 |
| Repayments of borrowings under commercial paper program | (7368015) | (4906950) | (2461065) |
| Payments of loan fees | (5406) | (10118) | 4712 |
| Changes related to debt | 1047155 | 1103662 | (56507) |
| Contributions from and sales of noncontrolling interests | 96055 | 159644 | (63589) |
| Distributions to and purchases of noncontrolling interests | (141436) | (171871) | 30435 |
| Repurchase of common stock | (208187) |  | (208187) |
| Dividends on common stock | (457217) | (443958) | (13259) |
| Taxes paid related to net settlement of equity awards | (6271) | (27017) | 20746 |
| Net cash provided by financing activities | $330099 | $620460 | $(290361) |

---

**Capital resources**

We expect that our principal liquidity needs for the year ending December 31, 2025 will be satisfied by the following multiple

sources of capital, as shown in the table below. There can be no assurance that our sources and uses of capital will not be materially

higher or lower than these expectations.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Key Sources and Uses of Capital**<br>*(In millions)* | 2025 Guidance | 2025 Guidance | 2025 Guidance | Certain <br>Completed <br>Items |
| **Key Sources and Uses of Capital**<br>*(In millions)* | Range | Range | Midpoint | Certain <br>Completed <br>Items |
| *Sources of capital:* |  |  |  |  |
| Net reduction in debt | $(290) | $(290) | $(290) | See below |
| Net cash provided by operating activities after dividends | 425 | 525 | 475 |  |
| Dispositions and sales of partial interests | 1450 | 2450 | 1950 | <sup>(1)</sup> |
| Total sources of capital | $1585 | $2685 | $2135 |  |
| *Uses of capital:* |  |  |  |  |
| Construction  | $1450 | $2050 | $1750 |  |
| Acquisitions and other opportunistic uses of capital<sup>(2)</sup> |  | 500 | 250 | $208<br><sup>(2)</sup> |
| Ground lease prepayment | 135 | 135 | 135 | $135 |
| Total uses of capital | $1585 | $2685 | $2135 |  |
| *Net reduction in debt (included above):* |  |  |  |  |
| Issuance of unsecured senior notes payable | $550 | $550 | $550 | $550 |
| Repayment of unsecured notes payable | (600) | (600) | (600) | $(600) |
| Repayment of secured note payable<sup>(3)</sup> | (154) | (154) | (154) |  |
| Unsecured senior line of credit, commercial paper program, and other | (86) | (86) | (86) |  |
| Net reduction in debt | $(290) | $(290) | $(290) |  |

---

(1)As of the date of this report, completed dispositions aggregated $260.6 million and our share of pending transactions subject to non-refundable deposits, signed letters

of intent, or purchase and sale agreement negotiations aggregated $524.7 million. We expect to achieve a weighted-average capitalization rate on our projected 2025

dispositions and partial interest sales (excluding land and including stabilized and non-stabilized operating properties) in the7.5% – 8.5% range. We expect dispositions

of land to represent 20%–30% of our total dispositions and sales of partial interest sales for the year ending December 31, 2025. Refer to "Dispositions and sales of

partial interests" in Item 2 for additional information on our real estate dispositions.

(2)Under our common stock repurchase program authorized in December 2024, we may repurchase up to $500.0 million of our common stock through December 31,

2025. During the three months ended June 30, 2025, we did not repurchase any shares of common stock. As of the date of this report, the approximate value of shares

authorized and remaining under this program was $241.8 million. Subject to market conditions, we may consider repurchasing additional shares of our common stock.

(3)In August 2025, we expect to repay a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, a development project where

we have a76.9% interest. We expect to repay the loan aggregating $153.5 million which matures in 2026 and bears an interest rate of 7.16% as of June 30, 2025. As a

result, we expect to recognize a loss on early extinguishment of debt of $99 thousand for the write-off of unamortized deferred financing costs during the three months

ending September 30, 2025.

The key assumptions behind the sources and uses of capital in the table above include a favorable real estate transaction and

capital market environments, performance of our core operating properties, lease-up and delivery of current and future development

and redevelopment projects, and leasing activity. Our expected sources and uses of capital are subject to a number of variables and

uncertainties, including those discussed as "Forward-looking statements" under Part I; "Item 1A. Risk factors"; and "Item 7.

Management's discussion and analysis of financial condition and results of operations" in our annual report on Form 10-K for the year

ended December 31, 2024; as well as in "Item 1A. Risk factors"; and "Item 2. Trends that may affect our future results" within "Part II –

Other information" of this quarterly report on Form 10-Q. We expect to update our forecast for key sources and uses of capital on a

quarterly basis.

<u>Sources of capital</u>

*<u>Net cash provided by operating activities after dividends</u>*

We expect to retain $425 million to $525 million of net cash flows from operating activities after payment of common stock

dividends, and distributions to noncontrolling interests for the year ending December 31, 2025, excluding the payment of our final

installment of$135.0 million made in January 2025 for the ground lease at the Alexandria Technology Square<sup>®</sup> Megacampus. For

purposes of this calculation, changes in operating assets and liabilities representing timing differences are excluded. For the year

ending December 31, 2025, we expect our recently delivered projects, our development and redevelopment projects expected to be

delivered, and contributions from Same Properties to contribute to income from rentals, net operating income, and cash flows. We

anticipate contractual near-term growth in annual net operating income (cash basis) of $57 million related to the commencement of

contractual rents on the projects recently placed into service that are near the end of their initial free rent period. Refer to "Cash flows"

in Item 2 for a discussion of cash flows provided by operating activities for the six months ended June 30, 2025.

*<u>Debt</u>*

We expect to fund a portion of our capital needs for 2025 from issuances under our commercial paper program, issuances of

unsecured senior notes payable, and/or borrowings under our unsecured senior line of credit.

As of June 30, 2025, our unsecured senior line of credit, which matures in2030, including extension options under our control,

had aggregate commitments of $5.0 billion and bore an interest rate of SOFR plus 0.855%. In addition to the cost of borrowing, the

unsecured senior line of credit is subject to an annual facility fee of 0.145% based on the aggregate commitments outstanding. Based

upon our ability to achieve certain annual sustainability targets, the interest rate and facility fee rate are also subject to upward or

downward adjustments of up to four basis points with respect to the interest rate and up to one basis point with respect to the facility fee

rate.

Based on certain sustainability metrics achieved in accordance with the terms of our unsecured senior line of credit

agreement, the borrowing rate was reduced by two basis points to SOFR plus 0.855%, from SOFR plus 0.875%, and the facility fee

was reduced by 0.5 basis point to 0.145% from 0.15%. As of June 30, 2025, we had no outstanding balance on our unsecured line of

credit.

Our commercial paper program provides us with the ability to issue up to $2.5 billion of commercial paper notes with a maturity

of generally 30 days or less and with a maximum maturity of 397 days from the date of issuance. Our commercial paper program is

backed by our unsecured senior line of credit, and at all times we expect to retain a minimum undrawn amount of borrowing capacity

under our unsecured senior line of credit equal to any outstanding balance under our commercial paper program. We use borrowings

under the program to fund short-term capital needs. The notes issued under our commercial paper program are sold under customary

terms in the commercial paper market. They are typically issued at a discount to par, representing a yield to maturity dictated by market

conditions at the time of issuance. In the event we are unable to issue commercial paper notes or refinance outstanding commercial

paper notes under terms equal to or more favorable than those under the unsecured senior line of credit, we expect to borrow under the

unsecured senior line of credit. The commercial paper notes sold during the six months ended June 30, 2025 were issued at a

weighted-average yield to maturity of 4.67%. As of June 30, 2025, we had $1.1 billion of commercial paper notes outstanding.

In February 2025, we issued $550.0 million of unsecured senior notes payable, due 2035, with an interest rate of 5.50%.

The following table presents our average debt outstanding and weighted-average interest rates during the three and six

months ended June 30, 2025 (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Average Debt Outstanding | Average Debt Outstanding | Weighted-Average Interest Rate | Weighted-Average Interest Rate |
|  | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 |
|  | Three Months Ended | Six Months Ended | Three Months Ended | Six Months Ended |
| Long-term fixed-rate debt | $12314715 | $12374695 | 3.88% | 3.85% |
| Short-term variable-rate unsecured <br>senior line of credit and commercial <br>paper programdebt<br>| 926720 | 651302 | 4.70 | 4.65 |
| Blended average interest rate | 13241435 | 13025997 | 3.94 | 3.89 |
| Loan fee amortization and annual facility <br>fee related to unsecured senior line of <br>credit<br>| N/A | N/A | 0.13 | 0.14 |
| Total/weighted average | $13241435 | $13025997 | 4.07% | 4.03% |

---

*<u>Real estate dispositions and sales of partial interests</u>*

We expect to continue to focus on the disciplined execution of select sales of real estate. Future sales will provide an important

source of capital to fund our development and redevelopment projects and opportunistic share repurchases and also provide significant

capital for growth. We may also consider additional sales of partial interests in core Class A/A+ properties, development projects, and/or

land. For the year ending December 31, 2025, we expect real estate dispositions and sales of partial interests in real estate assets to

range from$1.45 billion to $2.45 billion.The amount of asset sales necessary to meet our forecasted sources of capital will vary

depending upon the amount of EBITDA associated with the assets sold.

Refer to Note 3 – "Investments in real estate," Note 4 – "Consolidated and unconsolidated real estate joint ventures," and

Note 13 – "Stockholders' equity" to our unaudited consolidated financial statements in Item 1 and to "Dispositions and sales of partial

interests" in Item 2 for additional information on our real estate dispositions.

As a REIT, we are generally subject to a 100% tax on the net income from real estate asset sales that the IRS characterizes as

"prohibited transactions." We do not expect our sales will be categorized as prohibited transactions. However, unless we meet certain

"safe harbor" requirements, whether a real estate asset sale is a "prohibited transaction" will be based on the facts and circumstances

of the sale. Our real estate asset sales may not always meet such "safe harbor" requirements. Refer to "Item 1A. Risk factors" in our

annual report on Form 10-K for the year ended December 31, 2024 for additional information about the "prohibited transaction" tax.

*<u>Common equity transactions</u>*

During the three and six months ended June 30, 2025, we have not issued any common stock under our ATM program. As of

June 30, 2025, the remaining aggregate amount available under our ATM program for future sales of common stock was $1.47 billion.

*<u>Other sources</u>*

As a well-known seasoned issuer, we may, from time to time, issue securities at our discretion based on our needs and market

conditions, including, as necessary, to balance our use of incremental debt capital.

Additionally, we, together with joint venture partners, hold interests in real estate joint ventures that we consolidate in our

financial statements. These existing joint ventures provide significant equity capital to fund a portion of our future construction spending,

and our joint venture partners may also contribute equity into these entities for financing-related activities. From July 1, 2025 through

December 31, 2027 and beyond, we expect to receive capital contributions aggregating $297.3 million from existing consolidated real

estate joint venture partners to fund construction. During the year ending December 31, 2025, contributions from noncontrolling

interests from existing joint venture partners are expected to aggregate $230.0 million.

<u>Uses of capital</u>

*<u>Summary of capital expenditures</u>*

One of our primary uses of capital relates to the development, redevelopment, pre-construction, and construction of properties.

We currently have projects in our development and redevelopment pipeline aggregating 4.4 million RSF of Class A/A+ properties

undergoing construction and one100% pre-leased committed near-term project expected to commence construction in the next year.

We incur capitalized construction costs related to development, redevelopment, pre-construction, and other construction activities. We

also incur additional capitalized project costs, including interest, property taxes, insurance, and other costs directly related and essential

to the development, redevelopment, pre-construction, or construction of a project, during periods when activities necessary to prepare

an asset for its intended use are in progress. Refer to "New Class A/A+ development and redevelopment properties: current projects"

and "Summary of capital expenditures" in Item 2 for additional information on our capital expenditures.

We capitalize interest cost as a cost of the project only during the period in which activities necessary to prepare an asset for

its intended use are ongoing, provided that expenditures for the asset have been made and interest cost has been incurred. Capitalized

interest, classified in investments in real estate in our consolidated balance sheets, aggregated $162.5 million for the six months ended

June 30, 2025, consistent with $162.9 millioncapitalized during six months ended June 30, 2024. This reflects a consistent weighted-

average capitalized cost basis of$8.1 billion for the six months ended June 30, 2025, as compared to $8.0 billion for the six months

ended June 30, 2024.

Property taxes, insurance on real estate, and indirect project costs, such as construction, administration, legal fees, and office

costs that clearly relate to projects under development or construction, are capitalized as incurred during the period an asset is

undergoing activities to prepare it for its intended use. We capitalized payroll and other indirect costs related to development,

redevelopment, pre-construction, and construction projects aggregating $47.8 million and $52.1 million, and property taxes, insurance

on real estate, and indirect project costs aggregating$73.1 millionand$63.0 million during the six months ended June 30, 2025 and

2024, respectively.

Pre-construction activities include entitlements, permitting, design, site work, and other activities preceding commencement of

construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time

required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and

are required for the vertical construction of buildings. Should we cease activities necessary to prepare an asset for its intended use, the

interest, taxes, insurance, and certain other direct and indirect project costs related to the asset would be expensed as incurred.

Expenditures for repairs and maintenance are expensed as incurred.

Fluctuations in our development, redevelopment, and construction activities could result in significant changes to total

expenses and net income. For example, had we experienced a 10% reduction in development, redevelopment, and construction

activities without a corresponding decrease in indirect project costs, including interest and payroll, total expenses would have increased

by approximately $28.3 million for the six months ended June 30, 2025.

We use third-party brokers to assist in our leasing activity, who are paid on a contingent basis upon successful leasing. We are

required to capitalize initial direct costs related to successful leasing transactions that result directly from and are essential to the lease

transaction and would not have been incurred had that lease transaction not been successfully executed. During the six months ended

June 30, 2025, we capitalized total initial direct leasing costs of $52.2 million. Costs that we incur to negotiate or arrange a lease

regardless of its outcome, such as fixed employee compensation, tax, or legal advice to negotiate lease terms, and other costs, are

expensed as incurred.

*<u>Real estate acquisitions and common stock repurchase program</u>*

Under our common stock repurchase program authorized in December 2024, we may repurchase up to $500.0 million of our

common stock in the open market, in privately negotiated transactions, or otherwise through December 31, 2025.

• During the three months ended June 30, 2025, we did not repurchase any shares of common stock.

• During the six months ended June 30, 2025, we repurchased 2.2 million shares of common stock for an aggregate value of

$208 million at an average price per share of $96.71.

• As of the date of this report, the approximate value of shares authorized and remaining under this program was $241.8 million.

We have not made any real estate acquisitions during the six months ended June 30, 2025.

For the year ending December 31, 2025, we expect real estate acquisitions and common stock repurchases to aggregate up

to $500 million.

*<u>Dividends</u>*

During the six months ended June 30, 2025 and 2024, we paid common stock dividends of $457.2 million and $444.0 million,

respectively. The increase of $13.3 million in dividends paid on our common stock for the six months ended June 30, 2025, compared to

the six months ended June 30, 2024, was primarily due to an increase in the related dividends to$2.64per common share paid for the

six months ended June 30, 2025 from $2.54 per common share paid for the six months ended June 30, 2024. We fund the payment of

our common stock dividends using net cash provided by operating activities. We expect to continue funding future quarterly common

stock dividends from net cash provided by operating activities, which may be supplemented by proceeds from periodic asset

dispositions, issuances of additional debt and/or equity securities, and borrowings under our unsecured senior line of credit and/or our

commercial paper program.

*<u>Secured note payable</u>*

Secured note payable as of June 30, 2025 consisted ofone note secured by one property. Our secured note payable typically

requires monthly payments of principal and interest and had a weighted-average interest rate of approximately 7.16%. As of June 30,

2025, the total book value of our investments in real estate securing debt was approximately$337.2 million. As of June 30, 2025, our

secured note payable, including unamortized discounts and deferred financing costs, is approximately$153.5 millionof unhedged

variable-rate debt. We expect to repay the entire $153.5 million balance in August 2025.

*<u>Unsecured senior notes payable and unsecured senior line of credit</u>*

The requirements of, and our actual performance with respect to, the key financial covenants under our unsecured senior

notes payable as of June 30, 2025 were as follows:

---

| | | |
|:---|:---|:---|
| Covenant Ratios<sup>(1)</sup> | Requirement | June 30, 2025 |
| Total Debt to Total Assets | Less than or equal to 60% | 31% |
| Secured Debt to Total Assets | Less than or equal to 40% | 0.4% |
| Consolidated EBITDA<sup>(2)</sup> to Interest Expense | Greater than or equal to 1.5x | 10.6x |
| Unencumbered Total Asset Value to Unsecured Debt | Greater than or equal to 150% | 309% |

---

(1)All covenant ratio titles utilize terms as defined in the respective debt agreements.

(2)The calculation of consolidated EBITDA is based on the definitions contained in our loan agreements and is not directly comparable to the computation of EBITDA as

described in Exchange Act Release No. 47226.

In addition, the terms of the indentures, among other things, limit the ability of the Company, Alexandria Real Estate Equities,

L.P., and the Company's subsidiaries to (i) consummate a merger, or consolidate, or sell all or substantially all of the Company's assets

and (ii) incur certain secured or unsecured indebtedness.

The requirements of, and our actual performance with respect to, the key financial covenants under our unsecured senior line

of credit as of June 30, 2025 were as follows:

---

| | | |
|:---|:---|:---|
| Covenant Ratios<sup>(1)</sup> | Requirement | June 30, 2025 |
| Leverage Ratio | Less than or equal to 60.0% | 32.2% |
| Secured Debt Ratio | Less than or equal to 45.0% | 0.3% |
| Fixed-Charge Coverage Ratio | Greater than or equal to 1.50x | 3.71x |
| Unsecured Interest Coverage Ratio | Greater than or equal to 1.75x | 9.30x |

---

(1)All covenant ratio titles utilize terms as defined in the credit agreement.

*<u>Estimated interest payments</u>*

Estimated interest payments on our fixed-rate debt are calculated based upon contractual interest rates, including interest

payment dates and scheduled maturity dates. As of June 30, 2025,90.6% of our debt was fixed-rate debt. For additional information

regarding our debt, refer to Note 10 – "Secured and unsecured senior debt" to our unaudited consolidated financial statements in

Item 1.

*<u>Ground lease obligations</u>*

Ground lease obligations as of June 30, 2025 included leases for 31of our properties and accounted for approximately 8% of

our total number of properties. Among these 31 properties, 17 properties are subject to ground leases with a weighted-average

remaining lease term of 41 years, including extension options that we are reasonably certain to exercise. These leases are with a single

lessor in our Greater Stanford submarket with whom we have extended three ground leases over the past 10 years.

Our remaining 14 properties subject to ground leases are located across multiple submarkets and have remaining lease terms

ranging from approximately 46 to 81 years. The weighted-average remaining lease term of these ground leases is74 years, including

extension options that we are reasonably certain to exercise.

In many cases, we seek to extend our ground leases well ahead of their scheduled contractual expirations. If we are

successful in extending ground leases, we could see significant up-front or increased recurring future payments to the ground lessor

and/or increased ground lease expense, which may require us to increase our capital funding needs.

*<u>Operating lease agreements</u>*

As of June 30, 2025, the remaining contractual payments under ground and office lease agreements in which we are the

lessee aggregated $762.5 million and $21.7 million, respectively. As of June 30, 2025, our operating lease liability, calculated as the

present value of the remaining payments aggregating $784.2 million under our operating lease agreements, including our extension

options that we are reasonably certain to exercise, was $363.4 million, which was classified in accounts payable, accrued expenses,

and other liabilities in our consolidated balance sheet. As of June 30, 2025, the weighted-average remaining lease term of operating

leases in which we are the lessee was approximately 54 years, including extension options that we are reasonably certain to exercise,

and the weighted-average discount rate was 4.7%. Our corresponding operating lease right-of-use assets, adjusted for initial direct

leasing costs and other consideration exchanged with the landlord prior to the commencement of the lease, aggregated $717.1 million.

We classify the right-of-use asset in other assets in our consolidated balance sheets. Refer to "Lease accounting" in Note 2 –

"Summary of significant accounting policies" to our unaudited consolidated financial statements in Item 1 for additional information.

*<u>Commitments</u>*

As of June 30, 2025, remaining aggregate costs under contract for the construction of properties undergoing development,

redevelopment, and improvements under the terms of leases approximated$924.3 million. We expect payments for these obligations to

occur over one to three years, subject to capital planning adjustments from time to time. We may have the ability to cease the

construction of certain projects, which would result in the reduction of our commitments. In addition, we have letters of credit and

performance obligations aggregating $5.3 million.

We are committed to funding approximately $380.3 million related to our non-real estate investments. These funding

commitments are primarily associated with our investments in privately held entities that report NAV and expire at various dates over

the next 12 years, with a weighted-average expiration of 8.0 yearsas of June 30, 2025.

Our former joint venture partner in our Greater Boston market has an option, subject to certain conditions, to obtain a

$50 million secured loan from us, which, if the option is exercised, will bear interest atSOFR plus 6.5%, with a floor of 9.0% and a term

not to exceed five years.As of June 30, 2025, the option has not been exercised.

*<u>Exposure to environmental liabilities</u>*

In connection with the acquisition of all of our properties, we have obtained Phase I environmental assessments to ascertain

the existence of any environmental liabilities or other issues. The Phase I environmental assessments of our properties have not

revealed any environmental liabilities that we believe would have a material adverse effect on our financial condition or results of

operations taken as a whole, nor are we aware of any material environmental liabilities that have occurred since the Phase I

environmental assessments were completed. In addition, we carry a policy of pollution legal liability insurance covering exposure to

certain environmental losses at substantially all of our properties.

*<u>Foreign currency translation gains and losses</u>*

The following table presents the change in accumulated other comprehensive loss attributable to Alexandria Real Estate

Equities, Inc.'s stockholders during the six months ended June 30, 2025 primarily due to the changes in the foreign exchange rates for

our real estate investments in Canada (in thousands). We reclassify unrealized foreign currency translation gains and losses into net

income as we dispose of these holdings.

---

| | |
|:---|:---|
|  | Total |
| Balance as of December 31, 2024 | $(46252) |
| Other comprehensive income before reclassifications | 18837 |
| Net other comprehensive income | 18837 |
| Balance as of June 30, 2025 | $(27415) |

---

*<u>Inflation</u>*

As of June 30, 2025, approximately91% of our leases (on an annual rental revenue basis) were triple net leases, which

require tenants to pay substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and

other operating expenses (including increases thereto) in addition to base rent. Approximately 97% of our leases (on an annual rental

revenue basis) contained effective annual rent escalations approximating 3% that were either fixed or indexed based on a consumer

price index or other indices. Accordingly, we do not believe that our cash flows or earnings from real estate operations are subject to

significant risks from inflation. A period of inflation, however, could cause an increase in the cost of our variable-rate borrowings,

including borrowings under our unsecured senior line of credit and commercial paper program, issuances of unsecured senior notes

payable, and borrowings under our secured construction loans, and secured loans held by our unconsolidated real estate joint ventures.

**Issuer and guarantor subsidiary summarized financial information**

Alexandria Real Estate Equities, Inc. (the "Issuer") has sold certain debt securities registered under the Securities Act of 1933,

as amended, that are fully and unconditionally guaranteed by Alexandria Real Estate Equities, L.P. (the "LP" or the "Guarantor

Subsidiary"), an indirectly 100% owned subsidiary of the Issuer. The Issuer's other subsidiaries, including, but not limited to, the

subsidiaries that own substantially all of its real estate (collectively, the "Combined Non-Guarantor Subsidiaries"), will not provide a

guarantee of such securities, including the subsidiaries that are partially or 100% owned by the LP. The following summarized financial

information presents, on a combined basis, balance sheet information as of June 30, 2025 and December 31, 2024, and results of

operations and comprehensive income for the six months ended June 30, 2025 and year ended December 31, 2024 for the Issuer and

the Guarantor Subsidiary. The information presented below excludes eliminations necessary to arrive at the information on a

consolidated basis. In presenting the summarized financial statements, the equity method of accounting has been applied to (i) the

Issuer's interests in the Guarantor Subsidiary, (ii) the Guarantor Subsidiary's interests in the Combined Non-Guarantor Subsidiaries,

and (iii) the Combined Non-Guarantor Subsidiaries' interests in the Guarantor Subsidiary, where applicable, even though all such

subsidiaries meet the requirements to be consolidated under GAAP. All assets and liabilities have been allocated to the Issuer and the

Guarantor Subsidiary generally based on legal entity ownership.

The following tables present combined summarized financial information as of June 30, 2025 and December 31, 2024 and for

the six months ended June 30, 2025 and year ended December 31, 2024 for the Issuer and Guarantor Subsidiary. Amounts provided

do not represent our total consolidated amounts (in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Assets: |  |  |
| Cash, cash equivalents, and restricted cash | $146076 | $103993 |
| Other assets | 170720 | 153913 |
| Total assets | $316796 | $257906 |
| Liabilities: |  |  |
| Unsecured senior notes payable | $12042607 | $12094465 |
| Unsecured senior line of credit and commercial paper | 1097993 |  |
| Other liabilities | 518737 | 542322 |
| Total liabilities | $13659337 | $12636787 |

---

---

| | | |
|:---|:---|:---|
|  | Six Months Ended <br>June 30, 2025<br>| Year Ended <br>December 31, 2024<br>|
| Total revenues | $24052 | $59023 |
| Total expenses | (164818) | (349437) |
| Net loss | (140766) | (290414) |
| Net income attributable to unvested restricted stock awards | (5269) | (13394) |
| Net loss attributable to Alexandria Real Estate Equities, Inc.'s common stockholders | $(146035) | $(303808) |

---

As of June 30, 2025,368 of our 384 properties were held indirectly by the REIT's wholly owned consolidated subsidiary,

Alexandria Real Estate Equities, L.P.

**Critical accounting estimates**

Refer to our annual report on Form 10-K for the year ended December 31, 2024 for a discussion of our critical accounting

estimates related to recognition of real estate acquired, impairment of long-lived assets, impairment of non-real estate investments, and

monitoring of tenant credit quality.

**Definitions and reconciliations**

This section contains additional information on certain non-GAAP financial measures, including reconciliations from the most

directly comparable financial measure calculated and presented in accordance with GAAP and the reasons why we use these

supplemental measures of performance and believe they provide useful information to investors, as well as the definitions of other

terms used in this report.

<u>Funds from operations and funds from operations, as adjusted, attributable to Alexandria Real Estate Equities, Inc.'s common</u> 

<u>stockholders</u>

GAAP-basis accounting for real estate assets utilizes historical cost accounting and assumes that real estate values diminish

over time. In an effort to overcome the difference between real estate values and historical cost accounting for real estate assets, the

Nareit Board of Governors established funds from operations as an improved measurement tool. Since its introduction, funds from

operations has become a widely used non-GAAP financial measure among equity REITs. We believe that funds from operations is

helpful to investors as an additional measure of the performance of an equity REIT. Moreover, we believe that funds from operations, as

adjusted, allows investors to compare our performance to the performance of other real estate companies on a consistent basis, without

having to account for differences recognized because of real estate acquisition and disposition decisions, financing decisions, capital

structure, capital market transactions, variances resulting from the volatility of market conditions outside of our control, or other

corporate activities that may not be representative of the operating performance of our properties.

The 2018 White Paper published by the Nareit Board of Governors (the "Nareit White Paper") defines funds from operations as

net income (computed in accordance with GAAP), excluding gains or losses on sales of real estate, and impairments of real estate, plus

depreciation and amortization of operating real estate assets, and after adjustments for our share of consolidated and unconsolidated

partnerships and real estate joint ventures. Impairments represent the write-down of assets when fair value over the recoverability

period is less than the carrying value due to changes in general market conditions and do not necessarily reflect the operating

performance of the properties during the corresponding period.

We compute funds from operations, as adjusted, as funds from operations calculated in accordance with the Nareit White

Paper, excluding significant gains, losses, and impairments realized on non-real estate investments, unrealized gains or losses on non-

real estate investments, impairments of real estate primarily consisting of right-of-use assets and pre-acquisition costs related to

projects that we decided to no longer pursue, gains or losses on early extinguishment of debt, changes in the provision for expected

credit losses on financial instruments, significant termination fees, acceleration of stock compensation expense due to the resignations

of executive officers, deal costs, the income tax effect related to such items, and the amount of such items that is allocable to our

unvested restricted stock awards. We compute the amount that is allocable to our unvested restricted stock awards with nonforfeitable

dividends using the two-class method. Under the two-class method, we allocate net income (after amounts attributable to noncontrolling

interests) to common stockholders and to unvested restricted stock awards with nonforfeitable dividends by applying the respective

weighted-average shares outstanding during each quarter-to-date and year-to-date period. This may result in a difference of the

summation of the quarter-to-date and year-to-date amounts. Neither funds from operations nor funds from operations, as adjusted,

should be considered as alternatives to net income (determined in accordance with GAAP) as indications of financial performance, or to

cash flows from operating activities (determined in accordance with GAAP) as measures of liquidity, nor are they indicative of the

availability of funds for our cash needs, including our ability to make distributions.

The following table reconciles net income (loss) to funds from operations for the share of consolidated real estate joint

ventures attributable to noncontrolling interests and our share of unconsolidated real estate joint ventures for the three and six months

ended June 30, 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Noncontrolling Interest Share of <br>Consolidated Real Estate Joint Ventures | Noncontrolling Interest Share of <br>Consolidated Real Estate Joint Ventures | Our Share of Unconsolidated <br>Real Estate Joint Ventures | Our Share of Unconsolidated <br>Real Estate Joint Ventures |
|  | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 |
|  | Three Months Ended | Six Months Ended | Three Months Ended | Six Months Ended |
| Net income (loss) | $44813 | $92414 | $(9021) | $(9528) |
| Depreciation and amortization of real <br>estate assets<br>| 36047 | 69458 | 942 | 1996 |
| Impairment of real estate |  |  | 8673 | 8673 |
| Funds from operations | $80860 | $161872 | $594 | $1141 |

---

The following tables present a reconciliation of net income attributable to Alexandria Real Estate Equities, Inc.'s common

stockholders, the most directly comparable financial measure presented in accordance with GAAP, including our share of amounts from

consolidated and unconsolidated real estate joint ventures, to funds from operations attributable to Alexandria Real Estate Equities,

Inc.'s common stockholders – diluted, and funds from operations attributable to Alexandria Real Estate Equities, Inc.'s common

stockholders – diluted, as adjusted, and the related per share amounts for the three and six months ended June 30, 2025 and 2024 (in

thousands, except per share amounts). Per share amounts may not add due to rounding.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income attributable to Alexandria Real Estate Equities, <br>Inc.'s common stockholders – basic and diluted<br>| $(109611) | $42917 | $(121210) | $209803 |
| Depreciation and amortization of real estate assets | 343729 | 288118 | 683110 | 573068 |
| Noncontrolling share of depreciation and amortization from <br>consolidated real estate JVs<br>| (36047) | (31364) | (69458) | (62268) |
| Our share of depreciation and amortization from unconsolidated <br>real estate JVs<br>| 942 | 1068 | 1996 | 2102 |
| Gain on sales of real estate |  |  | (13165) | (392) |
| Impairment of real estate – rental properties and land | 131090<br><sup>(1)</sup> | 2182 | 131090<br><sup>(1)</sup> | 2182 |
| Allocation to unvested restricted stock awards  | (1222) | (1305) | (1916) | (4736) |
| Funds from operations attributable to Alexandria Real Estate <br>Equities, Inc.'s common stockholders – diluted<sup>(2)</sup><br>| 328881 | 301616 | 610447 | 719759 |
| Unrealized losses on non-real estate investments | 21938 | 64238 | 90083 | 35080 |
| Impairment of non-real estate investments | 39216<br><sup>(3)</sup> | 12788 | 50396 | 27486 |
| Impairment of real estate | 7189 | 28581 | 39343 | 28581 |
| Increase in provision for expected credit losses on financial <br>instruments<br>|  |  | 285 |  |
| Allocation to unvested restricted stock awards | (794) | (1738) | (2116) | (1528) |
| Funds from operations attributable to Alexandria Real Estate <br>Equities, Inc.'s common stockholders – diluted, as adjusted<br>| $396430 | $405485 | $788438 | $809378 |

---

(1)Refer to Note 3 – "Investments in real estate" to our unaudited consolidated financial statements for additional information. Includes an impairment charge of $8.7 million

related to an unconsolidated real estate joint venture, which is classified in equity in earnings of unconsolidated real estate joint ventures in our consolidated statement

of operations.

(2)Calculated in accordance with standards established by the Nareit Board of Governors.

(3)Primarily related to one non-real estate investment in a privately held entity that does not report NAV.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
| *(Per share)* | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income per share attributable to Alexandria Real <br>Estate Equities, Inc.'s common stockholders – diluted<br>| $(0.64) | $0.25 | $(0.71) | $1.22 |
| Depreciation and amortization of real estate assets | 1.81 | 1.50 | 3.61 | 2.98 |
| Gain on sales of real estate |  |  | (0.08) |  |
| Impairment of real estate – rental properties and land | 0.77 | 0.01 | 0.77 | 0.01 |
| Allocation to unvested restricted stock awards | (0.01) | (0.01) | (0.01) | (0.02) |
| Funds from operations per share attributable to Alexandria <br>Real Estate Equities, Inc.'s common stockholders – diluted<br>| 1.93 | 1.75 | 3.58 | 4.19 |
| Unrealized losses on non-real estate investments | 0.13 | 0.37 | 0.53 | 0.20 |
| Impairment of non-real estate investments | 0.23 | 0.08 | 0.30 | 0.16 |
| Impairment of real estate | 0.04 | 0.17 | 0.23 | 0.17 |
| Allocation to unvested restricted stock awards |  | (0.01) | (0.01) | (0.01) |
| Funds from operations per share attributable to Alexandria <br>Real Estate Equities, Inc.'s common stockholders – <br>diluted, as adjusted<br>| $2.33 | $2.36 | $4.63 | $4.71 |
| Weighted-average shares of common stock outstanding – <br>diluted<sup>(1)</sup><br>|  |  |  |  |
| Earnings per share – diluted | 170135 | 172013 | 170328 | 171981 |
| Funds from operations – diluted, per share | 170192 | 172013 | 170390 | 171981 |
| Funds from operations – diluted, as adjusted, per share | 170192 | 172013 | 170390 | 171981 |

---

(1)Refer to "Weighted-average shares of common stock outstanding – diluted" in this section for additional information.

<u>Adjusted EBITDA and Adjusted EBITDA margin</u>

We use Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-

making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated

as earnings before interest, taxes, depreciation, and amortization ("EBITDA"), excluding stock compensation expense, gains or losses

on early extinguishment of debt, gains or losses on sales of real estate, impairments of real estate, changes in provision for expected

credit losses on financial instruments, and significant termination fees. Adjusted EBITDA also excludes unrealized gains or losses and

significant realized gains or losses and impairments that result from our non-real estate investments. These non-real estate investment

amounts are classified in our consolidated statements of operations outside of total revenues.

We believe Adjusted EBITDA provides investors with relevant and useful information as it allows investors to evaluate the

operating performance of our business activities without having to account for differences recognized because of investing and

financing decisions related to our real estate and non-real estate investments, our capital structure, capital market transactions, and

variances resulting from the volatility of market conditions outside of our control. For example, we exclude gains or losses on the early

extinguishment of debt to allow investors to measure our performance independent of our indebtedness and capital structure. We

believe that adjusting for the effects of impairments and gains or losses on sales of real estate, significant impairments and realized

gains or losses on non-real estate investments, changes in provision for expected credit losses on financial instruments, and significant

termination fees allows investors to evaluate performance from period to period on a consistent basis without having to account for

differences recognized because of investing and financing decisions related to our real estate and non-real estate investments or other

corporate activities that may not be representative of the operating performance of our properties.

In addition, we believe that excluding charges related to stock compensation and unrealized gains or losses facilitates for

investors a comparison of our business activities across periods without the volatility resulting from market forces outside of our control.

Adjusted EBITDA has limitations as a measure of our performance. Adjusted EBITDA does not reflect our historical expenditures or

future requirements for capital expenditures or contractual commitments. While Adjusted EBITDA is a relevant measure of performance,

it does not represent net income (loss) or cash flows from operations calculated and presented in accordance with GAAP, and it should

not be considered as an alternative to those indicators in evaluating performance or liquidity.

In order to calculate the Adjusted EBITDA margin, we divide Adjusted EBITDA by total revenues as presented in our

consolidated statements of operations. We believe that this supplemental performance measure provides investors with additional

useful information regarding the profitability of our operating activities.

We are not able to forecast the net income of future periods without unreasonable effort and therefore do not provide a

reconciliation for Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or

amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and

financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate

investments, impairments of real estate, impairments of non-real estate investments, and changes in provision for expected credit

losses on financial instruments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be

potentially misleading for our investors.

The following table reconciles net income, the most directly comparable financial measure calculated and presented in

accordance with GAAP, to Adjusted EBITDA and calculates the Adjusted EBITDA margin for the three and six months ended June 30,

2025 and 2024 (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income | $(62189) | $94049 | $(23527) | $313225 |
| Interest expense | 55296 | 45789 | 106172 | 86629 |
| Income taxes | 1020 | 1182 | 2165 | 2946 |
| Depreciation and amortization | 346123 | 290720 | 688185 | 578274 |
| Stock compensation expense | 12530 | 14507 | 22594 | 31632 |
| Gain on sales of real estate |  |  | (13165) | (392) |
| Unrealized losses on non-real estate investments | 21938 | 64238 | 90083 | 35080 |
| Impairment of real estate | 129606 | 30763 | 161760 | 30763 |
| Impairment of non-real estate investments | 39216 | 12788 | 50396 | 27486 |
| Increase in provision for expected credit losses on financial <br>instruments<br>|  |  | 285 |  |
| Adjusted EBITDA | $543540 | $554036 | $1084948 | $1105643 |
| Total revenues | $762040 | $766734 | $1520198 | $1535842 |
| Adjusted EBITDA margin | 71% | 72% | 71% | 72% |

---

<u>Annual rental revenue</u>

Annual rental revenue represents the annualized fixed base rental obligations, calculated in accordance with GAAP, including

the amortization of deferred revenue related to tenant-funded and tenant-built landlord improvements, for leases in effect as of the end

of the period, related to our operating RSF. Annual rental revenue is presented using 100% of the annual rental revenue from our

consolidated properties and our share of annual rental revenue for our unconsolidated real estate joint ventures. Annual rental revenue

per RSF is computed by dividing annual rental revenue by the sum of 100% of the RSF of our consolidated properties and our share of

the RSF of properties held in unconsolidated real estate joint ventures. As of June 30, 2025, approximately 91% of our leases (on an

annual rental revenue basis) were triple net leases, which require tenants to pay substantially all real estate taxes, insurance, utilities,

repairs and maintenance, common area expenses, and other operating expenses (including increases thereto) in addition to base rent.

Annual rental revenue excludes these operating expenses recovered from our tenants. Amounts recovered from our tenants related to

these operating expenses, along with base rent, are classified in income from rentals in our consolidated statements of operations.

<u>Capitalization rates</u>

Capitalization rates are calculated based on net operating income and net operating income (cash basis) annualized,

excluding lease termination fees, on stabilized operating assets for the quarter preceding the date on which the property is sold, or

near-term prospective net operating income.

<u>Capitalized interest</u>

We capitalize interest cost as a cost of a project during periods for which activities necessary to develop, redevelop, or

reposition a project for its intended use are ongoing, provided that expenditures for the asset have been made and interest cost has

been incurred. Activities necessary to develop, redevelop, or reposition a project include pre-construction activities such as

entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building

improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective

tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of

buildings. If we cease activities necessary to prepare a project for its intended use, interest costs related to such project are expensed

as incurred.

<u>Cash interest</u>

Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of

loan fees and debt premiums (discounts). Refer to "Fixed-charge coverage ratio" in this section for a reconciliation of interest expense,

the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest.

<u>Class A/A+ properties and AAA locations</u>

Class A/A+ properties are properties clustered in AAA locations that provide innovative tenants with highly dynamic and

collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity,

efficiency, creativity, and success. These properties are typically well-located, professionally managed, and well-maintained, offering a

wide range of amenities and featuring premium construction materials and finishes. Class A/A+ properties are generally newer or have

undergone substantial redevelopment and are generally expected to command higher annual rental rates compared to other classes of

similar properties. AAA locations are in close proximity to concentrations of specialized skills, knowledge, institutions, and related

businesses. It is important to note that our definition of property classification may not be directly comparable to other equity REITs.

<u>Credit rating</u>

Represents the credit ratings assigned by S&P Global Ratings or Moody's Ratings as of June 30, 2025. A credit rating is not a

recommendation to buy, sell, or hold securities and may be subject to revision or withdrawal at any time.

<u>Development, redevelopment, and pre-construction</u>

A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new

Class A/A+ properties, as well as property enhancements identified during the underwriting of certain acquired properties. These efforts

are primarily concentrated in collaborative Megacampus™ ecosystems within AAA life science innovation clusters, as well as other

strategic locations that support innovation and growth. These projects are generally focused on providing high-quality, generic, and

reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each development or

redevelopment project is expected to generate increases in rental income, net operating income, and cash flows. Our development and

redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher

occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Development projects generally consist of the ground-up development of generic and reusable laboratory facilities.

Redevelopment projects consist of the permanent change in use of acquired office, warehouse, or shell space into laboratory space.

We generally will not commence new development projects for aboveground construction of new Class A/A+ laboratory space without

first securing significant pre-leasing for such space, except when there is solid market demand for high-quality Class A/A+ properties.

Pre-construction activities include entitlements, permitting, design, site work, and other activities preceding commencement of

construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time

required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and

are required for the vertical construction of buildings. Ultimately, these projects will provide high-quality facilities and are expected to

generate significant revenue and cash flows.

Development, redevelopment, and pre-construction spending also includes the following costs: (i) amounts to bring certain

acquired properties up to market standard and/or other costs identified during the acquisition process (generally within two years of

acquisition) and (ii) permanent conversion of space for highly flexible, move-in-ready laboratory space to foster the growth of promising

early- and growth-stage life science companies.

Revenue-enhancing and repositioning capital expenditures represent spending to reposition or significantly change the use of

a property, including through improvement in the asset quality from Class B to Class A/A+.

Non-revenue-enhancing capital expenditures represent costs required to maintain the current revenues of a stabilized

property, including the associated costs for renewed and re-leased space.

<u>Dividend payout ratio (common stock)</u>

Dividend payout ratio (common stock) is the ratio of the absolute dollar amount of dividends on our common stock (shares of

common stock outstanding on the respective record dates multiplied by the related dividend per share) to funds from operations

attributable to Alexandria's common stockholders – diluted, as adjusted.

<u>Dividend yield</u>

Dividend yield for the quarter represents the annualized quarter dividend divided by the closing common stock price at the end

of the quarter.

<u>Fixed-charge coverage ratio</u>

Fixed-charge coverage ratio is a non-GAAP financial measure representing the ratio of Adjusted EBITDA to cash interest and

fixed charges. We believe that this ratio is useful to investors as a supplemental measure of our ability to satisfy fixed financing

obligations and preferred stock dividends. Cash interest is equal to interest expense calculated in accordance with GAAP plus

capitalized interest, less amortization of loan fees and debt premiums (discounts).

The following table reconciles interest expense, the most directly comparable financial measure calculated and presented in

accordance with GAAP, to cash interest and computes fixed-charge coverage ratio for the three and six months ended June 30, 2025

and 2024 (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Adjusted EBITDA | $543540 | $554036 | $1084948 | $1105643 |
| Interest expense | $55296 | $45789 | $106172 | $86629 |
| Capitalized interest | 82423 | 81039 | 162488 | 162879 |
| Amortization of loan fees | (4615) | (4146) | (9306) | (8288) |
| Amortization of debt discounts | (335) | (328) | (684) | (646) |
| Cash interest and fixed charges | $132769 | $122354 | $258670 | $240574 |
| Fixed-charge coverage ratio: |  |  |  |  |
| – quarter annualized | 4.1x | 4.5x | 4.2x | 4.6x |
| – trailing 12 months | 4.3x | 4.6x | 4.3x | 4.6x |

---

We are not able to forecast the net income of future periods without unreasonable effort and therefore do not provide a

reconciliation for fixed-charge coverage ratio on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing

and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and

financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate

investments, impairment of real estate, impairments of non-real estate investments, and changes in provision for expected credit losses

on financial instruments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be

potentially misleading for our investors.

<u>Gross assets</u>

Gross assets are calculated as total assets plus accumulated depreciation as of June 30, 2025 and December 31, 2024 (in

thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Total assets | $37623629 | $37527449 |
| Accumulated depreciation | 6146378 | 5625179 |
| Gross assets | $43770007 | $43152628 |

---

<u>Incremental annual net operating income on development and redevelopment projects</u>

Incremental annual net operating income represents the amount of net operating income, on an annual basis, expected to be

realized upon a project being placed into service and achieving full occupancy. Incremental annual net operating income is calculated

as the initial stabilized yield multiplied by the project's total cost at completion.

<u>Initial stabilized yield (unlevered)</u>

Initial stabilized yield is calculated as the estimated amounts of net operating income at stabilization divided by our investment

in the property. For this calculation, we exclude any tenant-funded and tenant-built landlord improvements from our investment in the

property. Our initial stabilized yield excludes the benefit of leverage. Our cash rents related to our development and redevelopment

projects are generally expected to increase over time due to contractual annual rent escalations. Our estimates for initial stabilized

yields, initial stabilized yields (cash basis), and total costs at completion represent our initial estimates at the commencement of the

project. We expect to update this information upon completion of the project, or sooner if there are significant changes to the expected

project yields or costs.

• Initial stabilized yield reflects rental income, including contractual rent escalations and any rent concessions over the

term(s) of the lease(s), calculated on a straight-line basis, and any amortization of deferred revenue related to tenant-

funded and tenant-built landlord improvements.

• Initial stabilized yield (cash basis) reflects cash rents at the stabilization date after initial rental concessions, if any, have

elapsed and our total cash investment in the property.

<u>Investment-grade or publicly traded large cap tenants</u>

Investment-grade or publicly traded large cap tenants represent tenants that are investment-grade rated or publicly traded

companies with an average daily market capitalization greater than $10 billion for the twelve months ended June 30, 2025, as reported

by Bloomberg Professional Services. Credit ratings from Moody's Ratings and S&P Global Ratings reflect credit ratings of the tenant's

parent entity, and there can be no assurance that a tenant's parent entity will satisfy the tenant's lease obligation upon such tenant's

default. We monitor the credit quality and related material changes of our tenants. Material changes that cause a tenant's market

capitalization to decrease below $10 billion, which are not immediately reflected in the twelve-month average, may result in their

exclusion from this measure.

<u>Investments in real estate</u>

The following table presents our new Class A/A+ development and redevelopment pipeline, excluding properties held for sale,

as a percentage of gross assets and as a percentage of annual rental revenue as of June 30, 2025 (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | | Percentage of | Percentage of |
|  | <br>Book Value | Gross Assets | Annual Rental <br>Revenue<br>|
| Under construction and committed near-term projects | $3806346 | 9% | —% |
| Income-producing/potential cash flows/covered land play<sup>(1)</sup> | 3183092 | 7 | 1 |
| Land | 1553645 | 4 |  |
|  | $8543083 | 20% | 1% |

---

(1)Includes projects with existing buildings that are generating or can generate operating cash flows. Also includes development rights associated with existing operating

campuses.

The square footage presented in the table below is classified as operating as of June 30, 2025. These lease expirations or

vacant space at recently acquired properties represent future opportunities for which we have the intent, subject to market conditions

and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up

development:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Dev/Redev | RSF of Lease Expirations Targeted for<br>Development and Redevelopment | RSF of Lease Expirations Targeted for<br>Development and Redevelopment | RSF of Lease Expirations Targeted for<br>Development and Redevelopment | RSF of Lease Expirations Targeted for<br>Development and Redevelopment |
| Property/Submarket | Dev/Redev | 2025 | 2026 | Thereafter<sup>(1)</sup> | Total |
| Committed near-term project: |  |  |  |  |  |
| Campus Point by Alexandria/University Town Center | Dev |  |  | 52620 | 52620 |
| Future projects: |  |  |  |  |  |
| 446, 458, 500, and 550 Arsenal Street/Cambridge/Inner Suburbs | Dev |  |  | 365898 | 365898 |
| Other/Greater Boston | Redev |  |  | 167549 | 167549 |
| 1122 and 1150 El Camino Real/South San Francisco | Dev |  |  | 375232 | 375232 |
| 3875 Fabian Way/Greater Stanford | Dev |  |  | 228000 | 228000 |
| 2100 and 2200 Geng Road/Greater Stanford | Dev |  |  | 62526 | 62526 |
| 960 Industrial Road/Greater Stanford | Dev |  |  | 112590 | 112590 |
| Campus Point by Alexandria/University Town Center | Dev |  |  | 96805 | 96805 |
| Sequence District by Alexandria/Sorrento Mesa | Dev/Redev |  |  | 555754 | 555754 |
| 410 West Harrison Street/Elliott Bay | Dev |  |  | 17205 | 17205 |
| Other/Seattle | Dev |  |  | 63057 | 63057 |
| 100 Capitola Drive/Research Triangle | Dev |  |  | 34527 | 34527 |
| 1001 Trinity Street and 1020 Red River Street/Austin | Dev/Redev | 198972 |  |  | 198972 |
| Canada | Redev |  |  | 247743 | 247743 |
|  |  | 198972 |  | 2326886 | 2525858 |
| Total |  | 198972 |  | 2379506 | 2578478 |

---

(1)Includes vacant square footage as of June 30, 2025.

<u>Joint venture financial information</u>

We present components of balance sheet and operating results information related to our real estate joint ventures, which are

not presented, or intended to be presented, in accordance with GAAP. We present the proportionate share of certain financial line items

as follows: (i) for each real estate joint venture that we consolidate in our financial statements, which are controlled by us through

contractual rights or majority voting rights, but of which we own less than 100%, we apply the noncontrolling interest economic

ownership percentage to each financial item to arrive at the amount of such cumulative noncontrolling interest share of each component

presented; and (ii) for each real estate joint venture that we do not control and do not consolidate, which are instead controlled jointly or

by our joint venture partners through contractual rights or majority voting rights, we apply our economic ownership percentage to each

financial item to arrive at our proportionate share of each component presented.

The components of balance sheet and operating results information related to our real estate joint ventures do not represent

our legal claim to those items. For each entity that we do not wholly own, the joint venture agreement generally determines what equity

holders can receive upon capital events, such as sales or refinancing, or in the event of a liquidation. Equity holders are normally

entitled to their respective legal ownership of any residual cash from a joint venture only after all liabilities, priority distributions, and

claims have been repaid or satisfied.

We believe that this information can help investors estimate the balance sheet and operating results information related to our

partially owned entities. Presenting this information provides a perspective not immediately available from consolidated financial

statements and one that can supplement an understanding of the joint venture assets, liabilities, revenues, and expenses included in

our consolidated results.

The components of balance sheet and operating results information related to our real estate joint ventures are limited as an

analytical tool as the overall economic ownership interest does not represent our legal claim to each of our joint ventures' assets,

liabilities, or results of operations. In addition, joint venture financial information may include financial information related to the

unconsolidated real estate joint ventures that we do not control. We believe that in order to facilitate for investors a clear understanding

of our operating results and our total assets and liabilities, joint venture financial information should be examined in conjunction with our

consolidated statements of operations and balance sheets. Joint venture financial information should not be considered an alternative

to our consolidated financial statements, which are presented and prepared in accordance with GAAP.

<u>Megacampus™</u>

A Megacampus ecosystem is a cluster campus that consist of approximately 1 million RSF or greater, including operating,

active development/redevelopment, and land RSF less operating RSF expected to be demolished. The following table reconciles our

annual rental revenue and development and redevelopment pipeline RSF as ofJune 30, 2025 (dollars in thousands):

---

| | | |
|:---|:---|:---|
|  | Annual Rental <br>Revenue<br>| Development and <br>Redevelopment <br>Pipeline RSF<br>|
| Megacampus | $1570877 | 20370529 |
| Core and non-core | 510353 | 7108567 |
| Total | $2081230 | 27479096 |
| Megacampus as a percentage of annual rental revenue and of total development and <br>redevelopment pipeline RSF<br>| 75% | 74% |

---

<u>Net cash provided by operating activities after dividends</u>

Net cash provided by operating activities after dividends is reduced by distributions to noncontrolling interests and excludes

changes in operating assets and liabilities as they represent timing differences.

<u>Net debt and preferred stock to Adjusted EBITDA</u>

Net debt and preferred stock to Adjusted EBITDA is a non-GAAP financial measure that we believe is useful to investors as a

supplemental measure of evaluating our balance sheet leverage. Net debt and preferred stock is equal to the sum of total consolidated

debt less cash, cash equivalents, and restricted cash, plus preferred stock outstanding as of the end of the period.Refer to "Adjusted

EBITDA and Adjusted EBITDA margin" in this section for further information on the calculation of Adjusted EBITDA.

We are not able to forecast the net income of future periods without unreasonable effort and therefore do not provide a

reconciliation for net debt and preferred stock to Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of

forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of

dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized

gains or losses on non-real estate investments, impairment of real estate, impairment of non-real estate investments, and provision for

expected credit losses on financial instruments. Our attempt to predict these amounts may produce significant but inaccurate estimates,

which would be potentially misleading for our investors.

The following table reconciles debt to net debt and preferred stock and computes the ratio to Adjusted EBITDA as of June 30,

2025 and December 31, 2024 (dollars in thousands):

---

| | | |
|:---|:---|:---|
|  | June 30, 2025 | December 31, 2024 |
| Secured notes payable | $153500 | $149909 |
| Unsecured senior notes payable  | 12042607 | 12094465 |
| Unsecured senior line of credit and commercial paper | 1097993 |  |
| Unamortized deferred financing costs | 78574 | 77649 |
| Cash and cash equivalents | (520545) | (552146) |
| Restricted cash | (7403) | (7701) |
| Preferred stock |  |  |
| Net debt and preferred stock | $12844726 | $11762176 |
| Adjusted EBITDA: |  |  |
| – quarter annualized | $2174160 | $2273480 |
| – trailing 12 months | $2208226 | $2228921 |
| Net debt and preferred stock to Adjusted EBITDA: |  |  |
| – quarter annualized | 5.9x | 5.2x |
| – trailing 12 months | 5.8x | 5.3x |

---

<u>Net operating income, net operating income (cash basis), and operating margin</u>

The following table reconciles net income to net operating income and net operating income (cash basis) and computes

operating margin for the three and six months ended June 30, 2025 and 2024 (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Net (loss) income | $(62189) | $94049 | $(23527) | $313225 |
| Equity in losses (earnings) of unconsolidated real estate joint <br>ventures<br>| 9021 | (130) | 9528 | (285) |
| General and administrative expenses | 29128 | 44629 | 59803 | 91684 |
| Interest expense | 55296 | 45789 | 106172 | 86629 |
| Depreciation and amortization | 346123 | 290720 | 688185 | 578274 |
| Impairment of real estate | 129606 | 30763 | 161760 | 30763 |
| Gain on sales of real estate |  |  | (13165) | (392) |
| Investment loss | 30622 | 43660 | 80614 | 376 |
| Net operating income | 537607 | 549480 | 1069370 | 1100274 |
| Straight-line rent revenue | (18536) | (48338) | (40559) | (96589) |
| Amortization of deferred revenue related to tenant-funded <br>and - built landlord improvements<br>| (2401) |  | (4052) |  |
| Amortization of acquired below-market leases | (10196) | (22515) | (25418) | (52855) |
| Provision for expected credit losses on financial instruments |  |  | 285 |  |
| Net operating income (cash basis) | $506474 | $478627 | $999626 | $950830 |
| Net operating income (cash basis) – annualized | $2025896 | $1914508 | $1999252 | $1901660 |
| Net operating income (from above) | $537607 | $549480 | $1069370 | $1100274 |
| Total revenues | $762040 | $766734 | $1520198 | $1535842 |
| Operating margin | 71% | 72% | 70% | 72% |

---

Net operating income is a non-GAAP financial measure calculated as net income (loss), the most directly comparable financial

measure calculated and presented in accordance with GAAP, excluding equity in the earnings of our unconsolidated real estate joint

ventures, general and administrative expenses, interest expense, depreciation and amortization, impairments of real estate, gains or

losses on early extinguishment of debt, gains or losses on sales of real estate, and investment income or loss. We believe net operating

income provides useful information to investors regarding our financial condition and results of operations because it primarily reflects

those income and expense items that are incurred at the property level. Therefore, we believe net operating income is a useful measure

for investors to evaluate the operating performance of our consolidated real estate assets. Net operating income on a cash basis is net

operating income adjusted to exclude the effect of straight-line rent, amortization of acquired above- and below-market lease revenue,

amortization of deferred revenue related to tenant-funded and tenant-built landlord improvements, and changes in the provision for

expected credit losses on financial instruments required by GAAP. We believe that net operating income on a cash basis is helpful to

investors as an additional measure of operating performance because it eliminates straight-line rent revenue and the amortization of

acquired above- and below-market leases and tenant-funded and tenant-built landlord improvements.

Furthermore, we believe net operating income is useful to investors as a performance measure of our consolidated properties

because, when compared across periods, net operating income reflects trends in occupancy rates, rental rates, and operating costs,

which provide a perspective not immediately apparent from net income or loss. Net operating income can be used to measure the initial

stabilized yields of our properties by calculating net operating income generated by a property divided by our investment in the property.

Net operating income excludes certain components from net income in order to provide results that are more closely related to the

results of operations of our properties. For example, interest expense is not necessarily linked to the operating performance of a real

estate asset and is often incurred at the corporate level rather than at the property level. In addition, depreciation and amortization,

because of historical cost accounting and useful life estimates, may distort comparability of operating performance at the property level.

Impairments of real estate have been excluded in deriving net operating income because we do not consider impairments of real estate

to be property-level operating expenses. Impairments of real estate relate to changes in the values of our assets and do not reflect the

current operating performance with respect to related revenues or expenses. Our impairments of real estate represent the write-down in

the value of the assets to the estimated fair value less cost to sell. These impairments result from investing decisions or a deterioration

in market conditions. We also exclude realized and unrealized investment gain or loss, which results from investment decisions that

occur at the corporate level related to non-real estate investments in publicly traded companies and certain privately held entities.

Therefore, we do not consider these activities to be an indication of operating performance of our real estate assets at the property

level. Our calculation of net operating income also excludes charges incurred from changes in certain financing decisions, such as

losses on early extinguishment of debt and changes in provision for expected credit losses on financial instruments, as these charges

often relate to corporate strategy. Property operating expenses included in determining net operating income primarily consist of costs

that are related to our operating properties, such as utilities, repairs, and maintenance; rental expense related to ground leases;

contracted services, such as janitorial, engineering, and landscaping; property taxes and insurance; and property-level salaries.

General and administrative expenses consist primarily of accounting and corporate compensation, corporate insurance, professional

fees, rent, and supplies that are incurred as part of corporate office management. We calculate operating margin as net operating

income divided by total revenues.

We believe that in order to facilitate for investors a clear understanding of our operating results, net operating income should

be examined in conjunction with net income or loss as presented in our consolidated statements of operations. Net operating income

should not be considered as an alternative to net income or loss as an indication of our performance, nor as an alternative to cash flows

as a measure of our liquidity or our ability to make distributions.

<u>Operating statistics</u>

We present certain operating statistics related to our properties, including number of properties, RSF, occupancy percentage,

leasing activity, and contractual lease expirations as of the end of the period. We believe these measures are useful to investors

because they facilitate an understanding of certain trends for our properties. We compute the number of properties, RSF, occupancy

percentage, leasing activity, and contractual lease expirations at 100%, excluding RSF at properties classified as held for sale, for all

properties in which we have an investment, including properties owned by our consolidated and unconsolidated real estate joint

ventures. For operating metrics based on annual rental revenue, refer to "Annual rental revenue" in this section.

<u>Same property comparisons</u>

As a result of changes within our total property portfolio during the comparative periods presented, including changes from

assets acquired or sold, properties placed into development or redevelopment, and development or redevelopment properties recently

placed into service, the consolidated total income from rentals, as well as rental operating expenses in our operating results, can show

significant changes from period to period. In order to supplement an evaluation of our results of operations over a given quarterly or

annual period, we analyze the operating performance for all consolidated properties that were fully operating for the entirety of the

comparative periods presented, referred to as same properties. We separately present quarterly and year-to-date same property results

to align with the interim financial information required by the SEC in our management's discussion and analysis of our financial

condition and results of operations. These same properties are analyzed separately from properties acquired subsequent to the first day

in the earliest comparable quarterly or year-to-date period presented, properties that underwent development or redevelopment at any

time during the comparative periods, unconsolidated real estate joint ventures, properties classified as held for sale, and corporate

entities (legal entities performing general and administrative functions), which are excluded from same property results. Additionally,

termination fees, if any, are excluded from the results of same properties. Refer to "Same properties" in Item 2 for additional information.

<u>Stabilized occupancy date</u>

The stabilized occupancy date represents the estimated date on which the project is expected to reach occupancy of 95% or

greater.

<u>Tenant recoveries</u>

Tenant recoveries represent revenues comprising reimbursement of real estate taxes, insurance, utilities, repairs and

maintenance, common area expenses, and other operating expenses and earned in the period during which the applicable expenses

are incurred and the tenant's obligation to reimburse us arises.

We classify rental revenues and tenant recoveries generated through the leasing of real estate assets within revenues in

income from rentals in our consolidated statements of operations. We provide investors with a separate presentation of rental revenues

and tenant recoveries in "Results of operations" in Item 2 because we believe it promotes investors' understanding of our operating

results. We believe that the presentation of tenant recoveries is useful to investors as a supplemental measure of our ability to recover

operating expenses under our triple net leases, including recoveries of utilities, repairs and maintenance, insurance, property taxes,

common area expenses, and other operating expenses, and of our ability to mitigate the effect to net income for any significant

variability to components of our operating expenses.

The following table reconciles income from rentals to tenant recoveries for the three and six months ended June 30, 2025 and

2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Income from rentals | $737279 | $755162 | $1480454 | $1510713 |
| Rental revenues | (553377) | (576835) | (1105489) | (1158235) |
| Tenant recoveries | $183902 | $178327 | $374965 | $352478 |

---

<u>Total equity capitalization</u>

Total equity capitalization is equal to the outstanding shares of common stock multiplied by the closing price on the last trading

day at the end of each period presented.

<u>Total market capitalization</u>

Total market capitalization is equal to the sum of total equity capitalization and total debt.

<u>Unencumbered net operating income as a percentage of total net operating income</u>

Unencumbered net operating income as a percentage of total net operating income is a non-GAAP financial measure that we

believe is useful to investors as a performance measure of the results of operations of our unencumbered real estate assets as it

reflects those income and expense items that are incurred at the unencumbered property level. Unencumbered net operating income is

derived from assets classified in continuing operations, which are not subject to any mortgage, deed of trust, lien, or other security

interest, as of the period for which income is presented.

The following table summarizes unencumbered net operating income as a percentage of total net operating income for the

three and six months ended June 30, 2025 and 2024 (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Unencumbered net operating income | $535766 | $544268 | $1066457 | $1091098 |
| Encumbered net operating income | 1841 | 5212 | 2913 | 9176 |
| Total net operating income | $537607 | $549480 | $1069370 | $1100274 |
| Unencumbered net operating income as a percentage of total <br>net operating income<br>| 99.7% | 99.1% | 99.7% | 99.2% |

---

<u>Weighted-average shares of common stock outstanding – diluted</u>

From time to time, we enter into capital market transactions, including forward equity sales agreements ("Forward

Agreements"), to fund acquisitions, to fund construction of our development and redevelopment projects, and for general working

capital purposes. While the Forward Agreements are outstanding, we are required to consider the potential dilutive effect of our Forward

Agreements under the treasury stock method. Under this method, we also include the dilutive effect of unvested restricted stock awards

("RSAs") with forfeitable dividends in the calculation of diluted shares. Refer to Note 12 – "Earnings per share" and Note 13 –

"Stockholders' equity" to our unaudited consolidated financial statements in Item 1 for additional information.

The weighted-average shares of common stock outstanding used in calculating EPS – diluted, funds from operations per

share – diluted, and funds from operations per share – diluted, as adjusted, for the three and six months ended June 30, 2025 and 2024

are calculated as follows. Also shown are the weighted-average unvested RSAs with nonforfeitable dividends used in calculating the

amounts allocable to these awards pursuant to the two-class method for each of the respective periods presented below (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Basic shares for earnings per share | 170135 | 172013 | 170328 | 171981 |
| Unvested RSAs with forfeitable dividends |  |  |  |  |
| Diluted shares for earnings per share | 170135 | 172013 | 170328 | 171981 |
| Basic shares for funds from operations per share and funds from <br>operations per share, as adjusted<br>| 170135 | 172013 | 170328 | 171981 |
| Unvested RSAs with forfeitable dividends | 57 |  | 62 |  |
| Diluted shares for funds from operations per share and funds <br>from operations per share, as adjusted<br>| 170192 | 172013 | 170390 | 171981 |
| Weighted-average unvested RSAs with nonforfeitable dividends <br>used in the allocations of net income, funds from operations, <br>and funds from operations, as adjusted<br>| 1998 | 2878 | 2025 | 2933 |

---

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**Interest rate risk**

The primary market risk to which we believe we may be exposed is interest rate risk, which may result from many factors,

including government monetary and tax policies, domestic and international economic and political considerations, and other factors

that are beyond our control.

In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate

risks on our operations, we may utilize a variety of financial instruments, including interest rate hedge agreements, caps, floors, and

other interest rate exchange contracts. The use of these types of instruments to hedge a portion of our exposure to changes in interest

rates may carry additional risks, such as counterparty credit risk and the legal enforceability of hedge agreements. As of June 30, 2025,

we did not have any outstanding interest rate hedge agreements.

Our future earnings and fair values relating to our outstanding debt are primarily dependent upon prevalent market rates of

interest. The following tables illustrate the effect of a 1% change in interest rates, assuming a zero percent interest rate floor, on our

fixed- and variable-rate debt as of June 30, 2025 (in thousands):

---

| | |
|:---|:---|
| Annualized effect on future earnings due to variable-rate debt: |  |
| Rate increase of 1% | $(3841) |
| Rate decrease of 1% | $3841 |
| Effect on fair value of total consolidated debt: |  |
| Rate increase of 1% | $(766508) |
| Rate decrease of 1% | $876870 |

---

These amounts are determined by considering the effect of the hypothetical interest rates on our borrowings as of June 30,

2025. These analyses do not consider the effects of the reduced level of overall economic activity that could exist in such an

environment. Furthermore, in the event of a change of such magnitude, we would consider taking actions to further mitigate our

exposure to the change. Because of the uncertainty of the specific actions that would be taken and their possible effects, the sensitivity

analyses assume no changes in our capital structure.

**Equity price risk**

We have exposure to equity price market risk because we hold equity investments in publicly traded companies and privately

held entities. All of our investments in actively traded public companies are reflected in our consolidated balance sheets at fair value.

Our investments in privately held entities that report NAV per share are measured at fair value using NAV as a practical expedient to fair

value. Our equity investments in privately held entities that do not report NAV per share are measured at cost less impairments,

adjusted for observable price changes during the period. Changes in fair value of public investments, changes in NAV per share

reported by privately held entities, and observable price changes of privately held entities that do not report NAV per share are

classified as investment income (loss) in our consolidated statements of operations. There is no assurance that future declines in value

will not have a material adverse effect on our future results of operations. The following table illustrates the effect that a 10% change in

the value of our equity investments would have on earnings as of June 30, 2025 (in thousands):

---

| | |
|:---|:---|
| Equity price risk: |  |
| Fair value increase of 10% | $147670 |
| Fair value decrease of 10% | $(147670) |

---

**Foreign currency exchange rate risk**

We have exposure to foreign currency exchange rate risk related to our subsidiaries operating in Canada and Asia. The

functional currencies of our foreign subsidiaries are the local currencies in each respective country. Gains or losses resulting from the

translation of our foreign subsidiaries' balance sheets and statements of operations are classified in accumulated other comprehensive

income (loss) as a separate component of total equity and are excluded from net income (loss). Gains or losses will be reflected in our

consolidated statements of operations when there is a sale or partial sale of our investment in these operations or upon a complete or

substantially complete liquidation of the investment. The following tables illustrate the effect that a 10% change in foreign currency rates

relative to the U.S. dollar would have on our potential future earnings and on the fair value of our net investment in foreign subsidiaries

based on our current operating assets outside the U.S. as of June 30, 2025 (in thousands):

---

| | |
|:---|:---|
| Effect on potential future earnings due to foreign currency exchange rate: |  |
| Rate increase of 10% | $53 |
| Rate decrease of 10% | $(53) |
| Effect on the fair value of net investment in foreign subsidiaries due to foreign currency exchange rate: |  |
| Rate increase of 10% | $38953 |
| Rate decrease of 10% | $(38953) |

---

The sensitivity analyses assume a parallel shift of all foreign currency exchange rates with respect to the U.S. dollar; however,

foreign currency exchange rates do not typically move in such a manner, and actual results may differ materially.

Our exposure to market risk elements for the six months ended June 30, 2025 was consistent with the risk elements presented

above, including the effects of changes in interest rates, equity prices, and foreign currency exchange rates.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of disclosure controls and procedures**

As of June 30, 2025, we had performed an evaluation, under the supervision of our principal executive officers and principal

financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. These controls and

procedures have been designed to ensure that information required for disclosure is recorded, processed, summarized, and reported

within the requisite time periods. Based on our evaluation, the principal executive officers and principal financial officer concluded that

our disclosure controls and procedures were effective as of June 30, 2025.

**Changes in internal control over financial reporting**

There has not been any change in our internal control over financial reporting during the three months ended June 30, 2025

that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II – OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

In 2006, ARE-East River Science Park, LLC, a subsidiary of Alexandria Real Estate Equities, Inc., was granted an option to

incorporate a land parcel adjacent to and north of the Alexandria Center<sup>®</sup> for Life Science – New York City ("ACLS-NYC") campus

("Option Parcel") into the existing ground lease of that campus. The Option Parcel will allow ARE-East River Science Park, LLC to

develop a future world-class life science building within the ACLS-NYC campus. ARE-East River Science Park, LLC's investment in pre-

construction costs related to the development of the Option Parcel, including costs related to design, engineering, environmental,

survey/title, and permitting and legal costs, aggregated$173.8 millionas of June 30, 2025.

On August 6, 2024, ARE-East River Science Park, LLC filed a lawsuit in the U.S. District Court for the Southern District of New

York against its landlord, New York City Health + Hospitals Corporation ("H+H"), and the New York City Economic Development

Corporation ("EDC"). On January 24, 2025, ARE-East River Science Park, LLC filed a first amended complaint. The lawsuit alleges two

principal claims against H+H and EDC: fraud in the inducement, and, in the alternative, breach of contract in violation of the implied

covenant of good faith and fair dealing. As alleged in the complaint, ARE-East River Science Park, LLC's claims arise from H+H's and

EDC's misrepresentations and concealment of material facts in connection with a floodwall, which H+H and EDC are seeking to require

ARE-East River Science Park, LLC to integrate into the development of the Option Parcel. ARE-East River Science Park, LLC alleges

that H+H's and EDC's misconduct have prevented it from commencing the development of the Option Parcel. In light of the pending

litigation, the closing date for our option and thus the commencement date for construction of the third tower at the campus are

presently indeterminate. Among other things, ARE-East River Science Park, LLC is seeking significant damages and equitable relief

from the court to confirm our understanding that the option is in full force and effect.

This matter exposes us to potential losses ranging from zero to the full amount of the investment in the project aggregating

$173.8 millionas of June 30, 2025, depending on any collection of damages and/or the ability to develop the project. We performed a

probability-weighted recoverability analysis based on initial estimates of various possible outcomes and determined no impairment was

present as of June 30, 2025.

**ITEM 1A. RISK FACTORS**

In addition to the information set forth in this quarterly report on Form 10-Q, one should also carefully review and consider the

information contained in the other reports and periodic filings that we make with the SEC, including, without limitation, the information

contained under the caption "Item 1A. Risk factors" in our annual report on Form 10-K for the year ended December 31, 2024. Those risk

factors could materially affect our business, financial condition, and results of operations. The risks that we describe in our public filings

are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we presently deem to be

immaterial, also may materially adversely affect our business, financial condition, and results of operations.

There have been no material changes in our risk factors from those disclosed under the caption "Item 1A. Risk factors" in our

annual report on Form 10-K for the year ended December 31, 2024, except for the following updates:

**Changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. government could** 

**adversely affect our business operations or those of our tenants and our venture investment portfolio companies.**

Domestic and international policy shifts may introduce considerable uncertainty to the macroeconomic and regulatory

landscape in which we, our tenants, and our venture investment portfolio companies operate. Our tenants and our venture

investment portfolio companies include entities in the pharmaceutical, biotechnology, medical device, life science, and related

industries, academic and private institutions, government institutions that determine their research and development budgets

based on several factors, including the availability of government and other funding, and the operational efficiency and reliability

of public regulatory institutions.

Since January 2025, the current U.S. administration has enacted and proposed substantial policy changes that affect

federal health agencies, research funding, public health priorities, and international trade. These measures — ranging from

staffing and budget reductions at the U.S. Food and Drug Administration ("FDA") and the National Institutes of Health ("NIH") to

sweeping tariff actions, as described below — may significantly disrupt the life science ecosystem in which we, our tenants, and

our venture investment portfolio companies operate.

*<u>Reductions in FDA Workforce and Budget</u>*

In 2025, the FDA laid off approximately3,500 employees, representing approximately 19%of its workforce at the

beginning of the year. Such workforce reductions at the FDA have raised some concerns regarding the agency's capacity to

perform timely regulatory reviews and approvals of drugs and other medical products. Recent and/or potential further reductions

in workforce or other personnel changes at the FDA, including terminations, may disrupt the agency's review and approval

processes for our tenants' and our venture investment portfolio companies' products. Such disruptions could lead to setbacks in

research and development timelines, negatively impacting life science companies' ability to advance their pipelines, secure

investor funding, or achieve commercial viability, which could severely affect their operations and financial performance and, as

a result adversely impact our operating and financial results.

*<u>NIH Grant Cuts and Impact on Research Institutions</u>*

The current U.S. administration has implemented significant policy changes affecting the NIH, leading to substantial

disruptions in biomedical research across the U.S. These actions included staff layoffs and funding cuts, as described below,

and resulted in the suspension of numerous research projects, posing risks to scientific advancement and introducing

uncertainty for some of our tenants and venture investment portfolio companies.

• *<u>NIH budget freeze and workforce cuts</u>*<u>.</u> On January 27, 2025, the U.S. administration issued an executive order to

suspend NIH grant funding, freezing much of NIH's nearly $48 billion budget for 2025. Though the suspension was

eventually blocked and reversed, during the first half of 2025 the NIH laid off approximately 5,000 employees and

contractors across its approximately 20,000-person workforce.

In May 2025, the White House introduced a budget proposal for fiscal year 2026 that would reduce the NIH budget by

40%, from $48 billion to $27.5 billion. The proposal has been met with push back from Congress, and, until a new

budget is approved by the legislature, the NIH budget will remain at 2024 levels through a continuing resolution.

Should the NIH budget be significantly reduced, it may affect funding of early research that drives the formation of new

life companies, potentially impacting the U.S.'s global life science leadership and long-term demand for life science

real estate.

• *<u>Termination of NIH grants and funding commitments to major research institutions</u>*<u>.</u> On January 20, 2025, President

Trump issued an executive order directing every U.S. agency, including the NIH, to "terminate, to the maximum extent

allowed by law" all grants relating to diversity, equity, and inclusion. On January 29, 2025, the President issued an

executive order to make it "the policy of the United States to combat anti-Semitism vigorously, using all available and

appropriate legal tools, to prosecute, remove, or otherwise hold to account the perpetrators of unlawful anti-Semitic

harassment and violence." As a result of one or both executive orders, the NIH, the world's largest funder of

biomedical research, has withheld funding from certain U.S. research institutions.

• *<u>15%</u> <u>cap on indirect cost reimbursements of all NIH grants.</u>* On February 7, 2025, the NIH introduced a policy limiting

indirect cost reimbursements to 15% for all NIH grants, representing a significant reduction from historic levels, which

were approximately double that rate on average, and in some cases significantly higher. This change threatens to

substantially impact the ability of research institutions to support their infrastructure and administrative costs, including

their ability to lease life science facilities.

A coalition of 22 state attorneys general, along with organizations like the Association of American Medical Colleges,

filed lawsuits challenging the NIH's policy changes, particularly the 15% cap on indirect costs. On April 7, 2025, a federal court

issued a permanent injunction blocking the enforcement of this cap. However, the U.S. administration has signaled its intent to

appeal and/or pursue similar funding restrictions through future legislative or administrative actions. If implemented, any such

funding cap could negatively impact our tenants that depend on grant funding for its operations. It could also reduce the

financial resources available to such tenants, forcing them to scale back operations, reduce leased space, or delay their plans

for lease expansion.

Termination of federal research funding that affected prominent academic institutions has already led to reductions in

postdoctoral hiring and the closure of critical programs. Moreover, recent changes to visa rules have introduced new uncertainty

around the ability of international graduate students and postdoctoral researchers to remain in the U.S. following graduation.

Many of these individuals represent years of training investment and historically have formed a key segment of the U.S. biotech

workforce. As limitations on their residency and employment take effect, a growing share of talent is migrating to foreign

markets. The U.S. life sciences real estate market has historically benefited from robust domestic R&D activity and venture

capital investment. However, other countries are increasingly positioned to attract top-tier biomedical talent, venture capital, and

clinical trials. The global leadership in biotechnology currently held by the U.S. may begin to shift abroad. The reduced

attractiveness of the U.S. as a destination for research and commercialization could lead to a substantial long-term decline in

the size of our life science tenant base and of life science real estate.

*<u>Drug Pricing Regulation</u>* <u>—</u>*<u>Most Favored Nation Executive Order</u>*

On May 12, 2025, President Trump issued an executive order titled "Delivering Most-Favored-Nation Prescription Drug

Pricing to American Patients," directing the U.S. Department of Health and Human Services to establish pricing benchmarks for

prescription drugs based on the lowest prices paid in other developed countries. While the President announced that the

"prescription drug and pharmaceutical prices will be reduced, almost immediately, by 30% to 80%," many of the proposed

changes would require formal rulemaking and are expected to face legal challenges. Although the implementation timeline and

extent of any actual price reductions remain uncertain. If enacted, these changes could materially affect our life science tenants

by potentially diminishing their profitability and constraining future growth, which in turn can reduce their future demand for life

science space.

*<u>Dismissal of the Entire Independent Vaccine Advisory Panel at the U.S. Centers for Disease Control and Prevention (CDC)</u>*

In June 2025, the U.S. Health Secretary unilaterally dismissed all 17 members of the Advisory Committee on

Immunization Practices (ACIP) at the CDC, and withdrew a recommendation for administering COVID shots to children and

pregnant women. Shortly thereafter, the Health Secretary named eight new members to serve on the panel, including several

anti-vaccine advocates.

*<u>Reductions in Medicaid Funding under the One Big Beautiful Bill Act</u>*

On July 4, 2025, the One Big Beautiful Bill Act was signed into law. Included in the bill is an estimated $1 trillion in cuts

to Medicaid spending, implemented through Medicaid work requirements, patient cost-sharing, and a phasedown of Medicaid

provider taxes and state-directed payments. Such reductions in Medicaid spending could result in lower revenue for some life

science tenants, adversely impacting financial performance and potentially resulting in reduced life science real estate

requirements.

*<u>The Rapid Expansion of China's Biotechnology Sector May Adversely Impact Demand for U.S. Life Sciences Real Estate</u>*

The U.S. life sciences real estate market has historically benefited from robust domestic R&D activity and venture

capital investment. The accelerated growth of China's biotechnology industry—fueled by state subsidies, regulatory reform, and

inexpensive talent —poses a potential threat to U.S. lab space demand. Given lower operational costs and faster clinical trial

recruitment timelines, China may attract biotech firms to conduct R&D activities in China rather than the U.S.

Additionally, the U.S. biopharma sector is increasingly sourcing innovative assets from China, with over one-third of in-

licensed molecules at major U.S. pharmaceutical companies now originating from Chinese firms. If biopharma companies

increasingly rely on acquiring or in-licensing assets from China instead of looking to innovation developed in the U.S., it could

negatively impact the fundamentals of the U.S. biotech market leading to reduced investment and fewer U.S.-based biotech

companies. Should this occur, demand for domestic lab space could decline.

*<u>Tariff Escalation, Trade Disruption, and Financial Market Instability</u>*

Beginning in March 2025, the U.S. government implemented a series of trade actions that have reshaped global

economic relations and triggered market volatility, specifically:

• OnFebruary 1, 2025, President Trump signed executive orders imposing a 25% tariff on all goods from Mexico and

Canada and a 10% tariff on China.

• OnMarch 3, 2025, the President increased tariffs on all products from China from 10% to 20%. He also implemented

new 25% tariffs on imports from Mexico and Canada.

• On April 2, 2025, the President declared a national emergency to address the U.S. trade deficit and imposed a 10%

universal import tariff on all goods, with higher rates for 57 trading partners. This announcement led to a significant

stock market decline, with the S&P 500 Index, Dow Jones Industrial Average, and the Nasdaq Composite dropping by

approximately 6.0%, 5.5%, and 5.8%, respectively.

• On April 9, 2025, facing a global market meltdown, the President announced a 90-day pause on tariffs for most

countries but raised the tax rate on Chinese imports to 125%. Following the announcement, the S&P 500 Index surged

9.5%. However, on April 10, 2025, U.S. stocks fell as the initial euphoria over the pause on tariffs faded. Subsequently,

on June 12, 2025, the President announced that the 125% tariff would be replaced with a 55% tariff on select Chinese

goods. Pharmaceutical ingredients and critical materials remain partially exempt.

• On April 14, 2025, the U.S. government launched an investigation into pharmaceuticals to justify tariffs that may be

implemented on pharmaceutical products. In 2024, over $200 billion in pharmaceutical products were imported to the

U.S., and it is estimated that U.S. tariffs could add $46 billion in costs to the pharmaceutical industry.

If financial markets continue to be disrupted, we may face the following risks:

• *<u>Restricted access to capital.</u>* Market instability may hinder our ability to raise capital, including through dispositions,

sales of partial interests, and new debt capital, and could potentially delay our current or future development and

redevelopment projects.

• *<u>Rising construction costs</u>*<u>.</u> Our general contractors may face difficulty procuring construction materials at reasonable

prices, particularly those subject to tariffs or disrupted supply, which may lead to project delays and/or increased costs.

Rising costs and procurement challenges could significantly impact the yields and delay net operating income

commencement from our current and future development and redevelopment pipeline.

• *<u>Risks to tenant operations.</u>*Many of our tenants rely on the import and export of materials, components, and/or

specialized equipment. As a result, their products may become prohibitively expensive to manufacture or sell. These

challenges may adversely affect our tenants' ability to meet their lease obligations or to renew their leases with us.

• *<u>Macroeconomic impact</u>*<u>.</u> Widespread tariffs, restricted trade, increased market volatility, and reduced investor

confidence may trigger inflationary pressure and elevate the risk of a U.S. recession.

The cost increases that may result from tariffs, trade conflicts, and financial market volatility may significantly impact our

development and redevelopment projects. Elevated material costs may lead to higher overall project budgets and extended

construction timelines or require modifications to project scope to preserve economic feasibility. Any such adjustments may adversely

affect our ability to deliver space on time and within budget, delay occupancy and commencement of rental income, and impact

projected net operating income and yields.

Any of the aforementioned and future developments may adversely affect occupancy rates, rental income, and the value of

our real estate portfolio in several ways. First, regulatory delays and reduced NIH funding may slow the pace of innovation and

company formation, leading to fewer early-stage tenants seeking lab space. Established tenants may face financial strain due to

reduced grant support, drug pricing pressures, and increased operational costs from tariffs, prompting them to downsize, consolidate,

or defer expansion plans. This could result in lower leasing, increased vacancy rates, and downward pressure on rental rates across

our portfolio.

Second, macroeconomic volatility and restricted access to capital markets may impair our ability to fund new developments or

raise new debt or equity capital at favorable terms. Rising construction costs and supply chain disruptions could delay project

completions, reduce development yields, and impact the timing of rental income generation. Additionally, if tenants are unable to absorb

higher operating costs or pass them on to customers, their financial health may deteriorate, increasing the risk of lease defaults or

renegotiations.

Finally, the growing competitiveness of international markets—particularly China's rapidly expanding biotech sector—may

shift R&D activity abroad, reducing domestic demand for specialized lab infrastructure. If U.S.-based life sciences companies

increasingly rely on foreign innovation or relocate operations to more favorable regulatory or cost environments, the long-term

fundamentals of the U.S. life sciences real estate market could weaken. This may lead to asset devaluation, reduced investor

confidence, and a more challenging environment for sustaining growth and delivering shareholder value.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

**Purchases of Equity Securities**

On December 9, 2024, we announced that our Board of Directors authorized a share repurchase program, allowing the

repurchase of shares with an aggregate value up to $500.0 million until December 31, 2025 in the open market, through privately

negotiated transactions, or otherwise, in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the

Exchange Act. During the three months ended June 30, 2025, we did not repurchase any shares of our common stock under the

program. As of June 30, 2025, we had remaining authorization to repurchase shares with an aggregate value up to $241.8 million.

**ITEM 5. OTHER INFORMATION**

**Disclosure of 10b5-1 plans**

During the three months ended June 30, 2025, none of our officers or directors adopted or terminated any contract, instruction,

or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

or any "non-Rule 10b5-1 trading arrangement."

**Updates to Federal Income Tax Considerations in Form S-3 Registration Statement**

Updates to our discussion of federal income tax considerations are included in Exhibit 99.1 attached hereto, which is

incorporated herein by reference. Exhibit 99.1 supplements, supersedes and replaces where inconsistent with, and should be read

together with, the disclosure under the heading "Federal Income Tax Considerations" in the prospectus dated February 1, 2024, which

is a part of our Registration Statement on Form S-3 (File No. 333-276803), as amended. Our updated discussion addresses recently

enacted tax law changes.

**ITEM 6. EXHIBITS**

---

| | | | |
|:---|:---|:---|:---|
| **Exhibit**<br>**Number**<br>| **Exhibit Title** | **Incorporated by** <br>**Reference to:**<br>| **Date Filed** |
| 3.1\* | [Articles of Amendment and Restatement of the Company, dated May 21, 1997](https://www.sec.gov/Archives/edgar/data/1035443/0000898430-97-003430.txt) | Form 10-Q | August 14, 1997 |
| 3.2\* | [Certificate of Correction of the Company, dated June 20, 1997](https://www.sec.gov/Archives/edgar/data/1035443/0000898430-97-003430.txt) | Form 10-Q | August 14, 1997 |
| 3.3\* | [Articles of Amendment of the Company, effective as of May 10, 2017](https://www.sec.gov/Archives/edgar/data/1035443/000103544317000096/exhibit32-articlesofamendm.htm) | Form 8-K | May 12, 2017 |
| 3.4\* | [Articles of Amendment of the Company, effective as of May 18, 2022](https://www.sec.gov/Archives/edgar/data/1035443/000103544322000166/a20228-kproxyresultsxex31.htm) | Form 8-K | May 19, 2022 |
| 3.5\* | [Articles Supplementary, dated June 9, 1999, relating to the 9.50% Series A](https://www.sec.gov/Archives/edgar/data/1035443/000104746999031959/0001047469-99-031959.txt)<br>[Cumulative Redeemable Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000104746999031959/0001047469-99-031959.txt)<br>| Form 10-Q | August 13, 1999 |
| 3.6\* | [Articles Supplementary, dated February 10, 2000, relating to the election to be](https://www.sec.gov/Archives/edgar/data/1035443/000091205700005173/0000912057-00-005173.txt)<br>[subject to Subtitle 8 of Title 3 of the Maryland General Corporation Law](https://www.sec.gov/Archives/edgar/data/1035443/000091205700005173/0000912057-00-005173.txt)<br>| Form 8-K | February 10, 2000 |
| 3.7\* | [Articles Supplementary, dated February 10, 2000, relating to the Series A](https://www.sec.gov/Archives/edgar/data/1035443/000091205700005173/0000912057-00-005173.txt)<br>[Junior Participating Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000091205700005173/0000912057-00-005173.txt)<br>| Form 8-K | February 10, 2000 |
| 3.8\* | [Articles Supplementary, dated January 18, 2002, relating to the 9.10%](https://www.sec.gov/Archives/edgar/data/1035443/000091205702001962/a2068018zex-3_4.htm)<br>[Series B Cumulative Redeemable Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000091205702001962/a2068018zex-3_4.htm)<br>| Form 8-A | January 18, 2002 |
| 3.9\* | [Articles Supplementary, dated June 22, 2004, relating to the 8.375% Series C](https://www.sec.gov/Archives/edgar/data/1035443/000104746904021772/a2139174zex-3_4.htm)<br>[Cumulative Redeemable Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000104746904021772/a2139174zex-3_4.htm)<br>| Form 8-A | June 28, 2004 |
| 3.10\* | [Articles Supplementary, dated March 25, 2008, relating to the 7.00% Series D](https://www.sec.gov/Archives/edgar/data/1035443/000110465908019527/a08-8916_1ex3d1.htm)<br>[Cumulative Convertible Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000110465908019527/a08-8916_1ex3d1.htm)<br>| Form 8-K | March 25, 2008 |
| 3.11\* | [Articles Supplementary, dated March 12, 2012, relating to the 6.45% Series E](https://www.sec.gov/Archives/edgar/data/1035443/000110465912018256/a12-7118_1ex3d1.htm)<br>[Cumulative Redeemable Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000110465912018256/a12-7118_1ex3d1.htm)<br>| Form 8-K | March 14, 2012 |
| 3.12\* | [Articles Supplementary, effective as of May 10, 2017, relating to Reclassified](https://www.sec.gov/Archives/edgar/data/1035443/000103544317000096/exhibit31-articlessuppleme.htm)<br>[Preferred Stock](https://www.sec.gov/Archives/edgar/data/1035443/000103544317000096/exhibit31-articlessuppleme.htm)<br>| Form 8-K | May 12, 2017 |
| 3.13\* | [Amended and Restated Bylaws of the Company (Amended December 6,](https://www.sec.gov/ix?doc=/Archives/edgar/data/1035443/000110465924126548/tm2429960d1_8k.htm)<br>[2024)](https://www.sec.gov/ix?doc=/Archives/edgar/data/1035443/000110465924126548/tm2429960d1_8k.htm)<br>| Form 8-K | December 9, 2024 |
| 10.1\* | [Amended and Restated 1997 Stock Award and Incentive Plan of the Company](https://www.sec.gov/Archives/edgar/data/1035443/000103544325000144/a20258-kproxyresultsxex101.htm) | Form 8-K | May 15, 2025 |
| 22.1 | [List of Guarantor Subsidiaries of the Company](a2025-ex221.htm) | N/A | Filed herewith |
| 31.1 | [Certification of Principal Executive Officer Pursuant to Section 302 of the](a2025-ex311.htm)<br>[Sarbanes-Oxley Act of 2002](a2025-ex311.htm)<br>| N/A | Filed herewith |
| 31.2 | [Certification of Principal Executive Officer Pursuant to Section 302 of the](a2025-ex312.htm)<br>[Sarbanes-Oxley Act of 2002](a2025-ex312.htm)<br>| N/A | Filed herewith |
| 31.3 | [Certification of Principal Financial Officer Pursuant to Section 302 of the](a2025-ex313.htm)<br>[Sarbanes-Oxley Act of 2002](a2025-ex313.htm)<br>| N/A | Filed herewith |
| 32.0 | [Certification of Principal Executive Officers and Principal Financial Officer](a2025-ex320.htm)<br>[Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of](a2025-ex320.htm)<br>[the Sarbanes-Oxley Act of 2002](a2025-ex320.htm)<br>| N/A | Filed herewith |
| 99.1 | [Updates to Federal Income Tax Considerations](a2025-ex991.htm) | N/A | Filed herewith |
| 101.1 | The following materials from the Company's quarterly report on Form 10-Q for <br>the quarterly period ended June 30, 2025, formatted in iXBRL (Inline <br>eXtensible Business Reporting Language): (i) Consolidated Balance Sheets <br>as of June 30, 2025 and December 31, 2024 (unaudited), (ii) Consolidated <br>Statements of Operations for the three and six months ended June 30, 2025 <br>and 2024 (unaudited), (iii) Consolidated Statements of Comprehensive <br>Income for the three and six months ended June 30, 2025 and 2024 <br>(unaudited), (iv) Consolidated Statements of Changes in Stockholders' Equity <br>and Noncontrolling Interests for the three and six months ended June 30, <br>2025 and 2024 (unaudited), (v) Consolidated Statements of Cash Flows for <br>the six months ended June 30, 2025 and 2024 (unaudited), and (vi) Notes to <br>Consolidated Financial Statements (unaudited)<br>| N/A | Filed herewith |
| 104 | Cover Page Interactive Data File – the cover page from this Quarterly Report <br>on Form 10-Q for the quarter ended June 30, 2025 is formatted in Inline XBRL <br>and contained in Exhibit 101.1<br>| N/A | Filed herewith |

---

(\*) Incorporated by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed

on its behalf by the undersigned, thereunto duly authorized, on July 21, 2025.

---

| |
|:---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC. |
| /s/ Joel S. Marcus |
| Joel S. Marcus<br>Executive Chairman<br>(Principal Executive Officer)<br>|
| /s/ Peter M. Moglia |
| Peter M. Moglia<br>Chief Executive Officer and Chief Investment Officer<br>(Principal Executive Officer)<br>|
| /s/ Marc E. Binda |
| Marc E. Binda<br>Chief Financial Officer and Treasurer<br>(Principal Financial Officer)<br>|

---

## Exhibit 22.1

**EXHIBIT 22.1**

**List of Guarantor Subsidiaries of Alexandria Real Estate Equities, Inc.**

The following subsidiary was, as of June 30, 2025, a guarantor of the registrant's 4.30% Senior Notes due 2026, 3.80% Senior Notes due 2026, 3.95% Senior Notes due 2027, 3.95% Senior Notes due 2028, 4.50% Senior Notes due 2029, 2.75% Senior Notes due 2029, 4.70% Senior Notes due 2030, 4.90% Senior Notes due 2030, 3.375% Senior Notes due 2031, 2.00% Senior Notes due 2032, 1.875% Senior Notes due 2033, 2.95% Senior Notes due 2034, 4.75% Senior Notes due 2035, 5.50% Senior Notes due 2035, 5.25% Senior Notes due 2036, 4.85% Senior Notes due 2049, 4.00% Senior Notes due 2050, 3.00% Senior Notes due 2051, 3.55% Senior Notes due 2052, 5.15% Senior Notes due 2053, and 5.625% Senior Notes due 2054.

---

| | |
|:---|:---|
| Name of Subsidiary | Jurisdiction of Organization |
| Alexandria Real Estate Equities, L.P. | Delaware |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Joel S. Marcus, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of Alexandria Real Estate Equities, Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 21, 2025

---

| |
|:---|
| /s/ Joel S. Marcus |
| Joel S. Marcus |
| Executive Chairman |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Peter M. Moglia, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of Alexandria Real Estate Equities, Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 21, 2025

---

| |
|:---|
| /s/ Peter M. Moglia |
| Peter M. Moglia |
| Chief Executive Officer and Chief Investment Officer |

---

## Exhibit 31.3

**EXHIBIT 31.3**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Marc E. Binda, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of Alexandria Real Estate Equities, Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 21, 2025

---

| |
|:---|
| /s/ Marc E. Binda |
| Marc E. Binda |
| Chief Financial Officer and Treasurer |

---

## Exhibit 32.0

**EXHIBIT 32.0**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**18 U.S.C. SECTION 1350.**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Joel S. Marcus, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Alexandria Real Estate Equities, Inc. for the quarter ended June 30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Alexandria Real Estate Equities, Inc.

Date: July 21, 2025

---

| |
|:---|
| /s/ Joel S. Marcus |
| Joel S. Marcus |
| Executive Chairman |

---

I, Peter M. Moglia, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Alexandria Real Estate Equities, Inc. for the quarter ended June 30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Alexandria Real Estate Equities, Inc.

Date: July 21, 2025

---

| |
|:---|
| /s/ Peter M. Moglia |
| Peter M. Moglia |
| Chief Executive Officer and Chief Investment Officer |

---

I, Marc E. Binda, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Alexandria Real Estate Equities, Inc. for the quarter ended June 30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Alexandria Real Estate Equities, Inc.

Date: July 21, 2025

---

| |
|:---|
| /s/ Marc E. Binda |
| Marc E. Binda |
| Chief Financial Officer and Treasurer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Other Information**

Legislation commonly referred to as the One Big Beautiful Bill Act (the "OBBBA") was signed into law on July 4, 2025. The following supplements, supersedes and replaces where inconsistent with, and should be read together with, the discussion of U.S. federal income tax considerations under the heading "Federal Income Tax Considerations" in the prospectus dated February 1, 2024, which is a part of our Registration Statement on Form S-3 (File No. 333-276803), as amended, to take into account OBBA.

**Taxation of Our Company**

*Asset Test*

At the close of each quarter of our taxable year, we must satisfy certain tests relating to the nature of our assets. For taxable years ending after December 31, 2017 through December 31, 2025, no more than 20% of the value of our total assets may be represented by securities of one or more taxable REIT subsidiaries. Under the OBBA, for taxable years after December 31, 2025, up to 25% of the REIT's asset value may be comprised of TRS securities.

**Taxation of Our Stockholders**

*Taxation of Taxable Domestic Stockholders*

As long as we qualify as a REIT, distributions made to our taxable domestic stockholders out of current or accumulated earnings and profits, and not designated as capital gain dividends, will be taken into account by them as ordinary dividends and will not be eligible for the dividends-received deduction for corporate stockholders. Generally our ordinary dividends will be taxable to our domestic stockholders as ordinary income. However, individual stockholders are allowed to deduct 20% of the aggregate amount of ordinary dividends distributed by us, subject to certain limitations. The deduction for 20% of ordinary REIT dividends was set to expire on December 31, 2025, but the OBBBA made this deduction permanent.

*Tax Rates Applicable to Individual Stockholders*

Because we are not generally subject to federal income tax on the portion of our REIT taxable income or capital gains distributed to our stockholders, our dividends generally are not eligible for the 20% maximum tax rate on qualified dividends. Instead, our ordinary dividends generally are taxed at the higher tax rates applicable to ordinary income, the current maximum rate of which is 37%. However, individual stockholders are generally allowed to deduct 20% of the aggregate amount of ordinary dividends distributed by us, subject to certain limitations, which would reduce the maximum marginal effective tax rate for individuals on the receipt of such ordinary dividends to 29.6%. The maximum tax rate of 37% was set to increase after December 31, 2025; however, the OBBBA made such rate permanent.

The OBBBA is a complex revision to the U.S. federal income tax laws with potentially far-reaching consequences. The OBBA will require subsequent rulemaking in a number of areas. The long-term impact of the OBBBA on us, our investors, our tenants and the real estate industry cannot be reliably predicted at this early stage of the new law's implementation. Our stockholders are urged to consult with their own tax advisors regarding the impact of the OBBA to them and their acquisition, ownership and disposition of our stock.

<br>